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Abstract
Immunoglobulin A (IgA) is the most abundant and heterogenous human 
antibody class, being present in two major subclasses, IgAl and IgA2, and different 
oligomeric states. Secretory component (SC) binds to dimeric IgAl (dlgA) to form 
secretory IgA (SIgA). In this thesis, X-ray and neutron scattering, analytical 
ultracentrifugation and constrained modelling were used to determine their structures 
in solution. Free SC consists of five Ig-variable domains, with seven glycosylation 
sites. SC was found to adopt a compact, J-shaped structure in solution, with the 
glycosylation sites probably located on one face of SC. In this model, one side of SC 
and SC Dl, containing known IgA-binding motifs, is free to interact with dlgA. 
Dimeric IgAl (dlgAl) is formed by two IgAl monomers covalently bound by the 
joining (J) chain. The modelling of the solution structure of dlgAl shows that the 
arrangement of the two monomers are near-planar in an extended arrangement. The 
two Fc regions form a slightly bent end-to-end contact. All four Fab antigen-binding 
sites are independent of one another. The model shows that the two Fc regions are 
accessible to the Fc alpha receptor (FcaRI) and the polymeric immunoglobulin 
receptor (plgR). This dlgAl structure suggests a mechanism for dlgAl aggregation 
in IgA nephropathy through oligomerisation caused by removal or movement of the 
Fab regions by proteolysis or changes in the glycosylation of the hinge region. SIgA 
is formed by the transcytosis of dlgA across epithelial cells, where after binding 
plgR (membrane-bound SC) it is secreted into the mucosa. At the mucosal surfaces 
SIgA acts as the first line of defence against pathogens. The solution structure of 
SIgAl suggests that the arrangement of the IgAl monomers are not altered when SC 
is binds to dlgA l, therefore retaining their near-planar structure. The five domains of 
SC are in an extended conformation along the convex Fc-Fc edge of the dimer. The 
SIgAl solution structure shows how SC and dlgAl confer mutual protection to one 
another from proteolysis. The modelling of the solution structure of SIgA2 shows 
that, although the IgA2 monomers are in a similar arrangment to that in SIgAl, 
SIgA2 has a non-planar structure in solution. SC is located in a similar extended 
arranagment on the Fc-Fc convex edge to that in SIgAl, yet the Fab regions are 
positioned out of the Fc-Fc plane. These structural differences between the SIgA 
isotypes may increase their efficiency in mucosal immunity but confer varied 
susceptibilities to mucosal proteases.
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Chapter One
Biochemistry of Secretory Immunoglobulin A
1
1.1 The adaptive immune system
1.1.1 The innate and adaptive immune system
The immune system is a versatile and complex defence system that has 
evolved to protect animals from a plethora of pathogens, such as bacteria, 
viruses, other microorganisms and also potentially dangerous host-cells. The 
human immune system can be divided into the innate and adaptive immune 
system. However, it is the ability of these two branches of the immune system to 
co-operate and interact with one another that makes the human immune system 
so highly regulated and competent in its elimination of pathogens. The co­
ordination of the innate and adaptive immune system can produce a more 
effective response when combined.
The innate immune system provides the first line of defence to an 
infection by using anatomic, physiologic, phagocytic and inflammatory defensive 
barriers. Innate immunity is more primitive and less specific than adaptive 
immunity. Most components of the innate immune system are present prior to an 
infection and are involved in pathogen-resistance mechanisms that eliminate 
invading organisms in a non-specific, generic way.
The adaptive immune system is highly evolved to invoke a specific 
immune response involving the production of immune system cells and 
antibodies against a particular pathogen. Throughout its life span an individual 
can adapt the response to an infection caused by a particular pathogen. The first 
encounter to an antigenic challenge may typically take up to six days, whereas a 
second response to the same antigen in the future may take only two days, 
producing a rapid and heightened immune response. This is because unlike 
innate immunity, adaptive immunity has immunologic^) memory, antigenic 
specificity, diversity and the ability to recognise self from non-self.
1.1.2 Lymphocytes of the adaptive immune system
The two major populations of lymphocytes are B cells and T cells. B cells 
mature in the bone marrow (defined after their identification in the bursa of 
Fabricus, the site of haematopoiesis in birds) and T cells mature in the thymus 
gland. These B and T cells mediate and define the attributes of the adaptive 
immune system.
2
Mature T lymphocytes express a unique, specific membrane-bound T cell 
receptor that will only recognise an antigen (Ag) when bound to cell membrane 
proteins called membrane histocompatibility complex (MHC) molecules. These 
MHC glycoproteins are genetically diverse and function in this Ag recognition 
process, known as Ag-presentation. MHC molecules are either class I or class II, 
which are expressed on different cell lines; MHC class I are expressed on most 
nucleated cells, and MHC class II are only present on Ag-presenting cells 
(APCs). After interaction with an Ag-MHC complex, the T cells differentiate and 
proliferate into effector cells to carry out specific functions. There are two 
subclasses of effector T cells; helper T cells (T h) and cytotoxic T cells (T c )  that 
are distinguished from one another depending on the type of membrane-bound 
accessory receptor expressed on their cell surface. Th cells express CD4 
glycoproteins and are generally activated by Ags in complex with MHC class II 
molecules. Effector Th cells secrete specific cytokines that will subsequently 
activate Tc cells, B cells and macrophages. After activation by Th cells, Tc cells 
recognise MHC class I bound Ags, and then differentiate into cytotoxic T 
lymphocyte (CTL) effector cells, which perform cell-killing activity. The CTL 
has an essential role in monitoring and consequently eliminating any altered self­
cells or those that display MHC class I bound Ag.
APCs include B cells, macrophages and dendritic cells. APCs express 
class II MHC molecules and also deliver a co-stimulatory signal to activate and 
carefully control Th cells.
B cells express a specific B cell receptor, which is a membrane-bound 
antibody (Ab). When a naive B cell first encounters a specific Ag that can 
interact with its membrane-bound Ab, it rapidly proliferates and the progeny 
differentiate into memory B cells or effector B cells called plasma cells (Section 
1.1.4).
1.1.3 The humoral immune system
The adaptive immune system can be further subdivided into humoral and 
cell-mediated immune responses (Figure 1.1). Cell-mediated immunity is the 
response generated by effector T cells, and includes cytokines released by Th 
cells that induce phagocytic cells and CTL cells eradicating altered self-cells.
3
AntigenMature 
B cell
Secreted
Antibodies
Figure 1.1 Overv iew of the humoral immune system
The humoral immune response includes differentiation o f mature B cells after (a) 
an initial interaction with Ag into (b) Ab-secreting plasma cells, (c) Antibodies 
act as effector molecules that neutralise and clear pathogens, (d) Visualisation of 
a mature B cell using a scanning electron microscope (Adapted from Jane way et 
al., 2005).
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The humoral immune system is the interaction of B cells with an Ag and 
subsequently their differentiation into Ab-secreting plasma cells or memory B 
cells (Figure 1.1). The humoral immune system acquired its name as it involves
V I
molecules that are present in the humours, or body fluids. Ab molecules function 
as effector molecules by recognising, neutralising and eliminating Ags (Figure
1.1). The removal of Ags involves the cross-linking of an Ag by multiple Abs, 
forming a large complex that can be phagocytosed or opsonised. Binding of an 
Ab to an Ag on a microorganism can also activate complement, a branch of the 
innate immune system that can lyse and destroy the invading microorganism. 
The binding of Abs to an Ag can also prevent their attachment to, and 
consequent invasion of host cells.
1.1.4 B-cell maturation and effector functions
As shown in Figure 1.2, B cell development commences in the bone 
marrow, where a lymphoid stem differentiates into the earliest cell distinctive in 
the B cell lineage, namely a progenitor B cell (pro-B cell). Pro-B cells proliferate 
within bone marrow and then differentiate into precursor B cells (pre-B cell), for 
which the microenvironment of bone-marrow stromal cells is required. Stromal 
cells secrete interleukin 7 (IL-7), which drives B cell maturation by down- 
regulating pre-B cell adhesion molecule expression to encourage their 
detachment from the stromal cells.
During pre-B cell maturation into immature B cells, immunoglobulin (Ig) 
gene rearrangement occurs. The process of Ig gene rearrangement allows B cells 
to code for and express one functional heavy-chain and light-chain variable 
region in the Ab molecule. This makes each individual B cell antigenically 
committed to a specific epitope. Immature B cells express the p isotype o f the Ig 
constant heavy chain gene. This bone marrow phase of B cell development 
therefore culminates in the production of B cells that express membrane-bound 
immunoglobulin M (IgM). At this stage, the immature B cells are not fully 
functional and interaction with an Ag will induce cell death or anergy rather than 
proliferation and differentiation. Maturation of B cells is signalled by the co­
expression of the 6 and p heavy chain constant genes, leading to the production
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Figure 1.2 B cell maturation
Development and differentiation of a B cell from a non-committed lymphoid 
stem cell to either a memory B cell or an Ab-secreting plasma cell. Membrane- 
bound IgD and IgM are shown. Interleukin-7 (11-7) is released by stromal cells in 
the bone marrow to drive pre-B cell maturation. If an immature B-cell encounters 
an Ag it will induce cell death or anergy.
membrane- membrane- 
bound laM bound IgD
Memory 
B cell
Mature
Bcell
gene 
rearrangement
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of membrane-bound IgM and membrane-bound immunoglobulin D (IgD) (Figure
1.2). Each mature B cell expresses approximately 1.5 x 105 Ab molecules on its 
cell surface (Figure 1.1 d), with specificity for a single Ag. Mature B cells 
circulate the body in the lymph fluid and blood to lymphoid organs such as the 
spleen and lymph nodes (Figure 1.3). Mature B cell activation occurs upon 
interaction with the Ag specific for its membrane-bound Ab, followed by 
proliferation and clonal expansion of the mature B cells. Mature B cells then 
differentiate into memory B cells or Ab-secreting plasma cells. After antigenic- 
stimulation, IgD expression ceases. However, IgM expression continues, and 
mature B cells now secrete large amounts of IgM. Plasma cells then go on to 
carry out further Ig constant-region gene rearrangements to change the isotype of 
Ab they express (Section 1.2.4). This then specifically alters the effector 
functions and localisation of the Ab without altering its Ag specificity (Figure
1.3).
1.2 Antibodies
An antibody is the membrane-bound B cell receptor and the effector 
molecule secreted by plasma cells. When membrane-bound, Abs confer Ag- 
specificity to the cell. When secreted, Abs circulate in the serum of blood and in 
lymph fluid throughout the body, being available to neutralise Ags. Although the 
Abs secreted by one plasma cell are monoclonal and therefore only recognise one 
specific epitope on the Ag, a humoral immune response recruits several B cell 
clones, each producing Abs with different antigenic determinants. These 
monoclonal Abs therefore constitute a polyclonal, heterogeneous pool of Abs 
that can potentially recognise a variety of epitopes on a pathogen.
1.2.1 General antibody structure
Antibodies have a generic common structure, consisting of four 
polypeptide chains; two identical immunoglobulin heavy chains (H) and two 
identical immunoglobulin light chains (L). Each L chain is generally bound to an 
H chain by a covalent disulphide bond, and also by non-covalent salt-bridges, 
hydrogen bonds and hydrophobic interactions, to form a heterodimer (H-L). Two 
identical heterodimer H chains are then covalently linked (H-L)2 . H and L chains 
each contain constant (C h and C l) and variable ( V h and V l) regions (Figure 1.4).
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Figure 1.3 Distribution of effector sites of the different antibody classes 
throughout the body
IgA in its secretory form is the predominant Ab class present in mucosal 
secretions, including the gastrointestinal, respiratory and urogenital tracts, breast 
milk, saliva and tears. The main Ab classes in plasma are IgG and IgM, and in 
extracellular fluid are IgG and monomeric IgA. IgE is mainly associated with 
mast cells beneath epithelial surfaces. The neonate can receive IgG from the 
mother by transplacental transport. No antibodies are usually present in the brain.
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Figure 1.4 Generic antibody structure
Antibodies consist o f two identical heavy chains (blue) and two identical light 
chains (red). The heavy and light chains are divided into variable (green outline) 
and constant (purple outline) regions. The heavy and light chain domains and the 
Fab and Fc regions are highlighted. The hinge and domain linkers are shown as 
blue lines. Inter-chain disulphide bonds are shown as black lines. Each Ig domain 
(oval) contains two intra-chain disulphide bonds (not shown). Complementarity 
determining regions (CDRs) are shown as black crescents.
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The general structure of Abs was discovered by experimental 
observations of enzymatic cleavages. Immunoglobulin G (IgG) in serum was the 
first Ab class identified, and was subjected to experiments that allowed the 
determination of the general Ab structure (Figure 1.4). Digestion of IgG with 
papain produced three fragments; two identical Fab fragments (Fragment, 
antigen binding) that retained the ability to bind an Ag, and one Fc fragment 
(Fragment, crystallisable). Papain cleaves just above the inter-heavy chain 
disulphide bonds. Pepsin cleaves just below the inter-heavy chain disulphide 
bonds to yield a single fragment, which similarly retains the ability to bind an 
Ag, the F(ab’ ) 2  fragment. Reduction of IgG with mercaptoethanol separates the 
H and L chains by reducing all of the inter-chain disulphide bonds.
1.2.2 Immunoglobulin domains
Immunoglobulin (Ig) domains are a major domain type found in protein 
structures (Figure 1.5). This globular fold was first identified and described in 
immunoglobulins. The first high-resolution structure of an Ig fold was 
determined in 1973 and was of an intact Ab Fab fragment (Poljak et al., 1973). It 
was initially thought that Ig domains were only present in immunoglobulins. 
However, the structure of the non-immunoglobulin molecule P2-microglobulin 
that forms the light chain of the MHC class I complex was determined and found 
to consist of a single Ig domain, homologous to that of a Ig constant-type domain 
(Peterson et al., 1972). It therefore became apparent that the Ig fold has a greater 
significance in protein structures. The term Tg superfamily’ is now used to 
describe proteins that contain Ig domains and the Ig fold has been described as 
one of the nine ‘superfold’ structures (Orengo et al., 1994). A superfamily 
describes proteins whose corresponding genes are derived from a common 
primordial gene encoding the basic domain structure. There is a widespread 
occurrence of Ig domains in cell-surface receptors (Williams & Barclay, 1988), 
including Ab Fc receptors and the polymeric immunoglobulin receptor (plgR). 
Also, cell adhesion molecules and muscle protein domains have been found to 
contain Ig domains (Smith & Xhe, 1997).
10
Figure 1.5 Tw o-dimensional topology diagrams for each of the four Ig folds
(a-d) An arrow represents the direction o f the seven to ten p-strands (A, A ’, B, C, 
C \  C ” , D, E, F, G) and the direction from N to C terminus. The three loops 
forming the CDRs o f the Ig V-type domain (red) are shown between P-strands B 
and C, C ’ and C ”  and F and G. The P-strands viewed end-on as a p-sheet 
sandwich fold for the V and C l type Ig folds are shown underneath. The 
intradomain disulphide bond in the Ig folds is shown with a straight black line.
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Ig domains are all p-class protein folds that consist of two antiparallel p- 
sheets packed face-to-face to form a sandwich structure. The polypeptide chain 
traverses the length of the fold an odd number of times (either seven or nine 
times) so that the N- and C- terminals reside at opposite ends of the long axis of 
the Ig fold (Figure 1.5). Ig domains can be classified as one of four different sets 
known as the variable (V) type, constant-1 (C l) type, constant-2 (C2) type and 
intermediate (I) type (Figure 1.5).
The V-type Ig domain is composed of a polypeptide chain that traverses 
the length of the domain nine times and has a maximum of ten p-strands. The V- 
type Ig domains contains an extra p-strand arising from the polypeptide chain 
switching sheets after strand A to form the A’ strand. The ten strands are 
arranged as a four strand DEBA p-sheet, packed against a six strand 
A’GFCC’C”  P-sheet. Both p-sheets are antiparallel except for the short parallel 
P-ladder between strand A’ and G (Figure 1.5a). The Vh and Vl domains in Abs 
are V-type Ig folds.
In the Cl-type Ig fold the polypeptide chain traverses the length of the 
domain seven times and has seven p-strands. The p-strands are arranged as two 
antiparallel P-sheets, where one four stranded DEBA p-sheet is packed against 
the three stranded GFC p-sheet (Figure 1.5b). The constant domains in Abs 
are Cl-type Ig folds.
The C2-type Ig domain consists of a polypeptide chain traversing the 
length of the domain seven times. The C2-type fold is characterised by a peptide 
connection between the end of p-strand C and the beginning of p-strand E. This 
causes the p-strand D present in the Cl-type fold to switch p-sheets and form a 
C’ p-strand. The C2-type fold is consequently also called the switch (S)-type 
domain. Three p-strands are arranged as one EBA p-sheet packed against a four 
strand GFCC’ p-sheet (Figure 1.5c).
The I-type of Ig fold has a polypeptide chain that traverses the domain 
length seven times. The I-type domain has eight p-strands, with the polypeptide 
chain switching sheets after A to also form A’ similar to the V-type fold. The 
eight strands form one DEBA p-sheet with four stands packed against an A’GFC
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P-sheet. Both p-sheets are antiparallel except for the short parallel p-ladder 
between strand A ’ and strand G (Figure 1.5d).
1.2.2.1 Ig domain common core and intradomain disulphide bonds
Even though there are significant structural disparities between the Ig 
domain types, a structural core is common to all the types of Ig domains (Bork et 
al., 1994). All four Ig folds contain the four p-strands B, C, E and F (Figure 1.5). 
Strands B and E form an antiparallel P-ladder in the centre of one sheet that 
packs against and interacts with an antiparallel p-ladder formed by strands F and 
C in the centre o f the other sheet. This structural core is stabilised by the aligned 
packing o f mainly hydrophobic residue side chains, to form a hydrophobic core. 
The variation between the four Ig-fold types (and slight variation between 
domains within each Ig fold type) result from differences in the length and 
presence o f the other strands, A, A’, C, C’, C ”  and D, and the surrounding loop 
regions, which are present at the periphery o f the P-sheets.
The V-type and Cl-type of Ig folds contain a conserved intradomain 
disulphide bridge, usually formed between two cysteine residues in p-stands B 
and F (Lesk & Chothia, 1982; Figure 1.5a,b). It is thought that the presence of 
this disulphide bond increases the stability of the domain. However, in some 
domains these cysteine residues may be absent and in other domains the position 
or number o f disulphide bonds is increased (Williams & Barclay, 1988; Bork et 
al., 1994).
1.2.2.2 Complementarity Determining Regions
The differences between Ab molecule colonies that confer specific 
epitope recognition arise due to differences in the amino acid sequence in 
discrete regions o f the Vh and V l chains, called complementarity-determining 
regions (CDRs). CDRs are hypervariable regions that constitute the Ag-binding 
site. X-ray crystallography studies have established that the Ag-binding sites on 
an Ab are formed by three CDRs in the light chain (CDRI-CDRIII) and three 
corresponding CDRs (CDRI-CDRIII) in the heavy chain, all of which have high 
degree o f sequence variability (Kabat et al., 1976). The three CDRs are in loop 
regions at the same end of the P-barrel, connecting p-strands B-C, C ’-C”  and F-
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G (Figure 1.5a). The loop between the two extra P-strands in the V-type Ig 
domain, C’ and C” , which is not present in the other classes of Ig fold, contains 
the hypervariable region CDRII (Figure 1.5a).
CDRs are regions of sequence hypervariability, yet within the same Ab 
class, very few sequence differences are seen throughout the rest of the Ab 
molecule. Therefore, the locations of CDRs are determined by comparing the 
sequences of light and heavy chains to determine those areas of significant 
variability. Plotting sequence variability as a function of residue number along a 
polypeptide chain for hundreds of different variable domains shows three large 
peaks corresponding to the hypervariable regions CDRI, CDRII and CDRIII (Wu 
et al., 1970). CDRs have been defined as heavy chain residues 31-35, 50-65 and 
95-102 and light chain residues 24-34, 50-56 and 89-97 (Figure 1.6).
Residues within CDRs are thought to have different roles, including (1) 
residues whose side-chains are in direct contact with the antigenic determinant 
and contribute to the binding-energy of the Ag-Ab interaction, (2) residues which 
fulfil a structural role and whose side-chains do not contact the Ag and (3) 
residues which are not in contact with the Ag but may exert a conformational 
influence on contacting residues and are therefore essential to the specificity 
(Kabat et al., 1976).
1.2.3 Fab arm and antigen-binding site formation
The hypervariable CDRs from both the heavy chain Vh and light chain 
V l have a close association to form an Ag-binding site. The Fab arms of an Ab 
are arranged in two globular regions where ChI associates with Cl, and Vh 
associates with VL (Figure 1.4). The six CDRs are positioned together at the end 
of the variable domains and Fab arms meaning that they are free to interact with 
their specific Ag with little steric hindrance.
The ChI and Cl domains are paired through their DEBA four-stand p- 
sheet. The interface between the two domains contains close-packed hydrophobic 
residues. The p-sheets in the two constant domains are arranged at near-right 
angles to one another, burying the central hydrophobic residues. However, the 
Vh and Vl domains interact very differently. If the interaction between the two
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Figure 1.6 Location of the complementarity determining regions (CDRs) in 
v ariable immunoglobulin domains of antibody light chains
The regions o f high sequence variability are highlighted and constitute CDRI 
(residues 24-34), CDRII (residues 50-56) and CDRIII (residues 89-97). The Y-axis 
variability is defined as the number o f different amino acids at a given position 
divided by the frequency o f the most frequently occurring amino acid at that position, 
where the frequency is calculated from the number o f times the most common amino 
acid occurs divided by the total number o f proteins studied. (Adapted from Wu et al., 
1970).
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variable domains, Vh and Vl were similar to that between ChI and Cl where the 
four-stranded DEBA p-sheets interacted, it would mean that the loops containing 
the CDRs would be positioned far apart from one another as the majority of the 
CDRs are loops between the A’GFCC’C” p-strands (Figure 1.5a). In contrast to 
the ChI and Cl domain pairing, variable domains are paired though their 
A’GFCC’C” p-strands. Therefore, the variable domains are in a more parallel 
orientation than the constant domains, and consequently do not pack as tightly 
(Branden & Tooze, 1999).
1.2.4 Antibody classes and biological activities
There are two different isotypes of light chains, X and k , yet no 
functional distinction between them is known. There are five different isotypes of 
the heavy chain that divides the Abs into five different classes: y (IgG), p (IgM), 
a  (IgA), 5 (IgD) and 8 (IgE). Each heavy chain isotype can combine with either 
light chain isotype to form a fully functional Ab (Figure 1.4). The effector 
function and effector sites of each Ab class depend on which heavy chain they 
contain (Figure 1.3; Table 1.1).
The differences between heavy and light chain Ig gene expression are due 
to a phenomenon called gene rearrangement. Functional genes that encode the Ig 
heavy and light chain are assembled at recombinational events at the DNA level. 
There are many genes encoding the light and heavy chains of Ab molecules. 
Light chain polypeptides arise from a short leader (L) exon, a variable (V) gene 
segment (X or k ) ,  a joining (J) gene segment and a light chain constant gene 
segment (X or k ) .  Light chain Ig genes are rearranged to form a polypeptide 
consisting of VJC (of the X or k isotype). Like the light chain, heavy chains 
possess these gene segments as well as a diversity (D) gene segment, yet their 
constant gene segments are a , 8, s, y or p. Heavy chain gene rearrangement 
produces polypeptides consisting of VhDhJhCh- The Ch regions code for the 
heavy chains of the Ab, and are present as exons separated by introns in the order 
5 ’ -p-5-y3-y 1 -a  1 -y2-y4-s-a2-3 ’. An analysis of functional light and heavy chain 
V, D and J gene segments in the germ-line DNA of one human individual 
revealed 51 VH, 25 D h , 6 Jh, 40 VK, 5 JK, 31 Vx and 4 Jx segments. This
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A n tib o d y
C lass
Mvv
(kD a)
H ea v y
C h a in
S eru m
lev e ls
(m g/m l)
In Vivo 
h a lf  life
(days)
B io lo g ica l a c tiv it ie s
IgA  Ig A l 150-
6 0 0
a l 3 6 ■ Main Ab present in external 
secretions (mucus, saliva, tears)
■ Present in breast milk for immune 
system of neonate
■ First line of defence in mucosal 
immunity
■ When polymeric in secretions can 
cross-link large Ag
■ Activates complement pathway
IgA 2 150-
6 0 0
a 2 0.5 6 ■ Mucosal immunity
■ Present in secretions (mucus, saliva, 
tears)
■ Present in breast milk
IgG  IgG l 150 Yl 9 23 ■ Binds to phagocyte Fc receptors and mediates opsonisation ++
■ Activates complement pathway +
■ Crosses the placenta +
IgG2 150 72 3 23 ■ Binds to phagocyte Fc receptors and 
mediates opsonisation +/-
■Activates complement pathway +/-
■ Crosses the placenta +/-
IgG3 150 Y3 1 8 ■ Activates classical complement pathway ++
■ Binds to phagocyte Fc receptors and 
mediates opsonisation ++
■ Crosses the placenta +
IgG4 150 Y4 0.5 23 ■ Crosses the placenta +
■ Binds to phagocyte Fc receptors +
IgM 180-
900
1.5 5 ■ First Ab class produced in a 
primary immune response
■ First Ab class synthesised by the 
neonate
■ Present on mature B cell 
membranes
■ High valency when pentameric to 
bind Ag with repeating epitopes, 
e.g. viral particles
■ Activates complement pathway 
+++
■ Present in external secretions with 
accessory role as secretory Ab
IgD 150 6 0.03 3 ■ Present on mature B cell 
membranes
IgE 190 e 0.0003 2.5 ■ Mediates hypersensitivity reactions 
(allergies)
■ Induces basophil and mast cell 
degranulation
Table 1.1 Antibody bioactivities
(Adapted from Goldsby et al., 2002).
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mechanism of Ig gene rearrangement therefore generates a minimum of 1.5 x 106 
combinations and subsequently a huge Ab repertoire.
B cells can undergo further gene rearrangement during their lifetime, in 
which their VhDhJh unit can combine with different Ch gene segments, 
stimulated by specific cytokine signals that can dictate the Ab isotype to which 
the B cell switches. This process is known as class switching. This allows the 
immune system to control which Ab class is produced by the B cells, creating 
specific effector responses in the correct area of the human body (Figure 1.3; 
Table 1.1).
1.2.4.1 Immunoglobulin G
IgG is the most abundant Ab class present in human serum, present at 
approximately 12.3 mg/ml, which constitutes around 80% of the total serum Ab 
content (Table 1.2). It is monomeric with a molecular mass of 150 kDa. It 
consists of two y heavy chains bound to two k  or X light chains. The heavy chain 
of IgG has three constant domains, ChI, Ch2 and Ch3, similar to the general Ab 
structure shown in Figure 1.4. Four subclasses of IgG exist; IgGl, IgG2, IgG3 
and IgG4. The different subclasses of IgG all possess between 90-95% sequence 
similarity, with the main sequence and structural disparity present in the hinge 
region connecting the Fc region to the Fab fragments, and the number and 
position of inter-heavy chain disulphide bonds. These structural differences give 
the IgG subclasses varying biological potency in activating complement, their 
ability to cross the placenta and their affinity of binding to their Fc receptor on 
phagocytes and triggering opsonisation (Figure 1.3; Table 1.1)
1.2.4.2 Immunoglobulin M
IgM is the first Ab class to be expressed on immature B cells and also the 
first Ab class secreted in a primary immune response (Figure 1.2). IgM accounts 
for approximately 5-10% of the total serum immunoglobulins, and is at a serum 
concentration o f -1.5 mg/ml. Monomeric IgM has a molecular mass of around 
180 kDa and is membrane-bound. The heavy chain of IgM contains an extra 
constant domain to the generic Ab structure that is designated Ch4 (Figure 1.4; 
Figure 1.7). When secreted, IgM is pentameric with a molecular mass of
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J chain
Figure 1.7 Electron micrograph and solution structure of pentameric IgM
(a) Visualisation o f pentameric IgM molecules by scanning electron microscopy 
(Adapted from Janeway et a l ,  2005). (b) Solution structure o f pentameric IgM 
(PDB code 2RCJ; Perkins et a l ,  1991). The light chains o f the five IgM 
monomers are shown in red, the heavy chains are shown in dark blue, green, 
light blue, purple and orange and the J chain is shown in pink.
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around 900 kDa (Figure 1.7). It also contains an 18 kDa joining (J) chain that is 
required for Ab polymerisation (Johansen et al., 2001). Electron microscopy 
(EM) analyses have shown that the IgM pentameric structure has all Fc regions 
of the IgM monomer subunits in the centre and the ten Ag-binding sites on the 
periphery (Figure 1.7a). The solution structure of IgM confirmed the EM 
findings, and shows the structure of pentameric IgM to be planar and contain one 
J chain which is preferentially positioned between the Ch4 domains of two 
monomers (Perkins et al., 1991; Volkov et al., 2003; Figure 1.7b). Pentameric 
IgM is thought to be able to bind ten small hapten molecules, yet only five larger 
Ags due to steric hindrance arising from neighbouring IgM molecules. IgM has a 
higher valency than all the other Ab classes, making it very effective in binding 
weakly to repeating epitopes such as on viral particles, prior to the development 
of a stronger IgG response. It is thought that upon binding to an Ag, the Ag- 
binding sites of the IgM subunits all come together to form a ‘tulip’ structure, to 
allow their Fc regions to bind to the receptors to trigger immune responses such 
as complement activation. IgM is a strong complement activator as complement 
activation requires two Fc regions in close proximity. IgM also has an accessory 
role as a secretory Ab in mucosal surfaces. (Figure 1.3; Table 1.1; Section 1.4.3)
1.2.4.3 Immunoglobulin D
IgD is a monomeric Ab with a molecular mass of 185 kDa and a serum 
concentration of ~30 pg/ml. IgD represents about 0.25% of the total serum 
immunoglobulins (Vladutiu, 2000). Human IgD exists in two forms; membrane- 
bound IgD and secreted IgD. Membrane-bound IgD is co-expressed with 
membrane-bound IgM by mature B cells, and together they act as antigenic 
receptors on the surface of the lymphocytes (Figure 1.2). IgD is most abundant in 
its membrane-bound form and little is known about the function of secreted IgD 
(Geisberger et al., 2006). The majority of IgD-expressing plasma cells have been 
identified in the upper respiratory tract, particularly in the nasal passages and the 
tonsils, and few have been found in the bone marrow (Preud’homme, 2000)
IgD has three constant heavy chain domains and the longest hinge of all 
Ab classes, with 64-residues connecting the Fab and Fc regions. Secreted IgD 
has been shown to be more sensitive to proteolytic enzymes than IgM, and this
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may be due to the long hinge region (Figure 1.4; Geisberger et al., 2006). The 
solution structure of serum myeloma IgD has been determined, which has shown 
IgD to possess a flexible T-shape structure, unlike the Y-shape seen for IgG (Sun 
et al., 2005). IgD contains a single intra-heavy chain disulphide bond, close to 
the C-terminus, permitting IgD to have a greater degree of freedom for Ag- 
binding than the other Ab isotypes (Table 1.1).
1.2.4.4 Immunoglobulin E
Immunoglobulin E (IgE) is monomeric with a molecular mass of 190 kDa 
and it is present in very low concentrations in serum (around 0.3 pg/ml). The 
heavy chain of IgE contains an extra constant domain compared to the generic 
Ab structure that is designated Ch4 (Figure 1.4). IgE mediates hypersensitivity 
reactions that are responsible for allergic reactions and anaphylactic shock. 
Cross-linking of Ag-bound IgE binding to their to Fc receptors on the 
membranes of basophils and tissue mast cells induces these cells to exocytose 
their granules in a process called degranulation. Pharmacologically active 
mediators are released to give rise to allergic manifestations. IgE is therefore 
mainly present below the surface of the epidermal tissue (Figure 1.3; Table 1.1).
1.3 Immunoglobulin A
Immunoglobulin A (IgA) is by far the most abundant antibody present in 
the human body. The daily production of IgA is estimated to be of the order of 
65 mg/kg, far exceeding the production of all the other antibody classes 
combined (Kerr, 1990). In its secretory form, IgA is the principle antibody on 
mucosal surfaces (Figure 1.3). In addition, IgA is the second most prevalent 
antibody in circulation in human serum. IgA is present in very different 
environments in the human body (Table 1.1). This is reflected in the unique 
heterogeneity in the molecular forms of IgA and characteristic distribution in the 
various body fluids (Table 1.2).
IgA exists as two subclasses, IgAl and IgA2 (Figure 1.8), the latter of 
which is found in at least two allotypic forms, IgA2m(l) and IgA2m(2). IgA2n 
represents a possible third allotype of IgA2 (Chintalacharuvu et al., 1994). Serum 
IgA is predominantly monomeric IgAl, with a concentration of about 2-3 mg/ml 
and low percentage of polymeric forms. In secretions, the IgAl and IgA2
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Human
Fluid
IgG
(mg/ml)
IgA
(mg/ml)
plgA
(%)
Ratio of 
IgAl/IgA2
Serum 12.3 3.28 13 89:11
Colostrum 0.1 12.34 96 65:35
Saliva 0.05 0.30 96 63:37
Jejunal 0.34 0.28 95 70:30
Colonic 0.86 0.83 n.d. 35:65
Hepatic
bile
0.18 0.11 65 74:26
Nasal 0.06 0.26 n.d. 95:5
Bronchial 0.02 n.d. 82 67:33
Table 1.2 Concentrations of IgA in serum and human secretions and 
comparison to that of IgG
Those concentrations of IgA that are not detectable are denoted n.d. (Adapted 
from Kerr, 1990).
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(a) lgA1
Cys311
N459
Tailpiece
(b) lgA2
Cys311
Tailpiece '
Figure 1.8 Solution structures of IgAl and IgA2m(l)
The best-fit solution structures of (a) IgAl (PDB 1IGA; Boehm et al., 1999) and
(b) IgA2m(l) (PDB 1R70; Furtado et al., 2004) are shown. The antibody heavy 
chains (blue and green) and light chains (red), N-linked and O-linked 
carbohydrates (cyan) are shown. The Cys311 that covalently binds to SC to form 
SIgA (yellow) are highlighted in both structures.
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subclasses are present as homodimers, with generally slightly more IgAl present 
than IgA2, except in colonic secretions when the IgA2 subclass predominates 
(Table 1.2).
1.3.1 Biochemistry o f monomeric IgA
IgA is a heterogeneous molecule comprising two identical light chains (k 
or k )  and two identical heavy chains, a l  or a2 , which give rise to IgAl or IgA2 
respectively. The monomeric form of all IgA subclasses and allotypes contains 
12 domains, including six constant heavy domains (C h I , Cr2 and C h 3 ), two 
variable heavy domains (Vh ), two constant light domains ( C l )  and two variable 
light domains (V l) (Figure 1.4; Figure 1.8).
There are few sequence differences between the heavy chains o f the 
human IgA subclasses. An alignment o f the amino acid sequence of human IgAl 
and IgA2 show that they differ most significantly in the hinge region, yet the rest 
of the sequence can be aligned without any significant insertion or deletion 
(Torano et a l 1978; Putnam et al., 1979; Flanagan et a l 1984). The hinge 
region in IgA is between the ChI and Ch2 domains, and includes a duplication of 
a sequence o f eight-residues (PSTPPTPS) (Senior & Woof, 2005). In total the 
IgAl hinge is 23 residues in length, with five O-linked oligosaccharides. 
IgA2m(l) has a shorter, ten residue hinge region, therefore lacking a 13-residue 
region that is rich in Pro, Ser and Thr amino acids, and the O-linked 
oligosaccharides that are present in IgAl. Different hinge lengths presumably 
provide the IgA subclasses with varied flexibility o f the Fab arms relative4to the 
Fc region, antigenic-reach and vulnerability to proteolytic degradation.
The best characterised allotypic forms of human IgA2 are IgA2m(l) and 
IgA2m(2). The IgA2m(l) allotype appears to be a hybrid gene possibly arising 
from a recombination or gene conversion involving IgAl and IgA2m(2), thus the 
Ch3 domain of IgA2m(l) is identical to that o f IgA l, whereas the Cn.land Ch2 
domains are related to IgA2m(2) (Flanagan et al., 1984). A major structural 
difference between IgAl and IgA2 is the arrangement o f inter-chain disulfide 
bridges. In IgA l, the light chains covalently bind to the heavy chains via Cys214 
in the C l domain and Cysl33 in the C h .1 domain. However, there are no 
disulphide bonds present to link the heavy and light chains in IgA2m(l) (Grey et
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a l , 1968). This lack of inter-chain disulphide bonds is due to the presence o f an 
asparagine residue instead of the Cysl33 in its Ch.1 domain. Instead, the two 
IgA2m(l) light chains bind via Cys214. Therfore, the IgA2m(l) light and heavy 
chain interact by non-covalent interactions (van Loghem & Biewenga, 1983; 
Furtado et al., 2004).
Both IgA subclasses and IgA2 allotypes possess an additional 18-residue 
C-terminal tail after the Ch3 domain, termed the tailpiece (Figure 1.8). The 
tailpiece is involved in the polymerisation o f the IgA monomers (Mestecky et al., 
1974). Cys471 in the tailpiece o f one heavy chain in each monomer covalently 
binds to the J chain. The deletion of the tailpiece and mutation o f Cys471 
prevents IgAl dimer assembly (Atkin et al., 1996).
IgA sequences from many species have been determined. In mouse 
serum, only one subclass has been identified that is most similar to that o f human 
IgA2, and exists only in polymeric forms (Kerr, 1990). In rabbits, 13 IgA 
subclasses have been identified with between 72% and 85% sequence similarity 
to each other, particularly in the Ch2 and Ch3 domains (Burnett et al., 1989). The 
human and mouse IgA hinge regions contain no cysteine residues, whereas the 
rabbit IgA isoforms contain between one and five cysteine residues. The 13 
rabbit IgA hinge sequences vary extensively, which may offer greater mucosal 
protection through differing susceptibility to proteases (Burnette et al., 1989). 
Homologues o f human IgAl are only found in higher apes, and sequence 
comparisons show significant sequence hypervariability in the hinge region. IgA 
is a secretory Ab and IgAl may be subject to positive selection, driven by its 
susceptibility to proteases in the mucosal environments (Sumiyama, et al., 2002). 
When secreted, IgAl is known to be susceptible to protease activity, rendering 
the Ab inactive by cleavage of its hinge region (Senior & Woof, 2005).
Electron micrographs of monomeric IgA show it to possess a Y-shaped 
structure, similar to that seen by IgG (Dourmashkin et al., 1971). The solution 
structure o f monomeric forms of IgAl and IgA2m(l) have been determined 
(Figure 1.8; Boehm et al., 1999; Furtado et a l ,  2004). Although both are 
predominantly T-shaped, the structural differences between IgAl and IgA2 due 
to the longer hinge region in IgAl are evident (Figure 1.8). IgAl has a more 
extended conformation than IgA2, which is thought to give IgAl a greater ability 
to intercept and bind to Ags. The variation in distance between the Fab CDR
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regions between IgAl and IgA2 suggests they recognise different antigenic- 
surfaces on pathogens. The flexibility of the IgAl hinge is thought to be reduced 
due to the presence of five O-linked oligosaccharides in each heavy chain of 
IgAl. The high percentage of proline residues and likewise the lack of glycine 
residues in both the IgAl and IgA2 hinges are thought to decrease their hinge 
flexibility.
IgA is heavily glycosylated, and its carbohydrate content accounts for 
approximately 9% of the total mass of IgA, which is thought to contribute to it 
being more negatively charged than IgG (Boehm et al., 1999; van Egmond et al., 
2001; Heremans, 1974). The carbohydrates residues may be involved in the 
protection o f IgA, especially when in its secretory form in the harsh acidic and 
proteolytic environment o f the mucosa. Within the IgA isotypes, IgA2 is more 
highly N-glycosylated than IgAl (Tomana et al., 1976). The IgAl heavy chain 
contains two N-linked glycosylation sites at Asn263 within the Ch2 domain and 
at Asn459 within the tailpiece. IgA2m(l) contains two additional N-linked sites 
at positions A snl66 in the ChI domain and Asn337 in the Ch2 domain. 
IgA2m(2) contains all these sites plus one more at position Asn211 in the Ch2 
domain. IgAl alone possesses the five O-linked glycosylation sites in the hinge 
region. The O-linked glycosylation residues are Thr225, Thr228, Ser230, Ser232 
and Thr236 in the hinge region (Mattu et al., 1998). The presence of these O- 
linked carbohydrates offers protection to the longer IgAl hinge, which is more 
vulnerable to proteolysis.
1.3.1.1 N- and O-linked carbohydrates
N-linked and O-linked glycosylation differ in several ways. N-linked 
carbohydrates are added as large 14-residue GlcNAc2 Man9 Glc3 precursors to 
proteins co-translationally in the endoplasmic reticulum prior to folding. O- 
linked carbohydrates are assembled sequentially onto folded proteins in the Golgi 
apparatus, where N-linked carbohydrates may continue to be enzymatically- 
processed to their mature form (Gala & Morrison, 2002). O-linked carbohydrates 
are often shorter with between one and four residues. N-linked carbohydrates 
bind to the nitrogen in the R-group o f asparagine, with the sequence Asn-X-Ser 
or Asn-X-Thr, where X is any amino acid except proline. O-linked carbohydrates
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are added to serine or threonine residues, where an N-acetylgalactosamine 
(GalNAc) monosaccharide is linked to the amino acids’hydroxyl group.
1.3.2 Overview o f the interaction o f IgA with other proteins
Human serum albumin (HSA), a  1-antitrypsin and a  1-microglobulin (also 
known as Protein HC) can form complexes with IgA (Grubb et a l, 1983; Calero 
et al., 1994). HSA binds to the IgA base o f the Fc region but not to the Fab 
region (Almogren et al., 2006). The level o f these complexes in normal human 
serum is minute. However in some diseases the expression of these complexes is 
markedly increased (Vaerman, 1971). For example, high levels of IgA-HSA 
complex are found in some IgA myeloma cases (Mestecky et al., 1977) and IgA- 
al-antitrypsin complex is associated with the pathogenesis o f rheumatoid 
arthritis (Stanworth et al., 1985). Some reports have shown that IgA -al- 
antitrypsin complex levels increase in the serum and synovial fluid o f rheumatoid 
arthritis patients (Mattey et al., 1997; Scott et al., 1998).
IgA is considered a poor activator o f complement in comparison to IgG 
and IgM. IgA does not activate complement by the classical pathway and does 
not bind C lq. IgA can activate the alternative pathway of complement, therefore 
mediating bacterial death via opsonisation or cell lysis. All isoforms of IgA are 
thought to be able to activate the alternative pathway, and an intact F(ab ' ) 2  
fragment is necessary (Hiemstra et a l ,  1988). However, IgA activation of the 
alternative pathway remains a controversial topic, as in those studies IgA has to 
be either immobilised or aggregated, and the activation has not resulted in the 
formation of the membrane-attack complex. More recently, it has been shown 
that polymeric IgA, upon binding mannan-binding lectin (MBL) can activate the 
lectin pathway (Roos et al., 2001). The role of IgA-complement activation in 
vivo remains unclear. With limited Ag present, IgA would actually inhibit 
complement activation by competing with IgG or IgM and blocking their binding 
to the Ag. If IgA does not activate complement or prevents complement 
activation, this may be important in preventing harmful inflammatory responses 
of complement system components. This is especially true in mucosal immunity, 
as IgA is in greater abundance in mucosal secretions and pro-inflammatory 
reactions may damage the mucosal tissue.
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1.3.3 Dimeric IgA
Dimeric IgA (dlgA) is formed through the binding of Cys471 in the 
tailpiece o f two IgA monomers to Cysl5 and Cys68 of the J chain (Figure 1.9; 
Figure 1.10; Mestecky et al., 1974; Garcia-Pardo, 1981). Electron micrographs 
o f dlgA depict the two IgA monomers arranged with both Fc regions together, in 
a double Y-shape, with some flexibility (Figure 1.9; Svehag & Bloth, 1970; 
Dourmashkin et al., 1971; Munn et al., 1971). The slight variations in dlgA 
structure seen in these electron micrographs may be due to flexibility or the harsh 
staining techniques used in this technique (Section 2.1.1).
IgA is implicated in numerous diseases (Section 1.7), and in its dimeric 
form it is involved in the pathology of IgA nephropathy (IgAN). Serum dlgAl 
levels are elevated in IgAN and there is deposition o f IgAl in the kidney glomerular 
mesangium (Section 1.7.2; Barratt et al., 2007).
1.3.3.1 Joining chain
Despite the similarity o f the overall structure of antibodies, their 
molecular masses vary dramatically from 150 kDa to 950 kDa, due to the ability 
o f Abs to polymerise. The formation of dimers and higher oligomers is attributed 
to covalent binding o f the Ab complex to the J chain. The J chain was first 
identified in 1970 (Halpem & Koshland, 1970) and was named after its ability to 
join two IgA monomers together to form dlgA.
The J chain is a 137-residue, 18 kDa glycoprotein with an acidic 
character due to its high glutamic and aspartic acid content. J chain contains one 
N-linked glycosylation site at Asn48 that accounts for approximately 12.5% o f 
its molecular mass. Only one J chain is present in each polymeric Ab 
macromolecule independent o f the size o f the polymer (Mestecky et al., 1974). 
One identical J chain is present in dlgA and pentameric IgM. The J chain 
dimerises IgA via its Cysl5 and Cys68 covalently linking with two Cys471 
residues in a tailpiece in each of the two IgA monomers (Figure 1.10). The 
carbohydrate moiety in J chain is also thought to be involved in its interaction 
with IgA (Krugman et al., 1997). It was once thought that through its high 
cysteine content o f eight residues, the J chain had enough free sulphyl-groups to 
bind to each heavy chain in each IgA or IgM in the complex, meaning that J
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(a) SlgA (b) dlgA
Figure 1.9 Electron micrographs of dimeric IgA and secretory IgA
(a) EM shows the structure of secretory IgA (SlgA) as a variable Y-shaped 
molecule and dlgA as a double Y-shape, with two IgA monomers bound at their 
Fc region. One dlgA Fab arm is arrowed and the scale bar represents 10 nm 
(Svehag & Bloth, 1970). (b) EM (x800,000) shows the dlgA structure as a 
double Y-shape. The scale bar represents 10 nm (Dourmashkin et al., 1971). (c) 
Using a different EM staining technique as in (a), EM (x245,000) suggests SlgA 
has a similar arrangement of the two IgA monomers as in dlgA, unlike the 
images shown in (a) (Bloth & Svehag, 1971). (d) dlgA from (i) humans and (ii) 
mouse have similar overall double-Y structures. The scale bar represents 20 nm 
(Munn et al., 1971). In (a) and (c) the SlgA preparations were obtained from 
colostrum and in (a-d) dlgA preparations were purified from human myeloma 
serum.
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Figure 1.10 Schematic structure of dimeric/secretory' IgA
dlgA is formed when two IgA monomers dimerise via covalently binding to J 
chain. When secretory component (SC) is covalently bound to dlgA (dashed 
line), SlgA is formed. Two IgA monomers are shown, with heavy chains (blue), 
light chains (red), O-linked carbohydrates (open circles), N-linked carbohydrates 
(filled circles) and inter-chain disulphide bonds (X) highlighted. The cysteine 
residues involved in disulphide bonds formation between IgA -  J chain and IgA 
-  SC are shown.
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chain would have a linear structure that could contact all heavy chains in the Ab 
polymer (Morrison & Koshland, 1972). The structure of the J chain is still 
controversial, and considering its importance in Ab polymerisation 
comparatively little is known about the three-dimensional structure of J chain.
This may be due to difficulties in purifying J chain and ensuring its correct 
folding, as it is co-expressed with and covalently bound to Ab structures. Two 
models have been proposed. The first is a two-domain J chain model (Cann et 
al., 1982) and the second is a one-domain, eight stranded P-barrel structure based 
on circular-dichrosim measurements (Zikan et a l , 1985). Three intra-chain disulphide 
bonds have been identified and characterised in J chain, with pairing between 
Cysl2 to CyslOO, Cys71 to Cys91 and Cysl98 to Cysl33 (Frutiger et a l, 1992).
Both models do not account for this disulphide bonds pairing. Therefore, two 
more models have since been proposed with consideration of the correct 
disulphide bond pairing (Frutiger et a l, 1992; Johansen et a l, 2001).
The J chain has been characterized in a range o f species including human 
(Johansen et a l, 1999; Max et al, 1985; Bhown, 1977), mouse (Matsuuchi, et 
a l, 1986), bovine (Kulseth & Rogne, 1994), rabbit (Hughes et a l, 1990), 
brushtail possum (Adamski & Demmer, 1991), chicken (Takahashi et a l, 1999), 
turtle (Iwata et a l, 2002), Frog, (Xenopus laevis (Hohman et a l, 1997) and Rana 
catesbeiana (Hohman & Steiner, 2000), nurse shark (Hohman et a l, 2003) and 
skate (Cannon et a l, 2002). High sequence identity between species is evident, 
and the J chains from mammals, birds and amphibians are able to induce 
polymerisation o f human IgA (Braathen, 2007; Johansen et a l, 2001).
The J chain not only permits the polymerisation of IgA, it is also essential 
in the binding interaction between secretory component (SC) and dlgA, through 
it C-terminal region, which shows particularly high sequence similarity between 
species (Braathen 2007, Johansen et a l, 2001). This therefore gives plgR/SC its 
selectivity in only binding polymerised Abs for transportation into the lumen 
(Brandtzaeg, 1975). These oligomeric Abs are so large and protected by SC that 
they stand a greater chance o f resisting proteolytic degradation in the harsh 
environment o f secretions than monomeric Abs would.
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1.4 Secretory IgA
The mucosal surfaces are the largest surface area of the human body in 
contact with environmental Ags. Consequently, mucosal surfaces are 
permanently exposed to foreign Ags and are a major entry point for pathogens, 
and therefore they must be efficiently protected (Lamm, 1997). In response to 
this threat, one o f the first lines o f defence of the mucosal immune system is 
SlgA, where SlgA exerts its function of Ag neutralization and clearance (Nagler- 
Anderson, 2001). SlgA also acts to restrict the indigenous commensal bacterial 
populations to the lumen (Macpherson & Harris, 2004).
1.4.1 Formation and secretion o f SlgA
IgA is produced in mucosal surfaces locally as polymeric IgA (plgA), 
which consists of (usually) dlgA, or higher oligomeric forms of IgA, with the 
IgA monomers bound covalently via the J chain (Johansen et al., 2001; Figure
1.10). In secretions, the IgAl and IgA2 subclasses form (usually) homodimeric 
or homo-oligomeric macromolecules. Secretory IgA (SlgA) is a large 
macromolecule, with a molecular mass o f -425 kDa.
The human polymeric Ig receptor (plgR) functions as a receptor for all 
polymeric forms o f IgA, as well as pentameric IgM. The plgR mediates their 
transport across the mucosal epithelium into external body fluids (Brandtzaeg & 
Prydz, 1984; Phalipon & Corthesy, 2003).
plgR is synthesised as an integral membrane protein in the rough 
endoplasmic reticulum where it is post-translationally modified by the addition 
o f seven N-linked oligosaccharides (Figure 1.11; Figure 1.12). plgR then travels 
to the Golgi apparatus. At the trans-Golgi network, plgR is sorted into vesicles 
that deliver it to the basolateral surface o f the epithelial cell. At the epithelial 
cell-surface, plgR can bind to dlgA that is locally produced by plasma cells, most 
commonly found in the lamina propria underlying the epithelium (Mostov, 
1994). The plgR and bound dlgA are then transcytosed across the cell (Figure
1.11). Firstly, the plgR-dlgA complex is endocytosed and delivered to 
endosomes, where the receptor and its ligand move through a series of 
endocytotic and transcytotic vesicles. At the apical membrane, a currently 
uncharacterised enzyme cleaves the extracellular domains o f plgR. This
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Figure 1.11 Transportation of dlgA across the epithelial lining and 
formation of SlgA
(1) dlgA in the lamina propria binds to the pigR. The complex is transcytosed 
across the cell. The five extracellular domains o f pigR are cleaved and become 
SC. SC remains bound to dlgA to form SlgA. (2) The pigR can be transcytosed 
across the cell without being bound to its ligand dlgA, to release free SC into the 
lumen.
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Figure 1.12 Structure and sequence of the polymeric immunoglobulin 
receptor
(a,b) SC (black) is composed of the first 585 residues of pigR, after the post- 
translational removal o f the 18-residue signal peptide (pink). SC is formed after 
the cleavage o f the five extracellular domains o f pigR at the apical membrane of 
mucosal epithelial cells (Figure 1.11). The five extracellular domains o f pigR 
are labelled D1 to D5. The lengths o f inter-domains linkers (bracketed numbers 
in (a) and grey in (b)), transmembrane region (blue), cytoplasmic tail (red) and 
seven N-linked glycosylation sites (inverted Y in (a) and yellow in (b)) o f pigR 
are highlighted. The extracellular portion of pigR that is not part of SC is shown 
in green.
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extracellular, ligand-binding portion o f pigR remains bound to dlgA, and SlgA is 
released into the mucosal lumen. The extracellular portion o f pigR is now termed 
SC (Figure 1.11; Figure 1.12). Free SC is also present in secretions, where the 
pigR has been transcytosed across the epithelial lining in a dlgA-unbound, free 
state (2 in Figure 1.11). The presence o f minimal amounts of IgG at mucosal 
surfaces is thought to be due to passive transport or epithelial leakage, rather than 
through active transcytosis via SC (Table 1.2; Heremans, 1974).
In contrast to the electron micrographs obtained for dlgA (Section 1.3.3), 
EM analysis o f SlgA first showed it to have a similar structure to monomeric IgA 
with the two monomers on top of each other (Figure 1.9a; Svehag & Bloth, 
1970). However, later micrographs o f SlgA published by the same authors then 
showed SlgA to have a similar structure to that of dlgA, suggesting that the 
presence o f SC does not disrupt the arrangement of the IgA monomers (Figure 
1.9.c; Bloth & Svehag, 1971). The reason for the discrepancy in the SlgA 
structure was due to two different staining techniques being employed. This is an 
indication of the difficulty involved in determining macromolecule structures by 
electron microscopy (Section 2.1.1). EM also suggested that the shorter hinge 
increases the rigidity o f IgA2 in comparison to IgAl, with little independent Fab 
movement relative to the Fc region (Roux et al., 1998).
1.4.2 Secretory component / polymeric immunoglobulin receptor
SC is a glycoprotein consisting of five Ig variable-type domains (D1-D5) 
to which up to seven carbohydrate chains are attached (Figure 1.12) that account 
for 15-25% of its total molecular mass (Cleveland et a l , 1991). SC comprises 
the first 585 residues in pigR (Figure 1.12; Hughes et al., 1997). SC ensures the 
correct localisation of SlgA in mucosal linings for it to carry out its effector 
functions. SC bound to dlgA confers protection o f the Ab to acid and proteolytic 
digestion (Crottet & Corthesy, 1998), and governs mucus anchoring o f SlgA at 
mucosal surfaces (Phalipon et al., 2002). The specificity o f the pigR for only 
polymeric Abs ensures that only those large enough and capable o f withstanding 
the harsh environment of the mucosa are delivered there.
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1.4.2.1 Structure of SC domains and their interaction with SlgA
Despite the importance of SC and its glycosylation in many biological 
and immunological processes, only partial information is available on its 
structure. Homology modelling of rabbit SC domains 1 and 2 (D1 and D2) 
indicates that both domains exhibit the typical features o f Ig variable (V)-type 
superfamily members,consisting of seven p-strands, A-G and an extra two 
designated C’ and C”  connected by loops o f variable sizes (Williams & Barclay, 
1988; Coyne et al., 1994; Corthesy et al., 1996; Section 1.2.2; Figure 1.5). A 
similar spatial arrangement was determined in the homology modelling of 
domains D2 and D3 of mouse SC (Crottet et a l, 1999). These studies were 
confirmed by the crystal structure of D1 o f human SC, which revealed a V-type 
fold (Hamburger et al., 2004; Figure 1.13). Three CDR are evident at one end of 
SCD1 (Figure 1.13).
SC binds to dlgA with a 1:1 stoichiometry (Crotett & Corthesy, 1999). 
SC D1 contains the three CDR, which are thought to contribute to the initial 
binding o f SC to dlgA (Frutiger et al 1986; Bakos et al.. 1991b). D2 and D3 are 
known to be necessary in SlgA formation, yet do not establish close contact with 
the dlgA backbone (Crotett & Corthesy, 1999). D5 contains Cys502, which is the 
covalent binding site to Cys311 in one monomer in dlgA (Figure 1.10; Figure 
1.12; Fallgreen-Gebauer et al., 1993). It is thought that the initial contact of D1 
with the dimer triggers a ‘zipper effect’, wrhere contact between SC and dlgA 
moves from D1 down the domains to bring D5 into correct alignment for 
disulphide bond formation (Bakos et al., 1991b; Crotett & Corthesy, 1999). The 
binding between SC and dlgA also involves the J chain (Johanson et al., 2001). 
The glycosylation o f SC is not thought to be relevant to its binding to dimeric 
IgA (Bakos et al., 1991b). Instead, the carbohydrates on SC give it its own 
immunogenic role and protection to itself and SlgA (Perrier et al., 2006). The 
binding o f SC to the different SlgA isotypes may differ, with SC covalently 
binding to SIgAl yet interacting with SIgA2 in a non-covalent manner only 
(Almogren et al., 2007).
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Figure 1.13 Cry stal structure of secretory’ component domain one
The crystal structure of SC domain one (D l) at 0.19 nm is shown (PDB 1XED; 
Hamburger et a l, 2004). The P-strands (red), alpha helices (blue), loop regions 
(white), N- and C-terminals and complementarity determining regions (CDRs) 
are highlighted. The p-strands are labelled in (a) and the D l is orientated to show 
the DEB A face to the front. In (b) D l has been rotated 90° on the X-axis in 
respect to (a).
CDRII
CDRIII
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1.4.2.2 Functions of free SC
SC is present in secretions in a free form (for example at concentrations 
up to 25 pM in human milk). As well as having a defined role in the transport, 
protection and anchoring of IgA in mucosal surfaces, SC also has strong bacterial 
scavenging properties. Free SC is an active antibacterial participant in the 
protection of mucosal surfaces. It has been shown to bind to Helicobacter pylori 
(Boren et al., 1993) and limit its adhesion to hamster brush-borders. SC also 
binds to enteropathogenic Escherichia coli, Clostridium difficile toxin A (Dallas 
& Rolfe, 1998) and Streptococcus pneumoniae choline binding protein A (cbpA) 
(Lu et al., 2003; Elm et al., 2004). The neutralising properties of SC have been 
shown to rely on the presence of the oligosaccharides on SC, particularly the 
terminal galactose and sialic acid residues. The carbohydrate chains are thought 
to be exposed when SC is bound to dlgA, as SlgA with no antigenic specificity 
for cpbA can still protect the epithelial cells from the action o f the toxin (Perrier 
et al., 2006). SC therefore confers further Ag-binding sites in addition to the four 
CDRs in SlgA, making the Ab more antigenically-active and bridging the 
distinction between innate and adaptive immunity.
1.4.2.3 Human breast milk and colostrum
Human colostrum and milk are important sources of nutritional and 
immunological requirements for the neonate. Colostrum is an inital form of 
breast milk that is produced in the first few days after giving birth, and contains 
high concentrations o f nutrients, including SlgA and other immune system 
components to help protect the neonate and the lactating mammary glands from 
pathogenic microorganisms. Unlike other external secretions, human milk 
contains viable leukocytes found at highest concentrations in colostrum 
(Brandtzaeg, 1983). Human milk contains a complex mixture o f aqueous and 
cellular components. The aqueous components include SlgA, free SC, 
lactoferrin, casein, a-lactalbumin and lactose. The presence of SlgA and free SC 
in colostrum and milk are an example o f the combination of adaptive and innate 
immune system working together for maximum effectiveness. The mother 
therefore provides the neonate with adaptive immune system components and
therefore Ag-specificity through SlgA, as well as though the delivery o f IgG 
across the placenta to the foetus (Figure 1.3).
1.4.3 IgM as an accessory secretory immunoglobulin
Pentameric IgM can be present in external secretions with an accessory 
role as a secretory immunoglobulin. This suggests that SC has a generic Ab- 
binding ability, being able to bind to both dlgA and polymeric IgM (Mach, 
1970). The J chain may confer this generic polymeric Ab-binding ability to SC, 
as the J chain is known to contribute to the SC binding site on polymeric 
immunoglobulins, and may give SC its selectivity in only binding those 
immunoglobulins that are polymerised and ready for transportation into the 
lumen (Brandtzaeg, 1975). This selectivity may be required to only permit larger, 
polymerised Abs, with protection in the form of heavily glycosylated SC, to enter 
the harsh environment of external secretions. Smaller, monomeric 
immunoglobulins would be readily subjected to proteolysis and would 
consequently be unable to fulfil their role o f pathogen exclusion.
1.5 Mucosal immunity and the SlgA response
The mucosal surfaces in the human body, including the gastrointestinal, 
respiratory and urogenital tracts represent around 400 m2. Mucosal surfaces are 
therefore the largest surface area in the human body in contact with the external 
environment (compared with 1.8 m2 for skin) (Childers et al., 1989). Pathogenic 
microorganisms and their potentially toxic products and antigens present in 
ingested food and inhaled air provide a constant threat to mucosal surfaces.
Mucosal surfaces possess powerful specific and non-specific defence 
mechanisms to prevent the entry of pathogens and exogenous materials invading 
the human body and to maintain local homeostasis. Mucosal surfaces have 
physical and mechanical barriers, such as a wall of epithelial cells, mucus and 
peristalsis. Also, the action of Abs, mucosal-associated lymphoid tissue (MALT), 
immunoreactive cells present in mucosal tissue and the populations of 
commensal microbiota all contribute to mucosal immunity (Corthesy, 2007). 
SlgA is the principle Ab class produced in the mucosal tissues (Mestecky & 
McGhee, 1987), with a total daily synthesis o f IgA around 66 mg/kg representing
39
more than 60% of the total immunoglobulin produced (Childers et al., 1989). 
Fine-tuning of all these effector mechanisms regulate the immune responses, oral 
tolerance and immune ignorance, to optimise the specific immune response and 
prevent local tissue damage.
1.5.1 Mucosal Associated Lymphreticular Tissue (MALT)
The mucosal immune system is considered distinct from the systemic 
humoral immune system that protects the rest of the human body. This concept 
was first proposed after the analysis of the immune system of rodents in 1919. It 
was shown that rabbits, which had been orally immunised with denatured 
Shigellae, were protected against fatal dysentery regardless o f serum Abs. In the 
1930s, this concept was supported after the identification that the upper 
respiratory tract was also part of the mucosal system (Mestecky et al. 1999). This 
has since been confirmed in humans.
The mucosal immune system is composed of mucosal-associated 
lymphoid tissue (MALT), which includes the gut-associated lymphoid tissues 
(GALT) and the bronchial-associated lymphoid tissues (BALT) (Mestecky & 
McGhee, 1987). Collectively, MALT is organised lymphoid tissue that contains 
lymphocytes necessary to protect the mucosal immune system from all Ags.
GALT is one o f the most intensively studied mucosal membranes. GALT 
is a highly evolved system that not only protects the host from ingested 
pathogens, but it has also developed mechanisms to prevent the host from 
reacting against ingested proteins and itself (Weiner et al., 1994). Organisation o f 
some o f the components o f GALT is shown in Figure 1.14. A specialised region 
of cells, called Peyer’s patches (PP) are located in the submucosal layer of the 
gastrointestinal tract. In humans, they are described as macroscopic lymphoid 
aggregates that can be seen by the naked eye on the serosal side of the small 
intestine, with the greatest intensity in the ileum. PP contain clusters of 
lymphocytes, and are surrounded by microfold (M) cells. M cells differ from 
normal epithelial cells in that they are flatter, lack microvilli and have large 
invaginations o f the basolateral membrane to form pockets. Lymphocytes are 
present in these M cell pockets, including B cells, T cells and APCs such as 
dendritic cells (DC) and macrophages.
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Figure 1.14 Antigen processing and mucosal immune response induction
(1) Pathogens enter a Peyer’s patch (PP) via M cells, where they are processed 
by immature dendritic cells (DC) in the sub-epithelial dome (SED) region. (2) 
Intraepithelial DC can also directly contact and process Ag. (3) T cells in 
lymphoid follicles are then activated. (4) B cells are activated by cytokines 
released by the T cells and (5) differentiate to mature B cells whilst circulating 
the body in the lymph fluid and the blood stream. (6) Most of the activated B 
cells return to effector sites, while (7) some migrate to systemic immune system 
organs. (6) In GALT, activated B cells preferentially express IgA by class- 
switching their heavy chain Ig gene from IgM. (8) Plasma cells in the lamina 
propria produce plgA to be transported across the epithelial cells for release into 
the lumen as SlgA to bind to and remove the Ag.
1.5.2 The role o f SlgA in mucosal defence
IgA responses have been found to be localised in specially adapted areas, 
including PP, solitary lymph nodes, the lamina propria and intraepithelial 
lymphocytes, the appendix and cecal patches (Childers et al., 1989; Murakami & 
Honjo, 1995). The production and transportation of SlgA is a major 
physiological investment, as the human intestine alone receives between 3g and 
5g of SlgA each day, demonstrating the biological significance o f this system.
SlgA is expressed and secreted by B cells. B cells in the gut preferentially 
express the a-heavy chain, therefore they secrete IgA (Section 1.2.4). It is 
thought that the presence o f Th2 cells producing specific growth factors and 
cytokines, including transforming growth factor p (TGFP), IL-4, IL-5 and IL-10, 
activate B cells and induce class switching from IgM to IgA (Whitmore, 1992; 
Brandtzaeg & Johansen, 2005). These Tr2 cells principally reside in the lamina 
propria. More than 80% of the human body’s activated B cell population is 
located in the gut (Brandtzaeg et al., 2001). The human gastrointestinal tract 
produces more total immunoglobulins than other immune system organs, 
including the bone marrow, the spleen and the lymph nodes.
A schematic version of some of the processes involved in activating B 
cells and triggering a specific SlgA response is shown in Figure 1.14. GALT 
exhibits the ability to endocytose Ags from the lumen, through M cells. M cells 
can phagocytose a luminal pathogen and then active APCs, such as DC, to 
generate an immune response against that Ag. DC are present in the sub- 
epithelial dome (SED) to sample Ag from the lumen, and control the activation 
o f naive T cells present in lymphoid follicles in PP. DC can also directly carry 
out Ag processing and presentation, by extending dendrites between epithelial 
cells to directly contact and capture Ag in the lumen. Activated B and T cells 
then emigrate from the inductive environment via the lymphatic system, and 
circulate in the lymph fluid and the bloodstream. Activated B cells travel to 
effector sites, represented by the lamina propria. During this migration, B cells 
differentiate to IgA-producing B cells, through class switching o f the Ab heavy 
chain (Section 1.2.4). SlgA can then be secreted with the capability of 
specifically recognising and eliminating the Ag, after its trancytosis across the 
epithelial cell into the lumen (Section 1.4.1; Figure 1.11; Corthesy, 2007).
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Once in the mucosal lumen, SlgA can bind Ag and then can adhere to the 
apical surface of M cells. The IgA-receptor complex is then endocytosed, as seen 
by gold-coated luminal SlgA molecules being present in the pockets o f M cells 
(Weltzin et al., 1989). The endocytosis o f SlgA by M cells is one of the main 
routes to deliver pathogens to mucosal immune system inductive sites (Figure
1.14). SlgA is thought to bind to M cells by interacting with a currently 
undefined receptor on the M cell surface, which is thought to bind the SlgA ChI 
and Ch2 domains and/or the hinge region (Mantis et a l , 2002).
SlgA also prevents pathogens invading the mucosa by ‘immune 
exclusion’, where SlgA prevents the attachment and penetration of 
microorganisms rather than their ultimate destruction. The four or more Ag- 
binding sites on SlgA block any adherence-determinants on the pathogen and 
facilitate their removal through muco-cilary flow or peristalsis. The presence of 
SC and the carbohydrate moieties are thought to be important in their anchorage 
to mucosal surfaces (Phalipon et al., 2003; Perrier et al., 2006).
1.5.3 Mucosal microflora and SlgA in mucosal tolerance
The tracts o f the human body, particularly the proximal and distal 
portions, are continuously colonised by commensal organisms. While the 
presence of commensal bacteria generally prevents the colonisation of pathogens 
through competitive exclusion, they represent an enormous antigenic-challenge 
to the mucosal immune system. Mucosal or oral tolerance is the down-regulation, 
hypo-responsiveness or suppression o f immune effector cell responses to an Ag 
after prior administration of the Ag by the same route. Mucosal tolerance is also 
important in the discrimination of self from non-self, as if the immune system 
reacted against self, an autoimmune disease would result. IgA and other immune 
responses to commensal bacteria are down-regulated by mechanisms such as 
clonal anergy o f B and T cell populations and the secretion of suppressive 
cytokines (Weiner, 1994). It is thought that IgA may prevent immune responses 
by excluding mucosal Ags from tissues. Mice with no pigR (therefore 
significantly decreased levels of mucosal IgA) showed signs of mucosal 
inflammation from unnecessary triggering o f systemic immunity against 
innocuous Ag and indigenous bacterial flora, as mucosal tolerance could not be
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initiated (Johansen et al., 1999). The lack of mucosal tolerance in thought to be a 
significant immunopathogenic mechanism in inflammatory diseases, such as 
celiac disease and irritable bowel syndromes. The GALT therefore cannot be 
used as the site of immunisation for vaccinations, as mucosal tolerance can be 
naturally generated (Weiner, 1994).
1.6 IgA receptors
The IgA receptor family consists o f a number of cell-surface receptors, 
including the pigR (Section 1.4.2), the IgA Fc receptor (FcaRI or CD89) (Figure
1.15) and the Fca/pR. At least two other IgA receptors have been identified, 
including the asialoglycoprotein receptor and the transferrin receptor.
Fc receptors (FcR) belong to the immunoreceptor family, which includes 
T-cell, B cell and NK receptors. FcR are present on many immune system cell 
types and they provide a crucial link between the humoral and cell-mediated 
branches o f the immune system. FcR are transmembrane receptors that recognise 
the Fc region o f immunoglobulins. FcR for all five-antibody classes have been 
described. The interaction between Abs and their FcR provides Ag-specific 
recognition to cells that express the specific FcR. Therefore, through this Fc-FcR 
interaction a variety o f responses can be initiated, including endocytosis, 
exocytosis, transcytosis, respiratory bursts, degranulation, antibody-dependent 
cell cytotoxicity (ADCC), cytokine release, superoxide generation and 
phagocytosis (Monteiro & van de Winkle, 2003).
1.6.1 IgA Fca receptor
IgA induces immune effector functions by binding to and activating the 
IgA-specific receptor IgA Fca receptor I (FcaRI, also called CD89). FcaRI is 
present on many immune cell types, including monocytes, neutrophils, 
macrophages, intestinal dendritic cells and eosinophils (Kerr & Woof, 1999). It is 
estimated that FcaRI-expressing cells contain between 6000 and 7000 molecules 
of the receptor per cell (Morton et al., 1996).
The FcaRI is a transmembrane glycoprotein. In its mature form (after the 
removal of the 21-residue signal peptide), FcaRI consists of 266 amino acids,
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Figure 1.15 Interaction betw een the Fc regions of IgA and FcaRI
The Dl and D2 ectodomains of the FcaRI (pink), Ch2 and Ch3 IgAl Fc domains 
(blue), asparagine residues constituting N-linked carbohydrate sites (green) are 
shown (PDB 1OW0; Herr et al., 2003b). (a) The regions involved in Fc-FcaRI 
interactions are black (FcaRI) and purple (IgA Fc). (b,c) The residues involved 
in Fc-FcaRI interactions are shown (sticks), where light blue residues constitute 
the hydrophobic core, and the charged residues flanking are shown in orange.
45
with a predicted protein molecular mass o f around 30 kDa. However, due to 
differential glycosylation, FcaRI has a molecular mass between 55 and 75 kDa 
(Morton et a l ,  1996). The 206-residue FcaRI extracellular portion contains two 
Ig-like domains at an angle of approximately 90° to one another, with four N- 
linked glycosylation sites (Figure 1.15). FcaRI has a 19-residue hydrophobic 
transmembrane region followed by a 41-reside cytoplasmic tail, involved in 
signal transduction and interaction with the cells cytoskeleton (Herr et al., 2003a; 
Herr et a l ,  2003b; Figure 1.15).
FcaRI does not discriminate between the IgA subclasses or serum, 
secretory, monomeric or polymeric forms of IgA (Stewart & Kerr, 1990). In all 
forms, IgA subclasses bind to the FcaRI, triggering effector responses such as 
phagocytosis, ADCC and specific cytokine release. FcaRI has a higher avidity 
for polymeric IgA forms than monomeric IgA (Mazengera & Kerr, 1990; 
Monteiro et a l ,  2002). The ability for dlgA and SlgA to bind to the FcaRI 
suggests that the presence of the J chain and SC does not obstruct or alter the 
FcaRI binding site on IgA Fc. SlgA binding to the FcaRI suggests it can 
successfully act as an opsonin, triggering phagocytosis on mucosal surfaces 
(Gorteref a/., 1987).
The FcaRI is a low-affinity receptor for monomeric IgA, with a Ka of 
approximately 106 M '1. It has been suggested that monomeric IgA binds only 
transiently to FcaRI, whereas IgA in an immune complex, IgA aggregates or 
higher polymeric IgA forms bind more efficiently (Wines et a l,  1999; Stewart & 
Kerr, 1990). Also, monomeric IgA dissociates more rapidly from the receptor 
than dlgA, altering the effects and signalling potency from the two IgA forms 
(Oortwijn, et a l ,  2007).
The stoichiometry o f FcaRI binding to monomeric IgA is a 2:1 complex, 
where 2  receptors bind to each C h2 - C h3 heavy chain in the Fc region (Figure 
1.15; Herr et a l ,  2003a). The crystal structure of human FcaRI ectodomain alone 
and in complex with an IgAl Fc region has been determined at 0.30 nm and 0.31 
nm respectively (PDB code lOVZ and 1OW0; Herr et a l ,  2003b). The binding 
interaction includes hydrophobic resides forming a hydrophobic core, which is 
flanked by charged residues, in IgAl Fc and the FcaRI (Figure 1.15). It has 
been shown that IgA carbohydrates do not participate in the interaction with its
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FcaRI, as the absence o f the IgA N-linked carbohydrates in the Ch2 constructs 
does not impede it binding to FcaRI on neutrophils (Mattu et a l,  1998; Herr et 
a l, 2003b). However, the carbohydrate moiety attached to FcaRI at Asp58 is 
involved in the IgAFc- FcaRI interaction, forming two hydrogen bonds and van 
der waals contacts with the IgA Fc (Herr et a l ,  2003b).
FcaRI is expressed either associated, or non-associated with a signalling 
receptor, called FcR y-chain, which contains an immunoreceptor tyrosine-based 
activation m otif (ITAM). Little is known about the residues involved in the 
interaction o f FcaRI with FcR y-chain, yet they are known to interact strongly 
and signal via tyrosine kinases Lyn, Syk and Btk (Guile et a l ,  1998; Launay et 
a l,  1998). When present together, the FcaRI signalling through ITAM is a 
mechanism by which FcaRI can carry out cellular functions such as calcium 
release, 11-2 secretion, degranulation or IgA degradation (Monterio & van de 
Winkel, 2003). FcaRI has been implicated in the pathogenesis o f IgAN 
(Monteiro et a l , 2002). A soluble form of the FcaRI with a molecular mass of 
around 30 kDa has been identified in human serum. The soluble FcaRI can 
covalently link to plgA (van de Boog et a l ,  2002). This soluble form of FcaRI 
may therefore contribute to IgA aggregation in IgAN mesangial deposits (Section
1.7.2).
1.6.2 IgA Fca/p  receptor
A 503-residue mouse Fca/p  receptor (Fca/pR) has been described, which 
contains one extracellular domain and four potential N-linked glycosylation sites. 
A human homologue has also been identified from sequence similarities, with the 
ability to bind both IgA and IgM (Monteiro & van de Winkle, 2003). The Fca/p  
receptor on B-cells and macrophages internalises IgM and IgM-coated microbes, 
and is thought to play a role in the primary stagess o f an antimicobial immune 
responses after B cell stimulation (Shibuya et a l ,  2000). Also, Fccc/pR mRNA 
transcripts have been shown to be present in human mesangial cells, suggesting 
that this receptor may be implicated in the pathology o f IgAN (McDonald et a l, 
2002; Section 1.7.2).
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1.6.3 Secretory component receptor
Secretory component receptor (SCR) binds SC and SlgA but not serum 
IgA. SCR is expressed on eosinophils and basophils and has a molecular mass of 
15 kDa. The binding of SC or SlgA to SCR is thought to trigger degranulation 
and the release of eosinophil cationic protein and peroxidase. Therefore, as well 
as FcaRI, SCR is another receptor involved in mucosal immunity specific for 
SlgA, which may facilitate the potency of SlgA to trigger eosinophil 
degranulation (Lamkhioued et al., 1995).
1.6.4 Transferrin receptor
Transferrin receptor (TfR or CD71) is involved in cellular iron 
metabolism. TfR is expressed on a wide range of tissues, including renal 
mesangial cells. A second isoform of this receptor have been identified (TfR2), 
which has only been identified on liver and erythroid cells (Vogt et al., 2003; 
Decot et al., 2005). TfR has been identified unexpectedly as an IgA receptor, 
where it selectively binds IgAl and preferentially monomeric IgAl over 
polymeric IgAl or SIgAl. This selectivity o f TfR for IgAl may be through the 
unique O-linked carbohydrates on the IgAl hinge region (Moura et al., 2001). 
The O-linked carbohydrate moieties on the IgAl hinge are thought to be altered 
on the IgA molecules in IgAN deposits (Section 1.7.2). Nevertheless, TfR is 
thought to be one o f the receptors responsible for binding IgAl, leading to the 
IgA-depositions in the kidney in IgAN (Moura et al., 2005).
1.6.5 Asialoglycoprotein receptor
The liver is known to play an important role in maintaining IgA 
homeostasis, principally through the regulation o f IgA catabolism. The 
asialoglycoprotein receptor (ASGP-R) is expressed on hepatocytes. ASGP-R 
recognises terminal galactose residues in carbohydrate moieties on serum 
glycoproteins, including IgA. Liver IgA catabolism may involve ASGP-R, as 
ASGP-R is proposed to be involved in IgA clearance from circulation (Stockert, 
1995). The major clearance pathway for the IgA2 isotype is mediated by 
hepatocytes ASGP-R, whereas only a small percentage of IgAl is cleared via this 
pathway and receptor (Rifai et al., 2000). This may explain the higher proportion
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of IgAl in blood serum relative to IgA2, and may be involved in elevating serum 
IgAl levels in IgAN.
1.7 Immunoglobulin A in disease
1.7.1 Selective IgA deficiency
More IgA is produced than all the other antibody classes combined, yet 
remarkably, many individuals with IgA deficiency, the most prevalent 
immunodeficiency of all, remain relatively healthy. The prevalence of IgA 
deficiency ranges from 1:223 to 1:1000 (Hanson, 1983), and is characterised as 
undetectable serum IgA levels in the presence o f normal serum levels o f IgG and 
IgM. IgA deficiency may be familial or acquired, following the parasitic disease 
toxoplasmosis, measles, or other viral infections. Patients with IgA deficiency 
are generally asymptomatic, but show increased susceptibility to infections, 
including sinopulmonary tract infections such as pneumonia and sinusitis, and 
gastrointestinal infections, particularly celiac disease and inflammatory bowel 
disease (Cunningham-Rundles, 2001). Patients with IgA deficiency also have an 
increased chance o f developing autoimmune diseases in middle age. The lack of 
disease and symptoms in IgA deficiency is attributed to a compensatory increase 
in secretory IgM. However, although IgM is a functionally active secretory 
immunoglobulin, it is thought to be unable to confer the same mucosal protection 
as IgA (Savilahti et al., 1988). In the absence o f IgA, a significant proportion of 
patients with IgA deficiency have anti-IgA antibodies, which can lead to severe 
reactions including anaphylaxis if a blood-transfusion is attempted 
(Cunningham-Rundles, 2001).
1.7.2 IgA nephropathy
IgA nephropathy (IgAN, also known as Berger’s disease) is the most 
common form of chronic glomerulonephritis (an inflammation of the glomeruli 
o f the kidney) in the world. IgAN was first described in 1968 (Berger and 
Hinglais, 1968). Primary IgAN is characterised by mesangial depositions of IgA, 
particularly polymeric and dimeric IgAl and increased serum levels o f dlgAl 
(Barratt & Feehally, 2005). Since dlgAl is predominantly mucosally-derived, it 
was thought that the IgA deposits may arise from over-production o f mucosal
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IgA abnormally entering circulation. However, the deposited IgA is now known 
to originate in the bone marrow (Feehally & Allen, 1999).
IgAN symptoms include renal impairment, haematauria, proteinuria, 
upper respiratory tract infection and hypertension. IgAN can frequently progress 
to acute or chronic renal failure (Barratt et al., 2007). Hypercomplementemia has 
been seen in IgAN patients, with mesangial co-deposits of the complement 
components C3 and properdin (Onda et al., 2007). Also, IgA is present in 
association with MBL and C4d (Oortwijn et al., 2007). A variety o f systemic 
disorders are associated with (secondary) IgAN, including liver disease, coeliac 
disease, rheumatoid arthritis and HIV infection and AIDS. Reoccurrence of 
IgAN in patients after transplantation of a normal kidney suggests that IgAN is 
caused by an abnormality related to the structure of IgA, IgA production and/or 
an IgA receptor rather than an intrinsic abnormality o f the kidney.
Alterations in the glycosylation patterns o f IgA may be involved in the 
formation of IgA aggregation in mesangial deposits. A reduced galactose (Gal) 
and sialic acid (Neu5Ac) content, increased exposure o f N-acetylgalactosamine 
(GalNAc) and increased O-glycosylation has been identified on circulating IgAl 
in IgAN (Coppo & Amore, 2004). Exactly how the IgA molecules are incorrectly 
glycosylated is currently poorly understood. IgA with truncated O-linked 
carbohydrates may arise from a specific B cell lineage secreting the incorrectly 
glycosylated IgA into circulation (or correctly glycosylated IgA into the wrong 
area o f the human body), or abnormalities may occur in the control of IgA 
glycosylation (Barratt et al., 2007).
Deposits may also form through IgA binding to an over-expressed and/or 
abnormal receptor(s) present on the mesangial cells surface, where FcaRI, 
Fca/pR  and/or the TfR are possible candidates (Section 1.6.1; Section 1.6.2; 
Section 1.6.4). Human mesangial cells can bind IgA yet, until recently, were not 
known to express an IgA receptor. Both the Fca/pR  and the TfR receptor have 
been shown to be over-expressed in IgAN patients (McDonald et al., 2002; 
Moura et al., 2001). mRNA encoding the Fca/pR  was identified in mesangial 
cells. The receptor was found to bind to IgA and IgM, but not IgG (McDonald et 
al., 2002), suggesting the receptor-Ab interaction involves a generic binding site 
on IgA and IgM that is absent in IgG, possibly the tailpiece. However, IgAN
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deposits primarily contain dlgAl or polymeric IgA l, o f which the binding ability 
to Fca/pR  was not tested. The over-expression o f the TfR and its co-localisation 
with IgAl in mesangial cells was found to be induced by the serum of IgAN 
patients, but not healthy individuals (Moura et al., 2005).
Soluble FcaRI may be involved in the IgA aggregation leading to the IgA 
deposition in IgN. Soluble FcaRI in complex with IgA has identified in the 
serum of IgAN patients (Launay et al., 1999; Monteiro et al., 2002). However, 
such complexes have not been identified in patients with other IgA-related 
diseases. Also, soluble FcaRI has been identified in the serum healthy 
individuals with no IgA depositions characteristic in IgAN (van de Boog et al., 
2002). This suggests a combination o f altered IgA structure, glycosylation and/or 
production as well as altered IgA FcaRI may be required for IgAN development.
1.7.3 Other diseases associated with IgA
Elevated levels o f serum IgA are commonly associated with a number of 
specific diseases. The liver is thought to play an important role in the metabolism 
of IgA, through the asialoglycoprotein present on hepatocytes (Section 1.6.5), yet
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its exact function is unclear. Serum IgA concentrations are markedly increased in 
liver disease, including polymeric and secretory IgA. The cause of this increase 
in IgA levels is not known. Raised levels o f IgA, IgA-containing immune 
complexes and/or IgA rheumatoid factor are found in individuals suffering from 
alcoholic cirrhosis, HIV infection and AIDS and rheumatoid arthritis (Deviere et 
al. 1992; Grossetette et al. 1995; Otten et al. 1992; Woof & Kerr, 2006).
IgA-deficient individuals have an increased incidence o f autoimmune 
diseases, particularly associated with the gastrointestinal tract. Coeliac disease is 
a genetically predisposed, autoimmune disease afflicting the small intestine in 
individuals o f all ages. Coeliac disease is caused by an immune reaction against 
gliadin, a wheat glycoprotein. Upon exposure, gliadin is modified by 
transglutaminase and consequently an immune inflammatory reaction occurs 
(Robins & Howdle, 2005). Patients with selective IgA deficiency have at least a 
tenfold risk of coeliac disease (Collin et al., 1992). Coeliac disease is often 
associated with dermatitis herpetiformis, an IgA-mediated chronic, extremely
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itchy rash consisting of papules, which are solid, conical elevations of the skin 
(Fry, 2002).
1.8 Therapeutic uses of Immunoglobulin A
Dysregulation o f antibodies can lead to formation of autoantibodies and 
subsequently autoimmune diseases. In some cases intravenous immunoglobulins 
can be administered as replacement therapy in patients with immunodeficiencies. 
However, anaphalaxis can occur, most commonly in IgA deficiency (Pyne et al., 
2002).
IgA antibodies are a useful tool in the diagnosis of certain diseases 
affecting the gastrointestinal tract. For example, elevated levels o f serum IgA 
anti-Saccharomyces cerevisiae antibodies have been detected in patients with 
Crohn’s disease. An increase in these IgA antibodies is specific for Crohn’s 
disease, therefore their detection by screening may help towards diagnosis, as 
increased IgA production is seldom seen in other inflammatory bowel diseases 
(Barnes et al., 1990).
The pigR is a potential vehicle for biologically-active molecules or drugs 
to specifically deliver them to epithelial cells or across epithelial linings to 
mucosal surfaces. For example, a binding site thought to be on domains three 
and/or four of the pigR, which specifically binds to an 11-residue peptide has 
been identified. The peptide binding site must be distinct from the region on 
pigR that interacts with its ligands, as the peptide must not compete with dlgA or 
pentameric IgM (Braathen et al., 2006). Similarly, a therapeutic strategy has 
been considered for the treatment o f cyctic fibrosis, exploiting the plgR-mediated 
cellular route. Agents for delivery have been linked to mouse monoclonal Abs, 
raised against the extracellular domains of pigR for delivery across epithelia 
(Ferkol et al., 1995). The pigR therefore may be a promising receptor for the 
delivery o f specific drugs or gene therapy agents, to treat diseases that 
specifically affect mucosal surfaces.
SIgA-based Abs against Steptococcus mutans adhesion proteins have 
been shown to offer host protection against oral streptococcal-recolonisation, 
showing that IgA Abs may be beneficial in caries control and other oral or 
mucosal infections (Ma et al., 1998).
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In addition to surgery, chemotherapy and radiotherapy, antibody-based 
immunotherapy is a novel treatment option for some oncological patients. This 
could be through direct or indirect actions. Direct effects are mediated by the Ab 
after binding to the target in order to inhibit growth, induce apoptosis or arrest 
the cell cycle and indirect effects are mediated by the host’s immune system and 
require the Ab to interact with cellular Fc receptors or complement components 
(Dechant & Valerius, 2001). The role o f IgA as an antibody for immunotherapy 
is not well investigated, but it is thought to have many advantages over IgG, the 
currently most widely used antibody isotype for cancer therapy. For example, 
IgA in its polymeric form has an increased valency, therefore potentially 
increasing signalling capacities. Also, IgA could be utilised to attack common 
tumours o f the lung and gastrointestinal tract due to its specific delivery to the 
mucosal surfaces (Sato et al., 1997).
Chapter Two
Methods to Determine Antibody Structures
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2.1 Introduction to antibody structure determination methods
In order to understand the functions o f a protein at a molecular level, it is 
often necessary to determine its three-dimensional structure. There are many 
protein structure determination techniques that give different yet often 
complementary information about the structure o f proteins. Protein amino acid 
primary structures can be resolved directly by mass spectrometry or Edman 
degradation, or indirectly through the determination of the nucleotide sequence 
o f the protein gene or cDNA. Circular dichroism and Fourier transform infrared 
spectroscopy are two low-resolution techniques that can be employed to study 
the secondary structure of proteins by analysing their characteristic P-sheet and 
a-helix content. Electron microscopy (EM) is a low-resolution technique where 
the shape o f the proteins can be visualised directly (Section 2.1.1). Small-angle 
scattering (SAS) is a low-resolution technique that includes small-angle X-ray 
scattering (SAXS) and small-angle neutron scattering (SANS), which can resolve 
three-dimensional protein structure to a resolution of about 2-4 nm (Perkins et 
al., 2008). By coupling SAS with constrained homology modelling (Chapter 3) 
the resolution o f structural data obtained by SAS can be increased to medium 
resolution (about 1-2 nm). Analytical ultracentrifugation (AUC) is another low- 
resolution technique that obtains hydrodynamic and shape information on the 
proteins by monitoring their sedimentation behaviour with the centrifugal forces 
that are applied (Section 2.3). High-resolution protein structure determination 
methods include nuclear magnetic resonance (NMR) (Section 2.1.2) and X-ray 
crystallography (Section 2.1.3), both of which resolve protein structures to give 
structural information at an atomic coordinate level. All o f these techniques are 
often complemented by biochemical and genetic information about the protein, 
particularly information on the evolution of the proteins and protein homologues 
that have similar structures or functions. Also, all o f these techniques have pros 
and cons for the structural determination o f different proteins. The technique that 
is best suited to gain the required structural information at as high a resolution as 
possible is employed.
An antibody (Ab) is an important effector molecule of the humoral 
immune system (Section 1.2). Determination o f the structure of Abs is essential 
to further understand their specific functions in immunity and their roles in
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immune diseases. However, Abs are large, flexible and generally highly 
glycosylated molecules that can form large polymeric molecules structures or 
complexes, which makes determination o f their structure by EM, NMR or 
crystallography very difficult. In a situation such as this, SAS and AUC 
combined with constrained modelling, allows the examination o f Abs in near- 
physiological conditions to result in an Ab solution structure of medium 
resolution. By this approach, important structural information is revealed, which 
paves the way for a better understanding of the biological roles of Abs in the 
human immune system.
2.1.1 Electron microscopy
EM is a similar technique to light microscopy, yet uses an electron beam 
in order to visualise the shape of protein molecules. EM has a greater 
magnification and resolving power than light microscopy, yet the high level of 
radiation can potentially damage the biological sample. EM provides low- 
resolution structural details, and a low signal to noise ratio means that the 
information from many macromolecules must be combined and averaged. In a 
typioal solution, protein molecules are not ordered but may exist in several 
conformations or views. This is particularly true for Ab samples, where the hinge 
regions and tailpieces increase molecular flexibility. Protein samples are 
visualised in vacuo. It is often necessary to process the protein samples to 
successfully visualise the protein structure. Protein fixation and staining 
techniques can damage or distort the protein structure, altering its three- 
dimensional arrangement from its native conformation in physiological 
conditions. Determinations of the site o f interaction between proteins or the 
structures of multiple proteins within a complex are difficult to determine by EM 
and this is exemplified by the two EM structures for SlgA (Figure 1.9; Svehag & 
Bloth, 1970; Bloth & Svehag, 1971).
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2.1.2 Nuclear Magnetic Resonance
NMR can provide information on the topology, dynamics and three- 
dimensional structure of molecules in solution by utilising the magnetic 
properties o f certain nuclei: !H, ljC and 15N. NMR experiments apply magnetic 
fields at different frequencies to labelled or non-labelled protein samples, and 
monitor the characteristic absorption energy of the nuclei, which may differ in 
accordance with their chemical microenvironment within the protein. The 
chemical shift is determined for each nucleus, which corresponds to the 
environment o f the nucleus. Multinuclear NMR permits the assignment o f 
chemical shifts to specific nuclei, and nuclear Overhauser effects are used to 
determine spatial restraints. This information on the nuclei allows the position of 
atoms to be assigned and models to be created for the three-dimensional structure 
o f the protein. NMR experiments study proteins in solution, and therefore these 
are often in near-physiological conditions. NMR is a good option to determine 
protein structure if  crystals cannot be formed for X-ray crystallography (Section 
2.1.3). However, structural information cannot be obtained for intact antibodies 
by NMR. Antibodies have a minimum molecular mass o f approximately 180 kDa 
(and up to 900 kDa for polymeric Abs) and NMR is most suitable for the study 
o f proteins with a maximum molecular mass of 30 kDa.
2.1.3 X-ray crystallography
X-ray crystallography is a technique that allows the individual atoms to 
be resolved by interpreting the diffraction o f X-rays from the repeating unit cells 
that constitute the crystal lattice. X-ray crystallography can give electron density 
maps at high structural resolution (0.1-0.3 nm). Protein crystals are grown, and 
exposed to a monochromatic, collimated X-ray beam. X-rays are scattered by the 
electrons within the protein, and the diffracted waves are recorded by a detector. 
The diffraction pattern depends on the phase, amplitude and frequency of the 
scattered waves. Only those waves that are in phase and constructively interfere 
with each other produce a positive beam and subsequently a diffraction spot 
(Rhodes, 2000).
The amplitude and frequency o f each wave is known from the diffraction 
pattern spots, yet the phase information is lost. This is the phase problem in 
crystallographic experiments. In order to overcome the phase problem to
57
calculate the phase o f the waves, the position o f the atoms in the crystal lattice 
and therefore create a map o f the electron density, two methods can be used. If a 
homologous protein is known and its three-dimensional structure available, a 
homology model can be created (Section 3.2). The homology model is used to 
carry out molecular replacement. The phase of the resulting molecular 
replacement model is calculated and the model is fitted to the electron density 
map. Manual fitting and computational refinement then gives a final three- 
dimensional structure at atomic resolution. Alternatively, the multiple 
isomorphous replacement method involves soaking the protein crystals in 
solutions o f heavy ions such as Hg, Pt or Au, or replacing a few atoms within the 
protein residues with heavy atoms, e.g. seleno-methionine. The strong scattering 
o f these heavy atoms alters the observed diffraction pattern o f the protein, and 
from this the phase can be determined. The protein atoms are fitted onto the 
electron density map by trial-and-error, and refined. Refinement methods 
calculate the R factor and R free values, which give the goodness-of-fit of the 
model to the electron density map (Rhodes, 2000).
Many antibody fragments have been crystallised and their three- 
dimensional structures determined to atomic resolution. However, intact Abs are 
much more difficult to crystallise. The movement between the antibody Fc and 
Fab regions, however minimal, make growing a crystal lattice o f identical 
repeating molecules hard to achieve. Also, the carbohydrates commonly present 
on Abs can increase the solubility o f the molecules and prevent crystal formation 
(Perkins & Bonner, 2008).
2.2 Solution scattering
SAS is a diffraction technique that is used to investigate the overall 
structure o f macromolecules in random orientations in solution at low-resolution 
(Glatter & Kratky, 1982; Perkins, 1988). The major strengths o f solution 
scattering are that it provides multi-parameter structural and compositional 
information on proteins that are analysed in near-physiological conditions. 
Medium-resolution protein models are produced based on the scattering data and 
known atomic structures (Perkins et al., 2008). SAS can therefore circumvent 
issues caused by the inability to crystallise the protein o f interest.
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2.2.1 Complementarity of solution scattering with other methods
SAS can be used to complement other protein structure determination 
methods. EM directly visualises macromolecules, but this occurs in vacuo and 
the proteins are subjected to processing that can be harsh and potentially alter 
their structure. Macromolecular dimensions are determined by SAS and these 
can be used to confirm those obtained by EM.
NMR does give atomic resolution structures in solution, yet it is limited 
to structures for small proteins with a molecular mass less than about 30 kDa. 
Scattering is a useful structure determination method for proteins with a 
molecular mass o f 10 lcDa or upward, with no upper limit. This means large 
molecules like Abs or macromolecular complexes can be studied by SAS.
X-ray crystallography results in atomic resolution electron density maps. 
The outcome can potentially be affected by artefacts caused by intermolecular 
contacts in the crystal or by conditions used to form the crystal such as high salt. 
SAS used in conjunction with X-ray crystallography can identify any significant 
conformational or oligomeric differences between the solution and crystal 
structure. If the protein is too large, flexible or heavily glycosylated to be 
crystallised intact, such as antibodies, and atomic structures are available for the 
constituent domains, SAS provides a medium-resolution structure when 
accompanied with constrained modelling.
AUC provides sedimentation or diffusion coefficients as a measurement 
o f macromolecular shape and can reveal sample polydispersity. The information 
obtained by AUC is independent yet complementary to the parameters obtained 
by SAS, and so both techniques can be used to confirm the findings of the other. 
As AUC can resolve sedimentation coefficients o f individual components in a 
mixture, this is a powerful supplement to SAS (Section 2.3).
2.2.2 Theory o f solution scattering
While electrons diffract X-rays, neutrons are diffracted by nuclei, yet the 
physical principles are the same in both small-angle X-ray scattering (SAXS) and 
small-angle neutron scattering (SANS) experiments.
A protein sample is irradiated with a collimated, monochromatic beam of 
X-ray or neutrons (Figure 2.1a). The scattering o f X-rays by protein molecules is 
due to the interaction o f the X-rays with electrons. Neutrons are scattered by the
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Figure 2.1 Schematic representation of a scattering experiment
(a) Scattering from two points P and Q in a protein molecule are shown (red 
circles). The scattering angle 20 and scattering vector (Q) are shown, (b) The 
accumulation o f diffraction as shown in (a) gives rise to a scattering pattern on an 
area detector shown in (b). The radial average o f the scattering pattern about the 
position of the direct main beam (masked by a beam stop) gives rise to the 
scattering curve I(Q) in reciprocal space. Fourier transformation of this to the 
P(r) curve gives real space information on the protein molecule. (Adapted from 
Pekins et al., 2008).
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nuclei o f atoms. When the sample is irradiated by X-rays of certain wavelength X 
each electron oscillates emitting or scattering electromagnetic radiation o f the 
same wavelength X. When the scattered X-rays are in phase, this is known as 
coherent interference or scattering.
The ability to analyse proteins by solution scattering is due to the 
difference between the scattering density of the solute (protein or glycoprotein) 
and the solvent (buffer). The scattering density of a protein is the sum o f its 
scattering lengths divided by molecular volume V. SAXS is based on the 
scattering of X-rays by electrons. The scattering length/ of an electron is 2.81 fin 
(or 2.81 x 10'1:1 m, the classical electron radius or Thompson scattering length). 
The X-ray scattering length o f an atom depends on the number of electrons the 
atom contains and accordingly is the atomic number multiplied by the electron 
scattering length. The atoms 12C, 14N, 160 , 31P and 32S, which are all relevant to 
glycoproteins, have/ values of 16.9 fm, 19.7 fm, 22.5 fm, 42.3 fm and 45.0 fm 
respectively (Table 2.1). The hydrogen isotopes, lH and 2H, both have the 
scattering length o f an electron of 2.81 fin. Using molecular volumes, the 
scattering densities can be calculated for the molecule and its buffer from the 
atomic Scattering lengths (Section 2.2.2.2). The X-ray scattering density of water 
is 334 e.nm° and that for proteins is between 410 e.nm'3 and 440 e.nm'3 (Table
2.2). Therefore, the X-ray protein scattering density is distinguishable from the 
scattering by the buffer as it has a higher scattering density (positive contrast; 
Section 2.2.2.3), which permits their structural analysis.
The neutron atomic scattering length b, which is equivalent to the X-ray 
scattering length /  does not show a simple relationship with the atomic number. 
SANS differs from SAXS in that neutrons interact directly with the nucleus of 
the atom, so the scattering length and therefore the contribution to the scattered 
intensity is different for the *H and 2H isotopes. The atoms 2H, 12C, 14N, 160 , 31P 
and 32S have comparable positive b values of 6.671, 6.651, 9.400, 5.804, 5.1 and 
2.847 fm respectively. However, the *H isotope has a large, negative b value of 
-3.742 fm (Table 2.1). From the molecular volume, the neutron protein scattering 
density in 2H20 becomes 40-45% 2H20, based on a scale ranging from 0% to 
100% 2H20  (Table 2.2). The large difference in the neutron scattering properties
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Atom Atomic Number /
(fm)
b
(fm)
Hydrogen ‘H 1 2.81 -3.742
2H 1 2.81 6.671
Carbon 12C 6 16.9 6.651
Nitrogen 14n 7 19.7 9.4
Oxygen “ o 8 22.5 5.8
Phosphorous 31p 15 42.3 5.1
Sulphur 32s 16 45.0 2.847
Table 2.1 Scattering lengths/ (X-rays) and b (neutrons) of biologically 
important atoms
(Taken from Perkins et al., 2008).
X-rays
(e.nm'3)
Neutrons 
(% 2H20)
h 2o 334 0
2h 2o 334 100
Lipids 310-340 13
Detergents 300-430 6-23
Proteins 410-440 40-45
Carbohydrates 490 47
DNA 590 65
RNA 600 72
Table 2.2 Scattering densities of solvents and biological macromolecules
(Adapted from Perkins, 1988).
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of the two hydrogen isotopes can be utilised in contrast variation neutron 
scattering experiments (Table 2.2; Section 2.2.2.3).
In SAXS, the effect of incoherent scattering (where the X-ray scattered 
by the electrons are out of phase) is negligible. In neutron scattering, incoherent 
scattering exists for nuclei with spin. This is significant for nuclei, where 
incoherent scattering is very large and leads to a background level of uniformly 
scattered neutrons, when the wavelength X is greater than 1 nm. When modelling 
neutron curves of proteins that were analysed in H2 O buffers, intensities at large 
Q can be affected by small background incoherent scattering so a flat- 
background correction is applied to remove it.
As a result of coherent scattering and the differences in scattering 
densities between the protein and buffer (the contrast), an intense circularly 
symmetric diffraction pattern is observed on a two-dimensional area detector at 
low scattering angles Q (Figure 2.1b). The intensity of scattering I(Q) diminishes 
as Q increases. The radially-averaged intensities I(Q) are measures as a function 
of Q, where Q = 4n sin 0 IX (X = wavelength; 20 = scattering angle). From this a 
one-dimensional wide-angle scattering curve I{Q) against Q is obtained (Figure 
2.1b; Figure 2.2). The scattering data is obtained in reciprocal space, in a Q range 
o f approximately 0.05 - 2 nm '1. The resolution of a scattering experiment is 
defined by 2nlQms^  where Qmax is the maximum scattering vector measured in the 
experiment. Classical SAS experiments view structures at a low resolution, of 
around 3 nm. The scattering curve is truncated at very low Q values due to the 
presence of the beamstop, which protects the detector and camera from the 
highest intensity of the direct main beam. At large Q values the scattering curve 
is truncated by the edge of the detector.
2.2.2.1 The Debye equation
The scattering pattern obtained by SAS is affected by the properties of the 
biological macromolecule and the spatial arrangement of scattering elements 
within the macromolecule (Perkins, 1988). The Debye equation considers both of 
these properties to calculate the I{Q) scattering curve o f the macromolecule.
The scattering for any pair o f scattering elements (electrons for X-rays 
and nuclei for neutrons) is shown in Figure 2.1a. The incident X-ray beam is
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Figure 2.2 General features of an X-ray solution scattering curve
The scattering curve is analysed in two regions. Analysis o f low Q regions gives 
the Guinier plots and the forward scattering intensity 1(0) value. Analysis of 
wide-angle region at larger Q gives more structural information. At low Q the 
scattering curve is truncated for reason of the beamstop. The scattering curve 
shown is that obtained for dlgAl (Chapter 5).
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defined by the unit vector so and is scattered from a scattering element in a 
direction denoted by the unit vector s and at scattering angle 20. Q is the 
scattering vector (s -  so), and its amplitude is 4n sinG/X. When 20 is zero the 
scattered waves scattered from all points are in phase and the intensity of 
scattering is the sum of the scattering lengths from all scattering elements. 
Therefore, at zero scattering angle the intensity of scattering 7(0) is a direct 
measurement of the molecular mass (as long as sample concentration is known).
When the scattering angle is non-zero, the intensity o f scattering is given 
by the Debye equation:
Equation 2.1 X / . ^ T p
The terms f p and f q (or bp and bq for neutrons) are the scattering lengths o f the 
electron (or nuclei) at points P and Q in the molecule and r is the distance 
between P and Q (Figure 2.1). At non-zero scattering angles, the scattered waves 
are out of phase and the Debye equation calculates the phase difference between 
each individual scatterer in the macromolecule to determine its scattering curve 
7 (0 . However, the Debye equation gives the 7 ( 0  for a scattering pattern that is 
circularly symmetrical about the incident beam, therefore assuming a 
monodisperse solution of identical molecules. A limitation of the Debye equation 
is that it describes particles in vacuo. Therefore, the Debye equation is modified 
in order to consider a two-phase model of aqueous proteins in a solution.
2.22.2 The two-phase model of solution scattering
An aqueous protein solution can be considered a two-phase system 
consisting o f solute and solvent. The Debye equation is modified to consider the 
contrast Ap, which is the difference between the mean scattering density o f the 
macromolecule pv and that of its buffer ps:
Equation 2.2 Ap = pv -  ps.
The terms pv and ps are calculated from the total scattering lengths divided by the 
volume V and replace the atomic scattering lengths l f p or l,bp (Equation 2.1; 
Perkins, 1988). A compilation of the scattering densities of some solvents and 
macromolecules are given in Table 2.2.
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2.2.2.3 Contrast variation
In biology, the variations in the scattering densities of different 
macromolecules are very useful in structural analysis of complexes or internal 
structures (Table 2.2), for example, protein-DNA or protein-lipid structures.
The main difference between scattering densities of the macromolecular 
classes by SAXS and SANS is the wider range o f solvent contrast variation in the 
SANS. Neutron contrast variation using H20-2H20 encompasses the scattering 
densities of all macromolecular classes. Lipids, proteins, carbohydrates, DNA 
and RNA each have their own characteristic scattering density that reflect the 
different density o f the proton in each one so that SANS can differentiate 
between them. They all have scattering densities between that of H2 O and 2H20 
(Table 2.2). Therefore, a particular ratio o f H2 O and H2 O in buffers or 
deuteration o f a component in a complex can be carefully chosen to select the 
contrast that will reveal the most structural information o f the macromolecule. 
Due to the low amounts of non-protein macromolecules studied in this thesis, the 
neutron work presented here did not involve contrast variation experiments. 
Instead, proteins were studied in the highest solute-solvent neutron contrasts, i.e. 
100% 2H20 ,  in order to maximise the strength of the scattered radiation. X-rays 
study macromolecules in high positive solute-solvent contrast, which is the 
opposite of the high negative solute-solvent contrast of neutrons (Perkins et al., 
2008). Analysis o f both provides a control of the inhomogeneity effects caused 
by the presence o f large amounts of carbohydrate moieties.
2.2.2.4 The hydration shell
The neutron scattering properties of atoms necessitates that neutron 
experiments are performed in 100% 2H2 0  buffers in order to minimise 
incoherent scattering and obtain scattering curves comparable to those measured 
in X-ray experiments. Even under these conditions, however, small differences 
are often observed between measurements from X-ray and neutron experiments, 
and these are attributed to the hydration shell that surrounds protein molecules in 
solution. The hydration shell refers to those solvent water molecules closely 
associated with the protein by way o f hydrogen bonding. While in X-ray 
scattering experiments the hydration shell is visible, in neutron scattering 
experiments the hydration shell is present yet it is almost undetectable. The
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model of scattering by an aqueous protein solution assumes that the solute and 
solvent are discrete entities, although in reality water molecules are hydrogen 
bonded to the protein surface. A water molecule that is bonded to the surface of a 
protein is electrostricted and therefore has a smaller volume (0.0245 nm3) than a 
water molecule in the bulk solvent (0.0299 nm3) (Perkins, 1986). As a result, the 
X-ray scattering density of water molecules hydrogen-bonded to the surface of a 
protein is increased relative to that of a water molecule in the bulk solvent, 
becoming more similar to the X-ray scattering density of the protein. X-rays 
typically detect a hydration shell o f 0.3 g H2 O for each gram of protein (Perkins, 
1986). In neutron experiments the hydration shell is not visible due to the rapid 
exchange o f and 2H atoms between the hydration shell and the bulk solvent, 
giving rise to little difference in scattering densities between the two.
2.2.3 Solution scattering methods
2.2.3.1 Sample preparation
X-ray solution scattering experiments are designed according to the two- 
phase model of solution scattering, with a monodisperse protein solution in a 
buffer (Section 2.2.2.2). The choice of buffer is important since in an X-ray 
scattering experiment, the greater the difference in scattering densities between 
the buffer and protein, the higher the contrast and sample transmission, and 
therefore the better the counting statistics. X-rays can be absorbed by high-salt 
buffers, which if used can increase the background scattering. Phosphate 
buffered saline (116 mM NaCl, 10.4 mM Na2H P04, 3.2 mM NaH2P 0 4 at pH 7.2) 
was used for X-ray scattering experiments. In order to ensure that the appropriate 
corrections are made for solvent scattering, the protein samples were dialysed 
against their buffer shortly before data collection, and the scattering o f the buffer 
was then subtracted from the scattering of the protein solution. Ideally, a sample 
volume of at least 1 ml with a maximum concentration above 2 mg/ml was used 
for X-ray experiments. A concentration series, with at least four concentrations 
was used to measure the protein to ensure consistent results and that no 
concentration-dependence occurred. The concentration of a protein solution can 
be determined from its tryptophan, tyrosine and cysteine content by measuring its 
absorbance at 280 nm, and using an absorption extinction coefficient calculated 
from its amino acid and carbohydrate composition (Perkins, 1986; Section 3.3.1).
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The optical densities were measured in a UV spectrophotometer in quartz cells 
with known pathlengths. The concentration is calculated from the Beer-Lambert 
law, c =A / si, where c is the protein concentration (mg/ml), A is absorbance at 
wavelength 280 nm, s is the protein extinction coefficient (mg/ml/mm) and 1 is 
the pathlength (mm).
Samples for neutron scattering experiments were prepared similarly as for 
X-ray scattering experiments, except that PBS buffer in 100% 2H20 was used. 
Each protein sample was dialysed with stirring against the 2H20 PBS buffer for a 
minimum of 36 hours, in which time the buffer was changed four times to ensure 
full !H-2H exchange.
2.2.3.2 X-ray data collection on instrument ID02 at the ESRF
X-ray scattering experiments were performed at the European 
Synchrotron Radiation Facility (ESRF) at Grenoble, France (Figure 2.3a,b). 
Synchrotron radiation is emitted from electrons that are accelerated while 
moving at speeds close to the speed of light. Several stages are used in the 
production o f synchrotron radiation at the ESRF. Electrons are produced by a 
triode gun hnd then accelerated to 200 MeV in a linear accelerator (LINAC). The 
electrons are then transferred to a 300m circumference booster synchrotron 
where they are accelerated to 6.0 GeV. The electrons are then injected into the 
storage ring. The purpose of the 844.4 m diameter storage ring is to store the 6.0 
GeV electron beam after injection from the booster. Sixty-four bending magnets 
(BMs) are employed to force the electrons to follow a pseudo-circular orbit 
(Figure 2.3b). Insertion devices (IDs) are used to force the beam onto a 
sinusoidal trajectory, stimulating additional radiation (Figure 2.3b). As the 
electrons pass through the BMs and IDs, they lose energy and so radio-frequency 
cavities are used to maintain the energy at 6 GeV. The intensity and lifetime (the 
time the electrons can be kept in orbit for before the storage ring has to be 
refilled) o f the beam depends on the operation of the storage ring. There are two 
modes of operation. Multibunch operation involves a long pulse (1 ps) of the 
LINAC delivering 992 electron bunches to the booster ring, filling its 
circumference, where in the storage ring the electron bunches are equally 
distributed around its circumference. This has a beam intensity of 200 mA and a
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Figure 2.3 X-ray solution scattering at the ESRF
(a) Photograph of the ESRF synchrotron ring in Grenoble, (b) Schematic 
representation of the synchrotron. The linear accelerator (LINAC), booster 
synchrotron and the storage ring are shown. The SAXS beamline ID02 is 
highlighted, (b) Schematic representation of the layout of the X-ray solution 
scattering cameras at beamline ID02. (Adapted from the ESRF Web Site 
http://www. esrf.'fir).
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lifetime of approximately 60 hours. The second mode of operation is single­
bunch operation, where a short pulse (2 ns) of the LINAC only delivers one 
electron bunch to the booster and subsequently the storage ring, and the beam 
intensity is 16 mA and has a lifetime of 6  hours.
As the electrons circulate the storage ring, they emit a white-beam of 
photons that comprises all wavelengths including X-rays. The photons are 
extracted tangentially to the source and directed down the beamlines to the 
experimental stations (Figure 2.3b).
SAXS experiments were performed on station ID02 (Narayanan et al., 
2001; Panine et al., 2006). A cryogenically cooled Si-111 double crystal 
monochromates the beam and displaces it vertically by 30 mm to reduce the 
background radiation from the storage ring. The beam is then focused by an 
uncooled double-focusing toroidal mirror. Primary, secondary and guard slits 
collimate the beam (with dimensions 0.2 mm x 0.4 mm that defines the 
minimum size o f the beamstop) and reduce parasitic background scattering 
(Figure 2.3c).
The ID02 detection system is composed o f two experimental cameras 
(Figure 2.3d). A Bonse-Hart camera is used to perform ultra-low small-angle 
scattering, and was not used. The work presented in this thesis utilised the SAXS 
equipment with pin-hole camera. The detection system for SAXS experiments on 
ID02 consists o f an X-ray image intensifier lens linked to a Fast-readout Low- 
noise (FReLoN) CCD camera. The CCD camera has a resolution up to 2048 x 
2048 pixels. A dark image (with no X-ray beam exposure) and a raw scattered 
image are measured, where the dark image is then subtracted from the raw 
image. The detector is housed in a vacuum within a long detector tube on a 
movable platform so that the sample-to-detector distance can be varied between 
1 and 10 m. For the X-ray work within this thesis, the distance between the 
detector and the sample was set to 3 m so that intensities were measured to a 
maximum Q value of 2.5 nm*1. A Lupolen sample is used for the calibration of 
detector intensities (Kratky et al., 1966), and a silver salt standard (silver 
behenate) is used for the calibration of the Q range (Huang et al, 1993). The X- 
ray wavelength on ID02 is 0.1 nm.
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The protein samples were placed in a specially designed Perspex cell with 
10 to 20 pm thick ruby mica windows. The mica windows were held in place 
with Teflon plugs. The sample cell had a 1 mm path length, a surface area o f 2 
mm (vertical) by 8  mm (horizontal) and held a maximum volume of 25 pi. The 
sample cell was positioned in the X-ray beam and held in place by a brass sample 
holder which was maintained at 15°C using a water bath. Prior to data collection, 
the sample holder was manually aligned in the beam.
X-rays produce free radicals that can cause proteins to aggregate quickly. 
In order to monitor possible protein aggregation, the scattering intensity of each 
sample was measured for a set time in 1 0  equal time frames, and the first and last 
frames were inspected to check for radiation damage. The ID02 SAXS detector 
is interfaced with a computer for data accumulation, which is networked to a 
workstation for data storage and processing. The online data reduction meant that 
the collected data was converted to the one-dimensional scattering curve that 
could be almost instantly visually inspected during data acquisition.
The protein samples were measured in alternation with their respective 
buffers in order to minimise errors in the buffer subtraction calculations as the 
incident beam decreased in intensity.
2.2.3.3 Neutron data collection on Instrument LOQ at ISIS
SANS experiments were performed on the LOQ instrument at the pulsed 
neutron source at ISIS at the Rutherford Appleton Laboratory (RAL) in Didcot, 
U.K. (Heenan et al., 1997). The neutrons at ISIS are produced by a spallation 
process (Figure 2.4a) that is designed to accommodate the pulsed main neutron 
beam.
High-energy H' ions pass though a LINAC where protons are then 
produced by stripping the electrons from the H' ions using a very thin aluminium 
foil. Pulses o f protons are then accelerated in a 52 m diameter synchrotron, 
extracted and sent to the heavy metal target station (Figure 2.4a). Uranium (U) or 
tantalum (Ta) heavy metal targets are bombarded with high-energy protons, 
causing neutrons to be ‘chipped’ out of the nuclei. Moderators are used to slow 
the neutrons and increase the wavelengths. On LOQ the moderator is liquid 
hydrogen, positioned 11.1 m from the sample rack. A supermirror bender 
removes neutrons with wavelengths of less than 0 . 2  nm, while another mirror
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Figure 2.4 Neutron solution scattering at ISIS.
(a) Layout o f the target station at ISIS located at the Rutherford-Appleton 
Laboratory, Didcot (Adapted from the ISIS Web Site http://www.isis.rl.ac.uk).
(b) Schematic diagram of the LOQ diffractometer. (Taken from the Rutherford- 
Appleton Laboratory Web Site http://www.rl.ac.uk).
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removes those with wavelengths of greater than 1.2 nm. A disc chopper spinning 
at 25 Hz removes every other neutron pulse to prevent frame-overlap between 
consecutive pulses on LOQ. The chopper is set so that only wavelengths in the 
range of 0.22 to 1.00 nm are used in SANS experiments. The neutron beam has a 
diameter of 8  mm, after it has been collimated. The neutron beam is 
monochromated by the time-of-flight method based on the total distance of 15.5 
m. SANS data was measured over a Q range of 0.08 to 2.5 nm '1. No radiation 
damage effects are seen in neutron scattering, therefore SANS can be used as a 
control for SAXS.
Samples were placed in 2 mm thick rectangular quartz Hellma cells 
which were held in a motorised rack at a constant temperature of 15°C. Neutron 
scattering intensities were measured using a JHe ORDELA detector, which had 
an active area o f 64 x 64 cm and was positioned at a fixed distance of 4.3 m from 
the sample. The sample rack held multiple samples, allowing the data collection 
procedure to be automated. Scattering intensities were measured for proteins and 
their corresponding buffers. The scattering from a partially deuterated 
polystyrene standard was also always measured, and this was used to normalise 
the spectral intensities (Wignall & Bates, 1987). Neutron transmissions were 
measured for each protein sample and buffer, for the polymer standard and for an 
empty beam position, and these were also used to normalise the scattering data. 
Raw data were collected in 100 time frames and reduced using the standard ISIS 
software package COLETTE (Heenan et al, 1989).
2.2.4 Analyses of reduced scattering curves I(Q)
Measurements of the overall structure o f a protein can be determined 
from its X-ray and neutron scattering curves.
2.2.4.1 Guinier analyses
At low Q values, the Debye equation (Equation 2.1) becomes the Guinier 
approximation (Guinier & Foumet, 1955):
Equation 2.3 In I(Q) = In 1(0) -
where 7(0) is the intensity at zero Q, and Rg is the radius o f gyration which is 
defined as the root-mean-square distance of all scattering centres in the
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macromolecule from its centre o f gravity. The Rg characterises the degree o f 
elongation of the protein, and is analogous to the sedimentation coefficient from 
AUC experiments (Section 2.3). Guinier plots are only valid at low Q, in a Q.Rg 
range of up to 0.7-1.3 depending on the macromolecular shape. Intensities at the 
lowest Q cannot be measured due to the presence of the beamstop. Rg and 7(0) 
are determined ffom an experimental scattering curve by plotting In 7 ( 0  against 
Q1 to give a straight line of slope -R g I2> and intercept In 7(0).
A useful application of Rg is the calculation of the anisotropy ratio of a 
macromolecule. The anisotropy ratio is Rg/R o, where Ro is the Rg o f a sphere of 
equal volume to the macromolecule. For typical globular proteins by X-ray 
scattering, the anisotropy ratio is approximately 1.28 (Perkins, 1988). The 
anisotropy ratio standardises the Rg value by considering molecular mass (Mr), 
and therefore permits the comparison o f molecular elongation between 
molecules.
The intensity at zero scattering angle 7(0) is proportional to Mx (Figure 
2.5). Molecular mass can be determined from 7(0)/c either as relative values from 
SAXS or absolute values ffom SANS, if  the scattering intensities of are 
normalised to a partially deuterated polystyrene standard. There is a linear 
relationship between the Mx determined ffom composition analyses and 7(0)/c, 
which is MT = 7(0)/c x 9  x 105 (Boehm et al., 1999) and can confirm molecular 
mass of proteins and hence their oligomeric state (Figure 2.5). The Mr calculation 
validates the Guinier analyses.
2.2.4.2 The cross-sectional radius of gyration
If the protein has an elongated structure, Guinier-type analyses of the 
scattering curve at larger Q values will give the mean radius of gyration of the 
cross-section Rxs•
Equation 2.4 In [l(Q)Q] = l n [ ( / © 0 ) ^  -
Rxs is determined from an experimental scattering curve by plotting ln [ 7 ( 0 0  
against Q1 to give a straight line of slope -Rxs2/2 and intercept ln[(7(00]g^o* 
The Q ranges to determine Rxs do not overlap with that used for the 
determination of Rg (Figure 2.2).
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Figure 2.5 Molecular mass against l(0)/c for proteins measured on LOQ
Linear relationship between molecular mass and the neutron l(0)/c is shown,
'y
using the values from 18 glycoproteins in 100% H 2 O buffers. The data points of 
IgA l, IgA2, IgGl/IgG2, SC, dlgA, SIgAl and SIgA2 are highlighted. 
Comparison o f the resulting molecular mass of the scattering sample to the 
sequence-derived molecular mass enables the oligomeric state o f the protein in 
solution to be determined.
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For bent protein structures such as T- or Y- shaped Abs, the cross- 
sectional plot exhibits two linear regions, a steeper innermost one and a flatter 
outermost one (Pilz et a l , 1973). In this type of analysis, the two regions are 
referred to as Rxs-i and Rxs-2 respectively (Figure 2 .2 ).
2.2.4.S Rg and Rxs determination of macromolecular dimensions
Assuming a protein is shaped like an elongated elliptical cylinder, the Rq 
and Rxs analyses can be combined to determine its length L (Glatter & Kratky, 
1982):
Equation 2.5 L = ^  12( R2G - R2^ )
2.2.4.4 The real space distance distribution function
The scattering curve I(Q) represents the macromolecular structure in 
reciprocal space. The experimental I(Q) curve can be converted by Fourier 
transformation into the distance distribution function P(r), which represents the 
macromolecular structure in real space with units in nm (Figure 2.1b; Perkins et 
al., 2008). The solution structure of the protein can now be directly visualised as 
P(r), which corresponds to the distribution of all the distances r between any two 
elements within the macromolecule. The maximum M  in the P(r) curve is the 
most frequently occurring intermolecular distance. The maximum length o f the 
molecule L is determined ffom when the P(r) reaches zero at larger values of r. 
A calculation o f Rq is also obtained from the P(r) curve offering an alternative 
method to the Guinier analysis to confirm the Rg value.
The transformation from reciprocal space into real space is ordinarily 
unstable since data points are missing at very low Q due to the presence o f the 
beamstop and at high Q at the edge of the detector. Also, high signal to noise 
ratios are associated with measurements at large Q. Calculation of the P(r) is 
performed using the GNOM program (Semenyuk & Svergun, 1991) which 
contains an automated regularisation procedure that stabilises the P(r) calculation 
and minimises the termination errors. Successful P(r) curves depend on several 
criteria: (i) P(r) should exhibit positive values; (ii) The Rg from GNOM should 
agree with that from the Guinier analyses; (iii) P(r) should be zero when r is 
zero; (iv) P(r) should be stable and reproducible for different experimental I(Q)
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curves. Dmax is the maximum macromolecular dimension, and corresponds to the 
maximum length L. Peaks M  in the P(r) curve give the r value of the most 
frequently occurring distances in the macromolecule and can be informative on 
the overall shape of the macromolecule. For example, if M  is half of L, then the 
most frequently occurring distance is half of the maximum length and shows that 
the protein is spherical or globular. Multidomain proteins, including antibodies, 
sometimes give rise to more peaks Mi and M 2 at different r values, which suggest 
they have semi-rigid complex structures.
2.3 Analytical ultracentrifugation
Analytical ultracentrifugation (AUC) is a dynamic technique that uses the 
effects o f centrifugal forces to characterise the structure of proteins in solution. 
The movement of proteins in a cell is monitored whilst they are subjected to high 
centrifugal forces.
An analytical ultracentrifuge consists of an optical system and a rotor, 
and specially designed cells within the rotor (Figure 2.6). At the beginning of an 
AUC experiment, the solute is present in a monodisperse, uniform concentration 
throughout the sample cell. As the rotor spins, the distribution of the protein 
molecules changes as they are subjected to centrifugal forces monitored in real 
time by the spectroscopic optics system. Two different spectroscopic methods 
can be used, based on either the absorption or refractive index difference 
between the sample and the reference buffer cell measured by absorbance optics 
(Section 2.3.1) and interference optics (Section 2.3.2) respectively. Both 
spectroscopic methods follow the sedimentation behaviour o f the molecules 
within the cell and can be used in the two types of AUC experiments: 
sedimentation velocity (Section 2.3.3) and sedimentation equilibrium (Section 
2.3.4).
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Figure 2.6 Schematic diagram of AUC optic systems
(a) Absorbance and (b) interference AUC optic and rotor systems are shown. 
(Adapted from Ralston, 1993).
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2.3.1 Absorption optics
Light from a high-intensity xenon flash lamp is passed through the 
sample cells held within the rotor. A photomultiplier tube beneath the rotor 
detects the light intensity from the sample sector in relation to that ffom the 
reference sector, which contains buffer. When the rotor is spinning, light passes 
through the reference sector first, and then through the sample sector. The 
photomultiplier detects this light, and the difference between these signals can 
then be translated into an absorbance value (Figure 2.6).
2.3.2 Interference optics
Interference data are obtained through a laser beam that is shone through 
the cells ffom above and detected, via a series of mirrors and lenses, by a 
camera. The emission ffom the sample sector is referenced against that o f the 
buffer sector. If the sample solution and the reference solution are the same, 
there is no refraction. This gives an achromatic fringe along the optical axis. 
When the two solutions are different in composition, the achromatic fringe 
shifts, reflecting the difference in the refractive indices of the solutions. The 
centrifugal forces cause diffusion and sedimentation of the protein, which then 
displaces the fringe pattern. The camera sends the data in digital form to a 
computer that performs a fast Fourier transformation to give an image o f the 
fringe pattern as a plot of fringe displacement against radius.
2.3.3 Sedimentation velocity
In sedimentation velocity (SV) experiments, a high centrifugal force is 
applied to the samples, and the sedimentation of the protein molecules is 
analysed. The sedimentation of a protein depends on its shape and size, and the 
information provided by AUC data are independent yet complementary to those 
obtained by scattering (Section 2.2).
The application o f high rotor speeds to a protein sample causes the 
protein to rapidly sediment to the base of the cell in a matter of hours. SV 
experiments are performed in long 12 mm columns within the cell. The 
sedimentation gives rise to the formation of a boundary between the solvent at 
the meniscus which is depleted of solute and the rest of the protein solution at 
uniform concentration. The rate of movement of the boundary is measured in real
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time, allowing the determination of the sedimentation coefficient, s°20,w (in 
standard conditions: in water at 20°C and 1 atmosphere pressure). The units of 
s°2o,w are seconds, although in ultracentrifugation work they are usually given in 
Svedbergs, S. One Svedberg is equal to 10' 13 seconds. The sedimentation 
coefficient is directly proportional to the mass of the protein, and indirectly 
proportional to the frictional coefficient /  as shown in the simplified Svedberg 
equation, S oc M I f  Higher S values reflect a higher molecular mass or a more 
compact protein shape. The frictional coefficient /  increases as the protein is 
more elongated. The frictional ratio f / fc  where fo is the frictional coefficient for a 
sphere of the same volume as the protein, shows the extent of elongation and is 
comparable with the scattering anisotropy ratio R<j/Ro.
SV data are collected over 16 hours at rotor speeds between 10,000 r.p.m. 
and 42,000 r.p.m for protein samples in a dilution series. After correction for the 
temperature and providing the buffer density p and protein partial specific 
volume v are known, the s°2o,w can be obtained by fitting the boundary fits 
(Figure 2.7a). The buffer density p is calculated using the program SEDNTERP 
(Laue et al., 1992) and the protein partial specific volume v is calculated ffom its 
amino acid and carbohydrate composition (Section 3.3.1).
Two programs, DCDT+ and SEDFIT can be used to analyse the SV scans 
to obtain the sedimentation coefficient, after correction for standard conditions. 
DCDT+ time-derivative analyses subtracts between approximately 4 to 20 pairs 
o f scans and extrapolates the individual subtractions to the start time to give the 
g(s*) function. From this, the sedimentation coefficient, and hence the molecular 
mass are determined ffom the peak position and width respectively. The number 
o f pairs of scans must be chosen carefully to ensure time-broadening effects are 
negligible (Philo, 2000). SEDFIT is a powerful program that carries out direct 
boundary fits of all the scans simultaneously. Species distribution analyses gives 
c(s) plots (or c(M) plots) that show the sedimentation coefficients (or the 
molecular mass values) of all species within a sample (Figure 2.8; Schuck, 
1998). This is a good supplement to the scattering analyses which do not report 
parameters for different species within a sample. SEDFIT also can calculate the 
f/fo value to confirm that determined ffom the DCDT+ sedimentation coefficient.
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Figure 2.7 Schematic and bitmap image showing SV and SE boundaries
(a) SV data are analysed to obtain the sedimentation coefficient by the fitting of 
boundaries that represent the sedimentation o f the protein in real-time. The 
sample meniscus is shown, (b) SE data are collected when the protein has 
reached equilibrium between its diffusion and sedimentation in the cell. The red 
curve represents the equilibrium state. Below the SV and SE schematic 
representations are images of the interference fringes recorded during the AUC 
experiments.
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Figure 2.8 SEDFIT analysis output
(a) The SV boundaries and fits to these are represented as data points. (b,c) The 
goodness-of-fit is reflected in the residual plot and bitmap. A good fit is shown 
by a monochromatic grey bitmap image and subsequently a low r.m.s.d. value, 
(d) The resulting fit gives the distribution of sedimentation coefficients o f all 
species in the sample, (e) The parameters window to input the partial specific 
volume, buffer density and other fit parameters is shown. The SV data shown are 
those obtained for SC (Chapter 4).
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2.3.4 Sedimentation equilibrium
Sedimentation equilibrium (SE) experiments involve much lower 
centrifugal forces than SV experiments. In SE systems, the solute molecules do 
not completely sediment to the base of the cell. Instead, the centrifugal force 
applied is small enough to allow the diffusion of solute molecules to be 
comparable with, and to oppose the sedimentation force. At equilibrium, the rate 
of sedimentation equals the rate of diffusion and there is therefore no net 
movement of solute molecules (Figure 2.7b). The SE sample column is 2 mm in 
length (much shorter than that in SV) to allow equilibrium to be reached in 
between 1 0 - 3 6  hours, depending on the protein shape and rotor speed. At 
equilibrium the exponential distribution of the solute is measured and providing 
that p and v are known, the molecular mass, the stochiometry of a complex, and 
any association and dissociation constants can be calculated. SE experiments are 
performed at multiple centrifugal speeds and protein concentrations to allow 
accurate molecular mass calculations and to analyse sample polydispersity, speed 
dependence or oligomerisation of the protein. A final run at a high speed of
42,000 r.p.m. is performed at the end of the SE experiment in order to determine 
the background levels for use in the curve fitting. In this thesis, the SE data are 
analysed using Microcal ORIGIN, provided by Beckman, to determine protein 
molecular mass values. The residuals are calculated to show the difference 
between the experimental and calculated fitted curves.
2.4 Combining solution scattering and AUC
Scattering and AUC can often provide the first structural view of a 
macromolecule if the high resolution structure determination techniques are not 
feasible. Scattering and AUC each provide independent, yet similar structural 
and compositional information about proteins in solution. The molecular mass 
(to confirm that calculated from the protein or DNA sequence) can be 
determined by 7(0)/c by scattering and AUC SE experiments. Subsequently, the 
oligomeric state and any associative properties of the protein can be determined. 
Both SAS and AUC SV analyse proteins in solution to derive information on 
their molecular elongation, through the Rg and S respectively. From these, the 
comparable anisotropy ratio and frictional ratio show the degree of elongation 
when compared to that of a globular protein.
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The combination o f analysing scattering and AUC improves the 
reliability o f the data relative to that obtained by the use of either technique on its own. 
However, the additional structural parameters obtained by scattering make it the 
more powerful tool. AUC can then be employed to provide confirmation of the 
structural insight determined by scattering, and to check for sample 
polydispersity (Perkins et al., 2005).
Scattering and AUC data interpretation is much improved by the use of 
molecular modelling based on available atomic structures (Chapter 3). This 
approach is particular useful in the study of antibodies, where the constituent Fab 
and Fc fragments have been crystallised, but crystallisation of the intact antibody 
is not possible (Perkins & Bonner, 2008).
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Chapter Three
Constrained Biomolecular Modelling
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3.1 Introduction to protein structure
3.1.1 Amino acids
Proteins are composed of amino acids that are linked by peptide bonds to 
form a polypeptide chain. It is the side chain, or R group, attached to the Ca atom 
that gives each residue characteristic properties and distinguishes one amino acid 
from the other (Figure 3.1). Amino acids are joined by the formation of a peptide 
bond, where the carboxyl group of one amino acid condenses with the amino 
group of another to eliminate water. This means that within a polypeptide chain, 
the first amino acid will have a free amino group and the last amino acid will 
have a free carboxy group, thus denoting the N- and C-termini, respectively.
The diversity of the amino acid side chains allows proteins to exhibit a 
great variety of structures, properties and functions. Residues can be grouped 
into classes by the chemical properties of their side chains (Figure 3.1). Alanine, 
valine, phenylalanine, methionine, proline, leucine and isoleucine all contain 
straight, branched or cyclic arrangements of carbon atoms and are hydrophobic 
amino acids. As these side chains become more extended, the amino acids 
become more hydrophobic. The side chain of proline is unique as it forms a bond 
with the N atom o f the proline amino group making a cyclic structure. Within a 
protein, proline can restrict the flexibility o f the polypeptide chain. The side 
chains of serine, threonine, tyrosine, asparagine, cysteine, tryptophan and 
glutamine are polar amino acids. Cysteine contains a free thiol goup, which can 
be oxidised to form covalent, disulphide bonds within protein structures. 
Phenylalanine, tyrosine and tryptophan have aromatic side chains. Phenylalanine 
is strongly hydrophobic, yet the polar groups in the side chains of tyrosine and 
tryptophan reduce their hydrophobic nature. Aspartic acid and glutamic acid side 
chains carry negative charges at pH 7. Lysine, arginine and histidine carry basic 
(positively charged) groups in their side chains. Histidine is the least basic of the 
three and since it can exchange protons near physiological pH, it often plays a 
role in enzymatic catalysis involving proton transfer. Glycine has a single 
hydrogen atom as its side chain, therefore reducing steric collision with other 
side chains and increasing the flexibility of the polypeptide chain (Figure 3.1).
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Figure 3.1 The 20 amino acid side chains
The 20 amino acids are divided into four groups (hydrophobic, polar, negatively 
charged and positively charged) based on the chemical properties of their side 
chains (R groups).
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3.1.2 Secondary structure
3.1.2.1 Peptide bonds and Ramachandran plots
The C=0 and N-H bonds of the carboxyl and amide groups that make up 
the peptide bond are nearly always parallel, and the O, C, N and H atoms are 
usually coplanar. Peptide bonds can exist in two configurations, trans and cis. 
The trans form is usually favoured as the cis form can cause steric clashes 
between bulky side chains of adjacent a-carbons (Figure 3.2a).
A polypeptide chain can be divided into repeating units, from the Ca atom 
of one residue to the next Ca atom (Figure 3.2a). The freedom for movement 
about the peptide backbone is only about the Ca-N bond and the Ca-C’ bond, 
measured by the phi (<()) and psi (\|/) angles respectively (Figure 3.2). A third 
angle is omega (Q), which measures the angle about the C’-N and therefore the 
planarity of the peptide bond. The conformation of a protein backbone can be 
described by the dihedral angles around these bonds' for each residue. The § and 
i}/ angles are calculated for each peptide and can be displayed as a Ramachandran 
plot (Figure 3.2b). The combination of <|> and \\f angles are easily visualised on a 
Ramachandran plot, which is particularly useful for assessing the quality of 
homology models and determined protein structures (Section 3.2.1). Most 
combinations of (|) and \|/ angles are not allowed because of steric collisions 
between the side chain and the main chain atoms. Only three small regions of the 
conformational map are physically accessible to the polypeptide chain (Figure 
3.2b). Glycine is the only residue without a Cp atom, and as a result is much less 
sterically hindered than the other amino acids. For this reason, glycine often 
occupies positions where a polypeptide backbone is seen to make a sharp turn. 
Proline is the most conformationally restricted residue due to its cyclic side chain 
binding with the main chain N atom.
3.1.2.2 Alpha helices and Beta sheets
a-helices and P-sheets form the secondary structure of proteins. The a- 
helix is defined by a stretch of residues with <|) and \|/ angle pairs of 
approximately -60° and -50°, respectively. This corresponds to the allowed region 
in the bottom left quadrant of the Ramachandran plot (Figure 3.2b). In contrast to
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Figure 3.2 Peptide bond angles
(a) Bond dihedral angles are shown in a peptide with Ri, R2 and R3 sidechains. 
The peptides are shown in the trans conformation. The NH-Ca is defined by the 
phi (<|>) angle. Ca-CO is defined by the psi (\|/) angle. The peptide bond (purple), 
defined by the omega (Q) angle, is rigid and maintained in a planar structure 
(yellow), (b) A Ramachandran plot is shown. A good quality model would be 
expected to have at least 90% of its residues in the most favoured regions. This 
Ramachandran plot was an output from PROCHECK, analysing the bond angles 
o f the crystal structure of SC D1 (PDB code: 1XED; Hamburger et al., 2004).
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the a-helix that is built from a continuous region of the polypeptide chain, the p- 
sheet is formed from numerous stretches o f five to ten residues that are in 
different sections of the polypeptide chain, p-sheet motifs have <|> and i|/ 
backbone angles within the upper left region of the Ramachandran plot (Figure 
3.2b). Within protein structures, a-helices and P-strands are combined to form 
stable hydrophobic pockets within the molecule. These secondary structure 
elements are connected by loop regions of various lengths and conformations. 
These loop regions almost always occur on the surface of the molecule. It is the 
loop regions of Ig V-type domains that form antibody CDRs (Section 1.2.2.2; 
Figure 1.5; Figure 1.13)
3.1.2.3 Domain structure
Within globular protein structures, several secondary-structure motifs 
combine to form compact regions of structure known as domains. A domain can 
be defined as part of a polypeptide chain that can be folded into a stable tertiary 
structure independently of the rest of the protein. Protein domains can also 
evolve independently to the rest of the protein. Protein domains can range in size, 
from around 25 to 250 amino acid residues.
3.2 Biomolecular modelling
Biomolecular modelling is the creation of models that represent the 
structure o f biological molecules. An atomic coordinate model is the most 
detailed representation of a protein molecule, and can be obtained by NMR 
(Section 2.1.2) or X-ray crystallography (Section 2.1.3). The models are 
deposited in the Protein Data Bank (PDB) with X, Y and Z coordinates 
specifying the position of every atom. The PDB currently contains over 49,000 
structures (February 2008; http://www.pdb.org) of which approximately 42,000 
are X-ray crystal structures. If the three-dimensional structure of a protein of 
interest (the target) is not available in the PDB, structural information can often 
be obtained by analysis of a homologous protein with known structure (the 
template). This is a useful substitute if high-resolution structural data cannot be 
obtained, especially when combined with low-resolution experimental structural 
data such as SAS and AUC (Chapter 2).
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3.2.1 Homology modelling
Homology modelling is a technique that uses known sequences and 
structures of homologous domains as a template to create a three-dimensional 
structure of the target domain.
The accuracy of homology models of protein domains generally depends 
on two main criteria, (i) Finding the best template structure with highest 
sequence similarity and similar secondary structure. The most accurate models 
are obtained with the fewest residues that need to be inserted into or deleted from 
the template in order to build the model. Template sequences and structures can 
be found by searching the PDB using web-based search tools such as BLAST, 
SwissProt, Pfam and Interpro. (ii) Generating a correct alignment of the target 
and template sequences. The optimal alignment for homology modelling should 
be identical to the alignment achieved if both structures were known and 
structurally aligned. Automatic sequence alignments can be obtained using 
methods such as CLUSTALW. However, they do not always achieve the optimal 
sequence alignment needed for homology modelling since they are concerned 
with sequence and not structure, and manual inspection and editing is necessary.
The secondary structure of the template structure is determined using the 
programme DSSP (Dictionary of Secondary Structure of Proteins). It allows 
secondary structure elements and loops within domains to be defined by 
analysing the pattern of hydrogen bonds within the structure and the Ca-Ca 
distances, bond dihedral angles and solvent exposure for each residue. Each 
residue is then classified into the secondary structure element it comprises; turns 
(T), helices (H, G or I), [3-bridges (B), extended p-stands (E), main-chain bend 
(S) or unclassified random coil (C) (Kabsch & Sander, 1983). In homology 
modelling, residue insertions and deletions should be restricted to structurally 
variable regions such as loop regions, and should be omitted from the structurally 
conserved regions and secondary structure elements defined by DSSP.
Homology domain models can be generated using modelling software 
such as MODELLER (Sali & Blundell, 1993). MODELLER creates homology 
models by assessing the conserved and variable regions of the template structure 
and then using molecular dynamics to fit the target sequence to it, based on the
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sequence alignment. Restraints are imposed to weight the structurally conserved 
regions (i.e. secondary structure elements) more highly than those of high 
variability (i.e. loop regions).
3.2.1.1 Limitations of homology modelling and assessing the structure
There are several things that can affect the accuracy of a homology 
model. It is important to realise that any NMR or X-ray experimental structure 
that is used as a template is itself a model based on experimental data. Therefore, 
a model of a structure obtained from homology modelling is in fact a model 
based on another model. The least accurate regions of the model will be the 
insertions and deletions within structurally variable regions as they have not been 
built directly from the template structure.
Homology models can be refined by energy minimisation, which involves 
moving atoms within a structure in order to find the minimum energy 
conformation. MODELLER automatically assesses and refines the domain 
models by energy minimisation, and therefore attempts to remove bad contacts 
and other structural artefacts such as those arising from changes in residue side- 
chain size, peptide backbone strain or non-optimal loop conformations.
PROCHECK can then be employed to check the validity of the model 
(Laskowski et al., 1993). PROCHECK assesses the PDB atomic coordinate file 
using stereochemical parameters to evaluate bond lengths and bond angles within 
every residue o f the protein. The output of PROCHECK includes a 
Ramachandran plot (Figure 3.2b).
3.3 Constrained scattering modelling
Modelling extends the scattering and AUC analyses by determining the 
three-dimensional structure that accounts for the observed scattering curve and 
calculated experimental parameters. Individual homology models of each domain 
are created (Section 3.2.1), and then combined to produce around ten 
thousand models that encompass all possible orientations of the intact protein. 
The X-ray and neutron scattering curves are then calculated for each model, and 
their sedimentation coefficients are determined for comparison with that 
experimentally obtained. However, unique structures for the protein are not 
possible due to the random orientation of the proteins in solution and the radial
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averaging of the scattering curve. Consequently, constrained scattering modelling 
is particularly efficient at ruling out poor-fit structures and determining a family 
of best-fit structures that are compatible with the experimental data. By 
constraining the 1 0 , 0 0 0  models by filtering out those that do not agree with the 
experimental data, the best-fit models can be determined that represent the 
structure at medium-resolution of the protein. The determined best-fit solution 
structure models are based on experimental data and therefore qualify for PDB 
deposition, and they can provide biologically important information on the 
proteins (Perkins et al., 2008).
3.3.1 Analysis of glycoprotein composition
Prior to solution scattering modelling, essential information is determined 
from the amino acid and monosaccharide composition of the protein using the 
program SLUV (Perkins, 1986). The partial specific volume v and molecular 
mass are determined. For concentration measurements, the extinction coefficient 
(at a wavelength of 280 nm) is calculated from the tryptophan, tyrosine and 
cysteine content o f the protein (Perkins, 1986).
3.3.2 Creating atomic models
If atomic resolution structures are available for the domains of the protein 
being studied, these are used as the basis for the models created by the automated 
modelling procedures. If there are no atomic resolution structures, the individual 
domains are modelled using the known structures of homologous domains as 
templates (Section 3.2.1).
In order to create an arbitrary series of models that test all possible 
orientations of the protein and domain arrangement, each peptide outside the 
fixed domain structure is designated as a linker, and a library of different 
conformations is generated for each linker. A library of around 5,000 random 
linker conformations for each linker peptide are generated using INSIGHT II
98.0 molecular graphics software with BIOPOLYMER, DISCOVER and 
HOMOLOGY modules (Accelrys, San Diego, CA, USA). A wide range of 
conformations are created by subjecting the peptide structure to molecular 
dynamics for 300 iterations at a temperature of 773K. After a temperature 
equilibration step of 5,000 fs, the simulation is run for 500,000 fs. The linker
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structure is then saved every 100 fs to produce the linker library (Section 4.4.5). 
In the automated modelling procedure, linkers are then randomly selected from 
the linker library to join the domains together to generate a series o f complete 
models (Figure 3.3a). In atypical randomised modelling search, 10,000 trial-and- 
error models are generated.
If the protein being studied contains putative glycosylation sites, a three- 
dimensional structure for the N- and O-linked oligosaccharide chains is 
positioned at the glycosylation sites on the protein. When present, the modelling 
of antibody carbohydrate chains presented in this thesis generally contained N- 
linked biantennary complex-type carbohydrates with a Man3GlcNAc2 core and 
two NeuNAc.Gal.GlcNAc antennae, and O-linked NeuNAc.Gal.GalNAc 
oligosaccharides.
3.3.3 Debye sphere modelling
To calculate a theoretical scattering curve from an atomic model of a 
protein, the protein is first converted into a sphere model consisting of small non­
overlapping spheres o f the same total volume as the original atomic model 
(Figure 3.3b). To do this, the atomic coordinate model is placed within a three 
dimensional grid o f cubes. The size of the cubes and the number of atoms that 
each cube contains is user-defmed, and both are tested empirically by trial and 
error, so that after the grid transformation the resulting sphere model has a 
volume as close to the unhydrated volume of the protein as possible. The 
unhydrated volume is calculated from the protein composition using SLUV 
(Section 3.3.1). The length of the cube side that is used to produce an unhydrated 
sphere model is typically between 0.5 and 0.6 nm, which is much less than the 
normal resolution of a normal scattering curve of around 3 nm (Section 2.2.2). 
Once a grid size has been determined, it is kept constant for the automated curve 
fit searches.
Neutron scattering experiments do not detect a hydration shell around 
proteins, so unhydrated sphere models are used for neutron scattering curve 
calculations (Figure 3.3b). In contrast, the hydration shell is detected in X-ray 
scattering experiments, and therefore the calculation of an X-ray scattering curve 
requires that the unhydrated sphere model is modified to consider the hydration
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Figure 3.3 Overview of the constrained modelling procedure
(a) A model for SC is shown (blue), with D1-D5 in an extended arrangement. 
(b,c) The unhydrated (green) and hydrated (pink) sphere models are shown, (d) 
The calculated scattering curve of the model (red) is compared to the 
experimental scattering curve (open circles) to determine the goodness-of-fit R 
factor.
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shell (pink in Figure 3.3c). The hydrated volume of a protein is calculated 
assuming a hydration of 0.3 g water/g protein and an electrostricted volume of 
0.0245 nm3 per bound water molecule (Perkins, 1986; Section 2.2.2.4). Spheres 
corresponding to water molecules are added evenly over the surface of the 
unhydrated sphere model to achieve the desired hydration volume. The hydrated 
sphere models are used for X-ray scattering curve calculations. The outcome of 
adding the hydration shell can be visually verified by overlaying the unhydrated 
and hydrated sphere models (Figure 3.3c).
3.3.4 Debye scattering curve calculation
For a glycoprotein, a sphere model containing spheres of a single 
scattering density is used to calculate an X-ray or neutron scattering curve I(Q) 
(Figure 3.3d). The curve is calculated using Debye’s Law (Equation 2.1) adapted 
for spheres (Glatter & Kratky, 1982; Perkins & Weiss, 1983):
Equation 3.1 = g(Q) (  „ ' +2^  Aj )
1(0)p
Equation 3.2 g(Q) = (3(sin QR - QR cos QR) f  /  Q6 R6
where g(Q) is the squared form factor for the sphere of radius R, n is the number 
of spheres filling the body, Aj is the number of distances r} for the value of j ,  rj is 
the distances between the spheres, and m is the number of different distances ry 
In brief, the Debye equation (Equation 3,1; Section 2.2.2.1; Equation 2.1) is 
amended to consider the spheres of the model rather than the electron or neutron 
scatterers in the molecule. The g(Q) function is therefore determined by 
calculating the distances r from each sphere to the remaining spheres and 
summing the results (Equation 3.2). The single density scattering curve 
calculation is applicable to proteins and glycoproteins with low carbohydrate 
content, provided that the comparisons between the experimental data sets are 
consistent for the neutron and X-ray curves.
If a glycoprotein has a high carbohydrate content, differences between the 
scattering densities of the protein and its carbohydrate moieties may give rise to
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systematic deviations between the neutron and X-ray curves. The glycoprotein 
can then, in principle be modelled using two-density sphere models. This was not 
necessary for the work presented in this thesis as no major discrepancies were 
seen between the X-ray and neutron modelled curves for the glycoproteins 
studied.
Synchrotron X-ray cameras utilise a pin-hole configuration that does not 
produce distortion of the beam (Figure 2.3), so a calculated X-ray curve does not 
have to be corrected for instrumental effects in order for it to be compared with 
an experimental curve. Although neutron cameras such as those at ISIS also use 
pin-hole geometries, their dimensions are larger than X-ray cameras and they 
also use longer wavelengths to maximise the available neutron flux (Figure 2.4). 
For these reasons, it is necessary to apply instrumental corrections to neutron 
scattering curves of the models. For LOQ, a Gaussian function based on a 10% 
wavelength spread and beam divergence o f 0.016 radians is applied to the 
modelled neutron curves during the automated modelling procedure (Ashton et 
a l , 1997).
3.3.5 Evaluation of models
Each model is evaluated using several criteria, (i) The volume of each 
sphere model, indicated by the number of spheres generated from the coordinates 
during the grid transformation, is used to determine whether the automated 
modelling procedure has produced significant steric overlap of the protein 
domains. Significant overlap means that the number of spheres is much reduced 
(usually >5%) compared to that predicted from its composition, (ii) Each model 
is also evaluated by comparison of its calculated scattering curves to the 
experimental data. X-ray and neutron Rq and Rxs values are calculated from each 
modelled scattering curve over the same Q ranges used for the experimental 
measurements, (iii) An R factor is calculated for a quantitative comparison of 
each model scattering curve /( 0 cai against experimental scattering data 7 ( 0 exP 
over the whole Q range, where /(0)cai is set as 1000:
„ .. , ,  „ n K Q U - H Q UEquation 3.3 R —-------------   x 100%
E l exp
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The R factor values reflect the goodness-of-fit between the calculated and 
experimental curves and are analogous to that used for the refinement of 
crystallographic models. R factor values should be less than 10% for a good fit. 
Using these three criteria, it is possible to minimise the number of models that 
have to be considered from a large automated search. Models that do not 
conform to the experimentally defined ranges of model volume, Rq and Rxs are 
rejected using filters in EXCEL, and the remaining models are further evaluated. 
The structure of the final models are manually visualised to ensure that they are 
stereochemically viable. Also, the modelled scattering curves are manually 
compared to the experimental curves and their sedimentation coefficients are 
calculated (Section 3.3.6) to ensure that there is no discrepancy between the 
modelled and experimental parameters. The theoretical sedimentation coefficient 
s°2 o,w of the best-fit models are determined directly from the PDB coordinates by 
using the programme HYDROPRO (Garcia de la Torre et al., 2000). Comparison 
of the sedimentation coefficients of the models with that experimentally obtained 
by SV experiments provides another means of validating the scattering 
modelling. The best-fit models are then determined based on their R factors. The 
models can be compared with the structures already obtained by EM, NMR or X- 
ray crystallography. The a-carbon coordinates are then deposited in the PDB and 
given accession codes (Perkins & Bonner, 2008).
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Chapter Four
Solution Structure of Human Secretory Component: 
Implication for Biological Function
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4.1 Introduction
Secretory component (SC) is involved in the formation of SIgA and its 
transportation to mucosal secretions, where SIgA mediates a major part of mucosal 
immune defence (Nagler-Anderson, 2001). IgA is produced locally as (generally) 
dimeric IgA (dlgA). Subsequent transport of dlgA (and to a lesser extent IgM) across 
the epithelium is ensured by the polymeric immunoglobulin receptor (plgR) which is 
expressed on the basolateral surface o f epithelial cells. Following cleavage at luminal 
surfaces, SIgA is released as a complex of dlgA bound to the cleaved extracellular 
portion o f the plgR which is now known as SC (Section 1.4.1; Figure 1.11).
SC consists of five immunoglobulin-like domains (D1-D5) to which up to 
seven glycan chains are attached (Figure 4.1) that account for 15-25% of its total 
molecular weight (Cleveland et al., 1991). SC bound to dlgA protects the Ab against 
proteolytic digestion (Crottet & Corthesy, 1998), and governs anchoring of SIgA at 
mucosal surfaces (Phalipon et al., 2002). Free SC is also found as such in secretions 
and is now recognized as an active antibacterial participant. Recombinant human SC 
produced from transfected Chinese hamster ovary (CHO) cells behaves identically to 
that purified from colostrum and its neutralizing properties have been shown to rely 
on the presence of carbohydrate moieties on SC (Perrier et al., 2006).
So far, the question of the three-dimensional domain arrangement of SC has 
not been considered, even though this is essential to appreciate molecular 
mechanisms that are involved in mucosal immunity. Its high glycosylation and the 
presence of long inter-domain linkers suggest that SC may be too flexible to be 
crystallised intact (Figure 4.1). In a situation such as this, X-ray and neutron 
scattering and AUC in combination with constrained modelling techniques will 
provide a model of the domain arrangement of SC (Perkins et al., 2008). By these 
methods, a solution structure for recombinant human SC has been determined. This 
is verified with data for the D1-D3 and D4-D5 fragments of SC. SC forms a compact 
domain arrangement in solution, and this structure rationalises many of the 
biological roles of both free and bound SC for the first time.
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Figure 4.1 The domain structure of SC and its sequence alignment
(a) The five immunoglobulin V-type domains of human SC are numbered D1 to D5 
and are coloured from blue (N-terminus) to red (C-terminus). The cleavage site that 
yields D1-D3 and D4-D5 lies between Arg336 and Ser337 (arrowed). The residue 
lengths of the N- and C-terminal peptides and the four linkers are shown in brackets. 
The sequence position for the seven putative TV-linked glycosylation sites are shown, 
denoted by inverted Y symbols.
(b) The sequence alignment of the D2 to D5 domains used for homology modelling 
using the D1 crystal structure as template. Fully conserved residues are highlighted 
in green, and residues conserved in four of the five sequences are highlighted in 
yellow. The N- and C-terminal peptides and the four linker peptides are highlighted 
in grey. Each putative glycosylation site is highlighted blue. The cleavage site at 
Arg336-Ser227 is highlighted in red in the D4 sequence. The free Cys502 that is 
covalently linked with Cys311 in SIgA is highlighted in red. The secondary structure 
is taken from the D1 crystal structure (PDB code 1XED; Hamburger et a l, 2004) 
from DSSP, and the secondary structure assignment of ten p-strands and a single a - 
helix is shown below the alignment.
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4.2 Results
4.2.1 Characterisation o f SC and its fragments
In SC, sequence similarities between D1 and the other four SC domains (D2- 
D5) show that all belong to the immunoglobulin (Ig) variable (V)-type classification 
(Figure 4.1a; Section 1.2.2). For clarification, the domains and interdomain linkers 
are depicted in Figure 4.1b. As glycosylation and proper disulphide bonding are 
essential features o f SC, it was produced in CHO cells which yields SC that is 
indistinguishable when compared to colostrum SC (Crottet & Corthesy, 1999; 
Perrier et al., 2006). Purified recombinant human SC resulted in a clean single band 
at an apparent molecular mass of 75 kDa when analysed by silver staining and 
immunodetection (Figure 4.2, lanes 1, 3, 5 and 7). This molecular mass agrees well 
with the sequence derived value of 79.6 kDa. Upon storage for several months at 
4°C, two additional bands at 45 kDa and 30 kDa appear (Figure 4.2, lanes 2, 4, 6 and 
8). In Western blots, detection with polyclonal antisera specific for D1 and D5 
established that the bands at 45 kDa and 30 kDa represent cleavage of full-length SC 
into D1-D3 and D4-D5 fragments. This was confirmed by N-terminal sequencing of 
fragment D4-D5 that identified the sequence SPTW KGVAG corresponding to the 
beginning of D4, and indicating cleavage between Arg336 and Ser337 in the SC 
sequence (SWISSPROT code P01833). The PeptideCutter web tool (Gasteiger et al., 
2005), available from the ExPASy server suggested that the enzymatic cleavage may 
be caused by one of trypsin, thrombin, clostripain or Arg-C proteinase. This 
unexpected observation provided us with three different polypeptides that were used 
to generate the results presented below.
4.2.2 X-ray and neutron Guinier analyses o f SC and its fragments
Solution scattering was used to investigate the domain arrangements in SC 
and the D1-D3 and D4-D5 fragments at concentrations between 0.40 mg/ml to 2.7 
mg/ml (Section 4.4.2). The acquired X-ray data showed no change during the ten 
successive time frames of each data acquisition, from which it was concluded that no 
X-ray induced radiation damage had occurred. Accordingly the ten time frames were 
averaged for data analyses. SDS-PAGE analyses of the samples before and after data 
acquisitions showed that, while SC and D4-D5 remained intact, further cleavages in 
D1-D3 occurred to give single domain fragments as well as the three-domain 
fragment.
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Figure 4.2 SDS-PAGE and Western blot analyses of SC and its fragments
SDS-PAGE and Western blot analyses of SC (75 kDa; lanes 1, 3, 5, 7) and cleaved 
SC (lanes 2, 4, 6, 8) containing a mixture o f SC, D1-D3 (major band at 45 kDa) and 
D4-D5 (30 kDa). Lanes 1 and 2 represents a silver stain of the SDS-PAGE analysis, 
while the three successive panels represent Western blots of the gel in lanes 1 and 2 
using (lanes 3 and 4) anti-SC, (lanes 5 and 6) anti-Dl and (lanes 7 and 8) anti-D5 
antibodies.
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At low Q values, Guinier analyses of In I(Q) against Q1 resulted in linear 
plots for SC and its two fragments, from which the radius of gyration (Rg) values 
were obtained (Figure 4.3a; Figure 4.4a,b). At larger Q values, analyses of In I(Q)Q 
against Q1 also resulted in linear plots, from which the Rg o f the cross-section (Rxs) 
were obtained (Figure 4.3c; Figure 4.4c,d). From seven measurements of SC, a 
mean X-ray Rg value of 3.53 (± 0.03) nm and mean Rxs value of 1.76 (± 0.08) nm 
were recorded using Q ranges of 0.19-0.39 nm '1 and 0.42-0.86 nm '1 respectively 
(Figure 4.3a,c; Table 4.1). These were confirmed from a second set of six 
measurements for another SC preparation that gave a mean X-ray Rq value of 3.64 
(± 0.17) nm and Rxs value of 1.63 (± 0.12) nm. A partially cleaved SC sample with 
an estimated content of 33% SC, 33% D1-D3 and 33% D4-D5 showed a small 
increase in the mean Rg to 3.77 (± 0.17) nm and a small decrease in the mean Rxs 
value to 1.60 (± 0.61) nm. The partially cleaved sample of D1-D3 showed from up to 
five measurements that this had an apparent Rg value of 3.44 (± 0.27) nm and an 
apparent RXs  value of 1.07 (± 0.07) nm using Q ranges o f 0.16-0.40 nm '1 and 0.52- 
LOO nm '1 (Figure 4.4a,c; Table 4.1). From five measurements, D4-D5 was found to 
have a mean Rg value of 3.16 (± 0.04) nm and a mean Rxs value of 1.11 (± 0.08) nm 
in the same Q ranges o f 0.16-0.40 nm '1 and 0.52-1.00 nm'1 respectively (Figure 
4.4b,d; Table 4.1). The Guinier analyses were confirmed by the ratio of the 
molecular mass values of SC, D1-D3 and D4-D5 using their Guinier l(0)/c values, 
where c is the protein concentration (Perkins et al., 1998). The observed 1(0)/c values 
were 0.0077, 0.0023 and 0.0041 for SC, D1-D3 and D4-D5 respectively, relative to 
the Lupolen standard, and these were in the ratio of 1 : 0.30 : 0.53. The sequence- 
derived molecular weight ratios for SC, D1-D3 and D4-D5 are 1 : 0.57 : 0.43 in that 
order. The value for D1-D3 is notably lower than expected from the sequence, which 
is attributed to the presence of single-domain cleavage products, while that for D4- 
D5 is in good agreement with that expected from the sequence.
Interestingly SC appeared more compact than either D1-D3 or D4-D5. Shape 
information on SC, D1-D3 and D4-D5 was obtained from the anisotropy ratio, Rg/Ro 
(where Ro is the Rg value o f a sphere of equal volume to that o f the hydrated 
glycoprotein). The ratios, calculated from the X-ray Rg values, were 1.44-1.49, 1.69 
and 1.70 for SC, D1-D3 and D4-D5 in that order (Table 4.1). As the anisotropy ratio 
for typical globular protein is close to 1.28 (Perkins, 1988), this shows that all three
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Figure 4.3 Guinier R g and Rxs analyses for SC
Data points included in the Guinier fits are indicated by filled circles between the 
arrowed QRq and ORxs ranges. The Q ranges for SC are 0.18-0.39 nm '1 (Rg) and 
0.42-0.86 nm '1 (Rxs)- (a, c) X-ray fits for SC at a concentration of 1.3 mg/ml. (b, d) 
Neutron fits for SC at concentrations of 2.0 mg/ml (upper) and 1.3 mg/ml (lower). In 
panels (a, c, d) the two Guinier plots are arbitrarily displaced on their vertical axes 
for reason of clarity.
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Figure 4.4 Guinier RG and Rxs analyses for D1-D3 and D4-D5
Data points included in the Guinier fits are indicated by filled circles between the 
arrowed QRq and QRxs ranges. The Q ranges for D1-D3 are 0.15-0.36 nm-1 (Rg) and 
0.58-1.07 nm '1 (Rxs), and those for D4-D5 are 0.16-0.40 nm'1 (Rg) and 0.52-1.00 nm' 
1 (Rxs)- (a, c) X-ray fits for D1-D3 at concentrations of 1.6 mg/ml (upper) and 1.2 
mg/ml (lower), (b, d) X-ray fits for D4-D5 at concentrations of 0.7 mg/ml (upper) 
and 0.6 mg/ml (lower). In panels (b, c, d), the two Guinier plots are arbitrarily 
displaced on their vertical axes for reason of clarity.
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Glycoprotein Guinier analyses P(r) analyses AUC analyses
Rc, (nm) Rxs (nm) Rc/Ro
L (nm) 
from Rc, 
and RXs
L (nm) 
from 7(0) and
[I(Q)Q\q^ o
R(i (nm) M (nm ) L (nm) S°20.w (S)  
SEDFIT
S°20,w (S) 
(DCDT+)
f/fo
SC (X-ray) 3.53 ± 0 .0 3 1.76 ± 0 .0 8 1.44 10.6 11.9 3.66 ± 0 .1 9 3.8 ± 0 .2 13.0 4.2 4.0 (int) 1.55
SC (X-ray) 3.64 ± 0 .1 7 1.63 ±  0.12 1.49 11.3 n.a 3.71 ± 0 .1 2 n.a. n.a. 3.9 (abs)
SC (Neutron) 3.63 ± 0 .2 8 1.30 ±  0.10 n.a. 11.7 13.1 3.73 ± 0 .1 7 3.2 12.0
D1-D3 (X-ray) 3.44 ±  0.27 + 1.07 ±  0.07 f  ^ 1.69 11.3 9.1 3.52 ± 0 .2 7 2.9 12.0 3.1 n.a. 1.42
D4-D5 (X-ray) 3.16 ± 0 .0 4 1.11 ± 0 .0 8 1.70 10.2 10.8 3.15 ±  0.18 2.7 10.0 2.4 2.4 (int) 1.48
2.3 (abs)
Table 4.1 Experimental X-ray and neutron scattering and AUC analyses for SC, D1-D3 and D4-D5
n.a. - data not available 
+ Apparent (see Section 4.2.2)
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protein are elongated, yet SC is more compact than its two fragments D1-D3 or D4- 
D5. This suggests that the SC domains do not form an elongated arrangement as 
depicted schematically in Figure 4.1a.
Assuming that the protein can be represented as a cylindrical shape, the 
lengths of SC, D1-D3 and D4-D5 were calculated from their Rg and R v a lu e s  to be 
10.6-11.3 nm, 11.3 nm and 10.2 nm respectively (Section 4.4). From the 1(0) and 
[I(Q)QJq-m) values, the lengths were calculated to be 11.9 nm, 9.1 nm and 10.8 nm 
respectively (Table 4.1). Despite the presence of cleaved products in the D1-D3 
sample, the similarity of these three lengths is again explained by postulating that SC 
is more compact and folded back upon itself to position the D1-D3 domains adjacent 
to those in D4-D5. If the end-to-end length of a single Ig fold in SC is taken to be 3.7 
nm from the crystal structure of the D1 domain of SC (PDB code 1XED; Hamburger 
et al., 2004; Figure 1.13), then SC, D1-D3 and D4-D5 would be predicted to be of 
lengths 18.5 nm, 11.1 nm and 7.4 nm if fully extended (although this estimate does 
not include the inter-domain and N- and C- terminal linkers). The disparity between 
the observed length of SC of 10.6-11.9 nm (Table 4.1) and the prediction o f 18.5 nm 
shows that SC must be folded back. That the observed length of 10.2-10.8 nm for 
D4-D5 (Table 4.1) is longer than the predicted value of 7.4 nm may result from the 
additional 42 C-terminal residues in SC (Figure 4.1). The two observed lengths of
11.3 nm and 9.1 nm for D1-D3 are in good agreement with the predicted extended 
length of 11.1 nm.
Neutron scattering data for SC confirm the X-ray findings. Neutron data were 
collected for SC concentrations between 0.68 mg/ml to 1.4 mg/ml (Section 4.4.2) as 
a control for possible radiation damage effects on the X-ray Rg measurements, as 
these effects are absent in neutron scattering. The neutron data are complementary to 
X-ray data in that the hydration shell surrounding SC is not detectable (Perkins, 
2001; Section 2.2.2.4). The high negative protein-solvent scattering contrast obtained 
using 100% 2H20  buffers acts as a control of any inhomogeneity effects caused by 
the 19% mass of carbohydrate in SC which has a higher scattering density than that 
of protein. Using the same Guinier Q ranges as those used for the X-ray data, the 
mean of three measurements for the Rg and Rxs values of SC were found to be 3.63 
(± 0.28) nm and 1.30 (± 0.10) nm respectively (Figure 4.3b,d; Table 4.1). The 
decrease in the neutron Rxs value compared to the X-ray Rxs value is attributed to the
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absence of hydration effects on the cross-sectional properties of SC (Boehm & 
Perkins, 2000). The length of SC was calculated from its neutron Rg and Rxs values 
to be 11.7 nm (in good agreement with the X-ray value of 10.6-11.3 nm), and from 
its 1(0) and [I(Q)Q]q->o values to be 13.1 nm (consistent with the X-ray determined 
value of 11.9 nm) (Table 4.1). It was concluded from the consistency of the X-ray 
and neutron data that satisfactory scattering data had been acquired.
The neutron data also permitted the determination of the molecular weight of 
SC using its linear correlation with the l(0)/c value from the Guinier Rq analysis, 
where c is the protein concentration. For proteins measured in 2H20 buffers, and 
normalised against a standard deuterated polymer standard, the observed 1(0)/c value 
of 0.087 (± 0.009) resulted in a molecular weight of 78 (± 8) kDa, where M =  l(0)/c 
x 9 x 105 (SC labelled in Figure 2.5; Boehm et al., 1999). This value is within 2 % of 
the sequence-derived molecular weight of 79.6 kDa, and showed that SC is 
monomeric in solution.
4.2.3 X-ray and neutron distance distribution analyses of SC and its fragments
The transformation of the 1(Q) scattering curve into the distance distribution 
function P(r) confirmed that SC has a folded-back structure in solution. The P(r) 
curves for SC (X-rays and neutrons) and for D1-D3 and D4-D5 (X-rays) resulted in 
reproducible P(r) curves with single maxima (Figure 4.5; Figure 4.6). As a control of 
the P(r) analyses, the Rq values calculated from these were compared with those 
determined in the Guinier analyses. These mean Rg values were 3.66 (± 0.19) nm 
and 3.71 (± 0.12) nm (two SC X-ray samples), 3.73 (± 0.17) nm(SC neutrons), 3.52 
(± 0.27) nm (D1-D3) and 3.15 (± 0.18) nm (D4-D5), all of which were consistent 
with the Guinier analyses (Table 4.1). The maximum M  corresponds to the most 
frequently occurring interatomic distance. These were 3.8 (± 0.2) nm and 3.2 nm 
respectively for the X-ray and neutron P(r) curves for SC, and were slightly smaller 
at 2.9 nm and 2.7 nm for D1-D3 and D4-D5 respectively (Table 4.1). The length L is 
determined from the point where P(r) becomes zero at large r values, and is not 
dependent on shape assumptions. For SC, L was determined to be 13 (± 1) nm and 
12 (± 1) nm from the X-ray and neutron analyses respectively (Figure 4.5a,b; Table
4.1). For the D1-D3 and D4-D5 fragments, L was determined to be 12 (± 1) nm and 
10 (± 1) nm respectively (Figure 4.6; Table 4.1). While the D1-D3 Guinier analysis
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Figure 4.5 X-ray and neutron distance distribution functions P(r) for SC
The maximum of the P(r) curve at M  depicts the most frequently occurring distance 
within the structure. The maximum dimension is denoted by L at the r value where 
the P(r) curve reaches 0. (a, b) The X-ray and neutron P(r) curves for SC resulted in 
M  values o f 3.6 nm and 3.2 nm respectively, and L values of 13 nm and 12 nm 
respectively, (c) P(r) curves are shown for three different sample of SC that are 
estimated from SDS-PAGE to have 100% intact SC (black continuous line, as shown 
in part a), 90% intact SC (red dashed line) or 66% intact SC (blue dashed line). In 
the cleaved samples (blue and red line), SC has been cleaved to yield a mixture of 
SC, D1-D3 and D4-D5. All three P(r) curve show the same M  values of 3.6 nm and 
L values of 13 nm.
(a) SC X-rays
(b) SC neutrons
(c) SC X-rays
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Figure 4.6 X-ray and neutron distance distribution functions P(r) for D1-D3 
and D4-D5
The maximum of the P(r) curve at M  depicts the most frequently occurring distance 
within the structure. The maximum dimension is denoted by L at the r value where 
the P(r) curve reaches 0. (a, b) The X-ray P(r) curves for D1-D3, and D4-D5 
resulted in M  values o f 2.9 nm and 2.7 nm respectively, and L values o f 12 nm and 
10 nm respectively.
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may be affected by cleaved products, this P(r) analysis is expected to reveal the 
maximum length of the intact protein as any cleavage products will be shorter in 
length. This is confirmed by the comparison of three SC P(r) curves for three 
different SC samples, each with a different degree of intact SC cleavage, estimated 
by SDS-PAGE (Figure 4.5c). The three SC samples with 100% intact SC and 
estimated 90% and 33% intact SC all showed no difference in L or M  values. The 
lengths from the P(r) analyses were consistent with those from the Guinier analyses 
(Table 4.1).
4.2.4 Analytical ultracentrifugation analyses of SC and its fragments
The oligomerisation state of SC was determined using sedimentation 
equilibrium (SE) experiments at concentrations between 0.2 and 2.5 mg/ml, 
monitored using both interference and absorbance optics (Section 4.4.3). On the 
assumption that a single species was present, good curve fits with small random 
residuals were obtained (Figure 4.7). SDS-PAGE analyses before and after data 
acquisitions confirmed that any cleavage was not detectable. The resulting SC 
molecular mass values showed a small increase with increasing dilutions from 2.5 
mg/ml (lower panels, Figure 4.7). This increase was attributed to an increased 
electrostatic interaction between SC molecules at higher protein concentrations. 
Regressions of the dilution series in Figure 4.7 resulted in molecular masses of 79.5 
(± 2.9) kDa (interference) and 81.6 (± 5.5) kDa (absorbance) at zero concentration. 
These values agree well with the sequence-derived molecular weight of 79.6 kDa 
calculated on the assumption o f seven biantennary complex-type oligosaccharides 
(19.4% by mass) (Figure 4.1a). The assumption of seven tetraantennary 
oligosaccharides would give an SC molecular mass of 88,800 Da. The SE data 
therefore showed that SC is a monomer in solution and that all seven putative 
glycosylation sites are filled. This is consistent with the molecular mass determined 
by neutron scattering.
The sedimentation coefficient s°2o,w from sedimentation velocity (SV) 
experiments monitors the extent of macromolecular elongation, and is independent 
from the Rg determinations. SV was used to examine both SC and its cleavage into 
the D1-D3 and D4-D5 fragments as well as an extra sample of cleaved SC with an 
estimated equimolar mixture of the three, by incubating an SC sample at room-
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Figure 4.7 Sedimentation equilibrium fits for SC
The curve fits correspond to (a) interference optics and (b) absorbance optics at a 
wavelength of 280 nm, both at a rotor speed of 14,000 r.p.m. In (a), the 
concentrations of SC are 2.5 mg/ml (red), 1.2 mg/ml (blue) and 0.48 mg/ml (green). 
In (b), concentrations are 0.64 mg/ml (red), 0.48 mg/ml (blue), and 0.21 mg/ml 
(green). Circles represent the experimental data and the continuous lines represent 
the fits to these. The curve fit residuals are shown in the smaller panels above the 
exponential fits, using the same colour schemes. The panels below the exponential 
curve fits show the concentration dependence of the observed molecular mass 
values.
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temperature. The SEDFIT c(s) distribution plots identified the s°2o,w values of the 
species present in each sample, and are therefore independent of degradation effects. 
All the calculated and experimental boundary fits are in good agreement (Figure 
4.8a,c; Figure 4.9a,c), with both optical detection systems studied giving similar 
results at all concentration ranges. The c(s) distribution plots showed that SC 
sedimented as a single species at 4.2 S (Figure 4.8b; Table 4.1), whereas major 
species were seen at 3.1 S for D1-D3 and 2.5 S for D4-D5 (Figure 4.9d; Table 4.1). 
This interpretation was confirmed by the three major peaks seen at 4.1 S, 3.0 S and
2.2 S in the cleaved SC sample (Figure 4.8d). The c(s) plot for D4-D5 showed a 
minor peak at 0.7 S (Figure 4.9d). The D1-D3 c(s) analysis showed additional peaks 
at 0.7 S and 2.2 S to indicate more extensive cleavage (Figure 4.9b), which is 
consistent with the X-ray and SDS-PAGE analyses of D1-D3 above. The c(M) 
analyses of the distribution plots represent the c(s) peaks as molecular mass values. 
The three values from Figure 4.8d were estimated as 24.5 (± 5.6) kDa, 44.7 (± 6.2) 
kDa and 79.0 (± 7.2) kDa. These are in good agreement with the expected values of
34.1 kDa, 45.5 kDa and 79.6 kDa from the sequence-derived composition for D4- 
D5, D1-D3 and SC respectively.
The SEDFIT analyses for SC and D4-D5 were corroborated by time- 
derivative analyses of pairs of sedimentation boundaries using the g(s*) method in 
DCDT+ for SC and D4-D5. Good fits with low residuals were obtained (Figure 
4.10). From these, the s°2o,w values were determined to be 4.0 S and 3.9 S for SC 
(interference and absorbance optics respectively) and 2.4 S and 2.3 S for D4-D5 
(interference and absorbance optics respectively) (Figure 4.10; Table 4.1). The D l- 
D3 data could not be analysed by DCDT+.
The s °2o,w values lead to frictional ratios f / f0, where f Q is the frictional 
coefficient of the sphere of volume equal to that of the hydrated macromolecule. The 
f / f0 is a monitor of structural elongation, in which a spherical globular protein will 
have an f / fQ ratio of 1.0, and many globular proteins show an f/ fQ ratio of 1.2 to 1.3. 
For SC, D1-D3 and D4-D5 the f/ fQ ratio were determined to be 1.55, 1.42 and 1.48 
respectively (Table 4.1). The similarity of the three f / f0 ratios shows that all three 
glycoproteins show similar degrees of elongations. As these are consistent with the 
Rg/Ro ratios of 1.44-1.49, 1.69 and 1.70 for SC, D1-D3 and D4-D5, they further 
confirm the folded back structure of SC.
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Figure 4.8 SEDFIT sedimentation velocity fits for SC
(a,c) The sedimentation coefficient distribution c(s) analyses were performed and the 
circles represent the experimental data and the continuous red lines represent the fits 
in the boundary fits. (b,d) The corresponding c(s) plots are shown, in which the 
sedimentation coefficients of the relevant major species are arrowed. (a,b) 
Absorbance data for SC at a concentration of 1.24 mg/ml and a rotor speed of 30,000 
r.p.m., in which only the fits for every fifth scan of the first 100 scans are shown for 
reason of clarity. (c,d) Absorbance data for a sample of cleaved SC (with estimated 
66% intact SC) at a concentration of 0.31 mg/ml and a rotor speed of 42,000 r.p.m., 
in which every fifth scan of the first 110 scans is shown.
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Figure 4.9 SEDFIT sedimentation velocity fits for D1-D3 and D4-D5
(a,c) The sedimentation coefficient distribution c(s) analyses were performed and the 
circles represent the experimental data and the continuous red lines represent the fits. 
(b,d) The corresponding c(s) plots are shown, in which the sedimentation 
coefficients of the relevant major species are arrowed. (a,b) Interference data for D l- 
D3 at a concentration of 1.6 mg/ml and a rotor speed of 42,000 r.p.m., in which 
every sixteenth scan of 500 scans is shown. (c,d) Absorbance data for D4-D5 at a 
concentration of 0.40 mg/ml and a rotor speed of 42,000 r.p.m., in which every fifth 
scan of the first 55 scans is shown.
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Figure 4.10 DCDT+ sedimentation velocity fits for SC and D4-D5
In the time-derivative method g(s*) plots, the experimental data are represented by 
circles, and the fits are shown by the continuous red lines. The goodness-of-fit 
residuals are shown above each g(s*) analysis. The arrowed S2o,w values for SC are 
(a) 4.0 S from interference data at a concentration of 2.5 mg/ml and (b) 3.9 S from 
absorbance data at a wavelength of 280 nm at a concentration of 1.2 mg/ml. The 
corresponding values for D4-D5 are (c) 2.4 S from interference data at 0.73 mg/ml 
and (d) 2.3 S from absorbance data at 0.40 mg/ml. A rotor speed of 35,000 r.p.m. 
was used for SC, and 30,000 r.p.m. (interference) and 42,000 r.p.m. (absorbance) for 
D4-D5.
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4.2.5 Constrained modelling of SC and its fragments
The D1 crystal structure of SC to 0.19 nm resolution has a standard two P- 
sheet sandwich structure composed of the DEBA and A’GFCC’C” p-strands (PDB 
code 1XED; Hamburger et al., 2004; Figure 1.13). This was used as the template for 
the generation of homology models of the SC domains (Section 3.2.1). The D1 
crystal structure showed a mean sequence identity o f 28% with the four D2-D5 
domains (Figure 4.1b). The individual identities ranged from 24% to 36%, where 
over 30% is considered a significant match between the target and the template 
(Sternberg, 1996). The two cysteine residues that form the internal disulphide bridge 
between P-strands B and F (Cys22 and Cys92) were conserved in all five D1-D5 
sequences, suggesting strong structural conservation. Gaps and insertions were 
minimal (except for the deletion of p-strand C” in D5) and were restricted to the 
hyper-variable loop regions between the P-strands. The alignment thus defined the 
sizes o f the five domains D1 to D5, the four linkers between them, and the N- 
terminal and C-terminal peptides. The linker was defined as the residues between the 
end of P-strand G of the preceding domain and the start of P-strand A of the 
following domain (Figure 4.1; Boehm & Perkins, 2000). Homology models for the 
four D2-D5 domains were constructed using MODELLER (Section 3.2.1; Sali & 
Blundell, 1993), all of which were structurally validated using PROCHECK (Section 
3.2.1.1; Laskowski et al., 1993). Seven oligosaccharide chains were attached to the 
D1-D5 models at the sites shown in Figure 4.1b in extended conformations.
In order to create full models for intact SC from the D1-D5 domains, 
randomised conformational libraries of 5,000 unconstrained structures were set up 
for all four linkers so that these could be used to connect the D1-D5 domains. As the 
crystal structure of D1 commenced at Ser2, no library was developed for the three 
residue N-terminal peptide. Lysl was added to the crystal structure of D1 using 
MODELLER in order to complete this linker for the SC modelling. Secondary 
structure analyses o f the 42 residue C-terminal peptide predicted that there is little 
secondary structure (Rost et al., 2003). BLASTP sequence searches of over 39,000 
structures in the PDB (September 2006) did not reveal any significant similarity with 
a structural template for the C-terminal peptide (Schaffer et a l , 2001). The amino 
acid composition showed that there is a high proportion of 12 negatively-charged 
Asp/Glu residues and nine positively-charged Arg/Lys residues in this sequence,
119
together with 14 small Gly/Ala/Ser residues, all of which promotes random 
structures (Sun et al., 2004). Accordingly the C-terminal peptide was modelled in the 
same way as the four linkers as another unconstrained structure.
The modelling of the smallest SC fragment, D4-D5 was used to initiate the 
SC modelling for reason of simplicity. The D4-D5 linker peptide and the C-terminal 
peptide were the only conformational variables. Five trial-and-error searches were 
carried out in which the assumptions made for these two conformations were varied. 
The initial use of unconstrained D4-D5 and C-terminal linkers in Search 1 resulted in 
5000 D4-D5 models, where many were too compact and showed steric overlaps 
between D4 and D5 (blue filled spheres in Figure 4.11d,e,f). The Search 1 D4-D5 
models gave Rg values ranging from 2.10 nm to 3.07 nm, which were too low 
compared to the experimental D4-D5 Rc value of 3.16 nm. Accordingly, Searches 2 
to 5 each generated a linker library of 5000 randomised conformations for the D4-D5 
linker that were constrained to be between 95%-100% of their maximum allowed 
length, but which were left free to reorientate. The maximum peptide bond length 
was 0.35 nm. In each of Search 2, 3, 4 and 5, the C-terminal peptide was set to be a 
minimum length of 5 nm, 7 nm, 9.8 nm and 11.8 nm respectively in order to enforce 
the generation o f a wide range of conformations for this. The combination of 
Searches 2 to 5 gave 6000 models that spanned a wide range of conformational 
separations of the N-terminus and C-terminus from 0.6 nm to 20.6 nm as required 
(Figure 4.1 If). The best-fit models were identified from the 6,000 models using 
filters. Filtering to retain a minimum of 346 hydrated spheres (i.e. retaining only 
those models that have no significantly overlapping regions) and a Rg value between 
3.00-3.20 nm gave 1011 satisfactory models (Table 4.2). Sorting the 1011 models 
using the R factor goodness-of-fit parameter identified the best nine models (yellow 
and red in Figure 4.1 ld,e,f). The best D4-D5 model with an Rg value o f 3.15 nm and 
a Rxs value of 1.14 nm (red in Figure 4.1 ld,e,f) was then selected as this gave the 
closest agreement with the experimental values of 3.16 ± 0.04 nm and 1.11 ± 0.08 
nm respectively. The visual fit of the best-fit D4-D5 calculated I(Q) curve with the 
experimental 1(Q) scattering curve in Figure 4.12d is excellent. The sedimentation 
coefficient of 2.04 S from this best-fit model is close to the experimental values of
2.3 S to 2.4 S (Table 4.2). All nine best-fit D4-D5 models showed that the D4 and 
D5 domains were V-shaped with an extended C-terminal peptide.
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G l y c o p r o t e i n F i l t e r M o d e l s S p h e r e s Rg ( n m ) Rxs ( n m ) R  f a c t o r  ( % ) N - C  t e r m i n a l  d i s t a n c e  ( n m ) s ' m .w  ( S )
S C  ( X - r a y ) N o n e 5000 678-869 3.43-4.71 1.05- 2.00 3.3- 19.4 2.2-22.3 n .a .
R c 268 680-865 3.46-3.75 1.40-2.00 3.4-7.4 3. 1- 18.3 n .a .
R c .  R x s -  N 10 824-865 3.53-3.74 1.71- 1.88 39- 7.4 4.7- 14.4 3.95-4.24
B e s t - f i t 1 850 3.53 1.80 4.4 7.2 4.06
C H O m 1 853 3.52 2.00 5.8 7.2 4.09
L i n e a r 1 1125 4.72 1.42 18.0 21.5 3.38
E x p e r i m e n t a l n .a . 830 3.53 ±  0.03 1.76 ± 0.08 n .a . n .a . 3.9-4.0
S C  ( n e u t r o n ) N o n e 5000 498-625 3. 17- 4.37 1.01- 1.77 3.8- 11.2 2.2-22.3 n a .
R c 268 3.22-3.52 1.24- 1.77 3.9- 7.1 3. 1- 18.3 n .a .
R g .  R x s .  N 10 592-630 3.30-3.51 1.58- 1.74 5.9-7.1 4.7- 14.4 n .a .
B e s t - f i t 1 619 3.30 1.70 6.8 7.2 n .a .
C H O i n 1 616 3.30 1.77 7.4 7.2 n . a
L i n e a r  m o d e l 1 850 4.38 1.33 10.7 21.5 r n a .
E x p e r i m e n t a l n .a . 626 3.63 ±  0.28 1.30 ± 0.10 n .a . n .a . n .a
D 1- D 3 ( X - r a y ) N o n e 1000 421-525 2.47-3.68 1. 19- 1.77 13.2- 16.8 4.6- 15.1 n .a .
R g 65 474-518 3.40-3.49 1.24- 1.44 13.2- 16.5 10.0-148 n . a
R g .  R x s 10 475-509 3.40-3.49 1.24- 1.30 13.2- 15.7 10.2- 13.3 2.64-3.02
B e s t  l i n e a r 1 484 3.40 1.27 13.2 11.7 3.02
C H O m 1 484 3.26 1.24 11.6 11.7 3.00
B e n t  m o d e l 1 507 3 11 1.66 15 8 6.6 3.04
B e s t  h y b r i d 1 n .a . 2.98 1.06 6.0 n .a . n .a .
D 1 d o m a i n 1 179 1.90 0.73 19.9 2.9 1.64
E x p e r i m e n t a l n .a . 474 3.44 ±  0.27 1.07 ± 0.07 n .a . n .a . 3.1
D 4- D 5 ( X - r a y ) N o n e 6000 278-410 2.02-3.71 0 90-1 76 7.3- 18.0 0.6-20.6 n .a .
R g . N 1011 346-410 3.00-3.20 0.98- 1.68 7.7- 17.2 5.3- 19.1 n .a .
R c .  N .  R - f a c t o r 9 346-368 3.06-3.19 1 10-1 22 7.7-8.1 10.5-177 2.00-2.26
B e s t - f i t 1 367 3.15 1.14 8.1 11.6 2.04
C H O i n 1 367 3.13 0.86 8.6 11.6 2.22
L i n e a r  m o d e l 1 384 3.71 1.45 16.4 18.5 1.94
E x p e r i m e n t a l n .a . 356 3.16 ± 0.04 1.11 ± 0.08 n a n a 2.3-24
Table 4.2 Summary of the X-ray and neutron modelling fits for the SC, D1-D3 
and D4-DS solution structures
n.a. - not available
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Figure 4.11 Constrained scattering analyses of the X-ray and neutron data for 
D1-D3 and D4-D5
(a,b,c) The 5000 D1-D3 models represented by blue circles show the outcome of all 
linkers being unrestrained and the 3000 models represented by yellow circled show 
the linker restrained between 95-100% of their maximum length. The final analysis, 
where 1000 models where only the D1-D2 linker was varied is shown by open 
circles. (d,e,f) The 5000 D4-D5 models where all linkers were unconstrained and 
varied are shown by blue circles. The 6000 models where the D4-D5 linker and the 
C-terminal peptide are constrained are shown by open circles. The ten best-fit 
models ( ) and within them the best-fit model ( • )  and the representative poor-fit 
model ( • )  are highlighted. The best-fit models with compact oligosaccharide 
conformations ( • )  and the best-fit hybrid D1-D3 model ( • )  are shown. Panels (a, d) 
compare the Rxs values with the Rg values. Panels (b, e) compare the R factor values 
with the Rg values. Panels (c, f) compare the distance between the N-terminal and C- 
terminal C a residues with the Rg values. The dashed lines correspond to the 
experimental Rq and Rxs values in each case as appropriate.
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Figure 4.12 Best-fit and poor-fit D1-D3 and D4-D5 models for the X-ray and 
neutron data
The colour coding of the models corresponds to that of Figure 4.11. The open circles 
denote the experimental scattering curves, while the continuous lines show the 
modelled curves. A ribbon trace of the model used in each fit is shown. The 
modelled P(r) curves are shown as insets to the right, with the experimental curve in 
black and the modelled curve in colour, (a) The best-fit hybrid D1-D3 curve is a 
dashed line. A ribbon trace of the model used in each fit is shown, with the 
oligosaccharides in cyan. (a,d) The best fit models in red, (b,e) the best-fit models 
with compacted oligosaccharide conformations in green and (c,f) the representative 
poor-fit models in blue are shown.
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A poor-fit D4-D5 model is exemplified by that with the largest Rg value of 
3.71 nm, an Rxs value of 1.45 nm and a sedimentation coefficient of 1.94 S (blue in 
Figure 4.11d,e,f). This model resulted in a large discrepancy with the experimental 
I(Q) curve with a high R factor value of 16.4% and showed a linear arrangement of 
the D4 and D5 domains (Figure 4.12f). This further confirms that the good-fit D4-D5 
models have a V-shaped arrangement of their domains. The best-fit D4-D5 models 
occur in the centre of the distributions of Figure 4.11d,e,f and not at the largest 
separation distances. Another D4-D5 model was created from the best-fit model in 
which the oligosaccharide chains were folded back against the protein surface of D4 
and D5 (green in Figure 4.11d,e,f; Figure 4.12e; ‘CHO in’ in Table 4.2). While the 
Rg value and the sedimentation coefficient from this model were slightly altered, the 
Rxs value was significantly reduced from 1.14 nm to 0.86 nm. This comparison 
favours the existence of an extended oligosaccharide structure in D4-D5.
The modelling of the D1-D3 fragment was examined in five conformational 
searches. As for D4-D5, the use of 5,000 unconstrained D1-D2, D2-D3 and D3-D4 
linkers (Figure 4.1) in Search 1 yielded few models that gave good curve fits and 
compatible Rg or RXs values (blue filled spheres in Figure 4.1 la,b,c). Hence Searches 
2 and 3 were based on 1000 randomised conformations for each of the three linker 
peptides that were each constrained to be at least 95% of its maximum allowed 
length, but which were free to reorientate. Search 4 with 1000 conformations was 
performed with linker lengths set to be 100% of their maximum lengths. The 
resulting D1-D3 models spanned a wide range of Rg values including the 
experimental value, but all of these gave Rxs values that were too high compared to 
the experimental Rxs value (yellow filled spheres in Figure 4.11a,b,c). The D2-D3 
linker is only one amino acid in length (Figure 4.1). For this reason, any movement 
in this linker resulted in steric overlap between the D2 and D3 domains. Hence in 
Search 5, the D2 and D3 domains were joined by a short linker in a single extended 
and fixed conformation. The C-terminal D3-D4 peptide was also fixed in one 
extended conformation. Only the D1-D2 linker was varied in Search 5, and as shown 
in Table 4.2, whilst 65 models show compatible Rg values to the experimental value, 
none show the expected Rxs value of 1.07 nm. The best-fit D1-D3 model with the 
lowest R factor was determined, yet the R factor value was high at 13.2% (red in 
Figure 4.11a,b,c; Table 4.2). All ten best-fit D1-D3 models exhibited linear domain 
arrangements (yellow in Figure 4.11a,b,c; Figure 4.12a). An alternative D1-D3
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model in which the extended oligosaccharide conformations were folded back 
against the protein surface was also unable to account for the reduced Rxs value 
(green in Figure 4.1 la,b,c; Figure 4.12b).
Good D1-D3 curve fits were finally obtained by postulating that the observed 
X-ray scattering curve is a mixture of three-domain and single-domain fragments. 
This heterogeneity had been identified by SDS-PAGE and the c(s) sedimentation 
analyses (Figure 4.09b). Composite scattering curves were computed from the 
extended D1-D3 model that gave the lowest R factor of 13.2% in Search 5 and the 
single D1 model on its own. The sum of 74 % of the D1-D3 curve and 26 % o f the 
D1 curve gave the best curve fit with a good R factor of 6.0 % (black in Figure 
4.11a,b,c; Figure 4.12a). Other poor-fit D1-D3 models were tested to confirm this 
interpretation. For example, the scattering curve of a U-shaped D1-D3 model (blue 
in Figure 4.11a,b,c; Figure 4.12c) similarly combined with the D1 model scattering 
curve were unsuccessful in reducing the R factor or the Rxs value.
The modelling of intact SC was performed using two different approaches. 
Search 1 was based on the use o f 5000 models made from all five unconstrained 
linkers (blue filled circles in Figure 4.13). Convex distributions of the Rxs values as a 
function of the Rg values were observed for both the X-ray and neutron modelling 
fits, where the maximum agreed well with the observed Rg values of 3.53 nm (X- 
rays) and 3.63 nm (neutrons). As desired, the R factor values showed minima at the 
observed Rg values in Figure 4.13b,e. However due to the unconstrained nature of 
this search many of these models showed steric overlap, thus a second approach was 
employed. Search 2 utilised the two best fit models of D1-D3 and D4-D5 and only 
varied the long D3-D4 linker (Figure 4.1). The distributions of the unfilled circles in 
Figure 4.13 showed that, while these followed the same trends as the cyan circles of 
the unconstrained Search 1, Search 2 resulted in fewer sterically overlapping models 
with low Rg values. The best SC structures were identified by filtering based on the 
extent of agreement with the Rg and Rxs values and the lowest R factor values (Table
4.2). Thus 268 SC models agree well with the experimental X-ray Rg value of 3.53 
nm, o f which 70 models agree well with the experimental Rxs value of 1.76 nm. The 
removal o f the SC models that showed partially overlapping domain structures and 
selection of the models with best R factor values then gave the 10 best-fit SC models 
(yellow in Figure 4.13; Table 4.2). Search 2 showed that all 10 best SC models 
showed a folded-back domain arrangement in which the D1-D3 domains are in
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Figure 4.13 Constrained scattering analyses of the SC X-ray and neutron data
The 5,000 SC models represented by blue circles show the outcome of all linkers 
being unrestrained in the generation of the X-ray and neutron SC models. The final 
analysis, where just the D3-D4 linker was varied and D1-D3 and D4-D5 was held 
fixed is represented by 5,000 unfilled circles. The ten best-fit models ( ) and the 
best-fit SC model ( • )  are shown. Separately from this, the best-fit model with 
compact oligosaccharide conformation ( • )  and the representative poor-fit SC model 
( • )  are shown. Panels (a, d) compare the Rxs values with the Rg values. Panels (b, e) 
compare the R factor values with the Rg values. Panels (c, f) compare the distance 
between the N-terminal and C-terminal Coe residues in SC with the Rg values. The 
dashed lines correspond to the experimental Rg and Rxs values in each case as 
appropriate.
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proximity to the D4-D5 domains in an overall J-shaped conformation. The SC 
experimental curve and that calculated for the best-fit model were in good agreement 
(Figure 4.14a,d). This outcome also occurred in the best-fit models from Search 1, 
which also included J-shaped models, although their R factors were slightly higher 
than those from Search 2 (data not shown).
The J-shaped model for SC was tested by three other modelling analyses. The 
neutron modelling analyses in Figure 4.13d,e,f also resulted in the same J-shaped 
best-fit models, and the good curve fit from this is shown in Figure 4.14d. The use of 
a linear domain arrangement for SC showed significantly worsened curve fits (blue 
in Figure 4.13; Figure 4.14c,f). Both tests support the J-shaped model. The 
modelling analyses provided partial insight on the location of the 19% carbohydrate 
content of SC. When the extended orientations in the best fit model of Figure 4.14a 
were replaced by those in which the oligosaccharides were turned toward the protein 
surface of the D1-D5 domains, slightly worsened effects on the curve fits were 
usually seen (green in Figure 4.13; Figure 4.14b,e).
Hydrodynamic modelling of the sedimentation coefficients for SC, D1-D3 
and D4-D5 supported the J-shaped SC model, the linear D1-D3 model and the V- 
shaped D4-D5 model. The best-fit SC models resulted in predicted sedimentation 
coefficients of 4.06 S, 3.02 S and 2.04 S in that order (Table 4.2). These values are in 
good agreement with the experimentally-observed values of 3.9-4.0 S, 3.1 S and 2.3-
2.4 S respectively, therefore further supporting the outcome of the X-ray and neutron 
modelling o f SC.
These results of SC modelling are summarised in the form of a comparison of 
SC with IgAl and IgA2 monomers (Figure 4.15), the superimposition of the ten 
best-fit SC models (Figure 4.16), a stereo view of the best-fit model with the 
carbohydrate chains shown (Figure 4.17a), an electrostatic map of D1-D3 and D4- 
D5 (Figure 4.17b) and a view showing the availability of dlgA binding motifs within 
SC (Figure 4.17c).
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Figure 4.14 Best-fit and poor-fit SC models for the X-ray and neutron data
The colour coding of the models corresponds to that in Figure 4.13. The open circles 
denote the experimental scattering curves, while the continuous lines show the 
modelled curves. A ribbon trace of the model used in each fit is shown. The 
modelled P(r) curves are shown as insets to the right, with the experimental curve in 
black and the modelled curve in colour. Panels (a, d) show in red the best-fit model. 
Panels (b, e) show in green the best-fit model with folded-back oligosaccharide 
chains. Panels (c, f) show in dark blue the extended poor-fit model that gives poor 
curve fits to the experimental scattering curves. The carbohydrate chains in each 
model are shown in cyan.
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Cys311
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D1 D2vl D3 D4 D5
Cys502
(c) D1-D3 (d) SC (e) D4-D5
Figure 4.15 Comparison of the solution scattering models for monomeric IgAl 
and IgA2 with the best-fit models of SC and its D1-D3 and D4-D5 fragments
(a,b) The models for IgAl and IgA2 are shown in green and blue respectively, in 
which the Cys311 are highlighted in yellow. (c,d,e) The best-fit D1-D3, SC and D4- 
D5 models are shown in the same colouring scheme used in Figure 4.1a for the D l- 
D5 domains. In the SC model, the covalent contact residue Cys502 on D5 is 
coloured yellow. The carbohydrate chains in each model are shown in cyan.
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(a)
Figure 4.16 Ten best-fit models of SC
(a) The ten best-fit models ( in Figure 4.13) are shown with the D1-D3 domains 
shown in the same orientation in all ten models (i-x). Model (i) is the best-fit model 
from Figure 4.14a. The five domains are coloured from blue (N-terminus) to red (C- 
terminus) to follow that of Figure 4.1a. (b,c) Two orthogonal views of the ten best-fit 
SC structures superimposed. The best-fit model from part a(i) is shown in the same 
colour scheme and the other nine models are shown in grey. Residue Cys502 in D5 
that covalently binds to IgA Cys311 in SIgA is coloured yellow.
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4.3 Discussion
Molecular modelling and crystal structures of SC domains from rabbit, 
mouse, and human have already contributed insight into the topology of SC and 
plgA complexes (Coyne et al., 1994; Corthesy et a l, 1996; Hamburger et al., 2004; 
Section 1.4.2.1). However, the analyses of only protein fragments, the use of strictly 
predictive computer-based modelling, and the absence of information on 
carbohydrate residues all represent limitations when compared to the determination 
of the three-dimensional structure of full-length SC. Given the demonstrated 
importance of free SC in innate immunity and its role in endowing SIgA with 
optimal biological activity, our study of intact SC provides further light on the 
structure-function relationship in the whole protein.
In view of the importance of glycosylation, and inter-domain flexibility to the 
SC structure, all the analyses were conducted in near-physiological solution 
conditions using complementary methods based on X-ray and neutron scattering and 
AUC. When analysed with constrained modelling programs, the three-dimensional 
structure of free SC was found to be a compact, folded-back structure (Figure 4.15). 
The ten best-fit models of Figure 4.16a are very similar to each other, with all 
showing a J-shaped structure as shown by their superimposition in Figure 4.16b,c. 
This emphasises the robustness of the procedure. The J-shaped structure of SC is 
confirmed by the P(r) lengths (Figure 4.5), the sedimentation coefficients (Figure 
4.8) and the constrained modelling (Figure 4.13; Figure 4.14). The point at which SC 
is folded back to form a compact J-shaped structure was located to the junction 
between the D3 and D4 domains by two different modelling searches of all five SC 
domains. The linker between D3 and D4 is unusually long in SC, being ten residues 
in length (Figure 4.1). In support of this model, the length and sedimentation 
coefficient data obtained with the D1-D3 and D4-D5 fragments both fit perfectly 
with the SC structure (Figure 4.6; Figure 4.9; Figure 4.11; Figure 4.12), and 
reinforce the accuracy of the SC model.
This compact, folded-back structure of SC was unexpected in the light of the 
extended domain arrangements of the structurally-related seven Ig-like domains in 
carcinoembryonic antigen and four Fnlll domains in anosmin-1 (Boehm & Perkins, 
2000; Hu et a l 2005). In fact, the linker between D3 and D4 comprises 10 amino 
acids, and is unusually long (Figure 4.1). This length provides the requisite 
flexibility needed to form the “J-shaped” conformation. It is noteworthy that the
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cleavage site between Arg336 and Ser337 is exposed on the surface of SC in all ten 
best-fit SC structures (Figure 4.16), thus accounting for its susceptibility to 
proteolytic cleavage, and justifying the appearance of the two D1-D3 and D4-D5 
polypeptides. The Poisson-Boltzmann electrostatic maps o f the carbohydrate-free 
surfaces in D1-D3 and D4-D5 (Figure 4.17b) suggest that there are spatially well- 
defined areas of negative and positive charges respectively on these which can attract 
each other to form the bent structure of SC. The short linker between D2-D3 may act 
to reduce flexibility between D2 and D3, hence facilitating the binding of D4 and D5 
to these.
The modelling showed that the 42 residue C-terminal peptide connecting SC 
with the transmembrane domain of the plgR exhibits no particular folding (Figure 
4.1; Figure 4.16). This suggests that D1-D5 of SC can freely move with respect to 
this C-terminal linker, thus enhancing their likelihood to encounter and interact with 
their cargo represented by polymeric immunoglobulins present in the lamina propria. 
This length and lack of secondary structure of the C-terminal peptide facilitates 
access to proteases in order that unbound SC or SIgA can be released at mucosal 
surfaces (Figure 1.11). The unfolded nature of the linker also suggests that the 
structure of SC identified in this work will be similar to that when incorporated in its 
plgR precursor, as steric interference with components on the cell membrane will be 
limited.
The seven Asn residues that constitute the attachment points for carbohydrate 
residues are located on the same side of SC, implying that these carbohydrate 
moieties are clustered within a restricted part of the SC structure (Figure 4.17a). The 
curve fits showed a preference for modelling the seven oligosaccharide chains in 
conformations extended from the protein surface (Figure 4.13; Figure 4.14a,b). Their 
precise spatial locations remain unassigned by constrained modelling, and it is likely 
that most of the oligosaccharides are free to interact with multiple target structures. 
A preferential distribution of oligosaccharides on one face o f SC can contribute to 
tether free and/or IgA-bound SC efficiently to antigenic structures found at the 
surface of microorganisms (Perrier et al., 2006).
In the context of the interaction between SC and dlgA, the location o f the 
oligosaccharides on one face of SC leave uncovered, and thus accessible, the three 
CDR-like motifs present in D l, as well as Cys502 in D5 (Figure 4.17c). These 
constitute two critical elements for the interaction with dlgA (Bakos et al., 1994;
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Cys502
Figure 4.17 Detailed views of the best-fit model of SC
D1-D5 are coloured from blue (N-terminus) to red (C-terminus) to follow that of 
Figure 4.1a. (a) Stereo view of the best fit model of Figure 4.13a. (b) Electrostatic 
views of the continuous protein surfaces seen in the D1-D3 and D4-D5 models Red: 
acidic; blue: basic. The oligosaccharide chains are numbered to follow that of Figure 
4.1a. (c) Structure of the best-fit SC model rotated by 180° highlighting SC Cys502 
(yellow) and the three CDRs (pink) in D l.
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Fallgreen-Gebauer et al., 1993). Indeed, the oligosaccharides of SC are not involved 
in the interaction with dlgA, but are nonetheless important for its resistance to 
proteases and its correct anchoring within the mucus laying on the epithelium 
(Phalipon et a l, 2002). Studies comparing deglycosylated and partly glycosylated 
D l revealed nearly equal binding affinities for dlgA (Hamburger et a l, 2004). 
Recovery of the Fd fragment after digestion of dlgA with proteases from intestinal 
fluids indicates that the Fc portion of the Ab is particularly sensitive in the absence 
of bound SC (Crottet & Corthesy, 1998). As illustrated in Figure 4.15, the 
determined length of SC fits very well with its likely association with dlgA without 
affecting the F(ab ’ ) 2  structure and the hinge region. This is supported by the 
observation that dlgA and SIgA of the same specificity show the same affinity for 
their cognate Ag (Lullau et al., 1996). Additionally, the labile link between D3 and 
D4 of SC is likely to be concealed within dlgA, thus providing an explanation to the 
mutual protection previously observed between SC and dlgA (Crottet & Corthesy, 
1998; Almogren et a l,  2003). This translates into the generation o f a complex 
macromolecule optimally designed to operate at mucosal surfaces.
Only J chain-containing polymeric immunoglobulins can interact with plgR 
(Hendrickson et al., 1996) and it is thought it is the C-terminal part o f the J chain 
that binds to SC. Although not covalent, this interaction is a critical step for transport 
of the plgR complex to mucosal surfaces (Johansen et al., 2001). Pentameric IgM 
and dlgA are both transported by plgR, but it is known that D l can discriminate 
among Ig subclasses in favour of IgA (Bakos et a l, 1994), and that D1-D2 and D l- 
D3 bind dlgA, but not monomeric IgA nor IgG (Bakos et a l,  1991a), explaining the 
predominance of SIgA in secretions. As far as dlgA is concerned, the integrity of D2 
and D3 is necessary for a covalent interaction to take place (Frutiger et al., 1987; 
Crottet & Corthesy, 1999), yet without establishing close contact with the dlgA 
backbone (Bakos et a l, 1991b; Crottet & Corthesy, 1999). This argues in favour of 
the “zipper effect” model initiated by the interaction of D l with one Ca chain of 
plgA, progression to the J chain and establishment o f the disulphide bond between 
Cys311 of the Ca2 domain of IgA and Cys502 of D5 of SC (Fallgreen-Gebauer et 
al., 1993).). In the J-shaped structure of SC (Figure 4.16; Figure 4.17), Dl remains 
appropriately exposed to initiate this “zipper” binding interaction.
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Several unsolved issues remain, such as the identification of the residues in 
SC that are involved in the interactions with the J chain and with the residues 402- 
410 of the Ca3 domain in the Fc fragment o f IgA (Hexham et al., 1999). Likewise, 
even though the CDR-like motifs of D l have been extensively described 
(Hamburger et al., 2004), their ligands on the dlgA molecule remain unidentified. In 
this respect, based on electron micrographs of human dlgA displaying a partly bent 
tail-to-tail arrangement (Figure 1.9; Dourmashkin et al., 1971), one can envisage that 
the Fc domain spacing in dlgA is suitable for the binding of one SC molecule 
(Figure 4.15). Whether the compact conformation of SC opens up upon binding to 
dlgA is another open issue. Moreover, structural differences between human IgAl 
and IgA2 exists (Boehm et al., 1999; Furtado et al., 2004) which are consistent with 
findings showing distinct binding modes of human SC to dlgAl and dIgA2 
(Almogren et a l, 2007a). Knowledge of the three-dimensional structure of SC 
represents a mandatory first step toward the resolution of the complete structure of 
SIgA. If we assume that the model of SC is not that different to the extracellular 
portion of plgR, it might also be helpful per se to map binding site(s) to permit 
epithelial drug targeting through specific interaction with plgR itself (Ferkol et al., 
1995; White & Capra, 2002; Braathen et a l, 2006).
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4.4 Materials and Methods
4.4.1 Preparation of recombinant SC and its fragments
Recombinant human SC was produced in transfected Chinese hamster ovary 
cells and purified as reported (Phalipon et a l, 2002). The SC samples were kindly 
prepared by Dr. Clementine Perrier and Dr Blaise Corthesy. Filtered aliquots were 
stored at 4°C in PBS (116 mM NaCl, 10.4 mM Na2H P04, 3.2 mM NaH2P 0 4, pH 
7.2) prior to use for scattering and ultracentrifugation. Cleaved SC fragments were 
obtained from purified SC samples that were stored for at least 6 months at 4°C. 
Separation was performed by chromatography onto a 1 m x 1.6 cm Superdex-200 
column (Amersham-Pharmacia) in PBS. Pools of fractions containing fragments D l- 
D3 and D4-D5 were concentrated using Amicon Ultra (30 kDa molecular weight 
cut-off) and Centricon YM-10 (10 kDa molecular weight cut-off) filters respectively 
(Millipore). Further purification of fragments D1-D3 and D4-D5 was achieved by 
repeating chromatography onto the Superdex-200 column. To identify the SC 
cleavage site, N-terminal sequencing of purified D4-D5 from a polyvinylidene 
difluoride blot was performed by Edman degradation at Alta Biosciences (University 
of Birmingham, UK).
For the SAXS and AUC experiments, samples were recovered in PBS. For 
neutron scattering, the buffer was Dulbecco’s PBS (137 mM NaCl, 2.7 mM KC1, 8.1 
mM Na2H P04, 1.5 mM KH2P 0 4, pH 7.5), made up in 100% 2H20 . The neutron 
samples were dialysed at 6°C into this 100% 2H20  buffer for 36 h with four buffer 
changes. The two buffer densities in H20  solvent were predicted to be 1.00485 g/ml 
and 1.00543 g/ml respectively from these compositions using the program 
SEDNTERP (Laue et al., 1992). The SC, D1-D3 and D4-D5 concentrations were 
determined using absorption coefficients of 12.3, 7.1 and 18.7 (1%, 280 nm, 1 cm 
path length) that were calculated from its composition by assuming the presence of 
seven biantennary complex-type oligosaccharides Man3GlcNAc4Gal2NeuNAc2 
(Perkins, 1986; Figure 4.1). The partial specific volume v for SC, D1-D3 and D4- 
D5 was calculated to be 0.717 ml/g, 0.717 ml/g and 0.718 ml/g respectively from 
their compositions (Perkins, 1986; Section 3.3.1). The calculated molecular mass 
values for SC, D1-D3 and D4-D5 were 79.6 kDa, 45.5 kDa and 34.1 kDa
" X  ' X  orespectively, their unhydrated volumes were 99.7 nm , 56.9 nm and 42.7 nm
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3 3 3respectively, and their hydrated volumes were 132.2 nm , 75.5 nm and 56.7 nm 
respectively (assuming 0.3 g H20/g  glycoprotein).
4.4.2 X-ray and neutron scattering data collection
SAXS data was obtained during two independent sessions on the Beamline 
ID02 at the European Synchrotron Radiation Facility (ESRF), Grenoble, France at a 
ring energy of 6.0 GeV (Narayanan et a l, 2001; Section 2.2.3.2). The experiments 
were performed in 16-bunch mode with a storage ring current ranging from 92 mA 
to 53 mA (SC) and 4-bunch mode with a storage ring current ranging from 41 mA to 
23 mA (D1-D3 and D4-D5). The final data analyses were performed with a sample- 
to-detector distance of 3.0 m, which yielded a Q range from 0.07 nm '1 to 2.1 nm’1. 
Protein samples were measured at three or four concentrations between 0.62 mg/ml 
to 2.0 mg/ml (SC), 0.39 mg/ml to 1.6 mg/ml (D1-D3) and 0.40 mg/ml to 0.73 mg/ml 
(D4-D5). Data were acquired using five or ten time-frames, with each frame lasting 
for 0.5, 1, 2 or 4 seconds. Comparisons of the first time frame with the fully-merged 
ten time-frames were used to establish the absence of radiation damage. Data 
reduction involved the calibration of the detector intensities using a Lupolen sample 
and the Q range using a silver behenate salt standard respectively.
Neutron scattering data for SC was collected in one session on Instrument 
LOQ at the pulsed neutron source ISIS at the Rutherford Appleton laboratory, 
Didcot, UK (Heenan et al., 1997; Section 2.2.3.3). The pulsed neutron beam was 
derived from a proton beam current of 172-173 pA. Data acquisition were for fixed 
monitor counts of 80 x 106 or 160 x 106, during runs which lasted 1-2 hours for 
concentrations between 0.62 mg/ml to 2.0 mg/ml, measured at 15 °C. Other details 
including the Guinier analyses to determine the radius of gyration Rq, the cross- 
sectional radius of gyration Rxs and the calculation of the distance distribution 
function P(r) using GNOM, for which the Q range was 0.08-2.06 nm '1 are described 
in Section 2.2.4.
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4.4.3 Sedimentation equilibrium and sedimentation velocity data acquisition
AUC was performed at 20°C on a Beckman XL-I instrument, equipped with 
an AnTi50 rotor. SE data sets for SC were acquired over 45 h using six-sector cells 
with solution column heights of 2 mm at rotor speeds of 8,000 r.p.m., 11,000 r.p.m.,
14.000 r.p.m., 18,000 r.p.m. and 23,000 r.p.m, until equilibrium had been reached at 
each speed as shown by the perfect overlay of runs measured at five hour intervals 
(Section 2.3.4). Nine concentrations of SC between 0.20 mg/ml to 2.50 mg/ml were 
studied using absorbance optics at 280 nm and by interference optics. SV data for 
SC, D1-D3 and D4-D5 was acquired over 16 h at rotor speeds of 20,000 r.p.m.,
25.000 r.p.m., 30,000 r.p.m, 35,000 r.p.m (and 42,000 r.p.m. for D1-D3 and D4-D5) 
in two-sector cells with column heights of 12 mm (Section 2.3.3). SC was studied at 
five concentrations from 0.30 mg/ml to 2.50 mg/ml. D1-D3 and D4-D5 were each 
studied at two concentrations of 0.39 mg/ml to 1.6 mg/ml and 0.40 mg/ml to 0.73 
mg/ml respectively. For the DCDT+ g(s*) time-derivative analyses for SC and D4- 
D5, successive absorbance and interference scans were recorded at 5 min intervals at 
280 nm, the shortest interval possible under standard measurement conditions. The 
optimal rotor speeds were 30,000 r.p.m. to 42,000 r.p.m. for the interference and 
absorbance data sets. The subtraction of pairs o f boundary scans versus cell radius 
eliminates systematic errors from baseline distortions in the cell windows and 
permits the averaging of several pairs of subtractions. The extrapolation of individual 
subtractions to the start time gives the g(s*) function, which was computed using 
DCDT+ version 1.16 (Philo, 2000). The sedimentation and diffusion coefficients 
were determined using between 4 to 20 scans were used in order to ensure that the 
time broadening effects were negligible. The alternative approach to determine S°20,w 
is to perform direct boundary fits of up to 700 absorbance and interference scans to 
the Lamm equation using SEDFIT (Schuck, 1998). In this, c(s) size-distribution 
analyses were computed in order to identify the species that were sedimenting in the 
sample, from which the s°2o,w values were determined from the observed peak 
positions. The final SEDFIT analyses were optimised until the r.m.s.d and visual 
appearance of the fits and the residual bitmaps were satisfactory.
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4.4.4 Conformational searches for the best-fit solution model of SC
The SC sequence was taken from residues 19-603 of the polymeric 
immunoglobulin receptor (SWISSPROT code P01833) (Figure 4.1b). Using this 
sequence,BLASTP was employed to identify a known structural template with the 
closest sequence similarity to SC. Consequently, the homology modelling of the D2- 
D5 domains was based on a topological sequence alignment with the crystal 
structure of the D l domain at 0.19 nm resolution (PDB code 1XED; Hamburger et 
al., 2004; Section 3.2.1). The secondary structure of the crystal structure was 
identified using DSSP (Kabsch & Sander, 1983). The start and end of domains D2 to 
D5 is defined as residues 1 to 104 in Figure 4.1. Homology models of domains D2- 
D5 were created using MODELLERv7 (Sali & Blundell, 1993). The seven V-linked 
biantennary oligosaccharide chains Man3 GlcNAc4 Gal2NeuNAc2 were incorporated 
into these D l to D5 structures using procedures described for IgAl and IgA2 and 
based on the oligosaccharide structure seen in human IgGl Fc (Boehm et al., 1999; 
Furtado et al., 2004; Deisenhofer, 1981).
In order to model the interdomain linker structures, the C-terminal peptide 
543-AVEER....AEEKA-585 and the four interdomain linker peptides 109- 
VSQGPGLL-116, 219-VLK-221, 324-WQLFVNEESTIR-335 and 440-IEGEPNL- 
446 were initially created in an extended P-strand conformation with an additional 
residue at the start and end as required. INSIGHT II 98.0 molecular graphics 
software with BIOPOLYMER, DISCOVER, HOMOLOGY and DELPHI modules 
(Accelrys, San Diego, CA, USA) was used on Silicon Graphics 02  and OCTANE 
Workstations. A total of 5,000 random linker conformations for each of the five 
peptides were generated from the starting p-strand model by a molecular dynamics 
simulation using DISCOVER3 (Boehm et a l,  1999; Aslam et a l, 2003). A wide 
range o f conformations was generated by performing the simulation at a temperature 
of 773 K. First, the peptide structure was subjected to energy minimisation for 300 
iterations. After a temperature equilibration step of 5,000 fs, the simulation was run 
for 500,000 fs. The linker structure was saved every 100 fs to produce the linker 
library. Length constraints were applied when required in order to limit the 
conformational variability of the linkers. As residues SP of the N-terminal peptide 
KSP were already observed in the Dl crystal structure, the first residue K was added 
to the crystal structure using MODELLER v7 (Sali & Blundell, 1993).
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Each full model for SC was created in Search 1 by superimposing the four 
main-chain atoms of each N-terminal and C-terminal linker residue onto the D1-D5 
domain in question. After this, the duplicated residues were deleted from the SC 
model prior to the scattering calculations. Models for D1-D3 and D4-D5 were 
created independently from those for SC in up to five conformational searches. The 
final D1-D3 and D4-D5 models were then used in Search 2 for SC models in which 
only the 324-WQLFVNEESTIR-335 linker was varied.
4.4.5 Debye scattering and sedimentation coefficient modelling of SC
Each SC, D1-D3 and D4-D5 model was converted into Debye spheres in 
order to calculate X-ray and neutron scattering curves for comparison with the 
experimental curves (Section 3.3.3). For SC, D1-D3 and D4-D5, trial runs showed 
that a cube side length of 0.542 nm in combination with a cutoff o f 4 atoms 
consistently produced sphere models within 95% of the total unhydrated volume of 
99.7 nnT, 56.9 nm3 and 43.8 nm3 respectively calculated from their compositions. 
Hence the optimal totals of unhydrated spheres for the neutron modelling of SC, D l- 
D3 and D4-D5 were 626, 268 and 353 respectively. Since the hydration shell 
surrounding glycoproteins is detected by X-ray scattering, the sphere models were 
accordingly adapted by adding spheres to the surface of the unhydrated models using 
HYPRO (Ashton et al., 1997) based on 0.3 g H2 O / g glycoprotein to result in a total 
hydrated volume of 132.2 nm3 for SC, 75.5 nm3 for D1-D3 and 56.7 nm3 for D4-D5. 
The optimal totals of hydrated spheres for SC, D1-D3 and D4-D5 were 830, 474 and 
356 respectively. The calculations for the generation of the Debye scattering curves 
I(Q) for the models is give in Section 3.3.4. A flat background correction of 2.7% of 
1(0) was applied to the final neutron scattering curve fits in Figure 4.13 and Figure 
4.14 to allow for a uniform incoherent scattering contribution from residual protons 
in the sample (Section 2.2.2).
The number of spheres N  in the unhydrated and hydrated models after grid 
transformation was used to assess steric overlap between the Dl -  D5 domains, 
where models showing less than 95% of the optimal total were discarded. The 
models were initially assessed by calculation of the X-ray and neutron Rg and Rxs 
values in the same Q ranges used for the experimental Guinier fits. Models that 
passed these Rg and Rxs filters were then ranked using a goodness-of-fit agreement
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with the experimental curves (i^-factor), defined by analogy with protein 
crystallography and based on the Q range extending to 2.0 nm '1. (Beavil et al., 1995) 
The sedimentation coefficients S2 o?w were calculated directly from the SC, 
D1-D3 and D4-D5 PDB files using HYDROPRO. The hydration shell surrounding 
SC and its two fragments was represented by the recommended value o f 0.31 nm for 
the atomic element radius for all atoms as an empirical approximation (Sun et al., 
2004; Garcia de la Torre et al., 2000)
4.4.6 SC Protein Data Bank accession code
The ten best-fit SC a-carbon co-ordinate models have been deposited in the 
PDB with the accession codes 20CW  (Figure 4.16; Table 4.2).
141
Chapter Five
Implications of the Near-Planar Solution Structure of Human Myeloma Dimeric 
IgAl for Mucosal Immunity and IgA Nephropathy
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5.1 Introduction
Immunoglobulin A (IgA) is the most abundant antibody class found in mucosal 
surfaces and is also the most heterogeneous human antibody class. IgA occurs in serum 
predominantly as monomeric IgAl (with around 13% polymeric IgA) and at mucosal 
surfaces as (usually) dimeric IgA (dlgA) covalently linked with secretory component, 
with generally slightly more IgAl than IgA2 (Kerr, 1990). dlgA interacts with the cell- 
surface Fca receptor (FcaRI; CD89), which is present on the surface of neutrophils, 
monocytes, macrophages and eosinophils to perform immune functions (Morton et al., 
1996). An increased polymeric IgAl level in serum and mesangial polymeric IgAl 
depositions can be associated with IgA nephropathy (IgAN) which is the most common 
form of chronic glomerulonephritis world-wide (Barratt & Feehally, 2005).
This chapter focuses on the structure of myeloma dlgAl in serum (Figure 5.1). 
The three-dimensional structures of the different forms of polymeric IgA are not well 
understood. Structures for intact IgA at medium resolution for monomeric human IgAl 
and IgA2 together with the covalent adduct of IgAl with human serum albumin have 
been determined by constrained scattering modelling (Boehm et al, 1999; Furtado et al., 
2004; Almogren et al., 2006). The overall structure of human myeloma dlgA has been 
observed by electron microscopy as a tail-to-tail arrangement of the Fc regions in the 
two IgA monomers (Bloth & Svehag 1971; Munn et al., 1971; Feinstein et al., 1971; 
Nezlin, 1998; Figure 1.9). However the conditions of electron microscopy work using 
heavy metal stains in vacuo can be harsh, and the solution arrangement of the monomers 
in dlgAl is unknown up to now. The size of dlgAl, together with its high glycosylation 
and long flexible hinge and tailpiece regions, suggest that its crystal structure will be 
hard to achieve (Figure 5.1; Figure 5.2). In such a situation, X-ray and neutron scattering 
and analytical ultracentrifugation combined with constrained modelling, will result in a 
medium resolution structure determination that will reveal the first molecular details of 
the two IgA monomers within dlgA (Perkins et al., 2008). Myeloma dlgAl is shown to 
be formed as a near-planar molecule in solution with a bent arrangement of Fc regions 
in which the J chain does not act as a spacer between them. Its structure rationalises the 
accommodation of the J chain within dlgAl, as well as several known effector functions 
of dlgAl, particularly its interaction with FcaRI receptors on cells of the immune
143
system, and the interaction with secretory component in relation to the formation of 
SIgA. Insight is also provided into the role of dlgAl in the development of IgAN.
5.2 Results
5.2.1 Purification of human myeloma dlgA l
The conventional purification of polymeric IgA from normal human serum is 
lengthy and labour intensive, and is inadequate for purifying the polymeric forms of 
IgA. (Delacroix et a l, 1982; Loomes et al, 1991). A procedure based on thiophilic 
resins with a binding capacity of over 28 mg of immunoglobulins per ml of resin allows 
rapid purification of immunoglobulins which bind selectively to the resin whilst almost 
all the other serum proteins do not (Sun et al, 2005; Almogren et a l , 2007).
For the work presented in this chapter, dlgAl was purified from anonymised 
human myeloma serum selected for its high polymer content (Figure 5.3). The myeloma 
serum had an immunoglobulin content of IgA at 15 g/1, with a dimer to monomer ratio 
of 2:1, while IgG and IgM were present at 7 g/1 and 1.5 g/1 respectively. dlgAl was 
shown by non-reducing SDS-PAGE to be well resolved from monomeric IgAl in 
subsequent S-300 gel filtration (Figure 5.3a,b). Reducing SDS-PAGE showed the 
expected bands corresponding to the IgAl heavy chain at 62 kDa, and the light chain at 
30 kDa (Figure 5.3c). Monoclonal anti-K light chain and anti-human J chain antibodies 
were used in Western blots to confirm the presence of dlgAl (Figure 5.3d). In Sephacryl 
S300 size-exclusion gel filtration, dlgAl eluted as a single symmetrical peak (data not 
shown). The dlgAl sample was concentrated for scattering and ultracentrifugation data 
collection.
5.2.2 X-ray and neutron scattering analyses of dlgA l
The averaged solution arrangement of the two IgAl monomers within dlgAl 
was analysed by comparing X-ray scattering data I(Q) for dlgAl with previous X-ray 
data for serum IgA (Boehm et a l, 1999; Furtado et a l, 2004; Almogren et a l, 2006). 
Data were collected at dlgAl concentrations between 0.6 mg/ml to 1.2 mg/ml at the 
ESRF. The comparison of data from a single time frame exposure with the average over 
ten consecutive time frames showed that the X-ray Guinier analyses were unaffected by
144
Figure 5.1 The domain structure of d lgA l
dlgAl is formed by two IgAl monomers that are covalently linked with the J-chain 
(green). Each IgAl heavy chain (blue) contains the V h , C h I ,  Ch2 and Ch3 domains, and 
each light chain (red) contains the Vl and Cl domains. The variable (V) and constant 
(C) domains are highlighted with green and purple borders respectively. The 
complementarity-determining regions (CDR: black crescents), the 23-residue hinge 
peptide (pink), and the 18-residue C-terminal tailpiece (blue) are highlighted. Inter­
domain disulphide bridges are shown as an X. Cys471 in one tailpiece of each Fc region 
is disulphide-bridged with Cysl5 and Cys69 in the J chain. The N-linked 
oligosaccharide sites (•) at Asn263 and Asn459 on dlgAl and Asn49 on J chain, and the 
five O-linked oligosaccharides in each hinge ( o )  are shown.
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Figure 5.2 The sequence of an IgAl monomer and J chain
The IgAl variable domains (green), heavy chain constant domains (blue) and light chain 
constant domains (red) are separated by linkers (black underlined). The hinge region 
(pink) and tailpiece (pink), the six sets of CDR residues (underlined), the FcaRI 
receptor binding residues (orange), two N-linked oligosaccharide sites (yellow 
background) and five O-linked oligosaccharide sites (blue background), and 
Cys311/Cys471 (yellow with black background) are highlighted. The residue numbering 
of the IgA heavy chain constant domains follows that of IgAl Bur. The J chain sequence 
(white with green background) is shown, with the N-linked oligosaccharide (black with 
yellow background) and Cysl5/Cys69 (yellow with black background) is highlighted.
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Figure 5.3 Purification of human myeloma dlgA l
(a) Chromatogram of an S-300 gel filtration column showing separation of the different 
molecular forms of IgAl from the serum of a myeloma patient, (b) Western blot using 
an anti-IgAl Ab of non-reducing SDS-PAGE for every third S-300 eluted fraction from 
(a), (c) Reducing SDS-PAGE of the dlgAl peak fractions, (d) Western blot of the dlgAl 
preparation after S-300 gel filtration using (1) anti-J chain or (2) anti-K lght chain Abs. 
(Taken from Almogren, 2003).
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the exposure time, indicating that radiation damage or X-ray induced aggregation effects 
were absent. The time-averaged runs were thus used for data analyses. At the lowest Q 
values (where Q = 4 n sin 0 A.; 20 = scattering angle; X = wavelength), these analyses 
resulted in linear plots in Q ranges of 0.10-0.17 nm'1 that gave Rq values within 
satisfactory Q.Rg limits (Figure 5.4). The X-ray Rg value for dlgAl from eight values 
was 8.65 ± 0.27 nm (Figure 5.4a; Table 5.1). This is significantly larger than the RG 
value of 6.20 ± 0.13 nm and 5.18 ± 0.09 nm for monomeric IgAl and IgA2 (Boehm et 
al., 1999; Furtado et al., 2004; Table 5.1). The anisotropy ratio Rg/Ro (where Ro is the 
Rg value of the sphere with the same volume as the hydrated glycoprotein) for dlgAl 
was 2.16, where that for monomeric IgAl and IgA2 and the IgAl-HSA complex were 
1.99, 1.66 and 2.13 respectively. This showed that the formation of the dimer from the 
monomer had increased the degree of elongation of the structure.
X-ray cross-sectional Guinier analyses resulted in the Rxs-i and Rxs-2 parameters 
that monitor the shorter axes of dlgAl. The In (I(Q).Q) vs. Q2 plots showed two linear 
region in Q ranges of 0.20 -  0.28 nm'1 and 0.56 to 1.04 nm"1 (Figure 5.4c,d). The Rxs-i 
value of 3.94 ± 0.18 nm for dlgAl is almost double that for monomeric IgAl, IgA2 and 
the IgAl-HSA complex which are 2.20 nm, 2.47 nm and 2.31 nm respectively (Table
5.1). This indicates that the IgAl dimer is significantly different in shape from the 
monomer. The Rxs-2 value of 1.43 ± 0.07 nm is close to the RXs-2 of 1.56 nm, 1.47 nm 
and 1.31 nm for IgAl, IgA2 and IgAl-HSA. The similarity of these four RXs-2 values is 
interpreted to show that the Fab regions retain their conformationally distinct identity 
within the monomeric and dimeric structures. Assuming that dlgAl can be 
approximated as an elliptical cylinder in shape, the combination of the Rg and Rxs-i 
values resulted in an overall length L for dlgAl of 25 nm (Table 5.1). The comparison 
of this length with that of 20.1 nm for IgAl and 16.1 nm for IgA2 showed that the 
increased size of dlgAl does not correspond to a simple extended end-to-end association 
of the longest axes of the monomers.
Neutron scattering data were obtained for dlgAl at 0.6-1.5 mg/ml in 100% 2H20 
buffer as a control for possible X-ray-induced radiation damage. This buffer corresponds 
to a high negative protein-solvent scattering contrast, instead of the high positive 
contrast observed by X-rays, hence acts as a control of any internal scattering
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Figure 5.4 X-ray and neutron Guinier analyses for dlgA l
The Q.Rg and Q.Rxs ranges used to determine the RG, RXs-i and RXs-2 values are 
represented by filled circles between the arrowed data points. (a,b) The X-ray and 
neutron Q ranges used for the Rg analyses were 0.10 to 0.17 nm'1. (c,d) The Q ranges 
used to calculate the Rxs.j and RXS-2 values were 0.20 to 0.28 nm'1 and 0.56 to 1.04 nm'1 
respectively. In (a, c, d), the X-ray fits for dlgA 1 correspond to concentrations of 1.16 
mg/ml (upper) and 0.58 mg/ml (lower. In (b), the neutron fits for dlgAl correspond to 
1.16 mg/ml (upper) and 0.83 mg/ml (lower).
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Protein
Data Guinicr analyses P(r) analyses
Rg (nm) Rxs-i (nm) Rxs- 2  (nm) L (nm) Rg (nm) L (nm) M l (nm) M2 (nm)
D im er ic  I g A l X-ray 8.65 ± 0.27 3.94 ± 0.18 1.43 ± 0.07 25.0 8.67 ±0.17 26.0 4.9 9.9
Neutrons 7.60 ± 0.05 n.a. n.a. n.a. 7.42 23.0 5.1 10.1
M o n o m e r ic  I g A l X-ray 6.20 ±0.13 2.20 ± 0.26 1.56 ± 0.16 20.1 6.12 21.0 3.7 9.1
(Boehm et a l 1999) Neutrons 6.11 ±0.18 2.17 ± 0.23 1.18 ± 0.12 19.8 n.a. n.a. n.a. n.a.
M o n o m er ic  l g A 2 m ( l ) X-ray 5.18 ±0.09 2.47 ± 0.09 1.47 ± 0.08 16.0 5.21 ±0.15 17.0 4.5 6.8
(Furtado et al., 2004) Neutrons 5.03 ±0.01 2.21 ± 0.10 1.04 ± 0.06 15.5 5.12 ± 0.01 17.0 4.5 n.a.
I g A l - H S A X-ray 7.47 ±0.31 2.31 ±0.11 1.31 ±0.05 25.0 7.36 ±0.01 25.0 4.9 8.3
(Almogren et al., 2006) Neutrons 7.09 ±0.01 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
T ab le  5.1 C o m p a r iso n  o f  G u in ier  and  P(r) a n a lyses  for  h u m a n  d l g A l  w ith  three  fo rm s  o f  m o n o m e r ic  IgA
n.a. -  not available
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inhomogeneity effects caused by the estimated 9.6% carbohydrate content of dlgAl. 
Neutron scattering data also provided a different view of dlgAl in that the hydration 
shell surrounding dlgAl is visible by X-ray scattering, but not by neutron scattering 
(Perkins, 2001). The dlgAl neutron Rc from two values was 7.60 ± 0.05 nm (Figure 
5.4b; Table 5.1). This value supports the X-ray RG determination. However this is 1 nm 
less than the X-ray Rc value, and the difference is larger than seen previously with IgA 1 
and IgA2 (Boehm et a l 1999; Furtado et al., 2004). The non-visibility of the hydration 
shell when visualised by neutrons has a large effect, and this is attributed to the 
positioning of most of the hydration shell at large distances from the centre of the dlgAl 
structure. The neutron anisotropy ratio RJRo  was 2.08, and is similar to the X-ray- 
derived value to confirm an elongated conformation of dlgAl in solution. As the 
consequence of poor counting statistics at large Q, no neutron Rxs-] or Rxs-2 values could 
be determined for dlgAl. There is a linear relationship between the LOQ Guinier 1(0)/c 
values for proteins measured in 2H20  buffers and normalised against a standard 
deuterated polymer and the protein molecular mass Mr, where Mr = 1(0)/c x 9.105 
(Boehm et al., 1999). The dlgAl neutron Guinier l(0)/c value of 0.33 ± 0.05 resulted in 
a Mr value of 297 ± 45 kDa (Figure 2.5). This measurement is within error of the 
composition-derived value of 345 kDa for dlgAl, showing that the scattering data 
corresponded well to the expected composition of dlgAl with nine N-linked and 20 O- 
linked biantennary oligosaccharides (Figure 5.1; Figure 5.2).
Structural dimensions are provided by the transformation of the I(Q) curve into 
the distance distribution function P(r) curve. The mean Rg values determined from the 
X-ray and neutron P(r) curves were 8.67 ± 0.17 nm (6 values) and 1 A l  nm (2 values) 
respectively. These RG values were therefore consistent with the Guinier Rc values 
(Table 5.1). The X-ray P(r) curve for dlgAl was of better quality than the neutron P(r) 
curve for reason of better signal-noise ratios (Figure 5.5). Nonetheless the two curves 
were reproducible in that both showed a double peak with maxima of M l and M2 that 
were each located at similar r values of 4.9-5.1 nm and 9.9-10.1 nm respectively (Table
5.1). These two peaks correspond to an abundance of interatomic vectors within the 
dlgAl solution structure. The dlgAl peak M l at 4.9-5.1 nm was also evident in the P(r) 
curve for monomeric IgAl and IgA2 and for myeloma IgAl-HSA at 3.7 nm, 4.5 nm and
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Figure 5.5 X-ray and neutron distance distribution functions P(r) for dlgA l
The concentrations of dlgAl were 1.15 mg/ml (X-rays) and 1.16 mg/ml (neutrons). The 
maxima M l and M l  of the P(r) curve depict two frequently occurring distance within 
the dlgAl structure. The positions of M l and M l are 4.94 nm and 9.88 nm respectively 
(X-rays) and 5.06 and 10.14 nm respectively (neutrons). The length of IgAl is denoted 
by L at the r value where the P(r) curve reaches 0. The L values for dlgAl were 26 nm 
(X-rays) and 23 nm (neutrons).
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4.9 nm respectively (Table 5.1). This M l peak is assigned to the most commonly 
occurring distance within a single Fab or Fc region, given that each is approximately 8 
nm long. Hence the M l peak in Figure 5.5 is consistent with the well-defined existence 
of the Fab region within the solution structure of dlgAl. The peak M2 at 9.9-10.1 nm is 
of greater intensity than the peak M l when this is compared with monomeric IgA 1 and 
IgA2 (Boehm et al, 1999; Furtado et al., 2004). The reason for this intensity difference 
may be that there are a large number of interatomic vectors between the four Fab 
regions in the dimer that are close to 10 nm and held in a comparatively inflexible 
arrangement. The maximum length L is determined from where the P(r) curve reaches 
zero at large r values, and L is determined independently of shape assumptions. The 
dlgAl X-ray and neutron maximum length L was found to be 26 nm and 23 nm 
respectively. The shorter L value with neutrons indicates that a significant proportion of 
the hydration shell is located at the periphery of the dlgAl structure. Simple geometric 
considerations of planar end-to-end arrangements of two monomer structures suggested 
by Figure 5.1 readily leads to L values slightly greater than 26 nm. Hence it can be 
concluded that the dlgAl solution structure is composed of an extended arrangement of 
two monomers joined at the end of their Fc regions, and that the two monomers are not 
positioned as a more compact solution structure that might resemble a bouquet of four 
Fab flowers positioned on two Fc stalks.
5.2.3 Analytical ultracentrifugation of dlgAl
In order to confirm the molecular mass and oligomerisation state of dlgAl, 
sedimentation equilibrium (SE) experiments were performed at six concentrations 
between 0.07 mg/ml and 1.0 mg/ml and at six rotor speeds using both interference optics 
and absorbance optics at 280 nm. On the assumption that a single species was present, 
SE fits were carried out with nine curves at each dlgAl concentration using both data 
types (Section 5.4.3). The individual fits gave molecular mass values that ranged 
between 280 kDa to 345 kDa (Figure 5.6a,b). Their extrapolation to zero concentration 
gave a mean molecular mass of 335 kDa (± 15) kDa (Figure 5.6c). These are within 
error of the molecular mass of 345 kDa calculated from the sequence of dlgAl if the 29 
N-glycosylation sites in this are all occupied by biantennary oligosaccharides. Had the
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Figure 5.6 Sedimentation equilibrium analyses for dlgAl
dlgAl was analysed using (a) interference and (b) absorbance optics at concentrations of 
1.0 mg/ml (red), 0.65 mg/ml (blue) and 0.35 mg/ml (green). Circles represent the 
experimental data and the continuous lines represent their fits. The curve fit residuals are 
shown in the panels above the exponential fits, using the same colour scheme. The (c) 
panel below shows any dlgAl concentration and speed dependence of the observed 
molecular weights. The rotor speeds are denoted by (□ ) 8,000 r.p.m., (A ) 11,000 
r.p.m., and (▼) 14,000 r.p.m. (c) Calculations of the best-fit line and its extrapolation to 
zero gave a dlgAl molecular mass value of 335.0 ± 15 kDa.
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N-glycosylation of dlgAl corresponded to 29 tetraantennary oligosaccharides, the 
molecular mass would have been 357 kDa. This determination confirmed the neutron 
molecular mass calculation (Section 5.2.2).
The sedimentation coefficient s°2o,w provides an independent measure of 
macromolecular elongation to the Rg value. For dlgAl, sedimentation velocity (SV) 
experiments were performed at four speeds between 10,000 r.p.m. and 25,000 r.p.m. 
using two concentrations of 0.53 mg/ml and 1.0 mg/ml (Section 5.4.3). The c(s) 
distribution plots using SEDFIT software to process all the scans identifies the 
sedimenting species that are present in the sample. All the experimental and fitted dlgAl 
boundaries showed good visual agreement with satisfactory r.m.s.d. values (Figure 
5.7a,b). The resulting c(s) distribution plots showed that only a single species of dlgAl 
was present and that this had a s°2o,w value of 9.7 S (Figure 5.7c,d). The conversion of 
the c(s) plots to molecular mass distributions c(M) showed that this species 
correspondeds to a molecular mass value of 342 (±11) kDa. This agreed well with the 
SE dlgAl molecular mass of 335 (± 15) kDa and sequence-derived molecular mass of 
345 kDa. No higher oligomers were detected in the c(s) plots (Figure 5.7c,d). A different 
SV analysis based on 4-20 scans at the centre of the sedimentation experiment using the 
g(s*) method in DCDT+ software confirmed the SEDFIT results. Here, the dlgAl 
absorbance and interference scans gave s°20,w values of 9.8 S and 9.9 S respectively 
(Figure 5.8). The SEDFIT and DCDT+ determinations agree well with previous 
literature reporting a s°2o,w value of 10 S (Dourmashkin et al., 1971), 9.65 S (Feinstein et 
a l , 1971) and 9.2-9.3 S (Bjork & Lindh, 1974). The sedimentation coefficient s°2o,w 
leads to the frictional ratio £Ifo, where f 0 is the /  value of the sphere with the same 
volume as the hydrated glycoprotein. Its value for dlgAl of 1.63 is slightly larger than 
those of 1.56 found for monomeric IgAl and 1.53 for monomeric IgA2 (Furtado et al., 
2004). This indicates that dlgAl is more elongated than IgAl. This is consistent with the 
X-ray and neutron scattering results reported above, and shows that dlgA 1 is formed as 
an extended arrangement of two IgAl monomers.
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Figure 5.7 d lgA l sedimentation velocity c(s) distribution analyses using SEDFIT
(a,b) The circles represent the experimental data and the continuous red lines represent 
the fits, where only every sixth scan of the 120 scans used in the Lamm fits is shown for 
reason of clarity. The interference scans for dlgAl at a concentration of 0.96 mg/ml and 
a rotor speed of 20,000 r.p.m. are shown in (a), while the corresponding absorbance 
scans at 280 nm are shown in (b). The scans were recorded at 5 min intervals. (c,d) The 
corresponding c(s) plots are shown from which the sedimentation coefficient for dlgAl 
was determined to be 9.7 S.
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Figure 5.8 Time-derivative sedimentation velocity analyses of d lgA l using DCDT+
In the g(s*) plots, the experimental data are represented by circles, and the fits are 
shown by the continuous red lines. The goodness-of-fit residuals are shown above each 
g(s*) analysis. The arrowed S2o,w values for dlgAl using (a) interference and (b) 
absorbance optics are 9.8 S and 9.9 S, respectively. The fits are based on data for dlgAl 
at 0.96 mg/ml and a rotor speed of 20,000 r.p.m. The fits were determined from totals of 
4-20 scans mid-way through the sedimentation experiment shown in Figure 5.7a,b.
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5.2.4 Constrained modelling of the dlgAl solution structure
Constrained modelling of the X-ray data was used to determine the solution 
structure of dlgAl. Two cycles of constrained molecular modelling fits were performed 
(Table 5.2). The dlgAl modelling was initiated using the monomeric IgAl solution 
structure model and the sequence and composition of dlgAl (PDB code 1IGA; Boehm 
et al., 1999). The monomeric IgAl solution structure was assumed to be unchanged 
when incorporated into dlgA 1. The 18 kDa J chain domain was initially not included in 
the dlgAl constrained modelling because it comprises only 5.1% by mass of the dlgAl 
structure, and it is located centrally in the dlgAl structure where it will minimally 
perturb the scattering curve (Figure 5.1). These assumptions were each subsequently 
explored in control calculations (see below).
In the first cycle of fits, five modelling searches were performed. The generation 
of a sufficient number of trial dlgAl models assumed that the two monomer IgAl 
structures would be connected end-to-end through their Fc regions as shown 
schematically in Figure 5.1. This is consistent with the 26 nm length from the P(r) 
analyses (Figure 5.5a) and the dimensions of the IgAl monomer (Section 5.2.2) and the 
known covalent linkages between the J chain and the tailpiece in each monomer. A 
dummy atom position was defined between the two monomers in order to act as the 
origin for the rotations and translations required to generate the dlgAl models (Figure 
5.9a; Section 5.4.4). The five searches each created 6,859 models from an initially- 
planar starting model, shown in Figure 5.9a. All five searches held Monomer 1 fixed, 
and rotated Monomer 2 about the dummy atom about the X-, Y- and Z-axes between 0° 
and 180° in 10° steps. Search 1 systematically explored all possible orientations between 
Monomers 1 and 2. Searches 2-5 repeated this to explore the effect of increasing the Fc- 
Fc separation between the IgAl monomers. Searches 2-5 allowed for the possibility that 
the J chain acts as a spacer between the two IgAl monomers, separating the two ends of 
the Fc regions. Thus in Searches 1, 2 and 3, the starting position of Monomers 1 and 2 
were separated by 1.40 nm, 2.78 nm and 4.60 nm respectively between the base of the 
two Fc regions arranged coaxially with respect to each other (defined in Section 5.4.4). 
In Searches 4 and 5, while a separation of 2.78 nm was used again, Monomer 2 was now 
translated 2.0 nm and 4.0 nm respectively along the X-axis to explore asymmetry in
158
Filter for best-fit models M odels Hydrated  
spheres (TV)
X-ray R 0 
(nm)
X-ray 
Rxs-i (nm)
X-ray  
R xs - 2  (nm)
Neutron 
R (; (nm)
X-ray 
R  Factor
Neutron  
R  Factor
nOs 20, w
(S )
Monomer orientation fits 
(fit cycle one)
None 6859 2215-3700 6.51-9.01 1.87-5.37 0.93-2.16 5.97-7.94 5.5-20.6 5.9-14.7 n.a.
N, Ra  (O  Figure 5.9) 1410 3426-3700 8.22-9.01 3.86-5.37 1.21-1.94 7.28-7.94 5.5-11.0 5.9-9.4 n.a.
N, Rg> R-XS-l, RxS-2 54 3565-3681 8.22-8.52 3.92-4.33 1.36-1.51 7.30-7.53 5.5-7.5 7.5-9.3 n.a.
N, Ra, Rxs-i, Rxs-2, R  Factor 10 3587-3649 8.22-8.52 4.22-4.33 1.42-1.51 7.34-7.53 5.5-5.9 7.5-8.0 9.76-9.89
Best-fit (Figure 5.1 li) 1 3612 8.32 4.31 1.51 7.41 5.5 7.6 9.85
Fab conformational fits 
(fit cycle two)
N, R a, Rxs-i, Rxs-2, R Factor 10 3884-3933 8.70-8.89 3.78-4.11 1.58-1.70 7.49-7.63 5.5-5.7 7.3-8.0 8.84-9.03
Best-fit (Figure 5.16c; Figure 5.19) 1 3932 8.61 4.11 1.66 7.49 5.5 7.7 8.94
Experimental values n.a. 3606 8.65
±0.27
3.94
±0.18
1.43
±0.07
7.60
±0.05
n.a. n.a. 9.70 (SEDFIT) 
9.85 (DCDT+)
Poor-fit dlgAl models
•  (Figure 5.1 lj) 1 3616 7.87 4.13 1.57 7.12 10.6 9.7 10.17
A  (Figure 5.1 Ik) 1 3630 8.94 5.29 1.65 7.91 10.6 7.7 9.35
■  (Figure 5.111) 1 3559 7.76 3.54 1.61 7.00 10.8 11 10.18
Table 5.2 Summary of the X-ray and neutron modelling fits for the dlgA l solution structure
n.a. -  data not available
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Figure 5.9 The starting model for the d lgA l fit-cycle one searches and the 
orientations of the best-fit models for dlgAl
(a) The starting dlgAl molecule (red) with a separation of 1.40 nm is shown in relation 
to the X-, Y- and Z-axes. The X- and Y-axes are in the plane of the paper, and the Z-axis 
is perpendicular to this. The dummy atom acting as the centre of rotation between 
Monomer 1 and Monomer 2 is shown in green. Monomer 1 is held fixed in the searches, 
(b, c, d) Projections in the XY, XZ and YZ planes are shown of the 1410 best-fit 
structures (O) from the 1.40 nm search that satisfy the absence of steric overlap and RG 
filters (Table 5.2).The 54 ( • )  and 10 best-fit structures ( ) are highlighted. The best-fit 
model corresponds to a X, Y, Z rotation of 30°, 170°, 30° ( • ) .  The poor fit models ( • ,  
A, ■ ) show X-, Y- or Z-axis rotations close to 90°.
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dlgAl. Each search yielded 6,859 models, giving a total of 34,295 dlgAl models from 
the five searches. The scattering curves and their parameters were calculated from the 
models (Section 5.4.4; Section 3.3.4) and then compared with the experimental data.
dlgAl was revealed to have a near-planar structure in solution from the 6,859 
models from Search 1 (open circles in Figure 5.10). The initial removal of bad-fit 
models based on the absence of steric overlap (i.e. selecting models with at least 3606 
spheres) and the similarity of the modelled and experimental Rg values showed that only 
1,410 dimer models passed this filter (open circles in Figure 5.9; Table 5.2). This filter 
removed models with X-axis and Z-axis rotations of 90° (blue in Figure 5.9 and Figure 
5.10; Figure 5.11j,k,l), ruling out structures in which the two monomers were 
perpendicular to each other. Further filtering was based on the selection of Rxs-i and 
Rxs-2 values that were within 5% of the experimental values. This gave 54 dlgAl models 
(red, green and yellow circles in Figure 5.9 and Figure 5.10; Table 5.2). By this, all the 
models with Y-axis rotations of 90° in Figure 5.8, this showed that only near-planar 
dlgAl models fit the scattering data. No completely planar structures (i.e. with both the 
X- and Y-axis rotations close to 0° or 10° in Figure 5.9b) gave good fits. The best ten of 
these 54 models (red and yellow circles in Figure 5.9 and Figure 5.10; Table 5.2) were 
identified by their lowest R factor values which ranged from 5.5% to 5.9% (Table 5.2). 
The best-fit dlgAl model has the lowest R factor of 5.5% (red circles in Figure 5.9 and 
Figure 5.10; Table 5.2). This showed a near-planar structure with an X-, Y- and Z-axis 
rotation of 30°, 170° and 30° (Figure 5.1 li; Figure 5.12). It gave visually good curve fits 
out to a Q value of at least 1 nm' 1 for both the X-ray and neutron data, and reproduced 
the M and L values and the general appearance of the P(r) curves (Figure 5.1 la,e). The 
ten best-fit dlgAl models all showed a small degree of non-planarity (X-axis rotations 
between 0° to 40°; Y-axis rotations between 150° to 20°; Z-axis rotations between 20° 
to 40°). All ten models show that the two Fc regions of the monomers are approximately 
coaxial, but exhibit a small degree of bend between the two monomers (Figure 5.12).
The best-fit dlgAl structure accounted for the large difference between the X- 
ray and neutron RG data. The superimposition of an a-carbon view of this model with 
both the unhydrated and hydrated sphere models showed that a larger proportion of the 
hydration spheres occupied voids within the Fab region (i.e. those between the two V
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Figure 5.10 Outcome of the dlgA l modelling from fit-cycle one
The parameters for 6859 rotational models of dlgAl from the 1.40 nm search are shown 
as black open circles in all four panels. In Search 1, colour coding of the best-fit and 
poor-fit models follow that in Figure 5.9. The poor-fit models are arrowed in (a) for 
clarity. The results of Searches 2, 3, 4 and 5 are shown as green, yellow, pink and blue 
filled spheres respectively. The dashed lines indicate the experimental RG, Rxs-i or Rxs-2 
values.
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Figure 5.11 X-ray and neutron scattering curve fits for the best-fit model for dlgAl 
and three poor-fit models from fit-cycle one
The colour coding and shape scheme follows that of Figures 5.9 and Figure 5.10. Panels 
(a,e,i) show the best-fit dlgA 1 model from fit cycle one. The experimental I(Q) and P(r) 
curves are in black, and the red lines are the modelled best-fit curves. The P(r) curve is 
shown as an inset in the top right comer. The ribbon trace of this best-fit dlgAl model is 
shown in (i), with the (X, Y, Z) rotation and the carbohydrate chains (cyan) shown. The 
tip-to-tip distance between the two Fab regions in an IgAl monomer is arrowed in (i). 
Panels (b,f,j), (c,g,k) and (d,h,l) show the curve fits and structure of three poor fit 
models in which the two monomers are perpendicular to each other.
163
(30,150,30)
IV
(40,180,30)(40,170,30)
(a)
(30,170,30) (30,160,30)
(0,20,40) (50,30,20) (10,30,40)
CDRs,
CDRs
Cys311
Cys471
.Tailpiece
Figure 5.12 Best-fit models for dlgAl from fit-cycle one
(a) The ten best-fit dlgAl models from fit cycle one are shown projected on the XY 
plane, with the Fc-Fc regions in the same orientation in all ten views ( Figure 5.9; 
Table 5.2). Monomer 1 and 2 are shown in green and blue respectively. The best-fit 
dlgAl model from Figure 5.1 li is model (i). (b,c) Two orthogonal views of the best-fit 
model for dlgAl from Figure 5.1 li are shown. Heavy chains (blue), light chains (red), 
CDR residues (black), hinge regions (pink), tailpiece (purple) and residues in the Ch2 
and Ch3 domains that bind to the FcaRI (orange) are shown. Cys311 in the Ch2 domain 
and Cys471 in the tailpiece are highlighted in yellow, and carbohydrate chains are 
shown in cyan.
(10,150,40) (30,30,30)
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and C domain pairs), the O-glycosylated hinge peptides, and the upper part of the Fc 
region between the two Ch2 domains. As these hydration spheres are far from the centre 
of mass of the dlgAl structure, they have a proportionately larger effect on the Rg 
values. This is reflected in the shift of the minimum in the distributions of 
approximately 8.5 nm for X-rays in Figure 5.10a to approximately 7.6 nm for neutrons 
in Figure 5.10d.
The outcome of the first cycle of fits was corroborated by four further analyses.
(i) The near-planarity of the deduced dlgAl structure was clearly supported by 
the poor I(Q) and P(r) fits in Figure 5.11 b,c,d obtained with three out-of-plane dlgAl 
structures (blue symbols in Figure 5.9 and Figure 5.10). This result argues against a 
previously-discussed perpendicular arrangement for the two Fc regions (Munn et al., 
1971; Feinstein et al., 1971).
(ii) No improved dlgAl fits could be obtained with the increased separations 
between Monomers 1 and 2 in Searches 2-5. For Search 1, the lowest /^-factors of the 
best 54 dlgAl mdoels (yellow, green and red circles in Figure 5.10) agree well with the 
experimental Rg, Rxs-i and Rxs-2 values indicated by dashed lines in Figure 5.10. For 
Searches 2-5 (shown as green, blue, yellow and pink backgrounds respectively in Figure 
5.10), the Rg values of the models increased with an increased separation at the base of 
the Fc regions, and consequently deviated away from the experimental Rg value.
(iii) The effect of the J chain on the fit was examined by adding the D4 domain 
model of SC to four possible positions around the centre of the best-fit dlgAl structure 
(Chapter 4) (grey and green in Figure 5.13a). The position of the J chain that least 
affected the R factor of the best-fit model from Figure 5.1 li was determined (green in 
Figure 5.13a). This J chain position was located proximate to two IgAl tailpieces in the 
plane between two Fc regions, and agreed with the previous modelling of the IgM 
pentamer (Figure 1.7; Perkins et a l, 1991). As in the IgM modelling, it is stressed that 
both J chain model and its orientation within dlgAl are arbitrary. There is no crystal 
structure for this, although an eight stranded beta-barrel structural model and a two- 
domain model have been proposed (Zikan et al., 1985; Frutiger et al., 1992; Section 
1.3.3.1). The addition of the J chain to the best-fit dlgAl model caused small reductions 
in the X-ray RG, Rxs-i and Rxs-2 values of 0.01-0.07 nm, and the R factor to increase by
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Figure 5.13 Effect of adding J chain to d lgA l models from Search 1 of modelling 
fit-cycle one
(a) The best-fit dlgAl structure from Figure 5.1 li is shown in red with the four 
considered positions of the J chain also shown (J chain 1, green; J chains 2-4, grey). 
(b,c,d) The parameters for 6859 dlgAl models with J chain in position 1 included are 
shown. Compare with Figure 5.10a,b,c. (e) The difference in the R factor (pink box) 
between the X-ray scattering curve of the best-fit dlgAl model from Figure 5.1 li with 
no J chain present (red line; Figure 5.1 la) with the J chain present (green line) is 0.7%.
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0.7% (Figure 5.13e). Search 1 was also repeated in full with the J chain added in the 
same position (Figure 5.13b,c,d). Near-planar dlgAl structures were again obtained, and 
the best-fit J chain-containing dlgAl R factor increased by only 0.3%. This showed that 
the outcome of Search 1 was not significantly perturbed, as seen by comparing Figure 
5.12b-d to the Search 1 results, open circles in Figure 5.10a-c.
(iv) The crystal structure of IgAl Fc was superimposed upon the Fc structure in 
the IgAl model to show that this had little effect on the fits (Figure 5.14). The r.m.s.d. 
of the 418 superimposed a-carbon atoms was 0.43 nm, and the overall dimensions were 
unchanged (Figure 5.14a). The resulting RG, Rxs-i and Rxs-2 values only differed from 
the Search 1 best-fit model by 0.02 nm, 0.06 nm and 0.07 nm respectively, and the R 
factor improved slightly from 5.5 to 5.4% (Figure 5.14b).
A second cycle of curve fits was performed to investigate randomised 
reorientations in the Fab regions in dlgAl. The dimeric Fc region from the best-fit 
model of Figure 5.1 li was used to initiate this. Constrained modelling searches were 
performed to follow Method 2 used previously for monomeric IgAl (Boehm et al., 
1999; Section 5.4.4). A total of 3,000 dlgAl structures were created by superimposing 
four Fab regions and four identical IgAl hinges onto the Fc dimer to create the dlgAl 
model (Section 5.4.4). The randomised hinges spanned maximum lengths of 6.5 nm to
9.0 nm (Figure 5.15d) in order to test a sufficient range of Fab orientations, and this was 
verified by the minimum observed Figure 5.15a. The curve fits showed that, while the 
same minimum R factor of 5.5% was obtained again (Table 5.2), the modelled X-ray RG, 
Rxs-i and Rxs-2 values were now in better agreement with the experimental values 
(Figure 5.15). The good curve fits of Figure 5.11 a,b were similar to those of Figure 
5.16a,b. The superimposition of the 32 best-fit models (green, yellow and red in Figure 
5.15) showed that a small conformational family of best-fit structures had resulted in 
which the Fab regions displayed an extended and mostly T-shaped arrangement relative 
to their adjacent Fc region (Figure 5.17). All four Fab regions were conformationally 
independent of each other. When compared with the solution structure for monomeric 
IgAl (Boehm et a l, 1999; Figure 1.8a), the Fab regions were again positioned in 
approximately the same plane as the Fc region. However the comparison of Figure 5.1 li 
and Figure 5.16c shows that the Fab regions were displaced slightly upwards above the
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Figure 5.14 Effect of adding human IgAl Fc crystal structure to the best-fit d lgA l 
structure from fit-cycle one
(a,b) The best-fit dlgAl model from Figure 5.1 li (red) and the IgAl Fc crystal structure 
(blue; PDB code 1OW0; Herr et al., 2003b) are shown superimposed, (b) The X-ray 
scattering curve of the dlgAl models is shown in the same colour scheme as (a). The 
superimposition r.m.s.d value and difference in R factors between the scattering curves 
are shown (pink boxes).
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Figure 5.15 Outcome of the dlgAl modelling from fit-cycle two
The parameters for 3,000 models of dlgAl in which only the Fab regions and hinges are 
conformationally varied are shown as black open circles. The 32 ( • )  and 10 ( ) best-fit 
structures are shown. The best-fit dlgAl model ( • )  is shown (Table 5.2). The dashed 
lines indicates the experimental X-ray (a,b,d) RG or (b,c) Rxs-i or Rxs-2 values (d) The 
dependence of the X-ray RG values of the dlgAl models on the hinge distance between 
the a-carbon atoms of Pro221 and His242 (Figure 5.1; Figure 5.2).
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Figure 5.16 Scattering curves for the best-fit dlgAl model from fit-cycle two
The (a) X-ray and (b) neutron experimental I(Q) and P(r) curves are in black, and the 
red lines are the modelled best-fit curves. The P(r) curve is shown as an inset in the top 
right comer, (c) The ribbon trace of this best-fit model (red) and the carbohydrate chains 
(cyan) are shown.
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Figure 5.17 Superimposition of the 32 best-fit dlgAl structures from fit-cycle two
(a,b) Two orthogonal views of the superimposition of the 32 best-fit dlgAl models ( •  
Figure 5.15) are shown. The Fc region is shown as a red ribbon at the centre of dlgAl, 
while the 32 sets of four Fab regions are shown as blue a-carbon traces.
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Fc regions in dlgAl. Hence dimer formation may cause the Fab regions to move away 
from the Fc region when compared to the monomer. This suggests that the extended 
hinge conformation between the Fab and Fc region is semi-flexible.
The experimental sedimentation coefficient s°2o,w value of 9.7 S for dlgAl was 
compared with the values of the ten best-fit dlgAl models (Figure 5.12a; Figure 
5.18). Using the previously established simulation procedure (Section 5.4.4), the 
calculated S°20, w values for the ten dlgAl models ranged between 9.76 S to 9.89 S from 
the first cycle of fits and between 8.84 S to 9.03 S from the second cycle of fits (Table 
5.2). The best-fit dlgAl models have s°2o,w values of 9.85 S (fit-cycle one) and 8.94 S 
(fit-cycle two). While the second cycle of fits gives lower values, the modelled values 
agree well with the experimental s°2o,w value of 9.7 S (SEDFIT) and 9.85 S (DCDT+) 
(Table 5.2). This agreement supports the X-ray scattering best-fit dlgAl model of Figure
5.1 li and Figure 5.16c.
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Figure 5.18 Ten best-fit dlgAl structures from fit-cycle two
(a) The ten best-fit dlgAl models from fit-cycle two ( in Figure 5.15) are shown 
projected onto the XY plane, with the Fc-Fc regions in each one shown in the same 
orientation in all ten views. Monomer 1 and 2 are shown in green and blue respectively. 
The first model (*) is the best-fit dlgAl model from Figure 5.16c.
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5.3 Discussion
dlgA is a building block of SIgA, one of the most important components of the 
immune system. dlgA in serum is less well characterised, although it is believed that an 
altered structural form of dlgAl is central to the pathology of a number of IgA mediated 
diseases such as IgAN, the most common form of chronic glomerulonephritis. No 
differences in function between normal and myeloma dlgAl have been identified, thus 
the location of the IgAl monomers in myeloma dlgAl from this study will offer an 
insight into structure-fimction relationships of dlgAl. Myeloma dlgAl bound to Jacalin 
and was eluted in the same way as ‘normal’ dlgAl (Almogren & Kerr, 2007). The 
myeloma dlgAl was cleaved by IgA proteases, other proteases and by a glycosidase 
from a Steptococcus species in the same way as ‘normal’ dlgAl (Almogren & Kerr, 
2007; Almogren & Kerr, unpublished data). Functionally, the myeloma dlgAl triggered 
neutrophil respiratory bursts through FcaRI interactions, and bound to SC in the same 
way as ‘normal’ dlgAl. Hence the solution structure of myeloma dlgAl presented here 
will aid our understanding of the mucosal immune system and improve our 
understanding of the pathology of IgA-related diseases.
Up to now, while the constrained modelling of monomeric IgAl and IgA2 had 
contributed useful insights into the functions of IgA in mucosal immunity, the 
equivalent information on polymeric IgA had yet to be presented. The size of dlgAl, its 
high carbohydrate content and its flexibility mean that the crystallisation of intact dlgAl 
may not be realistic. Experimentally, we have shown here that dlgAl has a near-planar 
structure in solution with the two monomers orientated end-to-end through their Fc 
regions. The two Fc regions are in proximity to each other, and are slightly bent in their 
relative arrangement (Figure 5.19). Because the dlgAl structure was determined by 
fitting structural models against experimental scattering and ultracentrifugation data, this 
is not a prediction method and the final best-fit models qualify for deposition in the 
PDB.
While scattering modelling is not able to determine unique molecular structures, 
it is able to rule-out poor-fit models (Figure 5.1 ldj,k,l; Table 5.2). Both search cycles 
successfully converged on one small family of related best-fit structures after testing 
either all rotational orientations of Monomer 2 about Monomer 1, or all orientations of
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Monomer 1
TailpieceCys311
Cys471
J chain
Monomer 2
Figure 5.19 Molecular architecture of the dlgAl solution structure
The best-fit dlgAl structure from Figure 5.16 is shown. Heavy chains (blue), light 
chains (red) and the J chain (green) are shown. The hinge region and tailpiece (pink), the 
CDR residues (black) and the dlgAl residues in the Ch2 and Ch3 domains that bind to 
the FcaRI (orange) are shown. Cys311 in the Ch2 domain and Cys471 in the tailpiece 
are highlighted in yellow, and carbohydrate chains are shown in cyan.
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the four Fab regions about a fixed Fc-Fc region. One striking outcome is the close end- 
to-end proximity of the two Fc regions in dlgAl. The J chain does not act as a spacer as 
sometimes suggested in schematic cartoons of the IgA dimer. Likewise the two Fc 
regions do not overlap as discussed in earlier reviews (Mestecky & McGhee 1987; Kerr, 
1990). A bent Fc arrangement in dlgAl was determined, which has also been noted by 
electron microscopy (EM) (Bloth & Svehag 1971; Figure 1.9). The length of the Fc-Fc 
region within dlgAl in Figure 5.19 is approximately 14.4 nm. This agrees well with the 
14.0-15.5 nm, 13.8 (± 2.6) nm and 12.5 nm determinations from EM (Bloth & Svehag 
1971; Dourmashkin et al., 1971; Munn et al., 1971; Feinstein et al., 1971). The J chain 
was best accommodated in dlgAl within a crevice formed by the bent Fc-Fc region 
(Figure 5.13; Figure 5.18), although a crystal structure will be needed to confirm this. If 
the J chain had separated the Fc regions, this would add 2.0-2.5 nm to the length of the 
Fc-Fc region. This outcome was ruled out by Searches 2 and 3 from fit-cycle one. The 
location of the J chain in dlgAl is consistent with scattering modelling of the pentameric 
IgM structure (Perkins et al., 1991; Figure 1.7). There, the J chain was best fitted within 
the planar disc of the five IgM Fc regions, and not as a spacer at the centre of the IgM 
Fc pentameric ring.
The early EM studies of dlgAl indicated a flexible, planar structure, with the 
two Fc regions of the IgA monomers positioned end-to-end, but it was not known if 
these structures exist in solution (Dourmashkin et al., 1971; Munn et al., 1971; Feinstein 
et al., 1971; Nezlin, 1998; Figure 1.7). Both cycles of constrained modelling also 
demonstrated that the best-fit dlgAl structures are near-planar. This dlgAl study 
confirms that these near-planar structures exist in solution. Interestingly, a near-planar 
dlgAl structure is consistent with the planar IgM structure (Perkins et al., 1991; Figure 
1.7). dlgAl models showing perpendicular arrangements of the two IgAl monomers of 
the four Fab regions were eliminated by the constrained modelling filters. These 
perpendicular models resulted in visibly poorer I(Q) and P(r) curve fits (Figure
5.1 lb,c,d).
The solution structures for monomeric IgAl, the IgAl-FISA complex and dlgAl 
structure all demonstrated similar T-shaped structures for the two Fab regions relative to 
the Fc region (Boehm et al., 1999; Almogren et al., 2006). A well-separated Fab and Fc
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structure in IgA 1 in all three cases was deduced from the observation of the M2 peaks in 
the P(r) curves, meaning that the two Fab regions are seen, on average, to be extended 
away from the Fc region. Hinge flexibility of the Fab region relative to the Fc region is 
nonetheless expected, as observed from the variable Fab conformations seen in the EM 
studies of dlgAl (Figure 1.9), the small shift in the Fab regions in the 32 best-fit models 
from fit-cycle two (Figure 5.17; Figure 5.18), and the slightly altered position of the Fab 
regions when going from monomer to dimer (Figure 1.8a; Figure 5.19). This is in 
accordance with the ability of IgAl to bind efficiently to a range of Ags. The 
maintenance of these extended hinge conformations can be attributed to its primary 
structure (PVPSTPPTPSPPTPPTPSPSCCH) (Figure 5.2). Even though the hinge 
constitutes a comparatively long peptide of length 23 residues, the presence of the O- 
linked NeuNAc.Gal.GalNAc trisaccharides, multiple proline residues and the absence of 
glycine residues are expected to decrease the flexibility of the hinge and maintain their 
extended conformations.
Interestingly, human IgD also possesses an O-glycosylated segment within its 
hinge peptide of length 64 residues, and this was determined to have a similar T-shaped 
structure as that for IgAl (Sun et al., 2005). The solution structures of chimeric 
antibodies CR2-Ig and Crry-Ig also suggest why the hinge of dlgAl may have reduced 
flexibility. Both chimeric antibodies contain a 39 residue hinge between the CR2 or Crry 
molecule and the Fc region of mouse IgGl. Due to the lack of hinge O-linked 
oligosaccharides, a low percentage of proline residues and no equivalent of 
immunoglobulin light chains being present these chimeric antibodies show increases in 
mobility about the hinge and do not exhibit two-fold symmetry (Gilbert et al., 2006; 
Aslam et al., 2003). As the four Fab regions are well separated within dlgAl, each Ag- 
binding site at the complementarity-determining regions (CDRs in Figure 5.19) is 
potentially able to interact with repeated epitopes independently of the three other Ag- 
binding sites with little steric interference. The valency of dlgAl is therefore predicted 
to be four, and its avidity is predicted to be higher than that of the IgAl monomer.
A near-planar dlgAl structure would be well adapted for interactions with its 
receptors. By this, dlgAl is able to approach the host cell membrane surface for 
effective interactions with a cell surface receptor, most notably FcaRI which is
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responsible for IgA-mediated phagocytosis, oxidative burst and antibody-dependent 
cellular cytoxicity amongst other roles (Monteiro & van de Winkel, 2003). Receptor 
binding would occur independently of Ag binding. The dlgAl residues involved in 
binding to FcaRI are highlighted in orange in Figure 5.19 (Herr et al., 2003b; Pleass et 
al., 1999). The superimposition of the Fc crystal structure complexed with two FcaRI 
molecules upon the dlgAl model shows that the two FcaRI molecules project out of the 
plane of dlgAl but on opposite sides of this dlgAl plane (green in Figure 5.20). The 
superimposition of a second crystal structure onto the other monomer within dlgAl 
shows likewise that the third and fourth FcaRI molecules likewise project outwards on 
both sides of this plane (yellow in Figure 5.20). Previously it has been shown that two 
FcaRI molecules can bind simultaneously to the monomeric Fc region in solution, and it 
has been speculated that this bivalent binding will occur at cell surfaces (Herr et al., 
2003a; Herr et al., 2003b; Furtado et al., 2004). Figure 5.20 likewise leads to the 
speculation that dlgAl is able to bind up to two FcaRI molecules on a given cell 
surface, even though its predicted valency for the receptors is four. The spatial 
separation between the C-terminal a-carbon atoms of the two FcaRI receptors bound to 
monomeric IgAl and dlgAl is similar at 12.3 nm and 10.2 nm respectively, meaning 
that the same arrangement of FcaRI molecules will theoretically bind equally well to 
IgAl monomers or dimers. However for reason of comparatively low binding affinities 
in relation to the IgAl serum concentrations, it seems more likely that a 1:1 
stoichiometry would result in vivo (Monteiro & van de Winkel, 2003; Woof et al., 
2005).
The appearance of dlgA 1 as a near-planar structure with a bend between the two 
Fc regions leads to a possible mechanism for the formation of SIgAl from dlgAl and 
SC. While its position cannot be directly determined by scattering, the J chain is 
covalently bound to Cys471 in the tailpiece of the two monomers via its Cys69 and 
Cysl5 residues, therefore joining the two monomers at the centre of the dimer. The bend 
between the two Fc monomers in the plane of IgAl in the models of Figure 5.19 offers a 
covalently-bound location for the J chain within the crevice that is created by this bend. 
This location may enable the J chain in dlgAl to be sufficiently exposed to bind to a 
central region in SC, this being the first event in the selective transportation of dlgAl
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Figure 5.20 Interaction of dlgAl with two FcaRI molecules
(a,b) The best-fit dlgAl model of Figure 5.19 is shown after superimposition of the 
crystal structure of the human IgA Fc region complexed with two FcaRI molecules 
(PDB code: 10WO; Herr et a l 2003b) onto each Fc region in the dlgAl model. The 
FcaRI molecules associated with Monomer 1 (green) and Monomer 2 (yellow) are 
labelled. The view in (b) corresponds to a rotation by 90° on the Y-axis of that in (a) to 
display the near-planarity of the dlgAl structure and the projection of the FcaRI 
molecules above and below the dlgAl structure, out of the dlgAl plane.
FcaRI-3
FcaRI-2
FcaRI-1 FcaRI-4
FcaRI-2
FcaRI-4
Monomer 2
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across epithelial cells to form SIgA (Johansen et al., 2001). The interaction between the 
C-terminal region of the J chain in dlgAl and plgR is non-covalent and represents a 
critical step for transport of the dlgAl-SC complex to mucosal surfaces and formation 
of SIgA (Johansen et a l , 2001). A ‘zipper effect’ binding of plgR to dlgAl has been 
proposed, where the N-terminal D1 domain of SC first interacts non-covalently with 
dlgAl (possibly with the Fc region) (Crottet & Corthesy, 1999). A central region in SC 
then interacts with the C-terminal region of the J chain, and dlgAl and SC are brought 
into the correct position for covalent binding between CysBll in the Ch2 domain of 
dlgAl and Cys502 in the D5 domain of SC. A J-shaped solution structure for free SC is 
shown in Chapter 4. If this J-shaped structure occurs when SC is membrane-bound as 
plgR, D1 is sufficiently exposed for initial non-covalent contact with dlgAl (Bakos et 
al., 1991b). plgR is known to interact with a binding-motif in the dlgA Ch3 domains 
(Hexham et al., 1999). It is possible that the centre of SC will then mediate the initial 
contact with the J chain in dlgAl, and SC will unfold towards both ends of dlgAl as the 
D1 and D5 domains interact successively across the two Fc regions. The interaction of 
the D1-D5 domains with the Fc regions in dlgAl then provides SIgAl with a greater 
ability to resist proteolysis in the harsh environment of mucosal surfaces.
The near-planar dlgAl structure deduced from this study provides insight into 
the formation of other polymeric IgA molecules. The structure of dimeric IgA2 (dIgA2) 
is predicted to be similar to that of dlgAl because the two monomers are joined through 
the base of their two Fc regions to the J chain and there are only minor sequence 
differences between the IgAl and IgA2 isotypes (Torano & Putnam, 1978; Chapter 7). 
The hinge region is not involved in the formation of the IgA2 dimer. However the 
binding site of SC to dIgA2 differs from that to dlgAl, as SC binds covalently to dlgAl 
but may not do so to dIgA2 (Almogren et al., 2006). The two dlgA isotypes may 
therefore differ in a manner that remains to be elucidated, most probably mediated by 
the closer proximity of the Fab regions to SC in secretory IgA2. The antigenic reach of 
the two isotypes will differ for reason of the different hinge structures (Boehm et al., 
1999; Furtado et al., 2004), and dimer formation is expected to accentuate this 
difference. The formation of trimeric and tetrameric IgA structures (Almogren & Kerr, 
2007; Vaerman et al., 1995) can be visualised by analogy with the solution structure
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determination of planar pentameric IgM in which its Fc regions are disulphide linked 
through the Cys414 residues in the Cp3 domains and the Cys575 residues in the 
tailpieces (Perkins et al., 1991; Figure 1.7). Hexameric IgM structures without J chain 
have been described in which a sixth IgM monomer is inserted within this plane (Davis 
et al., 1988). Cys311 in IgAl (Figure 5.1; Figure 5.2) is located at the identical sequence 
and structural position to that of Cys414 in IgM (Herr et al., 2003b). By analogy with 
IgM, It is relatively straightforward to insert further monomers within this Fc plane to 
form larger IgA oligomers. Using molecular graphics based on the IgAl Fc crystal 
structure and the constrained scattering model for human IgM, it was possible to create 
trimeric (and tetrameric) assemblies of three (and four) co-planar Fc regions starting 
from the dimer with the J chain present, but only if the Fab regions are absent. If the Fab 
regions are present, they will readily lead to significant steric conflicts in the assembly 
of trimers and tetramers unless the Fab regions in question are significantly displaced 
out of the plane containing the three or four Fc regions.
IgAN is defined by the deposition of IgA in the glomerular mesangium of the 
kidney, and this is predominantly dlgAl (Barratt & Feehally, 2005; Section 1.7.2). A 
high level of polymeric IgAl such as in IgA myelomas does not necessarily lead to 
IgAN. A reduced galactosylation of the hinge O-linked oligosaccharides has been 
implicated in the pathology of IgAN. It is possible that this change may destabilise and 
alter the extended conformation of the IgAl hinge peptide. Hence glycosylation changes 
may provide one possible mechanism for IgA aggregate formation by permitting the Fc 
regions to self-associate. Another possible mechanism for the formation of IgA 
deposition may arise from the observed consequences of the cleavage of the IgAl hinge 
by bacterial proteases (Almogren & Kerr, 2007). This was seen to cause the cleaved Fc 
fragments derived from polymeric IgAl (but not monomeric IgAl) to form disulphide- 
linked multimers (Almogren & Kerr, 2007). The molecular graphics modelling of planar 
Fc rings of IgA by analogy with IgM (see above) suggest that if the IgAl hinges become 
more flexible through their deglycosylation and cause the Fab regions to move away 
from the Fc-Fc region, or the Fab regions are partially or completely removed by 
bacterial proteolysis, the near-planar assemblies of trimers, tetramers and higher 
oligomers of IgA can be generated starting from the double Fc region of dlgAl and its J
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chain. If this hypothesis is correct, these oligomers can be stabilised by disulphide 
bridges through Cys311 at the surface of the Ch2 domain in IgA, and may be 
responsible for the IgA deposits seen in IgAN.
The elucidation of a near-planar solution structure of dlgAl has yielded a better 
understanding of the function of polymeric forms of IgA. This opens the way for the 
constrained modelling of SIgAl and SIgA2. Knowledge of the monomer arrangement 
within the dimer has provided insights into the assembly of this dimer and higher 
oligomers of IgAl, and the way that this potentially interacts with the FcaRI receptor 
and plgR and SC. However, many unsolved issues remain, including the exact binding 
motifs within dlgAl that interact with SC in the formation of SIgA, and the structure 
and composition of pathological dlgAl forms that are implicated in diseases such as 
IgAN.
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5.4 Materials and Methods
5.4.1 Preparation and composition of dlgAl
A monoclonal dlgAl with k  class light chain was isolated from a human 
myeloma serum using a combination of thiophilic chromatography and jacalin-agarose 
lectin affinity chromatography (Sun et a l , 2005). The human myeloma dlgAl samples 
were prepared by Dr. Adel Almogren and Professor Michael A. Kerr. Samples were 
subjected to size-exclusion chromatography to remove non-specific aggregates and 
checked by reducing and non-reducing SDS-PAGE to confirm sample integrities before 
and after data collection. For X-ray scattering and AUC experiments, dlgAl was 
dialysed into Dulbecco’s PBS supplemented with EDTA and sodium azide as anti­
bacterial preservatives (12.5 mM sodium phosphate, 140 mM NaCl, 0.5 mM EDTA, 
0.02% NaN3 , pH 7.4). For neutron scattering, the buffer was Dulbecco’s PBS as above, 
dialysed at 6 °C into 100% 2 H2 0  for 36 hours with four buffer changes. The amino acid 
sequence required for the dlgAl data analyses was taken from the monomeric IgAl 
solution structure (PDB code: 1IGA; Boehm et al., 1999) which was derived from the 
SWISSPROT sequence code P01876 for the heavy chain constant domains and the 
crystal structure of human TR1.9 IgGl Fab with a k  light chain (PDB code 1VGE; 
(Chacko & Padlan, 1996). The N-linked carbohydrates at Asn263 on the Ch2 domain 
and Asn459 on the tailpiece were each represented by a biantennary complex-type 
oligosaccharide with a Man3GlcNAc2 core and two NeuNAc.Gal.GlcNAc antennae. The 
five O-linked carbohydrates on each IgAl hinge (Figure 5.1; Figure 5.2) were taken to 
be NeuNAc.Gal.GalNAc trisaccharides. The human J chain sequence was taken from 
the SWISSPROT sequence code P01591, to which another biantennary complex-type 
oligosaccharide was added at Asn49 (Figure 5.1; Figure 5.2). This composition of 
dlgAl resulted in the following molecular parameters: molecular mass, 344,800 Da, an 
unhydrated volume of 439.4 nm3, a hydrated volume of 580.2 nm3, an absorption 
coefficient at 280 nm of 12.3 (1%, 1 cm), and a partial specific volume v of 0.724 ml/g.
5.4.2 X-ray and neutron scattering data collection and analysis
X-ray scattering data were obtained on the Beamline ID02 at the ESRF, 
Grenoble, France, collected by Dr. Patricia Furtado, with a ring energy of 6.0 GeV in
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single-bunch mode with storage ring currents that ranged from 11 mA to 12 mA to 
reduce the incident X-ray flux (Narayanan et al., 2001). The sample-to-detector 
distance of 3.0 m yielded a Q range from 0.07 nm ' 1 to 2.1 nm' 1 (where Q = 4 tc sin 0 / X; 
20 = scattering angle; X = wavelength). Samples were contained in water-cooled 
Perspex cells at 15°C, of path thickness 1 mm and mica windows of thickness 25 pm at 
concentration of 0.58 mg/ml and 1.16 mg/ml. Samples were measured in 10 time 
frames, each of which lasted for 2  sec, these being optimal for the elimination of 
radiation damage effects.
Neutron scattering data were obtained on Instrument LOQ in two beam sessions 
by Dr. Patricia Furtado, at the pulsed neutron source ISIS at the Rutherford Appleton 
Laboratory, Didcot, U.K (Heenan et a l, 1997). The pulsed neutron beam was derived 
from proton beam currents of approximately 180 pA. Samples and buffers were 
measured in 2 mm-thick rectangular quartz Hellma cells positioned in a thermostatted 
rack at 15°C. Data acquisitions were lasted 4 to 13 h for dlgAl samples at 
concentrations of 0.83 mg/ml and 1.16 mg/ml.
Other details, including calibrations and data reduction, the Guinier analyses to 
determine the radius of gyration RG and the radius of gyration of the cross-sectional 
structure Rxs, and the calculation of the distance distribution function P(r) using 
GNOM, are described previously in Section 2.2.4. For GNOM, the dlgAl X-ray I(Q) 
curve contained 524 data points between Q values of 0.98 to 2.02 nm' 1 and was fitted 
with Dmax set as 26 nm. The dlgAl neutron I(Q) curve contained 61 data points between 
Q values of 0.21 to 2.1 nm' 1 and was fitted with Dmax set as 23.5 nm.
5.4.3 Analytical ultracentrifugation data collection and analysis for dlgAl
SE data were acquired over 45 h using six-sector cells with column heights of 2 
mm at rotor speeds of 5,000 r.p.m., 8,000 r.p.m., 11,000 r.p.m., 14,000 r.p.m., 17,000 
r.p.m. and 20,000 r.p.m. at 20°C on a Beckman XL-I instrument equipped with an 
AnTi50 rotor. Absorbance scans at 280 nm and interference scans were recorded at six 
concentrations between 0.07 mg/ml and 0.97 mg/ml. Molecular mass values were 
determined on the assumption of a single species using ORIGIN v4.1 (Microcal). The 
buffer density was calculated to be 1.00543 g/ml and the viscosity was taken as 0.01002
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cp. Sedimentation velocity data were acquired at concentrations of 0.53 mg/ml and 1.00 
mg/ml over 16 h at rotor speeds of 10,000 r.p.m., 15,000 r.p.m. and 20,000 r.p.m in 
two-sector cells with column heights of 12 mm. Data were analysed using DCDT+ g(s*) 
time-derivative analyses and SEDFIT v9.4 based on the continuous c(s) distribution 
model with a resolution set as 150, while the cell meniscus and bottom, the frictional 
ratio of 1.638, and the partial specific volume v, buffer density and viscosity were held 
fixed, and the baseline was allowed to float. Other details are as described previously in 
Section 2.2.4 and Section 4.4.3.
5.4.4 Constrained modelling of dlgAl
The full coordinates of monomeric IgAl (PDB code 1IGA; Boehm et al., 1999) 
was used to generate dimer models. The first cycle of fits created a planar starting model 
for the dimer, by arranging the two monomers Fc to Fc (Figure 5.9a). One IgAl 
monomer was then rotated about a dummy atom created midway between the two Fc 
regions of the monomers, while the other monomer remained stationary. The J chain 
was not included. The rotations were in steps of 10° between 0° and 180° on each of the 
X-, Y- and Z-axes, hence this resulted in 193 or 6,859 models for each rotational search. 
Monomer separations were assessed by setting this as 1.40 nm, 2.78 nm and 4.60 nm in 
three searches in which the two starting monomers shared a common Y-axis. This 
separation was that between the two Ca atoms of Lys457 at the base of the two Fc 
regions, and the dummy atom is located at the mean position of all four Lys454 Ca 
atoms. In two final searches, the two IgAl monomers had a separation of 2.78 nm, but 
the IgAl monomer to be rotated was translated 2.0 nm and 4.0 nm along the X-axis.
The second cycle of fits randomised the hinge between the Fab and Fc regions in 
the best-fit dlgAl structure obtained from the first modelling cycle. Six linker libraries 
with 5000 hinge conformations in each were generated using molecular dynamics 
(DISCOVER module of INSIGHT II, Accelrys) for 25-residue hinge lengths set 
between 5.5 nm to 9.0 nm in 0.5 nm steps, from each of which 500 conformations were 
randomly selected. The hinge between the CH1 and CH2 domains is 220- 
CPVPSTPPTPSPSTPPTPSPSCCHP-244 (Boehm et al., 1999; Figure 5.2). Four 
identical hinges were used to generate the 3,000 dlgAl models for evaluation.
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In order to calculate the X-ray and neutron scattering curves for comparison with 
the experimental curves, each dlgAl model was converted into Debye spheres. A cube 
side length of 0.531 nm with a cut-off of four atoms consistently gave models within 2% 
of their total unhydrated volume of 417.2 nm3 (for that without the J chain as this had 
not been modelled), and gave a total of 2719 unhydrated spheres. After hydration, the 
number of hydrated spheres A was 3606. The values of A and the modelled R g , R x s-i and 
Rxs-2 parameters were calculated in the same Q  ranges used for the experimental Guinier 
analyses. Models that fit within 5% of A and the X-ray Guinier values were ranked 
using the goodness-of-fit R  factor of the model. A flat-background correction of 0.5% of 
1(0) was applied to the neutron fits to allow for residual incoherent scattering. The 
sedimentation coefficients s°2o.w were calculated from the coordinate models using 
HYDROPRO v7c. To take into account the hydration shell surrounding dlgAl, the 
recommended value of 0.31 nm for the atomic element radius for all atoms was used as 
an empirical approximation of this.
5.4.5 dlgAl and pentameric IgM Protein Data Bank accession codes
The ten best-fit dlgAl a-carbon co-ordinate models have been deposited in the 
Protein Data Bank with the accession code 2QTJ (Figure 5.18; Table 5.2). The a-carbon 
co-ordinate model of pentameric human IgM (Perkins e t  al., 1991; Figure 1.7) was 
deposited with the accession code 2RCJ.
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Chapter Six
Location of Secretory Component on the Fc Edge of Dimeric IgAl 
Reveals Insight into the Role of Secretory IgAl in Mucosal Immunity
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6.1 Introduction
The mucosal surfaces, including the gastrointestinal, respiratory and urogenital 
tracts are the largest surface area in the human body in contact with the external 
environment (Brandtzaeg, 2007). Pathogenic microorganisms, their potentially toxic 
products and some components of ingested food and inhaled air are potential threats and 
are therefore antigenic at mucosal surfaces. Secretory immunoglobulin A (SIgA) is the 
principle Ab isotype present at mucosal surfaces where it mediates the first line of 
immune defence by neutralising and clearing the Ag (Nagler-Anderson, 2001). SIgA 
also restricts the indigenous commensal bacterial population entering the body from the 
lumen by immune exclusion (Corthesy, 2007). More IgA is produced daily than all the 
other Ab classes combined (Kerr 1990).
SIgA is produced locally in the mucosa, consisting of two (or sometimes three or 
four) 12-domain IgA monomers bound covalently through the joining (J) chain at the 
base of the Fc region (Figure 6.1). The transport of predominantly dimeric IgA (dlgA) 
across the epithelial lining into the luminal secretions, and the consequent formation of 
SIgA, is mediated by dlgA binding to the polymeric immunoglobulin receptor (plgR) on 
the basolateral surface of epithelial cells. Following transcytosis of the complex across 
the cell and cleavage of plgR at the luminal membrane, SIgA is released with the 
extracellular portion of the plgR (now called secretory component (SC)) remaining 
bound to the IgA dimer (Figure 6.1). SC is not only necessary for the selective 
transportation and correct localisation and anchorage of SIgA, but it also stabilises 
markedly the structure of SIgA and increases its resistance to proteolysis in the harsh 
environment of mucosa (Crotett & Corthesy, 1998; Phalipon et al., 2002; Lindh, 1975). 
SC binds covalently to dlgA by Cys502 to Cys311 in one of the Ch2 domains in an 
IgAl monomer (Figure 6.1).
Despite the major role of SIgAl in mucosal immunity, no new structural 
information on the assembly of this complex protein has been revealed since the 
electron microscopy studies from 38 years ago (Svehag & Bloth 1970; Bloth & Svehag 
1971; Figure 1.9). The arrangement of the IgAl monomers and SC within SIgAl is as 
yet unknown. However solution structures for the IgAl monomer and dlgAl have been 
determined (Boehm et a l , 1999; Bonner et al., 2008; Chapter 5). The IgAl monomer
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Figure 6.1 Domain structure of SIgAl
SIgAl is composed of two IgAl monomers covalently bound to the J chain (orange 
outline) and SC (green). Each IgAl heavy chain (blue) contains the Vh, ChI, Ch2 and 
Ch3 domains, and each light chain (red) contains the Vl and Cl domains. The 
complementarity-determining regions (CDR, black crescents), the 23-residue hinge and 
the 18-residue C-terminal tailpiece are labelled. The inter-heavy chain disulphide 
bridges at Cys241, Cys242, Cys299 and Cys301 are shown as an X. Cys471 in one 
tailpiece of each Fc region is covalently linked with Cysl4 and Cys68 in the J-chain. 
Cys311 in one CH2 domain is covalently linked with Cys502 in SC D5. The N-linked 
(•)  and O-linked ( o )  oligosaccharide sites at Asn263 and Asn459 and the hinge regions 
are shown.
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has an extended and mostly T-shaped arrangement of Fab and Fc regions (Figure 1.8). 
The solution structure of dlgAl shows that the two IgAl monomers are orientated in a 
near-planar, tail-to-tail conformation with a slight bend in the Fc-Fc interface which 
may possibly accommodate the J chain (Bonner et al., 2008; Chapter 5). The large 
number of domains constituting SIgAl, together with the high glycosylation and flexible 
hinge and tailpiece regions (Figure 6.1), suggests that the crystallisation of intact SIgAl 
will be difficult to achieve. However, a solution structure can be determined at medium 
resolution using constrained scattering modelling (Perkins et al., 2008). Here, the first 
molecular view of the assembly of SIgAl has been determined. The SIgAl structure 
rationalises its known effector functions in mucosal secretions. The implications of this 
SIgAl structure are discussed in reference to its role in mucosal immunity, particularly 
its interaction with receptors, a mechanism for the selective transport of SIgA 1 into the 
mucosa, and how SC and dlgAl protect one another to increase SIgAl antimicrobial 
capabilities.
6.2 Results
6.2.1 Purification of colostrum SIgAl
A procedure based on thiophilic resins with a binding capacity of over 28 mg of 
immunoglobulins per ml of resin allows rapid and effective purification of colostral 
immunoglobulins which selectively bind to the resin whilst almost all other proteins do 
not (Sun et al., 2005; Almogren et al., 2007; Almogren & Kerr, 2007). Colostrum 
SIgAl was then separated from SIgA2, free SC, secretory IgM and other colostrum 
proteins through its selective binding to a jacalin column. Samples were further purified 
by Sephacryl S-300 size-exclusion gel filtration, where dimeric SIgAl eluted as a single 
symmetrical peak. After concentration, samples were checked by reducing and non­
reducing SDS-PAGE and Western blot using an anti-IgAl Fc-specific antibody. 
Reducing SDS-PAGE showed only the three expected bands for pure SIgAl 
corresponding to the IgAl heavy chain at 62 kDa, the light chain and J-chain which co- 
migrate at around 25 kDa and SC at around 80 kDa (Almogren et al., 2007; Almogren & 
Kerr, 2007). The recovery rate for SIgAl was in excess of 90%.
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6.2.2 X-ray and neutron scattering of SIgAl
X-ray scattering data for SIgAl were compared with previous scattering data for 
dlgAl (Section 5.2.2) Comparison of I(Q) data for SIgAl from a single time frame and 
those averaged over ten consecutive frames showed excellent signal-noise ratios with no 
radiation damage or SIgAl aggregation, and only the first time-frames were used for 
analyses. At the lowest Q values (Q = 4 n sin 0 /X; 20 = scattering angle; X = 
wavelength), the Guinier analyses resulted in linear plots, from which the RG value (a 
monitor of macromolecular elongation) was obtained within satisfactory Q.RG limits 
(Figure 6.2a,b). The mean X-ray RG value for SIgAl was 8.29 ± 0.20 nm (6 values) 
(Figure 6.2a; Table 6.1). This was compared with previous scattering data for dlgAl 
(Section 5.2.2) to indicate the extent to which the addition of SC (19% of the mass of 
SIgAl) to dlgAl modifies the structure of the latter. The RG for dlgAl was 8.65 ± 0.27 
nm (Table 6.1). The anisotropy ratio RgIRo (where Ro is the RG value of the sphere with 
the same volume as the dry glycoprotein) for SIgAl was 1.93. This is slightly less than 
that of 2.16 for dlgAl. These similarities between SIgAl and dlgAl suggest that SIgAl 
has a similar elongated arrangement of its two IgAl monomers in solution as that for 
dlgA 1. The reduction in RJRo  suggested the SC is bound to the central region of dlgA 1 
if it is assumed that dlgAl is unchanged in conformation.
The shorter axes of SIgAl were monitored using X-ray cross-sectional Guinier 
analyses of I(Q) that resulted in the Rxs-i and Rxs-2 parameters. The ln(I(Q).Q) plots 
revealed two linear regions in Q ranges between 0.20 -  0.28 nm'1 and 0.72 -  1.04 nm'1 
that were similar to those for dlgAl (Table 6.1). The mean Rxs-i value of 3.90 ± 0.13 
nm and mean Rxs-2 value of 1.27 ± 0.03 nm (5 determinations for both) (Figure 6.2c,d; 
Table 6.1) were close to those for dlgAl of 3.94 ± 0.18 nm and 1.43 ± 0.07 nm 
respectively. This further indicated the similarity of the solution structures of SIgAl and 
dlgAl.
Neutron scattering data acted as a control for X-ray-induced radiation damage, 
which does not occur with neutrons, any internal structural inhomogeneity caused by the 
11% carbohydrate content of SIgAl, and any hydration effect which is largely invisible 
by neutrons but not by X-rays (Perkins, 2001). Data were obtained using a 2H20  buffer 
to correspond to a high negative glycoprotein-solvent contrast, in distinction to the high
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Figure 6.2 SIgAl Guinier plots and distance distribution functions P(r) analyses
(a-d) The Q.Rg and Q.Rxs ranges used to determine the Rg, R xs-i and Rxs-2 values are 
represented by filled circles between the arrowed data points. The X-ray fits correspond 
to concentrations of 0.60 mg/ml (upper) and 0.30 mg/ml (lower). The neutron fit 
corresponds to data at 0.60 mg/ml. The X-ray and neutron Q ranges used for the Rg 
values were 0.11 to 0.17 n m 1 and 0.14 to 0.24 nm'1 respectively and that for the Rxs-i 
and Rxs-2 values were 0.2 to 0.28 nm'1 and 0.72-1.04 nm'1 respectively. (e,f) The two 
most frequently occurring distances in the P(r) curve are denoted by the maxima M\ and 
M l at 7.0 nm and 9.6 nm respectively (X-ray) and 6.8 nm and 10.0 nm respectively 
(neutron). The maximum length of SIgAl is denoted by L at 26 nm (X-ray) and 24 nm 
(neutron) when P(r) reaches 0.
(f) Neutrons
(b) Neutrons
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Protein Data Guinier analyses P(r) analyses
Rg (nm) Rxs-j (nm) Rxs- 2  (nm) L (nm) Rg (nm) L (nm) M l  (nm) M2  (nm)
Secretory IgAl X-ray 8.29 ± 0.20 3.90 ±0.13 1.27 ±0.03 26 8.30 ±0.17 26.0 7.0 9.6
Neutrons 7.22 n.a. n.a. 24 8.04 24.0 6.8 10.0
Dimeric IgAl X-ray 8.65 ± 0.27 3.94 ± 0.18 1.43 ± 0.07 25.0 8.67 ±0.17 26.0 4.9 9.9
(Chapter 5; Bonner et al., 2008) Neutrons 7.60 ± 0.05 n.a. n.a. 22 7.47 23.0 5.1 10.1
Monomeric IgAl X-ray 6.20 ±0.13 2.20 ± 0.26 1.56 ± 0.16 21.0 6.12 21.0 3.7 9.1
(Boehm et al., 1999) Neutrons 6.11 ±0.18 2.17 ± 0.23 1.18 ± 0.12 19.8 n.a. n.a. n.a. n.a.
Monomeric IgAl-HSA X-ray 7.47 ±0.31 2.31 ±0.11 1.31 ±0.05 25.0 7.36 ±0.01 25.0 4.87 8.25
(Almogren et al., 2004) Neutrons 7.09 ±0.01 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Table 6.1 Comparison of X-ray and neutron data analyses for SIgAl, d lgA l and monomeric IgAl
All proteins are from human sources, 
n.a. -  not available
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positive contrast observed by X-rays. The neutron RG value for SIgAl was 7.22 nm (1 
determination) (Figure 6.2b; Table 6.1) which is similar to the dlgAl neutron value of
7.6 nm. As for dlgAl, the neutron RG value for SIgAl is reduced by 1 nm compared to 
the X-ray RG value, and this is attributable to a significant hydration shell positioned at 
large distances from the centre of the SIgAl structure. The neutron anisotropy ratio 
RdRo  for SIgAl was 1.85, which is similar to the X-ray-derived value above. This is 
again slightly less than the corresponding neutron RG/Ro ratio of 2.08 for dlgAl. 
Neutron scattering also leads to the molecular mass from the linear relationship between 
the Guinier l(0)/c values for proteins measured in 2H20  buffers when normalised 
relative to a standard deuterated polymer (where the molecular mass = l(0)/c x 9.105) 
(Boehm et al., 1999). The neutron Guinier l(0)/c value of 0.43 resulted in a mass o f 390 
kDa for SIgAl (Figure 2.5), which compares well with the sequence-derived value of 
424 kDa from its composition which included four k  light chains, 16 N-linked 
biantennary and 20 O-linked oligosaccharides (Figure 6.1). The replacement of k  light 
chains by X light chains in SIgAl will result in a decrease of 7 kDa in mass.
The calculation of the distance distribution function P(r) from the I(Q) curve 
provides structural information in real space. The mean RG values determined from the 
X-ray and neutron P(r) curves were 8.30 ± 0.17 nm (6 values) and 8.04 nm (1 value) 
respectively, in good agreement with the Guinier analyses. The SIgAl X-ray and 
neutron P(r) curves reproducibly showed two maxima Ml and M2 located at 7.0 nm and
9.6 nm respectively (X-ray) and 6.8 nm and 10.0 nm respectively (neutron) (Figure 
6.2e,f). These two peaks correspond to an abundance of inter-domain vectors found 
within the SIgAl solution structure. While these were also observed for dlgAl (Table 
6.1), the X-ray M l values at 6.8-7.0 nm for SIgAl were larger than those of 4.9-5.1 nm 
for dlgAl, while the X-ray M2 values at 9.6 -  10.0 nm for SIgAl were similar to those 
of 9.9-10.1 nm for dlgAl. The movement in M l is attributed to the presence of bound 
SC in SIgA 1. The maximum length, L, is determined from where the P(r) curve reaches 
zero at larger r values. For SIgAl, L was determined to be 26 nm (X-ray) and 24 nm 
(neutron) (Figure 6.2e,f). These values agree well with those of 26 nm and 23 nm 
respectively for dlgAl, and provide further support to show that SIgAl possesses a 
similar extended topology to that for dlgAl. These results show that the overall
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structural differences between SIgAl and dlgAl are small.
6.2.3 SIgAl analytical ultracentrifugation analyses
In order to confirm the molecular mass of SIgAl, sedimentation equilibrium 
(SE) experiments were performed at three concentrations and four rotor speeds (Section
6.4.2). Assuming that a single species was present, the individual SE fits for the 
molecular mass at each SIgAl concentration and rotor speed gave values that ranged 
between 360 kDa to 420 kDa (Figure 6.3). Their extrapolation to zero concentration 
gave a mean molecular mass of 403 ± 43 kDa, which is within error of the composition- 
derived value of 424 kDa. This confirmed the neutron-derived molecular mass 
calculation (Section 6.2.3). The S°20,w value independently measures macromolecular 
elongation, and acts as a control for the absence of polydispersity effects. Sedimentation 
velocity (SV) experiments were performed on SIgAl (Section 6.4.2) and SEDFIT 
analyses gave a good visual agreement between experimental and fitted boundaries 
(Figures 6.4a,c). The resulting c(s) distribution plot revealed that a single SIgAl species 
was present with an s°2o,w value of 10.8 S from both the interference and absorbance 
data (Figures 6.4b,d). No other species were detectable and only dimeric SIgAl was 
detected, as tetrameric SIgA has an s°2o,w value of 15.5 S (Mestecky et al., 2005). The 
conversion of the c(s) plots to c(M) mass distributions showed that the 10.8 S species 
corresponded to a molecular mass of 440 kDa (data not shown), which is consistent with 
the neutron, SE and sequence-derived molecular masses above. The c(s) analyses were 
confirmed by the g(s*) time derivative analyses using DCDT+ of between 6-14 scans at 
the centre of the sedimentation profile. These gave an s o20,w value of 10.8 S 
(interference) and 10.9 S (absorbance) (Figure 6.4e,f). The new determinations agree 
well with a previous s°2o,w value of 10.9 S (Bjork & Lindh, 1974) and with six earlier 
values between 10.5 S to 11.7 S previously reviewed (Heremans, 1974). The frictional 
ratio f/f0 was determined from s°2o,w value, where f 0 is the frictional coefficient of a 
sphere with a volume equal to that of the hydrated macromolecule. The frictional ratio 
of SIgAl is 1.70, which is similar to 1.63 for dlgAl (Section 5.2.3). This comparison 
showed that SIgAl and dlgAl show similar elongated structures in solution, in 
agreement with the previous ultracentrifugation analyses and the new scattering results.
195
»  0.00
(a) interference
Radius (cm)
»  0.00
(b) Absorbance
6.0
Radius (cm)
  500re
S 400
2  300
-(C)
o on
o
A A A
V V
_______ L 1
0.0 0.5 1.0
Concentration (mg/ml)
Figure 6.3 Sedimentation equilibrium analyses for SIgAl
SIgAl was analysed using (a) interference and (b) absorbance optics at concentrations 
of 0.65 mg/ml (red), 0.43 mg/ml (blue), and 0.22 mg/ml (green). Circles represent the 
experimental data at a rotor speed of 8,000 r.p.m. and the continuous black lines 
represent their fits. The corresponding curve fit residuals are shown above the 
exponential fits, (c) The rotor speed dependence of the fitted molecular mass gave a 
mean value of 403 ± 10 kDa, denoted by (O) 5,000 r.p.m, (□ ) 8,000 r.p.m, (A ) 11,000 
r.p.m and (V) 14,000 r.p.m.
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Figure 6.4 Sedimentation velocity analyses for SIgAl using SEDFIT c(s) 
distribution and DCDT+ time-derivative fits
The black circles represent the experimental scans and the continuous red lines represent 
the fits. (a,c) In the SEDFIT fits, only every sixth scan of the 120 scans used is shown 
for reason of clarity. SIgAl was measured using (a) interference and (c) absorbance 
optics at a concentration of 0.58 mg/ml and a rotor speed of 20,000 r.p.m. (b,d) The 
corresponding c(s) plots from (a,c) are shown from which the sedimentation coefficient 
for SIgAl was determined to be 10.8 S. (e,f) DCDT+ g(s*) fits for SIgAl at 0.58 mg/ml 
and at a rotor speed of 20,000 r.p.m. The goodness-of-fit residuals are shown above each 
analysis. The arrowed S2o,w values using (e) interference and (f) absorbance optics are 
10.8 S and 10.9 S, respectively. The fits were determined using between four to 14 scans 
recorded mid-way through the experiment shown in (a,c).
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6.2.4 Constrained modelling of SIgAl
The comparison of the superimposed SIgAl and dlgAl I(Q) curves shows an 
inflexion in the dlgAl curve at approximate Q values of 0.5-0.8 nm'1 which is absent in 
the SIgAl scattering curve (Figure 6.5). The R factor difference between the dlgAl and 
SIgAl X-ray scattering curves is 8.5% (Figure 6.5). Together with the shift of peak M l 
in the P(r) curves between SIgAl and dlgAl, this shows that SC has a measureable 
effect on the SIgAl structure. As the experimental data showed that the overall 
arrangements of the two IgAl monomers within dlgAl and SIgAl are similar, the 
constrained modelling of the SIgAl structure was initiated starting from the best-fit 
dlgAl structure which was held fixed (PDB code 2QTJ; Chapter 5; Bonner et al., 2008).
In the first round of modelling searches, ten different locations of SC relative to 
the fixed dlgAl structure were evaluated. The SC models were based on the 5,000 
models with four conformationally-randomised linkers that were used to determine the 
SC solution structure by constrained scattering modelling (SC Search 1 in Section 4.2.5; 
Bonner et al., 2007). Three types of analyses were performed by holding one of the SC 
domains proximate to a specified domain in dlgAl, generating ten searches in total, (i) 
Searches 1 to 4 explored positions for SC D3 on the edge of the planar bent dimeric Fc 
region in dlgAl (Figure 6.6a; Figure 6.7a). Hence Search 1 held the long axis of D3 
parallel to the long axis of the Fc-Fc regions and next to the putative J chain position 
within the Fc-Fc crevice. Search 2 repeated this with D3 now rotated by 90° to be 
perpendicular in position to that used in Search 1. Searches 3 and 4 repeated these 
searches on the other edge of the Fc-Fc regions, (ii) Searches 5 and 6 explored locations 
for SC on top of the face of the planar Fc-Fc regions (Figure 6.6a; Figure 6.7a). 
Searches 5 and 6 positioned the long axis of D3 either parallel or perpendicular to the 
long axis of the Fc-Fc regions. Tentative models of this type where SC is wrapped 
around the planar Fc-Fc region are predicted in reviews but have no experimental basis 
(Kerr, 1990; Mestecky et al., 2005; Brandtzaeg, 2007; Heremans, 1974; Corthesy, 2003; 
Mestecky & McGhee, 1987; Woof & Kerr, 2006). (iii) Searches 7 to 10 explored SC 
models based on the knowledge that Cys502 in D5 forms a disulphide bridge with 
Cys311 in one of the four CH2 domains (Figure 6.1; Figure 6.6a; Figure 6.7a; Fallgreen- 
Gebauer et al., 1993). Accordingly D5 of SC was positioned next to each of the four
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Figure 6.5 Comparison of the SIgAl and dlgA l experimental I(Q) scattering 
curves
The difference between the SIgAl experimental X-ray scattering curve (red) and the 
dlgAl experimental X-ray scattering curve (blue; Figure 5.10; Figure 5.15) is shown. 
The R factor of the two curves is 8.5%.
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Figure 6.6 Constrained modelling Search 1 analysis of SIgAl
(a) Searches 1 to 10 are denoted by shaded ovals labelled D3 or D5 to correspond to the 
fixed location of the SC domain relative to dlgAl in each search. The ovals are shown 
in relation to Figure 6.1, and the searches are numbered from 1 to 10. (b,c,d) The RG, 
Rxs-i and Rxs-2 and R factor values calculated from the 1500 models in Search 1 are 
compared (Table 6.2). The dashed lines correspond to the experimental RG, Rxs-i and 
Rxs-2 values. The 34 best-fit models ( ) and the ten best-fit models ( • )  and of these the 
best-fit SIgAl model (arrowed; ♦ )  are shown. Two poor-fit models 1 (▼) and 2 (A) 
are shown.
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Figure 6.7 Analyses of all ten searches from the first-round of the SIgAl 
constrained modelling
(a) The fixed location of the SC D3 or D5 domain relative to dlgAl is shown for each 
search labelled 1 to 10 (as in Figure 6.6a). (b-e) Comparison of the X-ray RG and R 
factor values for the 15,000 SIgAl models from all ten searches. The axes remain 
constant for comparison. The experimental SIgAl RG value is shown by a dashed line, 
(a) Search 1 (white; Figure 6.6b), Search 2 (yellow), (c) Search 3 (cyan), Search 4 
(pink), (d) Search 5 (orange), Search 6 (green) and (e) searches 7, 8, 9 and 10 (dark 
blue). The searches are coloured as in (a).
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Ch2 domains in SIgAl, with their long axes parallel to each other, and Cys502 of D5 
was located within 2.0 nm of Cys311 in the Ch2 domain. Of the 50,000 SIgAl models 
that were created, only 15,000 remained after the removal of randomised SC models in 
which D1 to D5 showed steric overlap. The 15,000 SIgAl scattering curves were 
calculated for comparison with the experimental data (Section 6.4.3; Section 3.3.4).
The ten searches showed that Search 1 gave the most favourable outcome, giving 
best-fit extended SC structures that were aligned along one edge of the Fc-Fc plane. The 
search 1 best-fit Rg values were close to the experimental value of 8.29 nm (Table 6.2) 
and were close to the minimum of the R factors (Figure 6.6b). The best-fit SIgAl 
models from Search 1 also gave Rxs-i and Rxs-2 values that were close to the minimum R 
factor values (Figure 6.6c,d). Search 2 resulted in a best-fit SC structure that was very 
similar to that from Search 1, with SC in the plane of the Fc-Fc region. However, the 
best-fit models from search 2 did not improve upon the Search 1 R factors (Figure 6.7b; 
Table 6.2). The other eight searches gave slightly worsened fits. Searches 3 and 4 gave 
appropriate RG values of 8.1-8.4 nm, but many SC models sterically clashed with the 
Fab regions which were closer together on this side of the dlgAl structure (Figure 
6.7a,c). Searches 5 and 6 were clearly ruled out because these gave Rg values of 8.0-8.2 
nm that were too low compared to the experimental value of 8.29 nm (Figure 6.7d). 
Searches 7 to 10 were less favoured as these resulted in slightly too high Rg values and a 
minimum in the R factor values could not be identified. Also, many SC models sterically 
clashed with the Fab regions.
The outcome of Search 1 showed that 93 near-planar SIgAl models gave Rg and 
Rxs-i values within 5% of the experimental values (Table 6.2). The 34 best-fit models 
from these 93 were selected from their R factor values and were checked visually for the 
absence of steric overlap between SC and dlgAl (red, green and yellow in Figure 6.6). 
The ten best-fit models were selected from their R factor values (red and green in Figure 
6.6). The best-fit SIgAl structure has a good R factor of 8.5% (red in Figure 6.6) with a 
good visual X-ray curve fit in a Q range extending to 1 nm*1 (Figure 6.8a). The 
corresponding neutron curve fit also gave a good R factor of 9.3% despite a worsened 
signal-noise ratio (Figure 6.8b). The major features of the P(r) curves, notably the M  
and L values, were reproduced (Figures 6.8a,b). Two poor-fit solutions from the best
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Filter for best-fit 
models
Models Hydrated 
spheres (N)
X-ray Rg 
(nm)
X-ray RXs-i 
(nm)
X-ray Rxs-2  
(nm)
Neutron Rg 
(nm)
X-ray 
R Factor (%)
Neutron 
R Factor (%)
S °20,w
(S)
Search 1
None 1500 4610-5000 8.14-8.82 4.03-4.88 1.31-1.94 7.18-7.68 8.5-13.1 6.8-10.7 n.a.
N, Rg, Rxs-i 93 4610-4970 8.14-8.40 4.03-4.20 1.42-1.90 7.18-7.34 8.5-9.8 8.7-10.7 n.a.
N, Rg, Rxs-i, R Factor 34 4639-4914 8.21-8.40 4.09-4.20 1.49-1.82 7.22-7.34 8.5-9.0 9.0-10.7 n.a.
N, Rg, Rxs-i, R Factor 10 4643-4852 8.25-8.37 4.14-4.20 1.49-1.79 7.24-7.32 8.5-8.8 8.6-10.0 11.2-11.5
Best-fit (Figure 6.8c) 1 4791 8.32 4.20 1.72 7.30 8.5 9.3 11.4
Fab reorientation fits
None
N, Rg, Rxs-i
N, Rg, Rxs-i, R Factor
3000
349
50
3358-4849
4661-4835
4680-4797
4.73-9.74
7.88-8.70
7.97-8.46
0.39-4.87
3.80-4.20
3.82-4.19
0.18-2.36
1.84-2.09
1.42-1.92
4.42-7.73
6.77-7.19
6.82-7.07
7.9-32.9
8.0-10.3
8.0-8.4
7.8-29.1
8.5-11.5
9.2-10.8
n.a.
n.a.
n.a.
Experimental values n.a. 4757 8.29
±0.20
3.90
±0.13
1.27
±0.03
7.22 n.a. n.a. 10.8 (SEDFIT)
10.9 (DCDT+)
Poor-fit SIgAl
Figure 6.8f model 1 ▼ 1 4883 8.19 4.12 1.80 6.94 9.4 9.5 11.5
Figure 6.8f model 2 A 1 4947 8.09 3.93 2.02 6.96 10.8 10.1 11.7
Tabic 6.2 Summary of the X-ray and neutron modelling fits from Search 1 and the Fab reorientation search for the SgAl 
solution structure
n.a. -  not available
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Figure 6.8 X-ray and neutron fits for the best-fit SIgAl model from search 1 and 
two poor-fit SIgAl models
(a, b) The X-ray and neutron experimental I(Q) and P(r) curves are in black, and the red 
lines are the modelled best-fit curves. The P(r) curve is shown as an inset in the top right 
comer, (c) The best-fit model is shown as a ribbon trace with the IgAl dimer and J chain 
shown in red, and domains D 1 to D5 of SC shown in black, (d, e, f) The X-ray and 
neutron curve fits are shown for two poor fit SIgAl models 1 and 2. In model 1, SC is 
on the other edge of the Fc-Fc dimer compared to the best-fit SIgAl model. In model 2, 
SC is positioned on the central face of the Fc-Fc dimer. Other details follow those in (a, 
b, c). The colour and shape coding of the SIgAl models follows that in Figure 6.6.
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outcome of Search 3/4 and from Search 5/6 illustrated the extent to which a best-fit 
structure had been determined in Search 1 (blue triangles in Figure 6.6; Figure 6.8d,e,f). 
Both the poor curve fits deviated in the Q range of 0.5-0.8 nm'1 that corresponded to the 
main difference between dlgAl and SIgAl. If SC was on the other edge of the Fc-Fc 
region (poor-fit model 1 in Figure 6.8d,e,f), its Rg value was decreased below the 
experimental value, and its i?-factor increased to 9.4% (Table 6.2). If SC was on top of 
the Fc-Fc region (poor-fit model 2 in Figure 6.8d,e,f), its Rg value was decreased 
further, and its 7?-factor increased to 10.8%.
A second round of modelling was performed to investigate whether randomised 
reorientations in the four Fab regions in SIgAl would improve the fit. The best-fit 
location for SC against the Fc-Fc region from Search 1 was held fixed (Figure 6.8c). 
This round of searches utilised the 3,000 randomised dlgAl hinge structures created 
previously (Section 5.4.4; Section 6.4.3). The randomised hinges tested a sufficient 
range of Fab orientations, verified by the minima observed in Figure 6.9. The curve fits 
showed that the minimum R factor was reduced from 8.5% to 8.0%, and the modelled 
X-ray Rg, Rxs-i and Rxs-2 values were similar to the experimental values (Table 6.2). The 
quality of the curve fit was similar to that in Figure 6.8a,b. Superimposition of the 50 
best-fit models showed that a limited conformational family of structures had resulted 
(Figure 6.10) in which the two Fab regions displayed an extended and mostly T-shaped 
arrangement relative to their adjacent Fc region. All four Fab regions were independent 
of each other. When compared with dlgAl (Figure 5.16), the Fab regions were in 
approximately the same positions and included many of those revealed in the same 
dlgAl fits. This agreement indicates that no conformational change in dlgAl had 
occurred when this binds to SC.
The experimental sedimentation coefficient s°2o,w value of 10.9 S for SIgAl was 
compared with the S°20,w values of the ten best-fit SIgAl models (Table 6.2). Using a 
previously established simulation procedure (Section 6.4.3), the calculated s°2o;W values 
for the SIgAl models ranged between 11.2 S to 11.5 S (Table 6.2). The best-fit SIgAl 
model had a s°2o,w values of 11.4 S. Slightly larger values of 11.5 S and 11.7 S 
were obtained with the two poor-fit models of Figure 6.8f. These agreements support 
the X-ray scattering best-fit SIgAl model (Figure 6.8c).
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Figure 6.9 Analysis of the SIgAl Fab reorientation second-round modelling search
Comparison of the X-ray Rg and R factor values for the 3000 models. The 50 best-fit 
models are shown in yellow. The vertical dashed line indicates the experimental X-ray 
Rg, Rxs-i and Rxs-2 values.
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Fab
Figure 6.10 Superimposition of best 50 SIgAl models from the Fab-refinement 
search
Three orthogonal views of the superimposition of the 50 best-fit SIgAl models from the 
Fab reorientation second round search. The Fab regions are shown in blue, the two Fc 
regions are shown as red ribbons at the centre, J chain is shown in green, and SC is 
shown in black with the positions of D l, D3 and D5 indicated.
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6.3 Discussion
SIgA is one of the most important components of the immune system. This 
thesis chapter presents the SIgAl solution structure at medium resolution showing how 
SIgAl is assembled from its components. The homogeneity of the SIgAl preparation 
previously demonstrated by gel filtration and SDS-PAGE was confirmed here by AUC 
(Almogren et al., 2007 Almogren & Kerr, 2007). The AUC analyses also rule out the 
possibility of contamination of the dimeric SIgAl preparation by monomeric IgAl, 
tetrameric SIgAl or other immunoglobulins. This also supports previous findings that 
the same SIgAl purification binds to FcaRl (CD89), triggering a respiratory burst in 
neutrophils in the same way as serum dlgAl, which lacks SC (Almogren & Kerr, 2007). 
The SIgAl also binds to jacalin and is cleaved by proteases acting at both the hinge 
region and the Ch2/Ch3 interface, although the latter is cleaved at a much slower rate 
than serum IgAl. Taken together these results demonstrate the functional accessibility 
of much of the SIgAl molecule even though SC is bound to it.
The size of SIgAl, its high carbohydrate content and its flexibility mean that the 
crystallisation of intact SIgAl may not be realistic, and constrained scattering modelling 
presently offered the only route to a macromolecular structure. Experimentally, we have 
shown that SIgAl has a near-planar structure in solution similar to that of dlgAl, with 
the two monomers orientated end-to-end through a slightly-bent arrangement of their Fc 
regions. The 34 best-fit SIgAl structures support this (Figure 6.11; Figure 6.12). The 
scattering curve of SIgAl showed a small but significant alteration at medium Q values 
when compared to that of dlgAl (Figure 6.5). Most strikingly, the constrained 
modelling located the SC structure along the outermost edge of the Fc-Fc region, 
indicating that SC must unfold from its J-shaped structure when it is free in solution 
(Chapter 5; Bonner et a l , 2007), and did not reveal any conformational alteration of 
dlgAl when SC was bound to it. A similar position of SC has determined for SIgA2 
(Chapter 7). Because this SIgAl structure was determined from experimental scattering 
data, this is not a prediction method, and the ten best-fit models qualify for deposition in 
the PDB. These are best viewed as a single superimposed image to appreciate the 
precision of the curve fit method. It is stressed that the molecular interactions of the five 
individual SC domains relative to the Fc-Fc region are not precisely defined by this
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Figure 6.11 Superimposition of the 34 best-fit SIgAl models from Search 1
The 34 best-fit models of SIgAl from Search 1 from the first round of modelling 
searches ( in Figure 6.6) are shown in three orthogonal views. The two IgAl 
monomers are shown in red, the J chain is shown in green and the a-carbon traces of 
SC are shown in blue, except for the fixed domain D3 which is shown as a ribbon.
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Figure 6.12 The ten best-fit SIgAl models from Search 1
The ten best-fit SIgAl models are shown ( •  in Figure 6.6), with the dlgAl moiety in 
red and blue in each one shown in the same orientation, and the variable location of SC 
is shown in black. The J chain is shown in green. The first model (*) corresponds to the 
best-fit SIgAl model ( •  in Figures 6.6 and Figure 6.8). The R factor is shown beneath 
each SIgAl model.
work. Interestingly, these best-fit SIgA 1 models resemble the crystal structures for the 
FcaRI-Fca, FcRn-Fcy, FcyRIII-Fcy and FcsRI-Fcs complexes (PDB codes 10WO, 
1 A ll, 1E4K, 1F6A; Herr et al., 2003b) in the sense that all four complexes show the 
receptor molecule making contact at a diverse range of positions on the edge of the Fc 
region in the three Ab classes, and not at its face. The location of SC in the best-fit 
SIgA 1 models may also resemble the edge-to-edge contacts formed between the five Fc 
regions in the experimentally-determined scattering modelling structure for the human 
IgM pentamer (PDB code 2RCJ; Perkins et al., 1991) and likewise the location of 
Protein A on the edge of the Fc region (PDB code 1FC2; Deisenhofer, 1981).
The strength of scattering modelling is that, while not able to determine unique 
molecular structures, it is able to rank the conformationally-randomised models and rule 
out the poorer-fit ones (Table 6.2). The exploration of three types of models in ten 
searches identified SC to be positioned on the most exposed, convex edge of the Fc-Fc 
region in dlgAl. The final models were favoured for reason of their clearly better 
agreement with the experimental Rq values and the avoidance of steric overlaps between 
the Fab regions and SC domains (Figure 6.6; Figure 6.7; Table 6.2). The original 
electron microscopy study of SIgAl showed only a single Y-shaped structure, which 
was interpreted as two IgAl monomers superimposed upon one another (Svehag & 
Bloth, 1970; Heremans, 1974; Figure 1.9). This model is ruled out by the experimental 
data showing that dlgAl and SIgAl are similarly elongated. The subsequent study 
indicated an end-to-end arrangement of two IgAl monomers with various degrees of 
bending between them (Bloth & Svehag, 1971; Figure 1.9), and this is supported by the 
present scattering data. Neither of these electron microscopy studies showed the location 
of SC relative to dlgAl, nonetheless these SIgA images inspired many subsequent 
cartoons for extended SC arrangements on one face of dlgAl (Heremans, 1974; Kerr, 
1990). Many earlier hypothetical models that placed SC on one face or wrapped this 
around the Fc-Fc region in cartoons result in too low Rg values when modelled (e.g. 
Model 2 in Figure 6.8f; Table 6.2), and were not favoured by the constrained scattering 
modelling.
Our new SIgAl structure offers a further understanding of the mucosal immune 
system. A near-planar SIgAl structure with SC located at one edge of this would be
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readily visualised to interact effectively with cell surface receptors, most notably FcaRI 
which is involved in IgA-mediated phagocytosis, oxidative bursts and Ab-dependent 
cellular cytoxicity (Section 1.6.1; Monteiro & van de Winkle, 2003). The SIgAl model 
shows that receptor binding would occur independently of Ag binding as the Fc and Fab 
regions are well separated. Two FcaRI molecules will potentially bind at the junction 
between the Ch2 and Ch3 domains per Fc region, making this four per dlgAl structure 
(Herr et al., 2003; Pleass et a l, 1999). In fact, the location of SC on the outermost edge 
of the Fc-Fc region in SIgAl indicates that two FcaRI sites will be blocked by SC, but 
the other two will remain accessible to FcaRI (Figure 6.13). The dlgAl solution 
structure suggested that only two of the four potential FcaRI sites will bind to receptors 
on the cell surface for reason of their orientation relative to the Fc region and the cell 
surface (Chapter 5). Given that one FcaRI site is blocked by SC, this reasoning 
indicates that only a single binding site for FcaRI is expected to be available, being 
located on the inner edge of the Fc region (orange in Figure 6.13). This 1:1 
stoichiometry is as expected (Mazengera & Kerr, 1990). Accordingly it can be 
predicted that SIgAl and dlgAl will make similar interactions with FcaRI on cell 
surfaces.
The new SIgAl solution structure clarifies the formation of SIgAl from dlgAl 
and SC, and the manner in which plgR will transcytose dlgAl across cells. In the dlgAl 
structure, the convex bend between the two Fc regions offers a potential covalently- 
bound location for the J chain within the crevice that is created by this bend, even 
though it was not possible to deduce an exact molecular location for J chain at the 
resolution of scattering modelling (Chapter 5). However, the positioning of the J chain is 
consistent with the immunologically hidden location of the J chain (Heremans, 1974). 
Unbound SC shows a J-shaped arrangement of domains in solution (Chapter 4; Bonner 
et al., 2007). The new SIgAl modelling shows that SC becomes unfolded into an 
extended domain arrangement along the edge of the Fc-Fc region assigned to contain the 
J chain. This is consistent with previous observations showing that J chain is mandatory 
for SC binding (Brandtzaeg & Prydz, 1984; Johansen et al., 2001), and that bound and 
free SC can be distinguished by different conformational epitopes (Brandtzaeg, 1974). 
The extensive interactions between SC and the edge of the Fc-Fc region are consistent
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Figure 6.13 Stereo view of the best-fit SIgAl solution structure and its interaction 
with an FcaRI molecule
The best-fit SIgAl model (Figure 6.8c; Figure 6.12) and its interaction with an FcaRI 
molecule is shown as a stereo pair. The SIgAl heavy chains (blue), light chains (red) J 
chain (green), SC (black) and the FcaRI (orange; PDB code 10WO; Herr et a l , 2003b) 
are shown. Cys311 is shown in yellow spacefill.
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with biochemical studies. Thus the SC D1 domain is important for the initial interaction 
of SC with dlgAl, most notably the CDR regions (Figure 1.13), but D1 will not bind 
alone to Fc (Bakos et al., 1991b; Hamburger et al., 2004). The SC D2 and D3 domains 
increase the affinity for dlgAl (Norderhaug et a l, 1999). The SC D5 domain covalently 
binds with Cys311 at the edge of the Ca2 domain of IgA (Fallgreen-Gebauer et al., 
1993; Figure 6.13). Accordingly our SIgAl structure supports a ‘zipper effect’ binding 
mechanism of SC to dlgAl (Crottet & Corthesy, 1999). Likewise this positioning of SC 
on the convex Fc-Fc edge makes it possible to visualise more readily how plgR is 
sterically able to access the Fc-Fc region of dlgAl in order to mediate trancytosis.
The positioning of the SC D1-D5 domains along the edge of the Fc-Fc regions in 
dlgAl provides SIgAl with a greater ability to resist proteolysis in the harsh 
environment of mucosal surfaces. SC on its own is readily degraded to half its size 
(Chapter 4; Heremans, 1974; Beale, 1985), but this does not occur in the context of 
SIgAl. Trypsin, pepsin and two bacterial proteases cleave monomeric IgAl and dlgAl 
more readily than SIgAl (Lindh, 1975; Almogren et al., 2003). SC delays cleavage in 
the hinge/Fc region of the a-chain (Crottet & Corthesy, 1998). The determined SIgAl 
solution structure provides one explanation for this resistance in terms of the masking of 
likely cleavage sites at the loop regions in the Fc and SC domains along the convex edge 
of the Fc-Fc region, all of which become less accessible after SIgAl formation. This 
will however leave the concave edge of the Fc-Fc susceptible to proteolysis. That 
cleavage does not occur here after SIgAl formation is attributed to the reduced access to 
proteases mediated by the two Fab regions above and below it. This was suggested by 
visual inspection of the crystal structures for the bacterial Pseudomonas aeruginosa 
alkaline protease and the Serratia marcescens metalloprotease (PDB codes 1KAP and 
1SRP; Baumann et al., 1993; Hamada et al., 1996). The formation of SIgAl is likely to 
lead to a reduction of flexibility between the Fc and Fab regions, which in turn will 
reduce the susceptibility of surface loops to proteases at this concave edge. Accessibility 
to proteases at the concave edge of the Fc-Fc region will also be blocked further if 
SIgAl is bound at this edge to cell surface receptors. The surface location of eight N- 
glycosylation sites at Asn263 and Asn459 on the dlgAl Fc regions, togther with the 
seven glycosylation sites in SC when incorporated into SIgAl will mask these surfaces
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from protease cleavage (Chapter 4; Chapter 5).
The elucidation of a near-planar solution structure for SIgAl with SC positioned 
on the convex edge of the Fc-Fc region has transformed our understanding of the 
function of SIgA. This opens the way for further experimentation in order to refine and 
extend our structural knowledge of SIgA assembly, and the way that SIgAl performs its 
functions in mucosal immunity.
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6.4 Materials and Methods
6.4.1 Preparation and composition of SIgAl
Native SIgAl containing X and k  class light chains was isolated from human 
colostrum provided by consenting healthy volunteers, and purified using a combination 
of thiophilic chromatography and jacalin-agarose lectin affinity chromatography (Sun et 
al., 2005; Almogren & Kerr, 2007). These colostrum SIgAl samples were provided by 
Dr. Adel Almogren and Professor Michael A. Kerr. SIgAl samples were subjected to 
size-exclusion chromatography to remove non-specific aggregates and checked using 
reducing and non-reducing SDS-PAGE to confirm sample integrities before and after 
data collection. For X-ray scattering and AUC experiments, SIgAl preparations were 
studied in Dulbecco’s phosphate buffer saline (PBS; 12.5 mM sodium phosphate, 140 
mM NaCl, pH 7.4) supplemented with EDTA and sodium azide as anti-bacterial 
preservatives (0.5 mM EDTA, 0.02% NaN3). For neutron scattering, the buffer was 
Dulbecco’s PBS as above, and made up in 100% 2H20, into which the neutron samples 
were dialysed at 6°C for 36 h with four buffer changes. The composition of SIgAl 
corresponds to two IgAl monomers with k  light chains, J chain and SC. For the data 
analyses, the IgAl and J chain amino acid and carbohydrate composition was taken 
from that used previously (Section 5.4.1; Boehm et al., 1999), and combined with that 
used previously for SC (Section 4.4.1). Based on this composition, SIgAl has a 
molecular mass of 424.2 kDa; an unhydrated volume of 539.0 nm3, a hydrated volume 
of 712.2 nm3 (based on a hydration of 0.3g H20/g of glycoprotein and an electrostricted 
volume of 0.0245 nmJ per bound water molecule), an absorption coefficient at 280 nm
(1%, 1 cm path length) of 12.3, and a partial specific volume v of 0.723 ml/g (Perkins, 
1986).
6.4.2 X-ray and neutron scattering and ultracentrifugation data
SIgAl X-ray scattering data were obtained in one beam session at the European 
Synchrotron Radiation Facility (ESRF), Grenoble, France on the Beamline ID02 in 
single-bunch mode to reduce possible radiation effects (Narayanan et al., 2001; Section
2.23.2). The X-ray scattering data was collected by Dr. Patricia Furtado. Storage ring
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currents ranged from 11 mA to 18 mA with ring energy of 6.0 GeV. The sample-to- 
detector distance of 3.0 m yielded a Q range of 0.08 to 2.0 nm'1. SIgAl samples were 
contained in water-cooled Perspex cells at 15°C, of path thickness 1 mm and mica 
windows of thickness 25 pm, at concentrations of 0.30 mg/ml and 0.60 mg/ml. Samples 
were measured in 10 time frames, each of which lasted for 0.1 sec, 1 sec or 2 sec, in 
order to assess and eliminate possible radiation damage effects. Neutron scattering data 
for SIgAl were obtained by Dr. Patricia Furtado, in one beam session on Instrument 
LOQ at the pulsed neutron source ISIS at the Rutherford Appleton Laboratory, Didcot, 
U.K. (Heenan et a l 1997; Section 2.2.3.3). The proton beam current was approximately 
180 pA and data acquisition times was between 4 to 12 h for a SIgAl concentration of 
0.60 mg/ml, measured at 15°C over a Q range of 0.13 to 2.1 nm'1. Other details 
including the data reduction procedure, the Guinier analyses and the calculation of the 
distance distribution function P(r) using GNOM are as described previously (Section
2.2.4). For GNOM, the SIgAl X-ray I(Q) curve contained 521 data points between Q 
values of 0.83 to 2.00 nm'1 and was fitted with Dmax set as 26 nm. The dlgAl neutron 
I(Q) curve contained 66 data points between Q values of 0.13 to 2.1 nm'1 and was fitted 
with Dmax set as 24 nm.
AUC studies macromolecular structures in solution by following their 
sedimentation behaviour on subjecting these to a high centrifugal force. AUC analyses 
for SIgAl were performed at 20°C on a Beckman XL-I instrument equipped with an 
AnTi50 rotor. Interference and 280 nm absorbance scans were recorded at SIgAl 
concentrations of 0.20 mg/ml, 0.42 mg/ml and 0.65 mg/ml. SE data sets were each 
acquired over 45 h using six-sector cells with column heights of 2 mm at rotor speeds of
5,000 r.p.m., 8,000 r.p.m., 11,000 r.p.m. and 14,000 r.p.m. until equilibrium had been 
reached at each speed as shown by the perfect overlay of runs measured at 5 h intervals. 
A final run at 42,000 r.p.m. was performed at the end in order to determine the 
background levels for use in curve fits. Molecular weights were determined on the 
assumption of a single species using ORIGIN v4.1 (Microcal). The buffer density was 
calculated to be 1.00543 g/ml from its composition using SEDNTERP (Laue et a l , 
1992), and the viscosity was taken as 0.01002 cp. SV data were acquired over 16 h at 
rotor speeds of 10,000 r.p.m., 15,000 r.p.m. and 20,000 r.p.m at concentrations of 0.15
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mg/ml, 0.31 mg/ml and 0.58 mg/ml. Data were analysed using DCDT+ g(s*) time- 
derivative analyses (Philo, 2000) and SEDFIT v9.4 (Schuck, 1998) based on the 
continuous c(s) distribution model with a resolution set as 150, while the cell meniscus 
and bottom, the frictional ratio of 1.70, and the partial specific volume v, buffer density 
and viscosity were held fixed, and the baseline was allowed to float.
6.4.3 Constrained modelling of SIgAl
The scattering and sedimentation data were subjected to constrained modelling 
in order to determine the SIgAl solution structure (Perkins et al., 2008). One constraint 
was the use of the determined optimised dlgAl solution structural model (Chapter 5). 
This dlgAl model was derived from 6859 models created from the monomeric IgAl 
structure (PDB code 1IGA; Boehm et al., 1999). This dlgAl model was refined using a 
further 3000 models in which the orientation of the Fab regions were optimally 
positioned (Section 5.4.5). The other constraint was the use of 5,000 conformationally 
randomised full homology models for SC that were generated by the unrestrained linker 
search modelling for SC (Section 4.4.5). These were based on the crystal structure of 
domain D1 in SC (PDB code 1XED; Hamburger et al., 2004; Figure 1.13). The J chain 
in the dlgAl model was arbitrarily represented by domain D4 of SC and was located 
between the two Fc regions. Starting from the optimised dlgAl structure, the first-round 
of searches was performed by fixing the D3 or D5 domain of the 5,000 SC models in ten 
distinct positions adjacent to dlgAl (Figure 6.6a; Figure 6.7a), then evaluating the 
resulting SIgAl models. Searches 1 and 2 were performed with D3 next to the J chain 
domain on the convex edge of the Fc region in which D3 was aligned with the plane of 
the Fc region or perpendicular to this. Searches 3 and 4 held D3 in two similar 
orientations on the other concave edge of the Fc region. Searches 5 and 6 held D3 in two 
similar orientations on top of the centre of the dimeric Fc region. Four searches 7 to 10 
were performed with D5 next to each of the dlgAl CH2 domains at the top of the Fc 
regions.
As for dlgAl, the second-round of searches randomised the hinge between the 
Fab and Fc regions in the best-fit SIgAl structure obtained from the first modelling 
round (Figure 6.8c; Boehm et al., 1999). The SIgAl Fab-reorientation searches were
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performed by generating 3000 SIgAl models using the six 5000-linker libraries created 
for the 25-residue hinge. The hinge lengths were set between 5.5 nm to 9.0 nm in 0.5 nm 
steps, from each of which 500 conformations were randomly selected. The hinge 
between the CH1 and CH2 domains is 220-CPVPSTPPTPSPSTPPTPSPSCCHP-244 
(Boehm et al., 1999; Section 5.4.4).
Each SIgAl coordinate model was converted into Debye spheres in order to 
calculate X-ray and neutron scattering curves for comparison with the experimental 
curves. Each set of atomic coordinates for a model was placed within a three- 
dimensional grid of cubes. A sphere of equal volume to the cube was placed at the 
centre of each cube. A user-specified cutoff for the minimum number of atoms 
contained within a cube was determined. A cube side length of 0.531 nm in combination 
with a cutoff of 4 atoms consistently produced sphere models within about 1% of the 
total unhydrated volume of 539 nm3 calculated from its composition. The optimal total 
of dry spheres of radius 0.342 nm for SIgAl was 3600. To add the hydration shell that is 
visible by X-ray scattering (but not by neutron scattering), the sphere models were 
adapted by adding spheres to the surface of the dry models using HYPRO (Ashton et al., 
1997) based on 0.3 g H2 O / g glycoprotein to a total hydrated volume of 712.2 nm3. The 
optimal total of hydrated spheres for SIgAl was 4757. In order to reduce the computing 
time to evaluate best-fit SIgAl structures, the 5,000 SC models were first tested for 
steric overlap between their five domains using a 7% volume filter to leave only 1500 
models. The ten searches from the first round of modelling therefore evaluated a total of
15,000 SIgAl models. The values of A and the modelled Rg, Rxs-i and Rxs-2 parameters 
in the same Q  ranges used for the experimental Guinier analyses were calculated. 
Models that fit within 5% of A and the X-ray R g, Rxs-i and Rxs-2 values were ranked 
using the goodness-of-fit R factor of the model. No flat-background correction was 
required in the neutron fits. The sedimentation coefficients s°2o,w were calculated from 
the final SIgAl coordinate models using HYDROPRO v7c (Garcia de la Torre et al., 
2000). To take into account the hydration shell surrounding dlgAl, the recommended 
value of .0.31 nm for the atomic element radius for all atoms was used as an empirical 
approximation of this.
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6.4.4 SIgAl Protein Data Bank accession code
The ten best-fit SIgAl a-carbon co-ordinate models (Figure 6.12; Table 6.2) 
were deposited in the Protein Data Bank with the accession code 3CHN.
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Chapter Seven
Solution Structure of Human SIgA2:
Implications for Mucosal Immunity of the Non-Planar IgA2 and Near-Planar IgAl 
Solution Structures in Human Secretory IgA
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7.1 Introduction
IgA presents several unique features when compared with the other four human 
antibody classes IgG, IgM, IgD and IgE. It is the only one of the five that exists in 
multiple oligomeric states, and it is present as two subclasses, IgAl and IgA2, the latter 
of which is found in at least two allotypic forms, IgA2m(l) and IgA2m(2). IgA exists in 
different forms in the different mucosal environments (Kerr, 1990). SIgA is 
predominantly dimeric (with some higher oligomeric forms) and slightly more SIgAl is 
generally present than SIgA2 except in the colonic mucosa where there is more SIgA2 
(Kerr, 1990). The major interest in IgA2 is that this is more similar to the single IgA 
class present in other mammalian species. IgAl homologues have only been found 
in higher apes (Sumiyama et a l , 2002).
IgAl and IgA2 differ the most in the hinge between the Fab and Fc regions. The 
IgA2 hinge is 13 residues shorter than that in IgAl and consequently lacks the five O- 
glycosylation sites present in IgAl (Torano et a l , 1978; Putnam et al.9 1979; Figure 7.1; 
Figure 7.2). As well as the N-linked glycosylation sites at Asn263 and Asn459 present in 
IgAl, the IgA2 allotypes contain two extra N-linked glycosylation sites at Asnl66 and 
Asn337 in the ChI and Ch2 domains respectively (Figure 7.1; Figure 7.2). In the most 
common IgA2 allotype, IgA2m(l), the light chains are covalently linked by their C- 
terminal Cys214 residues, rather than to the heavy chains (Figure 7.1; Grey et a l, 1968). 
Like SIgAl, SIgA2 is composed of dimeric IgA2 (dIgA2) and secretory component (SC) 
(Figure 7.1). The two 12-domain IgA2 monomers are bound covalently through the J 
chain at the base of the two Fc regions (Figure 7.1). Dimeric IgAl (dlgAl) and SC 
confer mutually protective properties on each other in that, alone they are susceptible to 
proteolysis, but when SIgAl is formed, its resistance to proteolysis is significantly 
improved (Crotett & Corthesy, 1998; Lindh, 1975; Almogren et a l, 2003). This 
protection is reduced in SIgA2 (Almogren et a l, 2003). SC is covalently bound to a CH2 
domain in one IgAl monomer in SIgAl, yet this covalent bond appears to be absent in 
SIgA2 (Fallgreen-Gebauer, 1993; Almogren et a l, 2007).
The solution structure of monomeric IgA2 has been determined (Furtado et a l, 
2004; Figure 1.8b). The solution structures for dlgAl and SC in this thesis have led to an
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Figure 7.1 Domain structure of SIgA2
SIgA2 is composed of two IgA2 monomers, the J chain (orange outline) and SC (D1 to 
D5; green outline). The IgA2m(l) allotype has a Cys214-Cys214 disulphide bridge as 
shown, which is absent in the IgA2m(2) allotype. Each IgA2 heavy chain (blue) contains 
the VH, C h I, C h2 and C h3 domains, and each light chain (red) contains the V l and C l 
domains. The variable (V) and constant (C) domains are highlighted by dark and light 
backgrounds respectively. The CDRs (black crescents), the 13-residue hinge and the 18- 
residue C-terminal tailpiece (black lines) and the N-linked oligosaccharide sites at 
Asnl66, Asn263, Asn337 and Asn459 (•) are highlighted. The inter-heavy chain 
disulphide bridges are denoted by an X. Cys471 in one tailpiece of each Fc region is 
disulphide-bridged with either Cysl4 or Cys68 in the J-chain, which is located on the 
convex edge of the Fc-Fc region. A potential Cys311-Cys502 disulphide bridge between 
the Ch2 and SC D5 domain is shown as a dashed line.
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H u m a n  lg A 2 n  ASPTSPKVFPLSEDSTPQDGNWVACLVQGFFPQEPLSVTWSESGQNVTARHFPPSQDASGDLYTTSSQLTLPATQCPDGKSVTCHVKHYTNSSQDVTVPCRVP---------------------------- PPPPCCH
C h2  d o m a in
2 5 0  2 6 0  2 7 0  2 8 0  2 9 0  3 0 0  3 1 0  3 2 0  3 3 0  3 4 0
. +  | -------+  | ------- +  | -------- +  | ------- +  | -------- +  | ------- +  | -------- +  | ------- +  | -------- +  | ---------+  .
* SC *
_________________________________I J __________I___________
H u m a n  lgA 1 p r l s l h r p a l e d j a i ^ s e a n t .t c t l t g l r d a s g v t f t w t p s s g k s a v q g p p e i u j i c g ^ s v s s w .p g c a e p v w h g k t i t c t a a y p e s k t i ’l t a t t .s k s g n t f r  
H u m a n  lgA2m(1)pRLSLHRPAIll>IJLI^SEANT,TCTLTGLRDASGATFTW TPSSGKSAVQGPPERDLCGraSVSSVXPGCAQPW NHGETFTCTAAHPELKTPLTANTTKSGHTFR 
H u m a n  lgA 2m (2)pR E SL H R P A E E D IJJIX3SEANT/rCTLTGIJU}A£GATFTW TPSSGKSAVQGPPERDLCG^SVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTAHTTKSaNTFR 
H u m a n  lg A 2 n  PKLSLHRPALEDLLLGSEANLTCTLTGLRDASGATFTWTPSSGKSAVQGPPERDLCGWVSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTANITKSGNTFR
C h3  d o m a in  a n d  t a i lp ie c e
3 5 0  3 6 0  3 7 0  3 8 0  3 9 0  4 0 0  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0  4 6 0  4 7 0
. . . |  + |  + |  + |  + |  +  + |  + |  + |  + |  + |  + |  + | . .
<  T a i l p i e c e  >
J
H u m an  lgA 1 PEVHLLPPPSEEI^IlJELWLTCIJmGFSPKDVLVRWL^SQELPREKYLTWASRQEPS^TTTFAVTSILRVAAEDWKKGDTFSCMVGHEAEPIAFTQKTIDREAGKKrHVtav.svVMAKVIiG 
H u m an  lgA2m(1)pEVHLLPPPSEELAENELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDKLAQKPTHVWSVVt-lAI’VDG 
H u m an  lgA2m(2)PEVHLLPPPSEEIJUJJELVTLTCIJU*GFSPKDVLVRWUX5SQELPREKYLTWASRQEPSQGTTTYAVTSILRVAAEDynaa3ETFSCMVGHEAEPIAFTQKTIDRIAGKPTHINVSVVMAEADG
H u m an  lgA 2n  p e v h l l p p p s e e l a l n e l v t l t c u v r g f s p k d v e v r w l o g s o e l p r e k y l t w a s r o e p s o g t t t f a v t s i l r v a a e d w k k g d t f s c m v g h e a l p l a f t o k t i d r l a g k p t h v n v s w m a e v d g  
Figure 7.2 Sequence alignment of IgAl and the IgA2 allotypes 
The sequence of the ChI, Ch2 and Ch3 domains, linker regions connecting the domains (grey), the hinge (pink) and the tailpiece 
(pink) are shown. Cysteine residues are highlighted by vertical lines and the intra-chain disulphide bridges are connected. The inter- 
heavy-chain (*) disulphide bonds and those that bind with the light chain, J chain and SC (yellow with black background) are labelled. 
The N-linked (yellow) and O-linked (blue) glycosylation sites are shown. The residue numbering follows that of IgAl Bur.
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experimentally-based SIgAl structure (Chapter 4; Chapter 5; Chapter 6). In both dlgAl 
and SIgAl, the two IgAl monomers are orientated in a near-planar, tail-to-tail 
conformation with a slight bend in the Fc-Fc region that may accommodate the J chain 
at its convex edge. SC was located along the convex edge of the Fc-Fc region in SIgAl. 
Given the importance of this structure for mucosal immunity, the structure of SIgA is 
further analysed here by performing the corresponding constrained scattering modelling 
of human SIgA2. By combining X-ray and neutron scattering with AUC data, the first 
structural view of the assembly of SIgA2 is presented, and compared to SIgAl. The 
implications of this SIgA2 structure are discussed, in reference to its role in mucosal 
immunity, particularly its interactions with Ags and receptors. The comparison of the 
SIgA2 and SIgAl structures provides insight into their roles that lead to the efficient 
protection of mucosal surfaces.
7.2 Results
7.2.1 Purification of human colostrum SIgA2
The purification of SIgA2 is more difficult than that for SIgAl as no lectins 
specifically bind to IgA2. Accordingly, a three-stage procedure was employed in which 
the thiophilic resin column was used to bind colostral immunoglobulins, then SIgAl was 
removed by jacalin affinity chromatography to leave SIgA2, secretory IgM, higher 
polymers of SIgA2 and free SC in the eluate (Sun et al., 2005; Almogren & Kerr, 2008). 
Size-exclusion gel filtration then separated colostrum SIgA2 (mainly dimeric, with about 
10% tetrameric or trimeric SIgA2) from the mixture. Dimeric SIgA2 eluted as a single 
symmetrical peak. After concentration, SIgA2 samples were checked by reducing and 
non-reducing SDS-PAGE and in Western blots using anti-SIgA2 a-chain, anti-SIgA2 a- 
chain k and X light chain and anti-SC antibodies. Reducing SDS-PAGE showed only the 
three bands expected for pure SIgA2 that correspond to the IgA2 light chain and J-chain 
(25 kDa), the IgA2 heavy chain (60 kDa), and SC (80 kDa) (Almogren et al., 2007). The 
k  light chain in SIgA2 is 7 kDa larger than the X light chain, hence this cannot be 
resolved. Furthermore SIgA2 was assumed to be a mixture of the IgA2m(l) and 
IgA2m(2) allotypes.
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7.2.2 X-ray and neutron scattering of SIgA2
Comparison of the X-ray scattering I(Q) data from a single time frame and those 
averaged over ten consecutive frames showed no radiation damage or aggregation 
effects, and the merged ten time-frames were used for analyses for reason of improved 
signal-noise ratios. At the lowest Q values (Q = 4 n sin 0 IX; 20 = scattering angle; X = 
wavelength), the Guinier analyses resulted in linear plots, from which the RG value was 
obtained within satisfactory Q.Rg limits (Figure 7.3a,b). IgA2 myelomas are extremely 
rare, accordingly no scattering comparison could be made for dIgA2, unlike that 
between SIgAl and dlgAl (Table 7.1). The mean SIgA2 X-ray RG from five values was 8.13 
±0.1 nm (Figure 7.3a;), which is slightly less than that of 8.29 ± 0.20 nm for SIgAl 
(Table 7.1). The SIgA2 anisotropy ratio RJRo  (where Ro is the RG value of the sphere 
with the same volume as the glycoprotein) was 1.90, which is slightly less than that of
1.93 for SIgAl (Table 7.1). The same trend but with a larger difference was seen for 
monomeric IgA2m(l) and IgAl for which the RG/Ro ratios were 1.66 and 1.99 
respectively (Table 7.1). The similarities between the two SIgA isoforms suggest that 
they both have a similar extended arrangement of IgA monomers with SC located at its 
centre (Figure 7.1). The difference between the two isoforms is attributed to the 
variation in the length of their hinge regions, where that for IgA2m(l) is 10 residues 
while that for IgAl is 23.
The shorter axes of SIgA2 were monitored using the Rxs-i and Rxs-2 parameters 
from X-ray cross-sectional Guinier analyses. The ln(I(Q).Q) plots revealed two linear 
regions in Q ranges between 0.20 -  0.28 nm'1 and 0.72 -  1.04 nm '1 that were similar to 
those for SIgAl and dlgAl (Section 5.2.2; Section 6.2.2). The mean RXs-i and Rxs-2 
values were 4.22 ± 0.09 nm (5 values) and 1.93 ± 0.03 nm (4 values) respectively 
(Figure 7.3c,d; Table 7.1). In comparison, the Rxs-i and Rxs-2 values for SIgAl were 
slightly lower at 3.90 ± 0.13 nm and 1.27 ± 0.03 nm respectively, and the same was seen 
for dlgAl (Table 7.1). The Rxs-i and Rxs-2 values for monomeric IgA2m(l) and IgAl are 
similar at 2.47 nm and 1.47 nm respectively, and 2.20 nm and 1.56 nm respectively, 
however the RXs-i values are lower than those of dlgAl (Table 7.1). The larger Rxs-i and 
Rxs-2 values for SIgA2 may result from an alteration in the relative arrangement of the
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Figure 7.3 Guinier plots and distance distribution functions P(r) analyses for SIgA2
(a-d) The Q.Rg and O.Rxs ranges used to determine the Rg, R xs-i and RXs-2 values are 
represented by filled circles between the arrowed data points. The X-ray fits correspond 
to concentrations of 0.90 mg/ml (upper), 0.60 mg/ml (middle), and 0.32 mg/ml (lower). 
The neutron fit corresponds to a concentration of 1.0 mg/ml.(a,b) The X-ray and neutron 
Q ranges used for the RG values were 0.10 to 0.17 nm'1 and 0.10 to 0.18 nm '1 
respectively and (c,d) those for the RXs-i and Rxs-2 values were 0.20 to 0.28 nm '1 and 
0.72-1.04 nm"1 respectively. (e,f) The two most frequently occurring distances in the 
P(r) curve M\ and M l are 7.3 nm and 10.0 nm respectively (X-ray) and 7.2 nm and 9.6 
nm (neutron) respectively. The SIgA2 maximum length L is 25 nm (X-ray) and 24 nm 
(neutron) when P(r) reaches 0. Error bars are shown for the SIgA2 neutron P(r) plot.
227
Protein
Data Guinier analyses P(r) analyses
Rg (nm) Rxs-t (nm) Rxs-2 (nm) Rg/R o Rg (nm) L (nm) M \ (nm) M l  (nm)
Secretory IgA2 X-ray 8.13 ± 0.10 4.22 ± 0.09 1.93 ±0.03 1.90 8.19 ±0.37 25.0 7.3 10.0
Neutrons 7.57 n.a. n.a. 1.77 7.95 24.0 7.2 9.6
Secretory IgA 1 X-ray 8.29 ± 0.20 3.90 ±0.03 1.27 ±0.03 1.93 8.30 ±0.17 26.0 7.0 9.6
(Chapter 6) Neutrons 8.27± 0.33 n.a. n.a. 1.85 8.04 24.0 6.8 10.0
Dimeric IgAl X-ray 8.65 ± 0.27 3.94 ± 0.18 1.43 ± 0.07 2.16 8.67 ±0.17 26.0 4.9 9.9
(Chapter 5; Bonner et al., 2008) Neutrons 7.60 ± 0.05 n.a. n.a. 2.08 7.47 23.0 5.1 10.1
Monomeric IgA2m(l) X-ray 5.18 ±0.09 2.47 ± 0.09 1.47 ± 0.08 1.66 5.21 ±0.15 17.0 4.5 ± 0.3 6.8 ± 0.7
(Furtado et al., 2004) Neutrons 5.03 ±0.01 2.21 ± 0.10 1.04 ± 0.06 n.a. 5.12 ±0.01 17.0 4.5 n.a.
Monomeric IgA 1 X-ray 6.20 ±0.13 2.20 ± 0.26 1.56 ± 0.16 1.99 6.12 21.0 3.7 9.1
(Boehm et al., 1999) Neutrons 6.11 ±0.18 2.17 ± 0.23 1.18 ± 0.12 n.a. n.a. n.a. n.a. n.a.
Monomeric IgAl-HSA X-ray 7.47 ±0.31 2.31 ±0.11 1.31 ±0.05 2.13 7.36 ±0.01 25.0 4.87 8.25
(Almogren et al 2006) Neutrons 7.09 ±0.01 n.a. n.a. 2.22 n.a. n.a. n.a. n.a.
Secretory component X-ray 3.53 ± 0.43 1.76 ±0.08 n.a. 1.47 3.66 ±0.19 13.0 3.8 n.a.
(Chapter 4; Bonner et al., 2007) Neutrons 3.63 ± 0.28 1.30 ± 0.10 n.a. n.a. 3.73 ±0.17 12.0 3.2 n.a.
Table 7.1 Comparison of X-ray and neutron data analyses for the polymeric forms of human IgA and its secretory component
All proteins are from human sources except for SC which is recombinant and IgA2m(l) which is a recombinant human-mouse 
chimaera. The X-ray data were obtained on instrument ID02 at ESRF except for that for monomeric IgAl, which was from Stations 
2.1 and 8.2 at the SRS Daresbury, and the neutron data were all obtained on Instrument LOQ at ISIS. n.a. -  not available
Fab and Fc regions within the dimeric structure when compared to the near-planar 
SIgAl and dlgAl structures.
Neutron scattering data acts as a control against possible X-ray-induced radiation 
damage, any internal structural inhomogeneity caused by the 13% carbohydrate content 
of SIgA2, and any hydration effect which is less visible by neutrons but not by X-rays 
(Perkins et al., 2008; Perkins, 2001). SIgA2 data were collected using a 2H20  buffer to 
correspond to a high negative glycoprotein-solvent contrast, in distinction to the high 
positive contrast observed by X-rays. The SIgA2 neutron Rq value was 7.57 nm (Figure 
7.3b; Table 7.1), this being 0.56 nm lower than the X-ray value, for which the difference 
is attributed to a largely invisible hydration shell (Perkins, 2001). The neutron anisotropy 
ratio Rg/Ro was 1.77, and is slightly less than the X-ray value of 1.90. This ratio of 1.77 
is less than those of 1.85 and 2.08 for SIgAl and dlgAl, which is consistent with the 
relative values of the three X-ray ratios (Table 1.7). No neutron Rxs-i and Rxs-2 values 
could be calculated for reason of an insufficient signal-noise ratio. The Guinier 1(0)/c 
values for proteins measured in 2H20  buffers and normalised against a standard 
deuterated polymer leads to the protein molecular mass M (where M = 1(0)/c x 9.103) 
(Boehm et al., 1999). The neutron Guinier l(0)/c value of 0.47 resulted in a mass of 425 
Da for SIgA2 (Figure 2.5), in good agreement with the composition-derived value of 
424 kDa for SIgA2, showing that the scattering data corresponded to the expected 
composition of SIgA2, which included four k  light chains and 24 N-linked biantennary 
oligosaccharides (Figure 1). The replacement of k light chains by A, light chains in 
SIgA2 will result in a decrease of 7 kDa in mass.
The calculation of the distance distribution function P(r) from the I(Q) curve 
provides structural information in real space. The mean Rq values determined from the 
X-ray and neutron P(r) curves were 8.19 ± 0.37 nm (4 values) and 7.95 nm respectively 
(Figure 7.3e,f), in good agreement with the Guinier analyses (Table 7.1). The SIgA2 P(r) 
curves reproducibly showed two broad maxima M l and M2 located at 7.3 nm and 10.0 
nm respectively (X-ray) and 7.2 nm and 9.6 nm respectively (neutron). While these were 
also observed for SIgAl and dlgAl, the M l values for dlgAl were slightly smaller than 
those for SIgAl and SIgA2 (Table 7.1). The comparable appearance of the SIgA2 and
229
SIgAl P(r) curves indicates similarity in their overall solution structures, while the 
change in M l for dlgAl is attributed to the absence of SC in this. The maximum length, 
L, is determined from where the P(r) curve reaches zero at larger r values. For SIgA2, L 
was determined to be 25 nm (X-ray) and 24 nm (neutron) (Figure 7.3e,f). The L values 
for SIgAl and dlgAl (Table 7.1) were similar to those for SIgA2 and provide further 
evidence to show that SIgA2 possesses a similar extended topology to that for SIgAl 
and dlgAl.
7.2.3 Analytical ultracentrifugation of SIgA2
In order to confirm the molecular mass of SIgA2, sedimentation equilibrium 
(SE) experiments were performed at three concentrations and four rotor speeds (Section
7.4.2). Assuming that a single species was present, SE analyses determined molecular 
mass values for SIgA2 that ranged between 320 kDa to 490 kDa (Figure 7.4). Their 
extrapolation to zero concentration gave a mean molecular mass of 415 ± 60 kDa, which 
is within error of the sequence-derived value of 425 kDa. This confirmed the neutron- 
derived molecular mass calculation (Section 7.2.2).
The SIgA2 sedimentation coefficient s°2o,w was determined from sedimentation 
velocity (SV) experiments. SEDFIT analyses showed a good visual agreement between 
the experimental and fitted boundaries (Figures 7.5a,c). The resulting c(s) distribution 
analyses revealed that a single SIgA2 species was present with an s°2o,w value of 12.2 S 
and 12.1 S from the interference and absorbance data respectively (Figures 7.5b,d). No 
other species were detectable and this confirmed the monodispersity of the SIgA2 
preparation. The conversion of the c(s) plots to c(M) mass distributions showed that the
12.2 S species corresponded to a molecular mass of 422 kDa (data not shown), which is 
consistent with the neutron, SE and sequence-derived molecular mass values. The 
DCDT+ g(s*) time derivative analyses confirmed the c(s) analyses. Between 6-14 scans 
at the centre of the sedimentation profile were analysed to give an s°2o,w value of 12.1 S 
for both interference and absorbance data sets (Figure 7.5e,f). The SIgA2 sedimentation 
coefficient of 12.1 S is larger than that of SIgAl at 10.8 S. The frictional ratio f /fa (where 
f 0 is the frictional coefficient of a sphere with a volume equal to that of the hydrated
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Figure 7.4 Sedimentation equilibrium analyses for SIgA2
SIgA2 SE analyses are shown using (a) interference and (b) absorbance optics at 
concentrations of 0.90 mg/ml (red), 0.60 mg/ml (blue), and 0.32 mg/ml (green) at a rotor 
speed of 8,000 r.p.m. Circles represent the experimental data and the continuous black 
lines represent their fits. The corresponding curve fit residuals are shown above the 
exponential fits, (c) The rotor speed dependence of the fitted molecular mass gave a 
mean value of 415 ± 4 kDa denoted by ( • )  7,000 r.p.m, (■ ) 9,000 r.p.m, (A ) 11,000 
r.p.m and (V ) 14,000 r.p.m.
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Figure 7.5 Sedimentation velocity analyses for SIgA2 using SEDFIT c(s) 
distribution and DCDT+ time-derivative fits
The black circles represent the experimental scans and the continuous red lines represent 
the fits. (a,c) SEDFIT (a) interference and (c) absorbance analyses at a SIgA2 
concentration of (a) 0.93 mg/ml and (b) 0.40 mg.ml and a rotor speed of 20,000 r.p.m., 
where every fifth scan of the 120 scans is shown for reason of clarity. The 120 scans 
were recorded at 5 min intervals between consecutive ones. The corresponding c(s) plots 
from (a,c) are shown from which the sedimentation coefficient for SIgA2 was 
determined to be 12.2 S (interference) and 12.1 (absorbance). (e,f) DCDT+ g(s*) 
analyses, where the goodness-of-fit residuals are shown above each analysis. The 
arrowed S2o,w value was determined to be 12.1 S based on data at 0.93 mg/ml 
(absorbance and interference), at rotor speeds of 10,000 r.p.m. (interference) and 15,000 
r.p.m. (absorbance) The fits were determined using from 4 to 14 scans recorded mid-way 
through the experiment shown in (a,c).
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macromolecule) of SIgA2 is 1.52, which is slightly lower than that of 1.70 for SIgAl 
and 1.63 for dlgAl, showing that SIgA2 is more compact than SIgAl and dlgAl in 
agreement with the Guinier Rg analyses above (Table 7.1).
7.2.4 Constrained homology modelling of SIgA2
The experimental scattering and AUC data for SIgA2 indicated that the overall 
arrangements of SIgAl and SIgA2 in solution are extended and similar to each other, 
while SIgA2 is slightly more compact than SIgAl. No comparison between SIgA2 and 
dIgA2 was possible, as no scattering data are available for dIgA2. Accordingly the 
constrained scattering modelling of the SIgA2 solution structure started from the best-fit 
dlgAl structure (which is identical to that within SIgAl) which was initially held fixed 
(PDB codes 2QTJ and 3CHN; (Chapter 5; Chapter 6; Bonner et a i, 2008). The Fc a- 
carbon atoms in the best-fit IgA2m(l) structure (PDB code 1R70; Furtado et al., 2004) 
were superimposed onto the two Fc regions of dlgAl with a low r.m.s.d value of 0.58 
nm to create a model for dIgA2. Even though the SIgA2 sample comprises both the 
SIgA2m(l) and SIgA2m(2) allotypes, no allowance was made for this in the modelling 
fits (Figure 7.2).
In the first cycle of modelling searches, ten different locations of SC relative to 
the fixed dIgA2 structure were evaluated in models for SIgA2. This search is similar to 
the first round of modelling searches for SIgAl (Section 6.4.3). The SC models were 
based on the 5,000 models with four conformationally-randomised linkers that were 
used to determine the SC solution structure by constrained scattering modelling (Section
4.4.4). Three types of searches were performed by holding one of the SC domains 
proximate to a specified domain in the dIgA2 structure, (i) Searches 1 to 4 explored 
positions for SC D3 on the edge of the planar bent dimeric Fc region in dIgA2. Hence 
Search 1 held the long axis of D3 parallel to the long axis of the Fc-Fc regions and next 
to the putative J chain position on the convex edge of the Fc-Fc regions. Search 2 
repeated this with D3 now rotated by 90° to be perpendicular in position to that used in 
Search 1. Searches 3 and 4 repeated these searches on the other concave edge of the Fc- 
Fc regions, (ii) Searches 5 and 6 explored locations for SC on top of the planar Fc-Fc
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regions. These positioned the long axis of D3 either parallel or perpendicular to the long 
axis of the Fc-Fc regions. These models correspond to several tentative models of this 
type in which SC is postulated to be wrapped around the planar Fc-Fc region, even 
though they have no experimental basis (Kerr, 1990; Mestecky et a l, 2005; Brandtzaeg, 
2007; Heremans, 1974; Corthesy, 2003; Mestecky & McGhee, 1987; Woof & Kerr, 
2006). (iii) Searches 7 to 10 explored SC models based on the presumption that in 
SIgAl Cys502 in SC D5 forms a disulphide bridge with Cys311 in one of the four Ch2 
domains (dashed line in Figure 7.1; Fallgreen-Gebauer et al., 1993). However, recent 
evidence suggests this covalent bridge is absent in SIgA2 (Almogren et al., 2007). 
Nonetheless D5 of SC was positioned next to each of the four Ch2 domains in SIgA2, 
with their long axes parallel to each other, and Cys502 of D5 was located within 2.0 nm 
of Cys311 in the Ch2 domain. Of the 50,000 SIgA2 models that were created, only
15,000 remained after the removal of randomised SC models in which D1 to D5 showed 
significant steric overlap. The 15,000 scattering curves were calculated for comparison 
with the experimental data (Section 7.4.3; Section 3.3.4).
The ten searches showed that, like the SIgAl curve fits, Search 1 gave the most 
favourable outcome. This gave SIgA2 structures in which extended SC structures were 
aligned along the convex edge of the Fc-Fc plane. The distributions of the 1500 sets of 
R g  and RXs values showed that the best-fit models had R g , R x s-i and RXs-i values close to 
the experimental values of 8.13 nm, 4.22 nm and 1.93 nm respectively (Figure 7.6). The 
best-fit models from Search 1 also gave R g , R xs-i and RXs-2 values that were close to the 
minimum R factor values (Figures 7.6b,c). Search 2 resulted in a best-fit SC structure 
that was very similar to that from Search 1, with SC in the plane of the Fc-Fc region 
(yellow in Figures 7.7b). The other eight searches gave worsened fits (Figure 7.7). 
Searches 3 and 4 gave reduced RG values of 7.5-8.1 nm, in which many SC models 
sterically clashed with the two Fab regions which were relatively close in the dIgA2 
structure (Figure 7.7c). Searches 5 and 6 with SC located on the face of the Fc-Fc region 
were clearly ruled out because these gave too low Rg values of 7.5-7.9 nm (Figure 7.7d). 
Searches 7 to 10 gave a reasonable range of SIgA2 structures with Rg values close to the 
minimum of the 6,000 R factor values (Figure 7.7e). However 1760 (29%) of the 6,000
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Figure 7.6 Constrained modelling Search 1 analysis of SIgA2
(a) The ten searches numbered 1 to 10 are denoted by green shaded circles labelled D3 
or D5 to correspond to the SC domain held fixed relative to the two IgA2 monomers in 
each search. The shaded circles are shown in relation to the outline of Figure 7.1. Thus 
Search 1 held SC D3 fixed next to the J chain. (b,c,d) The X-ray RG, Rxs-i and Rxs-2 
values calculated from the 1500 models in Search 1 are compared (Table 7.2). The 50 
best-fit models ( ), the ten best-fit models ( • )  and the best-fit model (horizontal arrow; 
• )  are shown. Three representative poor-fit SIgA2 models are shown ( • ,  ■  , ▲; Table 
7.2; Figure 7.8). The dashed lines correspond to the experimental RG, Rxs-i and Rxs-2 
values.
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Figure 7.7 Analyses of all ten searches from the first-cycle of the SIgA2 modelling
(a) The fixed location of the SC D3 or D5 relative to dlgAl is shown for each search 
labelled 1 to 10 (as in Figure 7.6a). (b-e) Comparison of the /fc and R factor values for 
the 1500 models from Search 1 (open circles, as in Figure 7.6b), Search 2 (blue), 
Searches 3 (pink), 4 (blue), 5 (orange), 6 (green), and 7-10 (dark blue). The axes remain 
constant for comparison. The dashed lines correspond to the experimental /fc value.
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models showed significant steric overlap, and the best of the remaining structures were 
from Search 7 only and showed a fully extended SC with its D1-D4 domains extended 
along the concave edge of the Fc-Fc plane from the fixed position of D5 near the Ch2 
domain.
The filtering of the Search 1 structures to identify a minimum of 4509 hydrated 
spheres N, Rg values between 8.02 nm to 8.21 nm, Rxs-i values between 4.09 nm to 4.43 
nm and Rxs-2 values between 1.80 nm to 2.04 nm resulted in 505 satisfactory structures 
(Table 7.2). From these, the 50 best-fit structures were selected from their R factor 
values and were visually checked for the absence of steric overlap between SC and 
dIgA2 (red, green and yellow in Figure 7.6; Table 7.2). The ten best-fit SIgA2 structures 
showed the lowest R factors (red and green in Figure 7.6), with the best-fit SIgA2 
structure having a good R factor of 5.1% (red in Figure 7.6b,c; Table 7.2) and showing a 
good visual X-ray curve fit in a Q range extending to 1.4 nm'1 provided that a small flat 
background correction was applied (Figure 7.8a). The corresponding neutron curve fit 
also gave a good R factor of 7.4% despite a worsened signal-noise ratio (Figure 7.8b). 
The major features of the P(r) curves, notably the M  and L values, were closely 
reproduced (Figure 7.8 a,b). Three representative poor-fit models from Searches 2, 3 and 
5 illustrated the extent to which a best-fit structure had been determined in Search 1 
(Figures 7.8d-l). These variously illustrated the effect of wrapping SC around the Fc 
regions, aligning SC on the concave edge of the Fc regions, or placing SC on one face of 
the Fc-Fc region. Small deviations between experimental and modelled scattering curves 
were seen in the Q range of 0.3-0.9 nm'1, causing the R factors to increase to 7.3% to
11.5% (Figure 7.8d,gj; Table 7.2), and the modelled P(r) curves deviated more from the 
experimental P(r) curves.
A second cycle of modelling was performed to investigate whether the 
randomised positioning of the four Fab regions in SIgA2 would improve the Search 1 fit. 
Here, the best-fit location for SC against the Fc-Fc region from Search 1 (Figure 7.8c) 
was held fixed while the Fab regions were varied. Constrained modelling was performed 
to follow that previously used for monomeric IgA2m(l) (Section 7.4.3; Furtado et al., 
2004). A total of 3000 SIgA2 structures were generated, which were shown to test a
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Filter for best-fit models Models Hydrated 
spheres (N)
X-ray Rg 
(nm)
X-ray RXs-i 
(nm)
X-ray RXS-2 
(nm)
Neutron Rg 
(nm)
X-ray 
R factor (%)
Neutron 
R factor (%)
S °20,w
(S)
Search 1 fits
None 1500 4395-4737 7.68-8.42 3.70-4.72 1.46-2.04 6.64-7.25 5.0-10.6 6.5-12.0 n.a.
N, Rg, Rxs-i, R factor 50 4576-4709 8.02-8.20 4.16-4.42 1.80-1.98 6.93-7.08 5.1-7.7 6.9-8.9 n.a.
N, Rg, Rxs-i, R factor 10 4641-4705 8.03-8.14 4.25-4.37 1.81-1.92 6.93-7.05 5.1-7.1 7.4-8.2 11.3-11.9
Best-fit (Figure 6.8c) 1 4688 8.08 4.25 1.91 6.93 5.1 7.4 11.9
Poor-fit (Figure 6.80 • 1 4646 7.72 3.89 1.79 6.72 7.3 10.2 11.6
Poor-fit (Figure 6.8i) ■ 1 4654 7.76 3.74 1.92 6.68 8.9 11.3 12.2
Poor-fit (Figure 6.81) ▲ 1 4593 7.69 3.53 1.97 6.56 11.5 13.3 12.2
Randomised Fab fits
None 3000 2911-4641 4.65-8.76 0.05-4.42 0.55-2.59 4.30-7.63 6.7-33.8 8.0-33.5 n.a.
N, Rg, Rxs-i, R factor 31 4552-4640 7.95-8.30 4.00-4.37 1.48-1.84 7.09-7.34 7.3-9.3 8.1-10.1 n.a.
Experimental values n.a. 4757 8.13 4.22 1.93 7.57 n.a. n.a. 12.1
±0.10 ±0.09 ±0.03
Table 7.2 Summary of the X-ray and neutron modelling fits for the SIgA2 solution structure
n.a. -  not available
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Figure 7.8 X-ray and neutron fits for the best-fit SIgA2 model and three 
representative poor-fit SIgA2 models.
(a,b) The X-ray and neutron experimental I(Q) and P(r) curves are in black, and the 
modelled best-fit SIgA2 curves are in red. The experimental I(Q) curve is shown in the 
main panel while the P(r) curve is shown as an inset in the top right comer, (c) The best- 
fit model from Search 1 is shown as a ribbon trace with the two IgA2 monomers shown in 
red, the J chain in green and the five domains of SC in black, (d-1) The corresponding X- 
ray and neutron curve fits are shown for three poor-fit SIgA2 models: (d,e,f) from Search 
2 where SC is wrapped about the centre of the Fc-Fc region at the J chain between the 
two IgA2 monomers, (g,h,i) from Search 3, where SC is on the other (concave) edge of 
the Fc-Fc dimer compared to the best-fit SIgA2 model and (j,k,l) from Search 5, where 
SC is positioned on the central face of the Fc-Fc dimer. Other details follow those in 
(a,b,c). The colour and shape coding follow that in Figure 7.6.
Figure 7.9 Analysis of the SIgA2 Fab reorientation search from the second-cycle of 
modelling fits
Comparison of the X-ray R factors with the X-ray RG values for 3000 SIgA2 models. The 
parameters of the 31 best-fit SIgA2 models are shown in blue. The vertical dashed lines 
indicate the experimental X-ray RG, Rxs-i and Rxs-2 values.
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Figure 7.10 Superimposition of the 31 best-fit models for SIgA2 from the Fab 
reorientation search from the second-cycle of modelling fits
The SIgA2 structures are shown in three views, in which the Fab regions are shown in 
blue, the two Fc regions are shown as red ribbons, J chain is shown in green and SC is 
shown in black with the positions of D l, D3 and D5 indicated as shown.
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sufficient range of Fab random orientations by the minima seen in the R factor values of 
Figure 7.9a,b. The inter-Fab Cys214-Cys214 disulphide bridge present in the IgA2m(l) 
allotype (Figure 7.1) was no longer used as a constraint. Only 79 of the 3,000 models 
showed a Cys214-Cys214 Ca-Ca separation between 0.14 nm to 0.65 nm (where the 
preferred value is 0.56 nm), and this separation increased maximally to 11.5 nm. The 
filtering of the 3,000 models on the basis of N, Rg and Rxs-i values resulted in 31 models 
(blue in Figure 7.9; Figure 7.10). All 31 models showed a similar arrangement of Fab 
regions to those determined in the best-fit SIgA2 structure from Search 1 in the first cycle 
of modelling (Figures 7.8c). The Cys214-Cys214 Ca-Ca separation ranged from 2.5 nm 
to 5.6 nm, and the magnitude of this separation may reflect the presence of both the 
IgA2m(l) and IgA2m(2) allotypes. While no improvement in the R factors was seen 
(Table 7.2), all the SIgA2 models displayed a T-shaped structure similar to that 
determined for the IgA2m(l) monomer (Furtado et al., 2004). Of particular interest from 
this modelling cycle is that the four Fab regions appear to be arranged perpendicular to 
the plane of the Fc-Fc region in SIgA2, unlike the corresponding Fab search for the 
SIgAl structure (Figures 7.10; Chapter 6). This implies that the binding of SC along the 
edge of the Fc-Fc region has displaced the four Fab regions out of the plane of the two Fc 
regions. This may account for the differences between the Rxs-i and Rxs-2 values of SIgA2 
and SIgAl/dlgAl (Table 7.1).
The experimental sedimentation coefficient s°2o,w value of 12.1 S for SIgA2 was 
compared with the s°2o,w values of the ten best-fit SIgA2 models from Search 1 (Table
7.2). Using a previously established simulation procedure (Section 7.4.3), the calculated 
s°20.w values for the SIgA2 models ranged between 11.3 S to 11.9 S (Table 7.2). The best- 
fit SIgAl model with 11.9 S showed the closest agreement with experiment. Slightly 
larger s°2o,w values of 11.6 to 12.2 S were obtained with the three poor-fit models of 
Figures 7.8f,i,l. These comparisons support the X-ray scattering best-fit SIgA2 model of 
Figure 7.8c. The superimposition of the 50 best-fit SIgA2 structures is shown in Figure 
7.11, and the ten best-fit SIgA2 structures are displayed in Figure 7.12.
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Figure 7.11 Superimposition of the 50 best-fit SIgA2 models from Search 1
The 50 best-fit SIgA2 models ( in Figure 7.6) are shown superimposed in two 
orthogonal views that are face-on to (left) and in the plane of the Fc regions (right). dIgA2 
is shown in red, J chain is shown in green and the a-carbon traces of SC are shown in 
blue, except for the fixed domain D3 which is shown as a ribbon.
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6.8 6.9 7.0 7.0 7.1
Figure 7.12 The ten best-fit SIgA2 models from Search 1
The ten best-fit models are shown ( •  in Figure 7.6) with the two IgA2 monomers in red 
and blue, each pair being shown in the same orientation. The variable location of SC in 
the models is shown in black. The J chain is shown in green. The first model (*) 
corresponds to the best-fit SIgA2 model ( •  in Figure 7.6; Figure 7.8c). The R factor of 
each model is shown beneath each one.
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7.3 Discussion
Given that SIgA is one of the most important components of mucosal immunity, 
the solution structure for SIgA2 at medium resolution shows not only how this is 
assembled from its components, but also completes our structural understanding of the 
major forms of human mucosal IgA by its comparison with SIgAl. As for SIgAl, the 
homogeneity of our SIgA2 preparation previously demonstrated by gel filtration and 
SDS-PAGE was confirmed here by the single species observed by AUC (Figure 7.5b,c). 
This SIgA2 preparation has been shown to bind to FaR l (CD89) with the same affinity as 
SIgAl (Mazengera & Kerr, 1990), triggering a respiratory burst in neutrophils in the same 
way as SIgAl and dlgAl from serum which lacks SC (Stewart & Kerr, 1990; Almogren 
& Kerr, 2008). SIgA2 is resistant to IgAl proteinase that cleaves serum and SIgAl at the 
hinge region. However, SIgA2 is cleaved by other proteinases, which cleave both classes 
of IgA at the C h2 /C h3 interface, where SIgA is cleaved at a much slower rate than serum 
IgA. The SIgA2 molecule thus demonstrated full functional accessibility even though SC 
is bound to it.
One of the two most striking features in the extended SIgA2 solution structure 
when this is compared with SIgAl is the similar location of SC along the convex edge of 
the Fc-Fc region in both SIgA isotypes (Figure 7.11; Figure 7.12; Figure 7.13). The 
individual views of the ten best-fit SIgA2 structures in Figure 7.12 do not show this, yet 
Figure 7.11 is clearer in this regard. The experimental scattering parameters readily 
showed the similarity of their extended solution structures from the Rg/Ro ratios and the 
M  and L values in the P(r) curves (Table 7.2), with small differences being attributable to 
the four shorter hinges in SIgA2 (Figure 7.2). Even though no data were available for 
dIgA2 to act as a bench mark, good scattering modelling fits were nonetheless obtained 
by starting from the dlgAl solution structure with the two monomers orientated end-to- 
end through a slightly bent arrangement of their Fc regions (Figures 7.8a,b; Figure 7.13). 
As for SIgAl, the curve fits again located the SC structure along the outermost convex 
edge of the Fc-Fc region, although it is emphasized that the specific interactions of the 
five SC domains with the Fc-Fc region could not be identified at the resolution of this 
structural determination method. As for SIgAl, the best-fit location for SC within SIgA2 
was identified through the comparison of the modelled Rg values with the experimental
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Figure 7.13 Stereo view of the solution structure of SIgA2
The best-fit SIgA2 model (Figure 7.8c; Figure 7.12) is shown as a stereo pair. The heavy 
chains (blue), light chains (red), J chain (green) and SC (black) are shown. N-linked 
oligosaccharides are shown in cyan.
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value of 8.13 nm (Figure 7.6; Figure 7.7). Many earlier hypothetical models for SIgA that 
placed SC on one face of the Fc-Fc region (Heremans, 1974; Kerr, 1990) resulted in Rg 
values that were too low when modelled, and this was more clearly demonstrated by the 
SIgA2 fits compared to that for SIgAl (Figure 7.7; Figure 6.7). The ten best-fit SIgA2 
models of Figure 8(a) have been deposited in the PDB (Section 7.4.4).
The other striking difference between the two IgA isotypes is the non-planar 
structure of SIgA2 when this is compared with the near-planar SIgAl structure. Despite 
the similarity of the location of SC in SIgA2 and SIgAl, differences between the two 
isotypes were seen in their Rxs values (Table 7.1). Rxs values are influenced by the 
relative spatial arrangement of the Fab and Fc regions in Abs. Previously, the best-fit 
structure for the IgA2m(l) monomer did not show that the two Fab regions were in the 
same plane as that of the Fc region (PDB code 1R70; Furtado et al., 2004; Figure 1.7b). 
No tendency for the two Fab regions to lie in this Fc plane could be discerned in that 
earlier IgA2m(l) study, unlike that for the IgAl monomer (PDB code 1IGA; Boehm et 
a l, 1999; Figure 1.7a). In the present study, the best-fit structure from Search 1 in the 
first-cycle of fits carried this non-planar IgA2m(l) structure across into the SIgA2 dimer. 
This superimposition gave good curve fits with the experimental scattering curve (Figure 
7.8; Figure 7.13). Further analysis through the randomisation of the Fab orientations in 
the second-cycle of fits resulted in a more pronounced non-planar SIgA2 structure, as 
evidenced by the orthogonal views of the best-fit structures in Figures 7.10. Inspection of 
these models suggested that this non-planarity resulted from the location of SC along the 
convex edge of the Fc-Fc region, which leads to crowding between the D1 and D5 
domains of SC and the adjacent two Fab regions, caused by the shorter hinge region in 
IgA2. In turn, this effect appears to cause the four Fab regions to be displaced out of the 
plane of the Fc-Fc region.
A non-planar SIgA2 structure with SC located at one edge of its Fc-Fc region 
might result in a different mode of interaction with cell surface receptors compared to 
SIgAl, most notably to FcaRI which is responsible for IgA-mediated phagocytosis, 
oxidative burst and Ab-dependent cellular cytoxicity amongst other roles (Monteiro & 
van de Winkle, 2003). SIgA2 consistently triggers a slightly slower (though similarly 
sized) neutrophil respiratory burst than SIgAl (Mazengera & Kerr, 1990). Little is known
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about the differences in effector functions of the two SIgA isotypes. Like SIgAl, the 
SIgA2 structure shows that receptor binding would occur independently of Ag binding as 
the Fc and Fab regions are well separated. Visualisation of the best-fit SIgA2 structure 
with the FcaRI crystal structure (PDB code 1OW0; Herr et al., 2003b) shows that two 
FcaRI molecules will potentially bind at the junction between the Ch2 and Ch3 domains 
per Fc region, making this four per IgA2 dimer as Sc blocks two sites. This SIgA2 
interaction with FcaRI is similar to that seen for SIgAl (Figure 6.13). It has been deduced 
that a 1:1 stoichiometry of SIgA binding to FcaRI on cell surfaces will be the same for 
both SIgA isotypes, despite the difference in the planarity of their structures.
The SIgA2 solution structure provides insight into the way that SIgA2 is formed 
from dIgA2 and SC. The J chain is presumed to be located at the convex bend between 
the two Fc regions, even though the J chain could not be located at the resolution of 
scattering modelling (Figure 7.13; Chapter 5). This is consistent with the 
immunologically hidden location of the J chain (Heremans, 1974). Unbound SC shows a 
J-shaped domain arrangement which will have to unfold into an extended domain 
arrangement in order to bind to the IgA dimer. As for SIgAl, the SIgA2 structure 
supports a ‘zipper effect’ binding mechanism of SC to dimeric IgA (Crottet & Corthesy, 
1999). A non-planar arrangement of the Fab regions relative to the Fc-Fc regions in the 
IgA2 dimer makes the Fc-Fc region accessible to the plgR. The plgR is thought to still be 
able to interact with the IgA2 dimer prior to transcytosis. However, exact dIgA2 residues 
involved in the plgR interaction are currently unknown.
The location of the SC D1-D5 domains along the edge of the Fc-Fc regions in 
SIgAl provides SIgAl with a greater ability to resist proteolysis in the harsh environment 
of mucosal surfaces. SC on its own is readily degraded to half its size (Heremans, 1974; 
Beale, 1985), but this does not occur when SC is bound to SIgAl. Proteases cleave 
monomeric IgAl and dlgAl more readily than SIgAl (Lindh, 1975; Almogren et al., 
2003). However, the SC in SIgA2 is cleaved at a similar rate to free SC, which is much 
more rapidly than SC in SIgAl (Almogren et al., 2006). The SIgA2 model explains this 
decrease in resistance (when compared to SIgAl) in terms of the greater exposure of SC 
along the convex edge of the Fc-Fc region. For reason of its non-planarity, SIgA2 is no 
longer shielded by the Fab regions in the manner described for SIgAl (Section 6.3). Free
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SC is susceptible to cleavage between D3 and D4 for reason of the long peptide linker 
between these (Chapter 4). The non-covalent link between SC and the Ch2 domain in 
SIgA2 (Almogren et a l, 2007) is expected to contribute to this susceptibility. It is 
possible that the notably heavier glycosylation of IgA2 at 16 glycosylation sites at 
Asnl66, Asn263, Asn337 and Asn459 on the two Fc regions represents an evolutionary 
attempt to protect SIgA2 from proteolytic cleavage (Figure 7.13). However the evolution 
of the SIgAl isotype has provided a more satisfactory solution to this issue.
The non-planar solution structure for SIgA2 with SC located to the edge of the Fc- 
Fc region has rationalised the existence of the two human IgA isotypes. The isotypes have 
characteristic distributions within mucosal surfaces, with slightly more SIgAl than SIgA2 
except in colonic mucosa. SIgA2 is most similar to IgA homologues in other species, 
where SIgAl is only seen in higher apes and humans. The main difference between the 
SIgA isoforms was previously believed to be in the hinge region. The present work 
indicates that the solution structures of SIgA2 and SIgAl possess non-planar and planar 
structures respectively. These differences mean that, in the harsh environment of mucosal 
secretions, SIgAl and SIgA2 are able to bind to different Ags and have varied 
susceptibilities to mucosal proteases, therefore increasing the efficiency of the mucosal 
immune system. The outcome of this study has clarified the further work needed to 
understand SIgA assembly and function, in particular the molecular details of the binding 
motifs within IgA2 and SC within SIgA2.
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7.4 Materials and Methods
7.4.1 Preparation and composition of SIgA2
Native SIgA2 (expected to contain X and k  class light chains and both the 
SIgA2m(l) and SIgA2m(2) allotypes) was isolated from human colostrum provided by 
consenting healthy volunteers and purified using three-step procedure of thiophilic 
chromatography, jacalin-agarose lectin affinity chromatography and gel filtration (Sun et 
al., 2005; Almogren & Kerr, 2007). SIgA2 preparations were provided by Dr Adel 
Almogren and Professor Michael A. Kerr. Briefly, the thiophilic resin extracted the 
immunoglobulins (SIgAl, SIgA2, secretory IgM and free SC), and the jacal in-agarose 
column specifically bound to SIgAl to leave SIgA2, polymeric SIgA2, secretory IgM, and 
free SC in the eluate. A Sephyacryl S-300 gel filtration column separated these as three 
well-resolved peaks containing secretory IgM and polymeric SIgA2, dimeric SIgA2 and 
free SC. The dimeric SIgA2 fractions were collected and concentrated. The purity of the 
dimeric SIgA2 sample was ensured by FPLC (where a single symmetrical SIgA2 peak 
was produced), SDS-PAGE and Western blots using anti-human a  chain, anti-human k  
and X light chain and anti-human SC antibodies. Samples were also checked by reducing 
and non-reducing SDS-PAGE to confirm sample integrities before and after data 
collection. For X-ray scattering and AUC experiments, SIgA2 preparations were studied 
in Dulbecco’s phosphate buffer saline (PBS; 12.5 mM sodium phosphate, 140 mM NaCl, 
pH 7.4) supplemented with EDTA and sodium azide as anti-bacterial preservatives (0.5 
mM EDTA, 0.02% NaNs). For neutron scattering, the buffer was Dulbecco’s PBS as 
above, and made up in 100% % 2H20. The neutron samples were dialysed at 6°C into this 
100% 2H20  buffer for 36 h with four buffer changes.
For the data analyses, the composition of SIgA2 was taken to correspond to two 
IgA2m(l) monomers, J chain and SC. The a-chain sequence for the CH1, CH2 and CH3 
domains for IgA2m(l) was taken from SWISSPROT (database code: P01877), while the 
Vh, Vl and Cl sequences were taken as stated in the previous study of monomeric 
IgA2m(l) (Furtado et a l, 2004). The N-linked oligosaccharides at Asnl69, Asn253, 
Asn327 and Asn449 were represented by biantennary complex-type carbohydrates (Figure 
7.1; Figure 7.2). The J chain and SC compositions were taken from that used previously 
(Section 4.4.1; Section 5.4.1). Based on this, SIgA2 with four k  light chains has a
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molecular mass of 424 kDa, an unhydrated volume of 537 nm3, a hydrated volume of 711 
nm3 (based on a hydration of 0.3g FbO/g of glycoprotein and an electrostricted volume of 
0.0245 nmJ per bound water molecule), an absorption coefficient (1%, 1 cm path length) 
of 12.2, and a v of 0.721 ml/g (Perkins, 1986). The corresponding mass for SIgA2 with 
four X light chains is 417 kDa.
7.4.2 X-ray and neutron scattering and ultracentrifugation data
X-ray scattering data were obtained in two data sessions by Dr. Patricia Furtado at 
the European Synchrotron Radiation Facility (ESRF), Grenoble, France (Narayanan et al., 
2001; Section 2.2.3.2) on the Beamline ID02, both in single-bunch mode to reduce the 
incident flux. Storage ring currents ranged from 11 mA to 18 mA with a ring energy of
6.0 GeV. The sample to detector distance of 3.0 m yielded a Q range of 0.09 to 2.0 nm'1. 
Samples at 0.32 mg/ml to 1.94 mg/ml were contained in water-cooled Perspex cells at 
15°C, of path thickness 1 mm and mica windows of thickness 25 pm. Samples were 
measured in 10 time frames, each of which lasted for 0.1 sec, 1 sec or 2 sec, in order to 
assess and eliminate possible radiation damage effects. Neutron scattering data for SIgA2 
were obtained by Dr. Patricia Furtado on Instrument LOQ at the pulsed neutron source 
ISIS at the Rutherford Appleton Laboratory, Didcot, U.K. (Heenan et al., 1997; Section 
2.2.3.3). The proton beam current was approximately 180 pA and data acquisition times 
were between 4 to 12 h at a concentration of 1.00 mg/ml, measured at 15°C over a Q 
range of 0.06 to 2.3 nm'1. Other details including the data reduction procedure, the 
Guinier analyses and the calculation of the distance distribution function P(r) using 
GNOM are as described previously (Section 2.2.4). For GNOM, the SIgA2 X-ray I(Q) 
curve contained 488 data points between Q values of 0.09 to 2.00 nm'1 and was fitted 
with Dmax set as 25 nm. The SIgA2 neutron I(Q) curve contained 71 data points between 
Q values of 0.13 to 2.3 nm'1 and was fitted with Dmax set as 24 nm.
AUC analyses for SIgA2 were performed at 20°C on a Beckman XL-I instrument 
equipped with an AnTi50 rotor, recording both interference and 280 nm absorbance 
scans. SE data sets were recorded for SIgA2 concentrations of 0.90 mg/ml, 0.60 mg/ml 
and 0.32 mg/ml over 45 h. Data were acquired at rotor speeds of 7,000 r.p.m., 9,000 
r.p.m., 11,000 r.p.m. and 14,000 r.p.m. until equilibrium had been reached at each speed
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as shown by the perfect overlay of runs measured at 5 h intervals. A final run at 42,000 
r.p.m. was performed at the end in order to determine the background levels for use in 
curve fits. Molecular mass values were determined on the assumption of a single species 
using ORIGIN v4.1 (Microcal). The buffer density was calculated to be 1.00543 g/ml 
from its composition using SEDNTERP (Laue et al., 1992), and the viscosity was taken 
as 0.01002 cp. SV data were acquired at SIgA2 concentrations of 0.93 mg/ml, 0.57 mg/ml 
and 0.40 mg/ml. Data were collected over 16 h at rotor speeds of 10,000 r.p.m., 15,000 
r.p.m., 20,000 r.p.m., 25,000 r.p.m. and 30,000 r.p.m. Data were analysed using DCDT+ 
g(^*) time-derivative analyses (Philo, 2006) and SEDFIT v9.4 (Schuck, 2000) based on 
the continuous c(s) distribution model with a resolution set as 150, while the cell 
meniscus and bottom, the frictional ratio of 1.53, and the partial specific volume v, buffer 
density and viscosity were held fixed, and the baseline was allowed to float. Other details 
are as described previously (Section 2.3; Section 4.4.3).
7.4.3 Constrained modelling of SIgA2
The scattering and sedimentation data were subjected to constrained modelling in 
order to determine the SIgA2 solution structure (Perkins et al., 2008). One constraint was 
the solution structure of dlgAl, which was determined by constrained modelling starting 
from the monomer of IgAl (PDB codes 1IGA and 2QTJ; Boehm et a l, 1999; Chapter 5; 
Bonner et al., 2008). The Fc-Fc regions in this dimer was used as the template for 
superimposition of the Fc region in the solution structure for monomeric IgA2m(l) (PDB 
code 1R70; Furtado et al., 2004) to create a starting model for dIgA2. The sequence 
numbering follows that of IgAl Bur for ease of comparison (Boehm et al., 1999; Figure 
7.2). N-linked oligosaccharides were added to Asnl66, Asn253, Asn327 and Asn449 as 
bianntennary complex-type with a Man3 GlcNAc2 core and two NeuNAc.Gal.GlcNAc 
antennae. The other constraint was the use of 5,000 conformationally randomised full 
homology models for SC (including seven oligosaccharide chains) that were generated by 
the unrestrained linker search modelling for SC (Chapter 4; Bonner et al., 2007). The J 
chain in the dlgAl model was arbitrarily represented by domain D4 of SC and was 
located between the two Fc regions (Figure 5.13). Starting from this dIgA2 structure, the 
first cycle of searches was performed by fixing the D3 or D5 domain of the 5,000 SC
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models in ten distinct locations adjacent to dIgA2, then evaluating the resulting SIgA2 
models. Searches 1 and 2 were performed with D3 next to the J chain domain on the 
convex edge of the Fc region in which D3 was aligned with the plane of the Fc region or 
perpendicular to this. Searches 3 and 4 held D3 in two similar orientations on the other 
concave edge of the Fc region. Searches 5 and 6 held D3 in two similar orientations on 
top of the centre of the Fc dimeric region. Four searches 7 to 10 were performed with D5 
held adjacent to the four Ch2 domains at the top of the Fc regions (Figure 7.6a; Figure 
7.7a). The second search cycle randomised the hinge between the Fab and Fc regions in 
the best-fit SIgA2 model from the first search (Figure 7.8c). Six linker libraries with 5000 
hinge conformations in each one were generated using molecular dynamics for 12-residue 
hinge lengths set between 2.50 nm to 3.75 nm in six 0.25 nm steps, and 3,000 of the 
resulting 30,000 conformations were randomly selected for the SIgA2 models. The hinge 
between the ChI and Ch2 domains is 220-CPVPPPPPCCHP-244 (Figure 7.2). Four 
identical linker structures were used to generate 3,000 SIgA2 models for evaluation.
Each SIgA2 coordinate model was converted into Debye spheres in order to 
calculate X-ray and neutron scattering curves for comparison with the experimental 
curves (Section 3.3.3). A cube side length of 0.531 nm in combination with a cutoff of 4 
atoms consistently produced sphere models within 1% of the total unhydrated volume of 
537 nmJ calculated from its composition. The optimal total of dry spheres for SIgA2 was 
3589. To add the hydration shell that is visible by X-ray scattering, the sphere models 
were adapted by adding spheres to the surface of the dry models using HYPRO (Ashton 
et a l 1997) based on 0.3 g H20  / g glycoprotein to generate a total hydrated volume of 
711 nm3. The optimal total of hydrated spheres for SIgA2 was 4747. In order to reduce 
the computing time to evaluate best-fit SIgA2 structures, the 5,000 SC models were first 
tested for steric overlap between their five domains using a 7% volume filter to leave only 
1500 SC models. The ten searches thus evaluated a total of 15,000 SIgA2 models. The 
values of N  and the modelled Rg, Rxs-i and Rxs-2 parameters were calculated in the same 
Q ranges used for the experimental Guinier analyses. Models that fit within 5% of N  and 
the X-ray Guinier values were ranked using the goodness-of-fit R factor of the model. A 
flat background correction of 0.2% of 1(0) was subtracted from the modelled X-ray 
scattering curve shown in Figure 7.8 (where 7(0) is 1000) as an empirical correction of
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differences in the sample and buffer transmissions that were observed at larger Q values. 
No flat-background correction was required in the neutron fits. The sedimentation 
coefficients an s°2o,w were calculated from the final SIgA2 coordinate models using 
HYDROPRO v7c. To take into account the hydration shell surrounding SIgA2, the 
recommended value of 0.31 nm for the atomic element radius for all atoms was used as 
an empirical approximation of this.
7.4.4 SIgA2 Protein Data Bank accession code
The ten best-fit SIgA2 a-carbon co-ordinate models from Search 1 (Figure 7.12; 
Table 7.2) were deposited in the Protein Data Bank with the accession code 3CM9.
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Chapter Eight 
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8.1 Conclusions
8.1.1 History of structural models for secretory IgA
The structure of SIgA has been under much debate over the years and many 
models have been proposed that differ greatly from one another. With no high- 
resolution structures of intact SIgA available, low-resolution structural-determination 
methods were employed to determine the SIgA macromolecular structure in this 
thesis. SIgA was first visualised by EM in 1970, where SIgA was seen to have a 
structure similar to an IgA monomer, yet with greater electron density in the Fab 
regions (Figure 1.9a; Svehag & Bloth, 1970). Structural models of SIgA were 
consequently proposed, with the two IgA monomers congruently on top of one 
another, with SC hidden between the two Fc regions (Figure 8.1a,c,d; Svehag & 
Bloth, 1970).
In contrast, EM models for dlgA (Figure 1.9; Svehag & Bloth, 1970; 
Dourmashkin et al., 1971, Munn et al., 1971), positioned the two IgA monomers in 
an end-to-end arrangement (Figure 8.1b; Munn et al., 1971). The SIgA structural 
model was then reconsidered in 1971, based on further EM experiments (Figure 
1.9c; Bloth & Svehag, 1971). Revised models of SIgA were similar to that of dlgA, 
with the two IgA monomers arranged in an end-to-end conformation (Figure 8.1e,h- 
o; Heremans, 1974). Studies to assign the disulphide bonds with SIgA and dlgA 
were carried out from 1986, to determine the position of the covalent linkages 
between the components of SIgA (Figure 8.f,h,i; Garcia-Pardo et al., 1986; 
Underdown et al., 1986; Mestecky et al., 1987). It was not known whether the Fc 
regions of the two IgA monomers overlapped in dlgA and SIgA, or whether the J 
chain acts as a spacer between the Fc-Fc regions (Figure 8.1h,i,k).
An early model for the domain arrangement in free SC proposed this to be a 
compact cyclic structure (Figure 8.1g; Beale, 1985). However, the position of bound 
SC was undetectable in all these early studies, as SC is too small to be visualised by 
EM. However, SC was hypothesised to wrap itself around the dlgA Fc-Fc region, for 
reason o f the mutual protection of SC and dlgA from proteolysis (Figure 8.1j,m,n; 
Kerr, 1990, Woof & Mestecky, 2005; Arnold et al., 2007). These tentative models 
were common in many reviews of IgA (Figure 8.1).
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Figure 8.1 History of structural models for secretory IgA
Figure continued overleaf.
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Figure 8.1 History of structural models for secretory IgA
Models depicting the structure of (a,c-f,h,i,j,m,n,o) SlgA, (b,k,l) dlgA and (g) SC. 
(Taken from (a) Brandtzaeg, 1970; (b) Munn et al., 1971; (c) van Munster, 1972; (d) 
Tomasi & grey, 1972; (e) Heremans, 1974; (f) Garcia-Pardo et al., 1986; (g) Beale, 
1985; (h) Underdown & Schiff, 1986; (i) Mestecky et al., 1987; (j) Kerr, 1990; (k) 
Krugman et al., 1997; (1) Johansen et al., 2000; (m) Woof & Mestecky, 2005; (n) 
Arnold et al., 2007; (o) Brandztaeg, 2007).
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8.1.2 Solution structure of SC, dlgA and the SlgA isoforms
Despite the crucial role of SlgA, SC and dlgA in mucosal immunity, no new 
structural information on the assembly of these complex proteins has been revealed 
since the EM analyses from 38 years ago. This thesis presents the solution structural 
analyses of SC, dlgA, SIgAl and SIgA2 in that order, using complementary methods 
based on X-ray and neutron scattering and AUC (Section 2.2; Section 2.3; Section 
2.4). Constrained modelling then determined their three-dimensional solution 
structures, to medium resolution (Section 3.3).
The three-dimensional structure of free SC (Chapter 4) was found to be 
compact, with a folded-back arrangement of its five domains D1-D5 (Figure 8.2a). 
The point at which SC is folded back to form the J-shaped structure was attributed to 
the long ten-residue peptide linker between D3-D4 (Figure 4.1). This D3-D4 linker is 
exposed on the surface of the SC structure, and therefore may contribute to the 
susceptibility o f free SC to proteolysis (Beale, 1985; Almogren et al., 2003). The 42- 
residue C-terminal peptide on SC has no secondary structure. This suggests that, 
when membrane-bound as the polymeric immunoglobulin receptor (plgR), this 
peptide may position D1-D5 away from the cell surface to enhance the likelihood of 
plgR interacting with its ligand, dlgA. The long peptide may also permit protease 
access to facilitate the release o f free SC or the SC-dlgA complex at mucosal 
surfaces. The proposed SC-dlgA ‘zipper effect’ interaction to form SlgA is thought 
to first include SC D1 non-covalently interacting with dlgA, with the interaction 
progressing to D2-D3 to establish the correct alignment of SC for disulphide bond 
formation between SC and dlgA (Bakos et al., 1994; Hamburger et al., 2004; 
Fallgreen-Gebauer et a l , 1993). The J-shaped structure of SC supports this proposal, 
with D1 appropriately exposed to initiate this ‘zipper’ binding interaction.
The three-dimensional solution structure of dlgAl (Chapter 5) has been 
determined to be near-planar, with the two monomers orientated end-to-end through 
their Fc regions. The two Fc regions are in close proximity to each other, and are 
slightly bent in their relative arrangement (Figure 8.2b), supporting the EM findings 
and the subsequent proposed dlgA models (Figure 1.9; Figure 8.1b,k,l). However, 
the J chain does not act as a spacer between the Fc regions of the two IgA monomers 
(Figure 8.2b; Figure 8.1k). The J chain was best positioned in dlgAl within a crevice 
formed by the bent Fc-Fc region on the convex edge, although a crystal structure will 
be necessary to confirm this (Figure 8.2b). The central location of the J chain may be
259
Figure 8.2 Solution structures of SC and dlgAl
(a) The J-shape arrangement of the five SC domains D1-D5 are shown, which are 
coloured from blue (N-terminus) to red (C-terminus). The carbohydrate moieties 
(light blue), the CDR-like regions (pink) and Cys502 (yellow) are highlighted, (b) 
The near-planar arrangement of the two IgAl monomers within dlgAl is shown. 
Heavy chains (blue), light chains (red), J chain (green), SC (black), CDRs (black), 
carbohydrate moieties (light blue) and the hinge and tailpiece (pink) are shown. 
Cys311 and Cys471 are highlighted in yellow and dlgAl residues involved in FcaRI 
are shown in orange.
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sufficiently exposed to bind plgR/SC. The dlgAl near-planar structure seems well 
adapted to approach host cell-surface membranes for effective interactions with 
FcaRI and plgR. From this structure, it is thought that dlgAl will be able to bind up 
to two FcaRI molecules on a given cell surface (Herr et a l , 2003b; Pleass et al., 
1999). Also, this dlgAl structure is well adapted for Ag-neutralisation, with the four 
Fab regions separated and independent of one another (Figure 8.2b). The dlgAl 
structure also reveals an insight into IgA nephropathy. dlgAl aggregation may arise 
due to removal or movement of the Fab regions by proteolysis or changes in the O- 
glycosylation of the hinge region, causing near-planar assemblies of trimers, 
tetramers and higher oligomers of IgA to be generated. These IgA oligomers may be 
covalently stabilised through Cys311 at the surface of the Cr2 domain in IgA, 
analogous to the covalent Fc-Fc bonds in pentameric IgM (Perkins et a l,  1991).
The elucidation of the dlgAl and SC solution structures has also opened the 
way for the constrained modelling of SIgAl and SIgA2 (Chapter 6; Chapter 7). 
SIgAl has a near-planar structure in solution similar to that of dlgAl. SC was 
located in an extended conformation along the outermost, convex edge of the dlgAl 
Fc-Fc region (Figure 8.3). The binding of SC to dlgAl does not alter the 
arrangement of the IgA monomers in SIgAl and the similarity of the structures 
suggests that SIgAl will maintain the same effector functions as dlgAl, after SC has 
bound. SIgAl therefore maintains four independent Ag-binding sites, and can 
interact with cell-surface receptors. However, one FcaRI site is blocked by SC, 
reasoning that only a single binding site for FcaRI is expected to be available on 
SIgAl (Mazengera & Kerr, 1990). The SIgAl solution structure also supports the 
‘zipper effect’ of SC/pIgR interaction with dlgA. SC must unfold from its J-shaped 
structure when it is free in solution or membrane bound as plgR as hypothesised 
(Figure 8.2a). The SIgAl solution structure provides an explanation for the mutual 
protection effect of dlgAl and SC within SIgAl (Beale, 1985; Crottet & Corthesy, 
1998; Almogren et a l, 2003). The likely cleavage sites at the loop regions in the Fc 
and SC domains along the convex edge of the Fc-Fc region are masked in SlgA and 
will become less accessible after SlgA formation. Proteolysis at the concave edge of 
the Fc-Fc region may be reduced due to limited protease access, mediated by the two 
Fab regions above and below it, and the eight carbohydrate moieties in SIgAl.
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Fc
Cys311
D4
J chain
D3
D2
Fab
Fab
Figure 8.3 Solution structure o f SIgA l
The position of SC along the convex Fc-Fc edge in SIgAl is shown. The heavy 
chains (blue), light chains (red) and N-linked and O-linked oligosaccharides (cyan) 
are shown. The J chain (green) and SC (black) are shown. Cys311 is highlighted in 
yellow.
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The solution structure for SIgA2 was determined, and similarly to SIgAl, SC 
was positioned along the convex edge of the SIgA2 Fc-Fc region (Figure 8.4). One 
striking difference between the two IgA isotypes is the non-planar structure of SIgA2 
in comparison with the near-planar SIgAl structure. In SIgA2, the Fab regions are 
not in the Fc-Fc plane (Figure 8.4). This non-planarity may arise due to crowding 
between the D1 and D5 domains of SC and the adjacent two Fab regions, caused by 
the shorter hinge region in IgA2. A non-planar SIgA2 structure might result in a 
different mode of interaction with cell surface receptors to SIgAl. SIgA2 triggers 
FcaRI functions at a slightly slower rate than SIgAl (Mazengera & Kerr, 1990). 
However, like SIgAl, the four Ag-binding sites remain independent of one another. 
The IgA2 monomers and SC within SIgA2 are thought to be more susceptible to 
proteolysis than SIgAl (Almogren et al., 2003; Almogren et al., 2006). In SIgA2, 
SC is more exposed as it is no longer shielded by the Fab regions in the manner 
described for SIgA l.
X-ray and neutron solution scattering, in combination with AUC data and 
constrained modelling have provided structural and compositional information for 
SIgAl and SIgA2 in near-physiological conditions when high-resolution X-ray 
crystallography and NMR were not possible. The automated constrained modelling 
methods, based on known crystal structures, have revealed significant new insights 
on the SlgA structure-function relationships. Determination of the solution structures 
for the two SlgA isotypes has been possible due to the prior determination of the 
solution structures for SC and dlgAl, and likewise monomeric IgAl and IgA2 
(Figure 8.2; Boehm et al., 1999; Furtado et al., 2004). The structures for SIgAl and 
SIgA2 have provided insight into the existence of the two human IgA isotypes. Their 
near-planar and non-planar structures, and varied hinge lengths, mean that in the 
harsh proteolytic environment of the mucosa, SIgAl and SIgA2 are able to bind to 
different epitopes in a range of positions and orientations, therefore increasing the 
efficiency of the mucosal immune response.
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Figure 8.4 Solution structure o f SIgA2
The non-planar arrangement of the IgA2 monomers within SIgA2 is shown. One Fab 
region on each IgA2 monomer projects into the page (Fab) and the other projects 
outwards (Fab’). Heavy chains (blue), light chains (red), J chain (green) and Fl­
unked oligosaccharides (cyan) are shown. SC (black) is shown to be extended along 
the convex Fc-Fc SIgA2 face.
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Secretory component (SC) in association with polymeric IgA 
(plgA) forms secretory IgA, the major antibody active at muco­
sal surfaces. SC also exists in the free form, with innate-like neu­
tralizing properties against pathogens. Free SC consists of five 
glycosylated variable (V)-type Ig domains (D1-D5), whose 
structure was determined by x-ray and neutron scattering, 
ultracentrifugation, and modeling. W ith a radius of gyration of 
3.53-3.63 nm, a length of 12.5 nm, and a sedimentation coeffi­
cient of 4.0 S, SC possesses an unexpected compact structure. 
Constrained scattering modeling based on up to 13,000 trial 
models shows that SC adopts a J-shaped structure in which D4 
and D5 are folded back against D2 and D3. The seven glycosyla- 
tion sites are located on one side of SC, leaving known IgA- 
binding motifs free to interact with plgA. This work represents 
the first analysis of the three-dimensional structure of full- 
length free SC and paves the way to a better understanding of the 
association between SC and its potential ligands, Le. plgA and 
pathogenic-associated motifs.
The mucosal epithelia lining the gastrointestinal, respiratory, 
and urogenital tracts represent the largest surface (400 m2 for 
the human body) in contact with the external environment (1). 
Consequently, they are permanently exposed to foreign anti­
gens and must therefore be efficiently protected to prevent pos­
sible damage by pathogenic agents (2). In response to this 
threat, a major immune defense system is mediated by secre­
tory immunoglobulin A (SlgA)5 within the lumen (3), where 
SlgA exerts its function of antigen neutralization. IgA is pro­
duced locally as polymeric IgA (plgA), which consists of two or
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four IgA molecules linked covalently by a J chain (4). Subse­
quent transport of plgA (and to a lesser extent pentameric IgM) 
across the epithelium is ensured by the polymeric Ig receptor 
(plgR), which is expressed on the basolateral surface of epithe­
lial cells. Following cleavage at luminal surfaces, SlgA is 
released as a complex of plgA and the cleaved extracellular 
portion of the plgR which is termed secretory com ponent (SC). 
Because secretory IgM can be present in external secretions 
with an accessory role as a neutralizing antibody, this suggests 
that SC has a generic antibody-binding ability, being able to 
bind to both plgA and pentameric IgM (5). This selectivity may 
be required to allow only larger, polymerized antibodies pro­
tected by heavily glycosylated SCs to enter the harsh environ­
ment of external secretions.
SC consists of five immunoglobulin-like domains (D1-D5) 
and up to seven glycan chains. SC bound to plgA protects the 
antibody against proteolytic digestion (6) and governs anchor­
ing of SlgA at mucosal surfaces (7). Free SC is also found in 
secretions and is now recognized as an active antibacterial par­
ticipant to protect mucosal surfaces against Helicobacter pylori 
(8), enteropathogenic Escherichia coli and Clostridium difficile 
toxin A (9), and Streptococcus pneumoniae choline binding pro­
tein A (10,11). Recombinant human SC produced from trans­
fected Chinese hamster ovary (CHO) cells behaves identically, 
and its neutralizing properties rely on the presence of oligosac­
charides on SC (12).
Despite the importance of SC and its glycosylation, only par­
tial information is available on its structure. SC comprises the 
first 585 residues in plgR (Fig. 1A) (13). Homology modeling of 
rabbit SC domains 1 and 2 (D1 and D2) indicates that both 
exhibit the typical features of Ig variable (V)-type superfamily 
members with seven /3-strands A -G  and an extra two desig­
nated C ' and C" (14,15). A similar topology was determined in 
the modeling of domains 2 and 3 (D2 and D3) of mouse SC (16). 
These were confirmed by the crystal structure of D1 of hum an 
SC, which revealed a V-type fold (17). So far, the three-dim en­
sional domain arrangement of full-length SC has not been con­
sidered, even though this is essential to appreciate molecular 
mechanisms that are involved in mucosal immunity. Its high 
glycosylation and the presence of long interdomain linkers sug­
gest that SC may be too flexible to be crystallized intact. In a 
situation such as this, x-ray and neutron scattering and analyt­
ical ultracentrifugation in combination with constrained m od­
eling techniques will reveal the domain arrangement of SC (18). 
Here, we determine a solution structure for recombinant 
human SC produced in CHO cells. W e show that SC forms a
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compact domain arrangement, and this structure rationalizes 
many of the biological roles of both free and bound SC for the 
first time.
MATERIALS AND METHODS
Recombinant Secretory Component and Its Fragments— 
CHO cells producing human SC (7) were cultured in suspen­
sion in CHO-S-SFMII medium (Invitrogen) using CELLine 350 
bioreactors (Integra-Biosciences). Supernatants (8 ml) were 
collected twice a week, and immediately chromatographed 
onto a 1.6-cm X  1-meter long Superdex-200 column in PBS. 
Fractions containing hum an SC as confirmed by immunoblot- 
ting were pooled and filtered through 0.22-/xm cartridges. Fil­
tered aliquots were stored at 4 °C in PBS (116 mM NaCl, 10.4 
mM Na2H P 0 4, 3.2 mM NaH2P 0 4, pH 7.2) prior to use for scat­
tering and ultracentrifugation. Cleaved SC fragments were 
obtained from purified SC samples that were stored for at least 
6 months at 4 °C. Separation was performed by chromatogra­
phy onto a 1.6-cm X  1-m Superdex-200 column (Amersham 
Biosciences) in PBS. Pools of fractions containing fragments 
D 1-D 3 and D 4-D 5  were concentrated using Amicon Ultra 
(30-kDa molecular mass cut-off) and Centricon YM-10 (10- 
kDa molecular mass cut-off) filters (Millipore), respectively. 
Further purification of fragments D1-D 3 and D 4-D 5 was 
achieved by repeating chromatography onto the Superdex-200 
column. To identify the SC cleavage site, N-terminal sequenc­
ing of purified D 4-D 5 from a polyvinylidene difluoride blot 
was performed by Edman degradation at Alta Biosciences (Uni­
versity of Birmingham, UK).
For the x-ray scattering and ultracentrifugation experiments, 
samples were recovered in PBS. For neutron scattering, the 
buffer was Dulbecco's PBS (137 mM NaCl, 2.7 mM KC1, 8.1 mM 
N a ^ P O *  1.5 mM K H ^ O *  pH 7.5), made up in 100% 2H20 .  
The neutron samples were dialyzed at 6 °C into this 100% 2H20  
buffer for 36 h with four buffer changes. The two buffer densi­
ties in H20  solvent were predicted to be 1.00485 g/ml and 
1.00543 g/ml, respectively, from these compositions using 
SEDNTERP. The SC, D1-D3, and D 4-D 5 concentrations were 
determined using absorption coefficients of 12.3,7.1, and 18.7 
(1%, 280 nm, and 1-cm path length) that were calculated from 
its composition by assuming the presence of seven biantennary 
complex-type oligosaccharides Man3GlcNAc4Gal2NeuNAc2 
(see Fig. 1) (19). The partial specific volume v for SC, D1-D3, 
and D 4-D 5 was calculated to be 0.717, 0.717, and 0.718 ml/g, 
respectively, from their compositions (19). The calculated 
molecular masses for SC, D1-D3, and D 4-D 5 were 79.6,45.5, 
and 34.1 kDa, respectively, their unhydrated volumes were 99.7, 
56.9, and 42.7 nm 3, respectively, and their hydrated volumes 
were 132.2,75.5, and 56.7 nm 3, respectively (assuming 0.3 g of 
H20 /g  of glycoprotein).
X-ray and Neutron Scattering and Ultracentrifugation Data— 
X-ray scattering data were obtained in two sessions on the 
Beamline ID02 at the European Synchrotron Radiation Facility 
(Grenoble, France), operating at 6.03 GeV (20). To reduce the 
incident flux, the experiments were performed in 16-bunch and 
4-bunch mode with storage ring currents ranging between 92 
and 53 mA (SC) and 4-bunch mode with currents ranging 
between 41 and 23 mA (D1-D3 and D 4—D5). The sample-to-
detector distance of 3.0 m, yielded a Q range from 0.07 to  2.1 
nm -1 (where Q =  4 ttsin 61 A; 26 = scattering angle; A = wave­
length). Samples were measured at concentrations between 
0.62 and to 2.0 mg/ml (SC), 0.39 to 1.6 mg/m l (D1-D3), and 
0.40 to 0.73 mg/ml (D4-D5). Data were acquired using five or 
ten time frames of 0.5, 1, 2, or 4 s to  establish the absence of 
radiation damage. Neutron scattering data for SC were col­
lected in one session in a Q range between 0.02 and 1.93 n m -1 
on Instrum ent LOQ at the ISIS facility at the Rutherford Apple­
ton laboratory, Didcot, UK (21). The proton beam current was 
172-173 pA, and acquisition times were 1 -2  h for concentra­
tions between 0.62 and 2.0 mg/ml, measured at 15 °C. O ther 
details, including calibrations and data reduction, the Guinier 
analyses to determine the radius of gyration RG and the radius 
of gyration of the cross-sectional structure Rxs, and the calcu­
lation of the distance distribution function P(r) using GNOM 
for which Q ranged between 0.08 and 2.06 nm -1 , are described 
previously (22,23).
Analytical ultracentrifugation was performed at 20 °C on a 
Beckman XL-I instrument, equipped with an AnTi50 rotor. 
Sedimentation equilibrium data sets for SC between 0.20 and 
2.50 mg/ml were acquired over 45 h with column heights of 2 
mm at rotor speeds o f8,000,11,000,14,000,18,000, and 23,000 
rpm, until equilibrium had been reached at each speed as 
shown by the perfect overlay of runs measured at 5-h intervals. 
Sedimentation velocity data for SC, D1-D3, and D 4-D 5  were 
acquired over 16 h at rotor speeds o f20,000,25,000,30,000, and
35,000 rpm (and 42,000 rpm for D 1-D 3 and D4 -D 5) with col­
umn heights of 12 mm. SC was studied at five concentrations 
from 0.30 to 2.50 mg/ml. D1-D3 and D4 -D 5  were each studied 
at two concentrations of 0.39-1.6 mg/m l and 0.40 -  0.73 mg/m l 
respectively. DCDT + g(s*) time-derivative analyses and SED- 
FIT Lamm equation fits based on the non-interacting species 
model were performed as previously described (23).
Constrained Modeling o f SC—SC corresponds to  residues 
19 -  603 of the polymeric immunoglobulin receptor (SwissProt 
code P01833). The start and end of D 2-D 5 is defined as resi­
dues 1-104 in Fig. 1. The homology modeling of D 2-D 5 
employed MODELLER v7 (24) and was based on a topological 
sequence alignment with the D1 crystal structure identified 
using BLASTP (PDB code lxed) (17). The models were struc­
turally validated using PROCHECK. Seven biantennary oligo­
saccharide chains Man3GlcNAc4Gal2NeuNAc2 were incorpo­
rated in extended conformations in the D 1-D 5 models (25,23). 
The first SC residue Lys was added to the D1 crystal structure 
using MODELLER v7. To model the other interdomain linkers, 
residues 109-116,219-221, 324-335 ,440 -446 , and 543-585 
(Fig. IB) were created in extended j3-strand conformations 
using INSIGHT II 98.0 with BIOPOLYMER, DISCOVER, 
HOMOLOGY, and DELPHI modules (Accelrys, San Diego, 
CA), and 5000 randomized conformations for each were gen­
erated using DISCOVER3 (22). Linker length constraints of 
95-100% were applied to generate sufficient conformational 
variability when needed. Full SC models were created by super­
impositions of the domains and the linkers.
Each SC, D1-D3, and D 4-D 5 model was converted into 
Debye spheres to calculate the x-ray and neutron scattering 
curves (22,23). A cube side length of 0.542 nm in combination
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FIGURE 1. The D1-D5 domains of human SC and characterization of recombinant polypeptides. A, the sequence alignment o f D 2-D 5 with D1. Conserved 
residues are highlighted in gray. The linker peptides are boxed. Putative glycosylation sites are underlined. The Arg336-Ser337 cleavage site and Cys502 that is 
covalently linked within SlgA are highlighted in black. The Define Secondary Structure Prediction-assigned secondary structure and the labeling of the  
/3-strands are shown below the alignment. B, schematic representation o f the V-type D1-D5 domains. Residue numberings indicate the cleavage site that 
yields D 1-D 3and D 4-D 5 an d  the seven glycosylation sites. The lengths of linker peptides are shown in brackets. C, SDS-PAGE and Western blot analyses of SC 
(lanes 1,3,5, and 7) and cleaved SC (lanes 2,4,6, and 8). Silver stain (lanes 1 and 2) and Western blot performed with anti-SC (lanes 3 and 4), anti-D I (lanes 5 and 
6), and anti-D5 (lanes 7 and 8) identify full-length SC at 75 kDa, D 1-D 3 as a major band at 45 kDa, and D 4-D 5 at 30 kDa.
with a cutoff of 4 atoms consistently produced sphere models 
within 95% of the total unhydrated volume of 99.7, 56.9, and 
43.8 nm3, respectively, calculated from their compositions. 
Hence the optimal totals of unhydrated spheres were 626, 268, 
and 353 respectively, which were then hydrated. The number of 
spheres N  in the unhydrated and hydrated models after grid 
transformation was used to assess steric overlap between the 
D l, D2, D3, D4, and D5 domains.
The models were assessed by calculation of the RG and Rxs 
values in the same Q ranges used for the experimental Guinier 
fits. Models that passed these RG and Rxs filters were ranked 
using the 7?-factor goodness-of-fit agreement. A flat back­
ground correction of 2.7% of 7(0) was applied to the final neu­
tron scattering curve fits in Fig. 8 to allow for a uniform inco­
herent scattering of residual protons in the sample. Other 
details, including those of calibration studies used to validate 
this approach, are given elsewhere (22, 26). The sedimentation 
coefficients s°0 w were calculated directly from the hydrated SC, 
D1-D3, and D 4-D 5 sphere models using the GENDLA and 
HYDRO programs (22, 23). Control calculations of 0 w were 
performed using HYDROPRO shell modeling directly from the 
molecular models for SC, D1-D3, and D 4-D 5 (27). The ten 
best SC a-carbon co-ordinate models were deposited in the 
Protein Data Bank with the accession code 20CW .
RESULTS
Characterization o f SC and Its Fragments—In SC, sequence 
similarities between D l and the other four SC domains (D2- 
D5) show that all belong to the immunoglobulin (Ig) variable 
(V)-type classification (Fig. L4). For clarification, the domains 
and interdomain linkers are depicted in Fig. IB. As glycosylation 
and proper disulfide bonding are essential features of SC, we chose 
to produce the protein in CHO cells, which yields SC that is indis­
tinguishable when compared with colostrum SC (12,28). Purified 
recombinant human SC resulted in a major band at an apparent 
molecular mass of 75 kDa when analyzed by silver staining and 
immunodetection (Fig. 1C, lanes 1 ,3 ,5 , and 7). This molecular 
mass agrees well with the sequence-derived value of 79.6 kDa. 
Upon storage for several months at 4 °C, two additional bands 
at 45 and 30 kDa appear (Fig. 1C, lanes 2 ,4 ,6 , and 8). In W estern 
blots, detection with polyclonal antisera specific for D l and D5 
established that the bands at 45 and 30 kDa represent cleavage of 
full-length SC into D1-D3 and D 4-D 5 fragments. This was con­
firmed by N-terminal sequencing of fragment D4 -D 5 that identi­
fied the sequence SPTWKGVAG corresponding to the begin­
ning of domain 4 and indicating cleavage between Arg336 and 
Ser337. The PeptideCutter web tool (available from the ExPASy 
server) suggested that the enzymatic cleavage may be caused by 
one of trypsin, thrombin, or other related proteases. This unex­
pected observation provided us with three different polypep­
tides that were used to generate the results presented below.
X-ray and Neutron Scattering—X-ray scattering identified 
the domain arrangements in SC, D 1-D3, and D 4-D 5 at con­
centrations between 0.40 and 2.7 mg/ml (see “Materials and 
M ethods”). Because no radiation damage was detectable, the 
ten time frames of each acquisition were averaged for analyses. 
SDS-PAGE analyses before and after runs showed that, 
although SC and D 4-D 5 generally remained intact, further 
cleavages occurred in D1-D3 to give single domain fragments 
as well as the three-domain fragment. All the SC and D4 -D 5  
results below correspond to samples shown to be intact by SDS- 
PAGE before and after the experiment.
At low Q values, Guinier analyses of In 7(Q) against Q2 
resulted in linear plots for SC and its two fragments, yielding 
the radius of gyration (RG) (Fig. 2, A, E, and F). At larger Q
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values, analyses of In I(Q)Q against Q2 yielded the RG of the 
cross-section (Rxs). For SC, a mean x-ray RG of 3.53 (±  0.03) 
nm and mean Rxs of 1.76 (±  0.08) nm were recorded from 
seven runs (Table 1). Another SC sample gave a similar mean 
x-ray RG of 3.64 (±  0.17) nm and Rxs of 1.63 (±  0.12) nm from 
six runs. A partially cleaved sample with —33% SC, 33% D1-D3, 
and 33% D4 -D 5  showed a small increase in the mean RG to 3.77 
(±  0.17) nm and a small decrease in the mean Rxs to 1.60 (±  
0.61) nm. From five runs, the partially cleaved sample of D1-D 3 
showed an apparent RG of 3.44 (±  0.27) nm and an apparent 
Rxs of 1.07 (±  0.07) nm (supplemental Fig. SI). From five runs, 
D4 -D 5 was found to have a mean RG of 3.16 (±  0.04) nm and a 
mean Rxs of 1.11 (±  0.08) nm  (supplemental Fig. SI). The 
Guinier analyses were confirmed by the 1(0)/c values, which are 
proportional to molecular masses, where c is the concentration 
(18). The observed 1(0)/c values were in the ratio of 1:0.30:0.53, 
respectively, relative to Lupolen. The sequence-derived molecu-
-2
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o
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FIGURE 2. Guinier Rc  and Rxs analyses for SC. Data points included in the Guinier fits are indicated by filled 
circles between the arrowed QRG and Q/?xs ranges. Where required for clarity, the Guinier plots were displaced 
on their vertical axes. The Q ranges for SC are 0.18 -  0.39 nm “ 1 (Rc) and 0 .42 - 0.86 nm - 1 (/?xs). A and C, x-ray fits 
for SC (1.3 mg/ml); B and D, neutron fits for SC (2.0 mg/ml (upper) and 1.3 mg/ml (lower)). For the Guinier 
analyses for D 1-D 3 and D 4-D 5 , see supplemental Fig. SI.
lar mass ratios were 1:0.57:0.43 in that order. 1(0)Ic for D1-D3 was 
lower than expected, which is attributed to its cleavage, whereas 
that for D4 -D 5 was in fair agreement with the sequence.
Interestingly SC appeared more compact than either D 1-D 3 
or D4 -D 5. Shape information was determ ined from the anisot­
ropy ratio, Rg/R0  (where R0  is the RG value of a sphere of equal 
volume to that of the hydrated glycoprotein). The ratios were 
1.44-1.49, 1.69, and 1.70 for SC, D1-D3, and D 4-D 5 in that 
order (Table 1). Because RG/R0  for globular proteins is close to 
1.28 (29), all three proteins are elongated. Assuming that the 
proteins possess cylindrical shapes, the lengths of SC, D1-D3, 
and D 4-D 5 were calculated from its RG and Rxs values to  be 
10.6-11.3, 11.3, and 10.2 nm, respectively. From the 7(0) and 
[7(Q)Q]q^o values, the lengths were calculated to be 11.9, 9.1, 
and 10.8 nm, respectively (Table 1). Despite the cleavage in the 
D 1-D 3 sample, the similarity of these three lengths is explained 
by postulating that SC is folded back upon itself. If the end-to- 
end length of the SC domains is 
taken to be 3.7 nm from the D l crys­
tal structure (17), SC, D 1-D 3, and 
D 4-D 5 are predicted to  be 18.5, 
11.1, and 7.4 nm long if they are fully 
extended but with no linkers. The 
disparity between the observed SC 
length of 10.6-11.9 nm  and the 18.5 
nm prediction shows that SC m ust 
be folded back. That D 4-D 5  (Table 
1) is observed to be longer than the 
predicted value may result from the 
42 C-terminal residues in SC (Fig. 
L4). The observed lengths for 
D 1-D 3 are in fair agreement with 
the predicted length of 11.1 nm.
Neutron scattering data for SC 
confirm the x-ray RG values (Table 
1). These were obtained as a control 
of radiation damage by x-rays, 
because these effects are absent in 
neutron scattering. The neutron 
data are complementary in that the 
hydration shell surrounding SC is 
not detectable (26). The high nega­
tive protein-solvent scattering con­
trast acts as a control of any scatter­
ing inhomogeneity effects caused by 
the high proportion of carbohydrate
TABLE 1
Experimental x-ray and neutron scattering and ultracentrifugation analyses for SC, D1-D3, and D4-D5
G u in ie r  analyses P(r) analyses A U C  analyses
P ro te in
*G * x s R J R  o
L from  Rg 
an d  Rxs
L fro m  1(0) 
an d  [/(Q )Q ]<^o * G M L s°0iH, (SED FIT ) s°0 w (D C D T + ) flfo
nrh nm S
SC (x-ray) 3.53 ± 0 .0 3 1.76 ±  0.08 1.44 10.6 11.9 3.66 ±  0.19 3.8 ±  0.2 13.0 4.2 4.0 (int) 1.55
SC (x-ray) 3.64 ± 0 .1 7 1.63 ±  0.12 1.49 11.3 N A “ 3.71 ±  0.12 N A NA 3.9 (abs)
SC (neutron) 3.63 ± 0 .2 8 1.30 ±  0.10 NA 11.7 13.1 3.73 ±  0.17 3.2 12.0
D 1 -D 3  (x-ray) 3.44 ±  0.27* 1.07 ±  0.07* 1.69 11.3 9.1 3.52 ±  0.27 2.9 12.0 3.1 NA 1.42
D 4 -D 5  (x-ray) 3.16 ± 0 .0 4 1.11 ±  0.08 1.70 10.2 10.8 3.15 ±  0.18 2.7 10.0 2.4 2.4 (int) 2.3 (abs) 1.48
* NA, data not available. 
b Apparent (see text).
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Implications of the Near-Planar Solution Structure of Human 
Myeloma Dimeric IgAl for Mucosal Immunity and 
IgA Nephropathy1
Alexandra Bonner,* Patricia B. Furtado,* Adel Almogren,+ Michael A. Kerr,* 
and Stephen J. Perkins2*
IgA is unique in being able to form a diverse range of polymeric structures. Increases in the levels of dimeric IgAl (dlgAl) in 
serum have been implicated in diseases such as IgA nephropathy. We have determined the solution structure for dlgAl by 
synchrotron x-ray and neutron scattering and analytical ultracentrifugation. The Guinier radius of gyration (RG) of 7.60-8.65 nm 
indicated that the two monomers within dlgAl are arranged in an extended conformation. The distance distribution curve P(r) 
gave an overall length (L) of 22-26 nm. These results were confirmed by the sedimentation coefficient and frictional ratio of dlgAl. 
Constrained scattering modeling starting from the IgAl monomer solution structure revealed a near-planar dimer structure for 
dlgAl. The two Fc regions form a slightly bent arrangement in which they form end-to-end contacts, and the J chain was located 
at this interface. This structure was refined by optimizing the position of the four Fab regions. From this, the best-fit solution 
structures show that the four Fab Ag-binding sites are independent of one another, and the two Fc regions are accessible to 
receptor binding. This arrangement allows dlgAl to initiate specific immune responses by binding to FcaRI receptors, while still 
retaining Ag-binding ability, and to be selectively transported to mucosal surfaces by binding to the polymeric Ig receptor to form 
secretory IgA. A mechanism for the involvement of dlgAl oligomers in the pathology of IgA nephropathy is discussed in the light 
of this near-planar structure. The Journal of Immunology, 2008, 180: 1008-1018.
I mmunoglobulin A is the most abundant Ab class found in mucosal surfaces and is also the most heterogeneous human Ab class, being present in two subclasses IgAl and IgA2 of 
which there are at least two different allotypes. This is reflected in 
the diverse functional properties of IgA, which are still not fully 
understood (1). Unlike any other Ig class, IgA occurs in different 
oliogomeric states, circulating in serum predominantly as mono­
meric IgA at 3 mg/ml, and at mucosal surfaces as polymeric IgA, 
mainly as dimeric IgA covalently linked with secretory component 
(SC)3 (2). In serum, IgA is the second most abundant Ab class, 
with ~90% being IgAl. Monomeric and dimeric IgA (digA) in­
teract with the cell surface FcaR (FcaRI; CD89) to perform im­
mune functions including the linking of the humoral and cellular 
immune response (3). In mucosal linings, lymphoid cells produce 
dlgA locally, which is secreted into the mucosa as secretory IgA
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(SIgA). Transport of dlgA across the epithelium into luminal se­
cretions, and the consequent formation of SIgA is facilitated by the 
polymeric Ig receptor (plgR). dlgA binds to plgR at the basolateral 
surface of the epithelial cell, whereupon it is transcytosed across 
the cell and released into the lumen following cleavage of plgR at 
the apical membrane. SIgA is released, with the extracellular plgR 
domains (now called SC) remaining bound to the IgA dimer. The 
solution structure of SC has recently been elucidated (4).
An increased IgA level in serum can be associated with IgA 
nephropathy (IgAN) which is the most common form of chronic 
glomerulonephritis worldwide. IgAN is a renal disease involving 
the inflammation of the glomeruli in the kidneys, and is charac­
terized by the mesangial deposition of polymeric IgAl. IgAN is 
caused by either an abnormality in IgAl itself or in the production 
of IgAl, rather than an intrinsic abnormality in the glomerulus (5). 
Some reported characteristics of IgA in IgAN include abnormal 
O-glycosylation and an increased AI k  L chain ratio (6). Serum 
from IgA myeloma patients can be rich in dlgAl and polymeric 
IgA, although this does not lead to IgAN. In IgA myeloma and in 
other diseases characterized by high levels of dlgAl and polymeric 
IgA, these forms of IgA are thought to play an important role in 
some of the pathology associated with these diseases (7).
Polymeric IgA consists of two (or sometimes three or four) IgA 
monomers bound covalently through a joining chain (J chain) (Fig. 
1). Monomeric IgA has a 12-domain structure arranged as two H 
and two L chains (Fig. 1). Crystal structures are known for the 
murine Fab region of IgA and the human Fc region of IgAl bound 
to FcaRI (8, 9). The topology of each of the IgA domains is a 
/3-sheet sandwich comprised of the DEBA and GFC /3-strands for 
the seven-stranded C-type domains and the DEBA and GFCC'C" 
/3-strands for the nine-stranded V-type domain (10). IgAl and 
IgA2 differ significantly in the hinge region where IgA2 lacks a 
Pro-, Ser-, and Thr-rich sequence of 13 aa that is present in IgAl
www.jimmunol.org
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FIGURE 1. The domain structure and sequence o f d lgA l. d lgA l is 
formed by two IgA l monomers that are covalently linked with the J chain. 
Each IgA l H chain contains the VH, CH1, CH2, and CH3 domains, and each 
L chain contains the VL and CL domains. The V and C domains are high­
lighted with gray and white backgrounds, respectively. The CDRs (black 
crescents), the 23-residue hinge peptide (dashed line), and the 18-residue 
C-terminal tailpiece (dashed line) are highlighted. Inter-H chain disulphide 
bridges at Cys241-Cys241 and two at C y s^ -C y s 299 are shown as three black 
lines. Cys471 in one tailpiece o f each Fc fragment is disulphide-bridged 
with either C ys14 or Cys68 in the J chain. The AMinked oligosaccharide 
sites at Asn263 and Asn459 are denoted by filled symbols ( • ) .  The approx­
imately five 0-linked oligosaccharides in each hinge are denoted by open 
symbols (O).
(11, 12). IgA2 also differs in that in the commonest allotype 
(IgA2m(l)), the L chains are not covalently linked to the H chains 
but to each other, and IgA2 is held together only by noncovalent 
interactions (13). Both IgA subclasses have an additional 18-aa 
C-terminal peptide on each H chain called the tailpiece (Fig. 1). 
Cys471 in the tailpiece of the two IgA monomers forms a disul­
phide bridge with the J chain (14). Thus, the tailpiece is important 
for the dimerization of IgAl and IgA2 (15). The J chain is an 
18-kDa Ig-related glycoprotein containing 137 residues and one 
A-linked carbohydrate.
The three-dimensional structures of the different forms of poly­
meric IgA are not well-understood. Structures for monomeric hu­
man IgAl and IgA2 together with the covalent adduct of IgAl 
with human serum albumin (HSA) have been determined by con­
strained scattering modeling (16-18). The overall structure of hu­
man myeloma dlgA has been observed by electron microscopy as 
a tail-to-tail arrangement of the Fc regions in the two IgA mono­
mers (19-22). However, the conditions of electron microscopy 
work using heavy metal stains in vacuo can be harsh, and the 
solution arrangement of the monomers in dlgAl was unknown up 
to now. The size of dlgAl, together with its high glycosylation and 
long flexible hinge and tailpiece regions, suggests that its crystal 
structure will be hard to achieve. In such a.situation, x-ray and 
neutron scattering and analytical ultracentrifugation combined 
with constrained modeling, will result in a medium resolution 
structure determination that will reveal molecular details within 
dlgA (23). By this, we show that myeloma dlgAl is formed as a 
near-planar molecule in solution with a bent arrangement of Fc 
regions. This structure rationalizes the accommodation of the J 
chain within dlgAl, as well as efiFector functions of dlgAl, par­
ticularly its interaction with FcaRI receptors and SC in relation to
the formation of SIgA. Insight is also provided into the role of 
dlgAl in the development of IgAN.
Materials and Methods
Preparation and composition o f dlgAl
A  monoclonal d lgA l with K-class L chain was isolated from a human 
myeloma serum using a combination o f  thiophilic chromatography and 
jacalin-agarose lectin affinity chromatography (24, 25). Samples were sub­
jected to size-exclusion chromatography to remove nonspecific aggregates 
and checked by reducing and nonreducing SDS-PAGE to confirm sample 
integrities before and after data collection. For x-ray scattering and ana­
lytical ultracentrifugation experiments, d lgA l was dialyzed into Dulbecco’s 
PBS supplemented with EDTA and sodium azide as antibacterial preser­
vatives (12.5 mM sodium phosphate, 140 mM NaCl, 0.5 mM EDTA, 
0.02% NaN3, pH 7.4). For neutron scattering, the buffer was D ulbecco’s 
PBS as above, dialyzed at 6°C into 100% 2HzO for 36 h with four buffer 
changes. The d lgA l amino acid and carbohydrate composition for data 
analyses corresponds to two IgA l molecules as previously described (16). 
The human J chain sequence was taken from the SWISSPROT sequence 
code P01591, to which another biantennary com plex-type oligosaccharide 
was added at Asn49. This resulted in the following: molecular mass, 344.8 
kDa, an unhydrated volume o f 439.4 nm3, a hydrated volum e o f  580.2 nm3, 
an absorption coefficient at 280 nm o f 12.3 (1%, 1 cm), and a partial 
specific volume v o f  0.724 ml/g.
X-ray and neutron scattering
Solution scattering is a diffraction technique that studies the overall struc­
ture o f biological macromolecules in random orientations in solution (23). 
X-ray scattering data were obtained on the Beamline ID02 at the European 
Synchrotron Radiation Facility (ESRF; Grenoble, France) with a ring en­
ergy o f 6.0 GeV in single-bunch mode with currents from 11 to 12 mA to 
reduce the incident x-ray flux. The sample-to-detector distance o f  3 .0 m 
yielded a Q  range from 0.07 nm-1  to 2.1 nm-1  (Q  =  4  i t  sin 6/A; 26 =  
scattering angle; A =  wavelength). Samples were contained in water- 
cooled Perspex cells at 15°C, o f path thickness 1 mm and mica windows 
o f thickness 25 p m  at concentrations o f  0.58 and 1.16 mg/ml. Samples 
were measured in 10 time frames, each o f 2 s, these being optimal to 
eliminate radiation damage effects. Neutron scattering data were obtained 
on Instrument LOQ in two beam sessions at the pulsed neutron source ISIS 
at the Rutherford Appleton Laboratory. Neutrons were derived from proton 
beam currents o f ~  180 p A . Samples and buffers were measured in 2-mm- 
thick rectangular quartz Hellma cells positioned in a thermostated rack at 
15°C. Data acquisitions lasted 4 -1 3  h using concentrations o f 0.83 and
1.16 mg/ml. Other details, including calibrations and data reduction, the 
Guinier analyses to determine the radius o f  gyration Rc  and the radius o f  
gyration o f the cross-sectional structure Rx s , and the calculation o f  the 
distance distribution function P(r) using GNOM, are described previously 
(17). For GNOM, the d lgA l x-ray I(Q) curve contained 524 data points 
between Q values o f 0.98 and 2.02 nm -1 and was fitted with a D max set as 
26 nm. The d lgA l neutron 1(Q) curve contained 61 data points between Q  
values o f  0 .21-2.1 nm-1 and was fitted with a D max set as 23.5 nm.
Analytical ultracentrifugation
Analytical ultracentrifugation studies macromolecular structures in solu­
tion by following their sedimentation behavior on subjecting these to a high 
centrifugal force (23). Sedimentation equilibrium data were acquired over 
45 h using six-sector cells with column heights o f  2 mm at rotor speeds o f  
5,000, 8,000, 11,000, 14,000, 17,000, and 20,000 rpm at 20°C on a B eck­
man XL-I instrument equipped with an AnTi50 rotor. Absorbance scans at 
280 nm and interference scans were recorded at six concentrations between 
0.07 and 0.97 mg/ml. Molecular weights were determined on the assump­
tion o f a single species using ORIGIN version 4.1 (Microcal). The buffer 
density was calculated to be 1.00543 g/ml and the viscosity was taken as 
0.01002 cp. Sedimentation velocity data were acquired at concentrations o f
0.53 and 1.00 mg/ml over 16 h at rotor speeds o f 10,000, 15,000, and 
20,000 rpm in two-sector cells with column heights o f  12 mm. Data were 
analyzed using DCDT+ g(s*) time-derivative analyses and SEDFIT v9.4  
based on the continuous c(s) distribution model with a resolution set as 
150, while the cell meniscus and bottom, the frictional ratio o f 1.638, and 
the partial specific volume v, buffer density and viscosity were held fixed, 
and the baseline was allowed to float. Other details are as described pre­
viously (17).
1010 SOLUTION STRUCTURE OF DIMERIC IgAl
Constrained modeling o f dlgAl
The scattering and sedimentation data were subjected to constrained mod­
eling to determine solution structures (23). The full coordinates o f mono­
meric IgA l (16) was used to generate dimer models. A planar starting 
model for the dimer was created by arranging the two monomers back to 
back. The J chain was not included. A dummy atom position was defined 
midway between the two Fc regions to act as the origin for the rotations 
and translations required to generate dlgA l models. One IgA l monomer 
was then rotated about the dummy atom, while the other monomer re­
mained stationary. The rotations were in steps o f 10° between 0° and 180° 
on each o f  the x-, y-, and z-axes, hence this resulted in 193 or 6859 models 
for each rotational search. Monomer separations were assessed by setting 
this as 1.40, 2.78, and 4.60 nm in three searches in which the two starting 
monomers shared a common y-axis. This separation was that between the 
two C a atoms o f Lys457 at the base o f the two Fc regions, and the dummy 
atom is located at the mean position o f  all four Lys454 C a  atoms. In two 
final searches, the two IgA l monomers had a separation o f 2.78 nm, but the 
IgA 1 monomer to be rotated was translated 2.0 and 4.0 nm along the x-axis.
The coordinate models were converted into Debye spheres to compute 
their scattering curves. A  cube side length o f 0.531 nm and a cutoff o f four 
atoms consistently gave models within 2% o f their total unhydrated volume 
o f 417.2 nm3, i.e., that without the J chain as this had not been modeled, 
and gave a total o f  2787 unhydrated spheres. After hydration, the number 
o f hydrated spheres n was 3678. The values o f n and the modeled Rc , Rxs./, 
and Rxs- 2  parameters were calculated in the same Q  ranges used for the 
experimental Guinier analyses. Models that fit within 5% of n and the x-ray 
Guinier values were ranked using the goodness-of-fit R factor o f the model. 
A flat-background correction o f 0.5% o f 1(0) was applied to the neutron fits 
to allow for residual incoherent scattering. The sedimentation coefficients 
s °2o.w w e re calculated from the coordinate models using HYDROPRO ver­
sion 7c. To take into account the hydration shell surrounding d lgA l, the 
recommended value o f 0.31 nm for die atomic element radius for all atoms 
was used as an empirical approximation o f  this. Other details, including 
those o f calibration studies that validate these modeling methods, are given 
elsewhere (16 ,17). The 10 best-fit d lgA l a-carbon coordinate models were 
deposited in the Protein Data Bank with the accession code 2QTJ. The 
a-carbon coordinate model o f the related pentameric human IgM structure 
was deposited with the accession code 2RCJ (24).
Results
Purification o f serum dlgAl
Conventional purifications of polymeric IgA from normal human 
serum are inadequate for purifying the polymeric forms of IgA. A 
procedure based on thiophilic resins with a binding capacity of 
over 28 mg of Ig/ml of resin allows rapid purification of Igs which 
bind selectively to the resin while almost all the other serum pro­
teins do not (25, 26). dlgAl was purified from anonymized my­
eloma serum selected for its high polymer content. The myeloma 
serum had an Ig content of IgA at 15 g/L with a dimer to monomer 
ratio of 2:1, while IgG was present at 7g/L and IgM was at 1.5 g/L. 
dlgAl was shown by nonreducing SDS-PAGE to be well-resolved 
from monomeric and trimeric IgAl species in subsequent gel fil­
tration (26). Its characterization is described in detail elsewhere 
(26). Reducing SDS-PAGE showed the expected bands corre­
sponding to the IgA 1 H chain at 62 kDa, and the L chain at 30 kDa. 
Monoclonal anti-K L chain and anti-human J chain Abs were used 
in Western blots to confirm the presence of dlgAl. In Sephacryl 
S300 size-exclusion gel filtration, dlgAl eluted as a single sym­
metrical peak, which was concentrated for data collection.
X-ray and neutron scattering
The averaged solution arrangement of the monomers within dlgAl 
was analyzed by comparing x-ray scattering data I(Q) for dlgAl 
with previous x-ray data for serum IgA (16, 17). Data were col­
lected at concentrations between 0.6 and 1.2 mg/ml at the ESRF. 
The comparison of data from a single time-frame exposure with 
the average over 10 consecutive time frames showed that the 
Guinier analyses were unaffected by the exposure time, indicating 
that radiation damage or x-ray induced aggregation were absent. 
The time-averaged runs were thus used for data analyses. At the
FIG U R E  2. X-ray and neutron Guinier analyses for d lg A l. The Q.RC 
and Q.Rxs ranges used to determine the Rc , R x s / ’ and RXS2 values are 
represented by filled circles between the arrowed data points. A and B, The 
x-ray and neutron Q  ranges used for the Rc  analyses were 0 .1 0 -0 .1 7  
nm - 1 . C and D , The Q  ranges used to calculate the Rxs-i and RXS2 values 
were 0 .2 0 -0 .2 8  nm -1  and 0 .5 6 -1 .0 4  nm - 1 , respectively. In A, C, and D, 
the x-ray fits for d lg A l correspond to concentrations o f  1.16 (upper) and 
0.58 mg/m l (lower). In B, the neutron fits for d lg A l correspond to 1.16 
(upper) and 0.83 mg/ml (lower).
lowest Q values, these analyses resulted in linear plots in Q ranges 
of 0.10-0.17 nm-1 that gave RG values within satisfactory Q.RG 
limits (Fig. 2). The x-ray Rc  value for dlgAl was 8.65 ±  0.27 nm 
(eight values) (Fig. 2A). This is significantly larger than the Rc  
value of 6.20 ± 0 .13  nm for monomeric IgAl (16) and 5.18 ± 
0.09 nm for monomeric IgA2m(l) (17). The anisotropy ratio 
RC:R0 (where R0 is the Rc  value of the sphere with the same 
volume as the hydrated glycoprotein) for dlgAl was 2.16, where 
that for monomeric IgAl was 1.99, that for monomeric IgA2 was 
1.66 and that for the IgAl-HSA complex was 2.13 (16-18). This 
showed that dimer formation had increased the degree of elonga­
tion of the IgAl structure to form a more extended one.
The shorter axes of dlgA 1 were monitored by x-ray cross-sec­
tional Guinier analyses that resulted in the Rxs.j anc* RXs~ 2  param­
eters. The In (I(Q).Q) vs Q2 plots showed two linear regions in Q 
ranges of 0.20-0.28 nm-1 and 0.56 to 1.04 nm-1 (Fig. 2, C and 
D). The Rxs j value of 3.94 ± 0.18 nm for dlgAl is almost double 
that for monomeric IgAl, IgA2, and the IgAl-HSA complex 
which are 2.20, 2.47, and 2.31 nm, respectively (16-18). This 
indicates that the IgAl dimer is significantly different in shape 
from the monomer. The RXS2 value of 1.43 ± 0.07 nm is close to 
the Rxs. 2  of 1.56, 1.47, and 1.31 nm for IgAl, IgA2, and IgAl- 
HSA (16-18). The similarity of these four Rxs_2 values suggests 
that the Fab regions retain their distinct identities within the mo­
nomeric and dimeric structures. If dlgAl is crudely approximated 
as an elliptical cylinder in shape, the combination of the Rc  and 
RXS } values resulted in an overall length L for dlgAl of 25 nm. 
The comparison of this length with that of 20.1 nm for IgA 1 and
16.1 nm for IgA2 (16,17) showed that the increased size of dlgAl 
does not correspond to a doubling in length of the monomers.
Complementary neutron scattering data was obtained for dlgAl 
at 0.6-1.5 mg/ml in 100% 2H20  buffer as a control for x-ray- 
induced radiation damage. This also acts as a control of internal 
scattering inhomogeneity effects caused by the estimated 9.6% car­
bohydrate content of dlgAl. A high negative protein-solvent scat­
tering contrast is now used in place of the high positive contrast 
observed by x-rays. Neutron scattering also provided a different
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FIG U R E 3. X-ray and neutron distance distribution functions P(r)  for 
d lg A l. A and B  show the x-ray and neutron P(r) curves respectively. The 
concentrations o f  d lg A l were 1.15 (x-rays) and 1.16 mg/ml (neutrons). The 
maxima M l  and M 2  o f  the P(r) curve depict two frequently occurring 
distances within the d lg A l structure. The positions o f M l and M 2  are 4.94  
and 9.88 nm, respectively (x-rays), and 5.06 and 10.14 nm, respectively 
(neutrons). The length o f  IgA l is denoted by L  at the r  value where the P(r) 
curve reaches 0. The L  values for d lg A l were 26 (x-rays) and 22 nm 
(neutrons).
view of dlgAl in that the hydration shell surrounding dlgAl is 
visible by x-ray scattering, but not by neutron scattering (27). The 
neutron RG value of dlgAl was 7.60 ± 0.05 nm (two values) (Fig. 
2B). This value supports the x-ray Rc  determination. However, this 
is 1 nm less than the x-ray RG value, which is a greater difference 
than that seen previously with IgAl and IgA2 (16, 17). This is 
attributed to the positioning of most of the hydration shell at large 
distances from the centre of the dlgAl structure. The neutron an­
isotropy ratio Rg :R0  was 2.08, and confirmed the x-ray value. As 
the consequence of poor counting statistics at large Q, no neutron 
Rxs-i or Rxs- 2  values were determined for dlgAl. Neutrons also 
lead to the molecular mass, as there is a linear relationship between 
the LOQ Guinier 1(0)/c values for proteins measured in 2H20  buff­
ers and molecular mass, where molecular mass -  l(0)/c X 9.10s
(16). The dlgAl neutron Guinier l(0)/c value of 0.33 ±  0.05 re­
sulted in a molecular mass value of 297 ± 45 kDa. This measure­
ment is within error of the composition-derived value of 345 kDa 
for dlgAl, showing that the scattering data is consistent with the 
expected composition of dlgAl with 9 N-linked and 20 O-linked 
oligosaccharides (Fig. 1).
Structural dimensions are provided by the transformation of 
the I(Q) curve into the distance distribution function P(r) curve. 
The mean RG values determined from the x-ray and neutron 
P(r) curves were 8.67 ± 0 .1 7  nm (six values) and 7.47 nm (two 
values), respectively. These were consistent with the Guinier 
Rg values. The x-ray P(r) curve for dlgAl was of better quality 
than the neutron P(r) curve for reason of better signal-noise 
ratios (Fig. 3), nonetheless the two curves were reproducible in 
that a double peak was observed with maxima of M l and M2 
that were located at similar r values of 4.9-5.1 and 9.9-10.1 
nm, respectively. These two peaks correspond to an abundance 
of interatomic vectors within the dlgAl solution structure. The 
peak M l at 4.9-5.1 nm was also evident in the P(r) curve for 
monomeric IgAl and IgA2 and for myeloma IgAl-HSA at 3.7, 
4.5, and 4.9 nm, respectively (16-18). M l is assigned to the 
most commonly occurring distance within a single Fab or Fc 
region, each of approximate length 8 nm. Hence, M l in Fig. 3
is consistent with a well-defined Fab region within the solution 
structure of dlgAl. M2 at 9.9-10.1 nm is of greater intensity 
than M l when this is compared with monomeric IgAl and IgA2 
(16, 17). In the absence of molecular modeling (below), the 
most likely reason for this intensity difference is that there are 
a large number of interatomic vectors close to 10 nm between 
the four Fab regions that are held in a comparatively inflexible 
arrangement. The maximum length, L, is determined from 
where the P(r) curve reaches zero at large r values. For dlgA l, 
L was found to be 26 nm (x-ray) and 23 nm (neutron). The 
shorter L value with neutrons indicates that a significant pro­
portion of the hydration shell is located at the periphery of the 
dlgAl structure. Simple geometric considerations of planar 
end-to-end arrangements of two monomer structures suggested 
by Fig. 1 readily lead to L values close to 26 nm. Hence, the 
dlgAl solution structure is concluded to be formed as an ex­
tended arrangement of two monomers joined at the end of their 
Fc regions, and not as a more compact solution structure that 
might resemble a bouquet of four Fab flowers positioned on two 
Fc stalks.
Analytical ultracentrifugation
To confirm the molecular mass of dlgAl, sedimentation equilib­
rium experiments were performed at six concentrations between 
0.07 and 0.97 mg/ml and at six rotor speeds using both interference 
optics and absorbance optics at 280 nm (Materials and Methods). 
On the assumption that a single species was present, sedimentation 
equilibrium fits were conducted with nine curves at each dlgAl 
concentration using both data types. The individual fits gave ran­
dom fit residuals and molecular mass values that ranged between 
280 and 345 kDa. Their extrapolation to zero concentration gave a 
mean molecular mass of 335 (±15) kDa (data not shown). These 
are within error of the molecular mass of 345 kDa calculated 
from the sequence of dlgAl if the 29 glycosylation sites in this 
are all occupied by biantennary oligosaccharides. Had the gly­
cosylation of dlgAl corresponded to 29 tetra-antennary oligo­
saccharides, the molecular mass would have been 357 kDa. This 
outcome confirmed the neutron molecular mass determination 
(see above).
The sedimentation coefficient s°20,w provides an independent 
measure of macromolecular elongation to the RG value. For dlgA 1, 
sedimentation velocity experiments were performed at three 
speeds at two concentrations (Materials and Methods). The c(s) 
distribution plots using SEDFIT software identify the species 
present. All the experimental and fitted dlgAl boundaries showed 
good visual agreement with satisfactory root mean square devia­
tion values (Fig. 4, A and B). The resulting c(s) distributions in Fig. 
4, C and D, showed that only a single species of dlgAl was present 
with a s°20fW value of 9.7 S. The conversion of the c(s) plots to 
molecular mass distributions c(M) showed that this corresponded 
to a molecular mass of 342 (±11) kDa. This agreed well with the 
sedimentation equilibrium value of 335 (±  15) kDa and sequence- 
derived molecular mass of 345 kDa. No higher oligomers were de­
tected in the c(s) plots. An analysis based on 4-20 scans at the center 
of the sedimentation profile using the g(s*) method in DCDT+ soft­
ware confirmed the SEDFIT results. Here, the dlgAl scans gave a 
s°2 o.w value of 9.8 S (interference) and 9.9 S (absorbance) (Fig. 5). 
The SEDFIT and DCDT+ determinations agree well with previous 
literature reporting a s°2 0 value of 10 S (28), 9.65 S (21), and 9.2-9.3 
S (29). The s°20,w value leads to the frictional ratio f/fo, where f G is the 
/value of the sphere with the same volume as the hydrated glycop­
rotein. Its value for dlgAl of 1.63 is slightly larger than those of 1.56 
found for monomeric IgAl and 1.53 for monomeric IgA2 (17). This
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Streptococcus species in the same way as normal dlgAl (Ref. 26, 
A. Almogren and M. A. Kerr, unpublished data). On SDS-PAGE, 
the myeloma dlgAl had the same mobility as normal dlgAl (26). 
Functionally, the myeloma dlgAl triggered neutrophil respiratory 
burst through CD89 in the same way as normal dlgAl, and bound 
to purified SC. Hence, our new structure of dlgA will aid our 
understanding and subsequent ability to manipulate the mucosal 
immune system and clarify the pathology of diseases. The size of 
dlgAl, its high carbohydrate content and its flexibility mean that 
the crystallization of intact dlgAl may not be realistic, thus con­
strained scattering modeling presently offers the only route to a 
molecular structure. Experimentally, we have shown that dlgAl 
has a near-planar structure in solution with the two monomers 
orientated end-to-end through their Fc regions. The two Fc regions 
are slightly bent in their relative arrangement (Fig. 9). Because the 
dlgAl structure was determined by fitting models against experi­
mental scattering data, this is not a prediction method, and the final 
models qualify for deposition in the Protein Data Bank.
Although scattering modeling is not able to determine unique 
molecular structures, it is able to rule out poorer-fit models (Table 
I). Both search cycles successfully converged on one small family 
of related best-fit structures. One striking outcome is the close 
end-to-end proximity of the two Fc regions in dlgAl. The J chain 
does not act as a spacer, as sometimes suggested in cartoons of the 
IgA dimer. Likewise, the two Fc regions do not overlap as dis­
cussed in earlier reviews (32). A bent Fc arrangement was mod­
eled, which has also been noted by electron microscopy (19). The 
length of the Fc-Fc region within dlgAl in Fig. 9B is close to 14.4 
nm. This agrees well with the 14.0-15.5 nm, 13.8 (±2.6) nm and 
12.5 nm determinations from electron microscopy (19-21, 28). 
The J chain is best accommodated in dlgAl within a crevice 
formed by the bent Fc regions, although a crystal structure will be 
needed to confirm this. If the J chain had separated the two Fc 
regions, this would add 2.0-2.5 nm to the length of the Fc-Fc 
regions. This outcome was ruled out by our Searches 2 and 3. Our 
location of the J chain in dlgAl is consistent with our scattering 
modeling of pentameric IgM (24). There, the J chain was best 
fitted within the planar disc of the five IgM Fc regions, and not as 
a spacer. The early electron microscopy studies of dlgAl indicated 
flexible planar end-to-end structures (20-22, 28), but it was not 
known whether these near-planar structures exist in solution. The 
constrained modeling showed that the best-fit dlgAl structures are 
near planar. Interestingly a near-planar dlgAl structure would be 
consistent with the planar IgM structure (24). Models showing 
perpendicular arrangements of the two monomers or the four Fab 
regions were eliminated during the rejection of poor-fit models 
(Figs. 6, B-D, and 7, B-D ).
The solution structures for monomeric IgAl, the IgAl-HSA 
complex and dlgAl all demonstrated similar T-shaped structures 
for the two Fab regions relative to the Fc region (16, 18). A well- 
separated Fab-Fc structure in all three cases was deduced from the 
observation of the M2 peak in the Pr curves, meaning that the two 
Fab regions are consistently seen on average to be extended away 
from the Fc region. Hinge flexibility of the Fab region relative to 
the Fc region is nonetheless expected, as observed from the vari­
able conformations seen in electron microscopy studies of dlgA 1, 
and the altered position of the Fab regions on going from the 
monomer to the dimer (Figs. IK  and 94). This is in accordance 
with the ability of IgAl to bind efficiently to a range of Ags. The 
maintenance of these extended hinge conformations can be ratio­
nalized in terms of its primary structure (PVPSTPPTPSPPTPPT 
PSPSCCH). Even though the hinge is comparatively long at 23 
residues, the presence of O-linked NeuNAc.Gal.GalNAc trisaccha­
rides, multiple prolines and the absence of glycines are expected to
maintain their extended conformations. Interestingly, human IgD 
also possesses an O-glycosylated segment within its 64-residue 
hinge, and this has a similar T-shaped structure to that for IgAl 
(24). As the four Fab regions are well separated within dlgAl, 
each Ag-binding site at the CDRs (CDR in Fig. 9B) is potentially 
able to interact with repeated epitopes independently of each other. 
The valency of dlgAl is therefore predicted to be four, and its 
avidity is predicted to be higher compared with its monomer. This 
assumes that the linearity of the dlgAl structure has no bearing on 
its capacity to bind independently to four Ag molecules.
A near-planar dlgAl structure would be well-adapted for inter­
actions with its receptors. By this, dlgAl is able to approach the 
host cell membrane surface for effective interactions with a cell 
surface receptor, most notably FcaRI which is responsible for IgA- 
mediated phagocytosis, oxidative burst, and Ab-dependent cellular 
cytoxicity among other roles (33, 34). The dlgAl model shows 
that receptor binding would occur independently of Ag binding. 
The dlgAl residues involved in binding to FcaRI are highlighted 
in orange in Fig. 9B (9, 35). By superimposition of the Fc crystal 
structure complexed with two FcaRI molecules (9) upon the 
dlgAl model, it is seen that the two FcaRI receptors will project 
out of the plane of dlgAl but on opposite sides of this dlgAl plane 
(green in Fig. 9, C and D). The superimposition of a second crystal 
structure onto the other monomer within dlgAl shows likewise 
that the third and fourth FcaRI receptors project outward on both 
sides of this plane (yellow in Figs. 9, C and D). Previously it has 
been shown that two FcaRI receptors can bind simultaneously to 
the monomeric Fc region in solution, and it has been speculated 
that this bivalent binding occurs at cell surfaces (9, 17, 36). Fig. 9, 
C and D, likewise leads to the speculation that dlgAl is able to 
bind up to two FcaRI receptors on a given cell surface, even 
though its predicted valency for receptors is four. The spatial sep­
aration between the C-terminal a-carbon atoms of the two FcaRI 
receptors bound to monomeric and dimeric IgAl is similar at 12.3 
and 10.2 nm, respectively, meaning that the same arrangement of 
FcaRI receptors will theoretically bind equally well to monomers 
or dimmers of IgAl. However, for reason of comparatively low 
receptor binding affinities in relation to the IgAl serum concen­
trations, it seems more likely that a 1:1 stoichiometry results in 
vivo (33, 34).
The appearance of dlgAl as a near-planar structure with a bent 
double Fc region leads to a possible mechanism for the formation 
of SIgAl from dlgAl and SC. The bend between the two Fc re­
gions in the final models of Fig. 6 offers a covalently bound loca­
tion for the J chain within the crevice that is created by this bend. 
This location may enable the J chain in dlgAl to be sufficiently 
exposed to bind to a central region in SC, this being the first event 
in the selective transportation of dlgAl across epithelial cells to 
form SIgA (37). The interaction between the C-terminal region of 
the J chain in dlgAl and SC is noncovalent and represents a crit­
ical step for transport of this complex to mucosal surfaces to form 
SIgA (37). A “zipper effect” binding of SC to dlgAl has been 
proposed, where the N-terminal Dl domain of SC first interacts 
noncovalently with dlgAl (possibly with the Fc region), a central 
region in SC then interacts with the C-terminal region of the J 
chain, and dlgAl and SC are brought into the correct position for 
covalent binding between Cys311 in the CH2 domain of dlgAl and 
Cys502 in the D5 domain of plgR. A J-shaped solution structure for 
free SC has been recently determined (4). It is possible that the 
center of this may form an initial contact with the J chain in dlgAl, 
then SC will unfold toward both ends of dlgAl as the Dl and D5 
domains interact successively across the two Fc regions. The wrap­
ping of the D1-D5 domains around the Fc regions in dlgAl then
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provides SIgAl with a greater ability to resist proteolysis in the 
harsh environment of mucosal surfaces.
The near-planar dlgAl structure provides insight into the for­
mation of other polymeric IgAs. The structure of dimeric IgA2 is 
predicted to be similar to that of dlgAl because the two monomers 
are joined through the base of their two Fc regions to the J chain 
and there are only minor sequence differences between the IgAl 
and IgA2 isotypes (11). The hinge region is not involved in the 
formation of the IgA2 dimer. However, the binding site of SC to 
dimeric IgA2 differs from that to dlgAl, as SC binds covalently to 
dlgAl but may not do so to dimeric IgA2 (18). The two dlgA 
isotypes may therefore differ in a manner that remains to be elu­
cidated, most probably mediated by the closer proximity of the Fab 
regions to SC in secretory IgA2. The antigenic reach of the two 
isotypes will differ for reason of the different hinge structures, as 
previously discussed (16, 17), and dimer formation is expected to 
accentuate this difference. The formation of trimeric and tetrameric 
IgA structures (38) can be visualized by analogy with the structure 
of planar pentameric IgM in which its Fc regions are disulphide 
linked through the Cys414 residues in the Cfx3 domains and the 
Cys575 residues in the tailpieces (24). Hexameric IgM structures 
without J chain have been described in which a sixth IgM mono­
mer is inserted within this plane (39). Cys311 in IgAl (Fig. 1) is 
located at the identical sequence and structural position to that of 
Cys414 in IgM (9). By analogy with IgM, it is relatively straight­
forward to insert further monomers within this Fc plane to form 
larger IgA oligomers. Using molecular graphics based on the IgAl 
Fc crystal structure and the IgM scattering structure, it was pos­
sible to create trimeric (and tetrameric) assemblies of three (and 
four) coplanar Fc regions starting from the dimer with the J chain 
present, but only if the Fab regions are absent. If the Fab regions 
and hinges are present, they will readily lead to significant steric 
conflicts with the assembly of Fc trimers and tetramers of IgAl 
unless these Fab regions are significantly displaced out of the plane 
containing the three or four Fc regions.
IgAN is defined by the deposition of IgA in the glomerular 
mesangium of the kidney and this is predominantly polymeric 
IgAl (5). A high level of polymeric IgAl such as in IgA myelomas 
does not necessarily lead to IgAN. A reduced galactosylation of 
the hinge 0-1 inked oligosaccharides has been implicated in the 
pathology of IgAN. It is possible that this change may destabilize 
the extended conformation of the IgAl hinge and cause the Fab 
regions to be displaced. Hence glycosylation changes may provide 
one possible mechanism for IgA aggregate formation by permit­
ting the Fc regions to self-associate. Another possibility for IgA 
aggregation arises from the consequences of the cleavage of the 
IgAl hinge by bacterial proteases. This was seen to cause the 
cleaved Fc fragments derived from dimeric and trimer IgAl (but 
not monomeric IgAl) to form disulphide-linked multimers (26). 
Our molecular graphics modeling of planar Fc rings of IgA by 
analogy with IgM (see above) lead to the hypothesis that, if the 
IgAl hinges become more flexible through deglycosylation and 
cause the Fab regions to move away, or the Fab regions are par­
tially or completely removed by bacterial proteolysis, then near- 
planar assemblies of trimers, tetramers, and higher oligomers of 
IgA can be generated starting from the double Fc region of dlgAl 
and its J chain. If this hypothesis is correct, these Fc oligomers can 
be stabilized by disulphide bridges through Cys311 at the surface of 
the Ch2 domain in IgA, and may lead to the IgA deposits seen 
in IgAN.
The elucidation of a near-planar solution structure of dlgAl has 
yielded a better understanding of the function of polymeric forms 
of IgA. This opens the way for the constrained modeling of SIgAl 
and SIgA2. Knowledge of the monomer arrangement within the
dimer has provided insights into the assembly of this and higher 
oligomers of IgAl, and the way that this potentially interacts with 
the FcaRI receptor and SC. However, many unsolved issues re­
main, including the exact binding motifs within dlgAl that interact 
with SC in the formation of SIgA, and the structure and compo­
sition of pathological dlgAl forms that are implicated in diseases 
such as IgAN.
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